The European College of Veterinary Internal Medicine – Companion Animals (ECVIM‐CA)
Congress and the Journal of Veterinary Internal Medicine (JVIM) are not responsible
for the content or dosage recommendations in the abstracts. The abstracts are not
peer reviewed before publication. The opinions expressed in the abstracts are those
of the author(s) and may not represent the views or position of the ECVIM‐CA. The
authors are solely responsible for the content of the abstracts.
MiCo Exhibition & Conference Centre, Milano, Italy, 19th to 21st September 2019
LIST OF ORAL RESEARCH COMMUNICATIONS
ESVC – European Society of Veterinary Cardiology
Thursday 19 September
15.55‐16.10
ESVC‐O‐1
Belachsen
Acute effect of oral pimobendan on left atrial function and mitral valve regurgitation
severity in dogs with stage B2 myxomatous mitral valve disease – A pilot study
16.10‐16.25
ESVC‐O‐2
Ward
Retrospective evaluation of the safety and tolerability of pimobendan in cats with
obstructive versus nonobstructive hypertrophic cardiomyopathy
16.25‐16.40
ESVC‐O‐3
Crosara
Aorto‐septal angle, isolated basal septal hypertrophy and systolic murmur in 122 cats
Friday 20 September
11.20‐11.35
ESVC‐O‐4
Menciotti
Accuracy of noninvasively determined pulmonary artery pressure in dogs with myxomatous
mitral valve disease (MMVD)
11.35‐11.50
ESVC‐O‐5
Ksiazek
Left atrial tear in dogs with myxomatous mitral valve disease ‐ clinical presentation,
echocardiographic features and long‐term survival
11.50‐12.05
ESVC‐O‐6
Claretti
Echocardiographic evaluation of left ventricular dimension and systolic function before
and 24 hours after percutaneous closure of patent ductus arteriosus in 120 dogs
12.05‐12.20
ESVC‐O‐7
Adin
Delayed Electrolyte Depletion and Azotemia in a Furosemide Rate Continuous Infusion
Model
12.20‐12.35
ESVC‐O‐8
Culshaw
Changes in renal endothelin activity with cardiac, renal and other chronic diseases
in dogs
12.35‐12.50
ESVC‐O‐9
Spalla
High grade AV Block and third degree AV Block in cats: a retrospective study of epicardial
pacemaker implantation (2006‐2018) focusing on signalment, presentation and survival
14.25‐14.40
ESVC‐O‐10
van Hoek
Diet‐induced reduction of cardiac wall thickness, Troponin‐I and IGF‐1 in cats with
asymptomatic hypertrophic cardiomyopathy
14.40‐14.55
ESVC‐O‐11
Patata
Biomarker discovery in cats with cardiomyopathy
14.55‐15.10
ESVC‐O‐12
Hanås
Blood pressure measurement by High Definition Oscillometry in different clinical settings
in healthy cats
15.10‐15.25
ESVC‐O‐13
Busato
Does pleural effusion protect against arterial thromboembolism in feline congestive
heart failure?
15.25‐15.40
ESVC‐O‐14
Ferasin
Iatrogenic heart murmur: a new cause of systolic murmurs in cats
15.40‐15.55
ESVC‐O‐15
Giraud
Point Of Care Ultrasound of the Caudal Vena Cava in Canine Degenerative Mitral Valve
Disease.
16.30‐16.45
ESVC‐O‐16
Bourguignon
Echocardiographically determined left ventricular volume indices obtained from two
views in dogs show good agreement
16.45‐17.00
ESVC‐O‐17
Greet
Supraventricular tachycardia in 23 cats; comparison with 21 cats with atrial fibrillation
(2004‐2014)
17.00‐17.15
ESVC‐O‐18
Perego
Electrocardiographic patterns of ventricular pre‐excitation in the dog
17.15‐17.30
ESVC‐O‐19
Perego
Use of the cutting balloon technique for the treatment of subvalvular pulmonary stenosis
17.30‐17.45
ESVC‐O‐20
Costa
Imaging and clinical features of canine right atrial appendage aneurysm: a single‐centre
cross‐sectional study in 10886 dogs
17.45‐18.00
ESVC‐O‐21
Franchini
Predictors of reoccurrence of congestive signs in dogs with ACVIM‐Stage C myxomatous
mitral valve disease (MMVD)
SCH – Society of Comparative Hepatology
Thursday 19 September
09.45‐10.00
SCH‐O‐1
Ferreira
Lactulose drives a reversible reduction and qualitative modulation of the faecal microbiota
diversity in healthy dogs
10.00‐10.15
SCH‐O‐2
Verwey
Prevalence of bactibilia in apparently healthy dogs
10.15‐10.30
SCH‐O‐3
Devriendt
Hyaluronic acid as a liver function test to asses extrahepatic portosystemic shunt
closure in dogs after surgical attenuation
ESVCP – European Society of Veterinary Clinical Pathology
Thursday 19 September
12.05‐12.20
ESVCP‐O‐1
Škor
Plasma lactate dehydrogenase as a prognostic marker for nodal diffuse large B‐cell
lymphoma in dogs
12.20‐12.35
ESVCP‐O‐2
Prasinou
The paradigm of erythrocyte membrane lipidome in healthy dogs: first evaluation of
the optimal interval values of a fatty acid cluster
12.35‐12.50
ESVCP‐O‐3
Zoia
Grade of severity, type of fibrinolysis and degree of agreement between rotational
thromboelastometry (ROTEM) and FDPs, D‐dimer and fibrinogen concentrations: a case‐
control study of 64 dogs with or without abdominal and/or pleural effusions
14.25‐14.40
ESVCP‐O‐4
Zoia
Rotational thromboelastometry (ROTEM) fibrinolytic activity in dogs with abdominal
and/or pleural effusions: a case control study in 64 dogs
14.40‐14.55
ESVCP‐O‐7
Johnsen
Investigation of the relationship between ionised and total calcium in dogs with ionised
hypercalcaemia
14.55‐15.10
ESVCP‐O‐6
Dewhurst
The effect of boric acid on bacterial culture of non‐cystocentesis canine and feline
urine samples
15.10‐15.25
ESVCP‐O‐5
Cervone
Prospective evaluation of inter‐ and intra‐observer agreement for standard visual
dipstick urinalysis in dogs and cats and comparison with an automated method
15.25‐15.40
ESVCP‐O‐8
Bennaim
Dilution and storage effects on free T4 concentrations measured by equilibrium dialysis
or analogue immunoassay
15.40‐15.55
ESVCP‐O‐9
Vizi
Detection of canine serum hepcidin with LC/MS method in healthy dogs
15.55‐16.10
ESVCP‐O‐10
Guzmán Ramos
Evaluation of hypocholesterolaemia in dogs
ESVNU – European Society of Veterinary Nephrology and Urology
Thursday 19 September
14.25‐14.40
ESVNU‐O‐1
Amram
Serum symmetric dimethylarginine in dogs and cats with acute kidney injury treated
with intermittent hemofiltration
14.40‐14.55
ESVNU‐O‐2
Faucher
Non‐obstructive “acute on chronic” kidney disease in the cat: is it possible to predict
survival?
14.55‐15.10
ESVNU‐O‐3
Ferreira
Effect of measurement location on systolic blood pressure (SBP) readings in out‐patient
and in‐patient dogs
15.10‐15.25
ESVNU‐O‐4
Rossi
Immune‐complex glomerulonephritis in cats: a retrospective study based on clinico‐pathological
data and morphological features
15.25‐15.40
ESVNU‐O‐5
Mantelli
Short course of immune‐suppressive doses of prednisolone is associated with renal
hyperfiltration and changes in hydration and electrolyte status in healthy beagle
dogs
15.40‐15.55
ESVNU‐O‐6
Snell
Characterization and in vitro susceptibility of clinical feline UPEC isolates to an
E. coli probiotic as a potential therapeutic for urinary tract infection
15.55‐16.10
ESVNU‐O‐7
Baumgartner
Prognostic factors in dogs with common causes of proteinuria
16.10‐16.25
ESVNU‐O‐8
Bijsmans
The effect of dietary sodium on urinary calcium and calcium oxalate relative supersaturation
(CaOx RSS) in dogs
16.25‐16.40
ESVNU‐O‐9
Caccamo
Proliferative urethritis in dogs: long‐term follow up and prognosis
ISCAID ‐ International Society for Companion Animal Infectious Diseases
Thursday 19 September
11.20‐11.35
ISCAID‐O‐1
Carrai
Detection of canine and feline parvovirus shedding in asymptomatic shelter cats in
Australia using a minor groove binder probe real‐time PCR assay
11.35‐11.50
ISCAID‐O‐2
Petini
Prognostic value of systemic inflammatory response syndrome (SIRS) presence, serum
acute phase proteins, cholesterol and total thyroxine concentrations in cats with
feline panleukopenia: a retrospective cohort study in 70 cats (2010‐2018)
11.50‐12.05
ISCAID‐O‐3
Bordicchia
Clinical and epidemiological features of the first reported outbreaks of feline calicivirus
virulent systemic disease in Australia and in vitro efficacy of three antiviral compounds:
nitazoxanide, 2’‐C‐methylcytidine and NITD‐008
12.05‐12.20
ISCAID‐O‐4
Bergmann
Antibody response to feline calicivirus vaccination in healthy adult cats
12.20‐12.35
ISCAID‐O‐5
Felten
Correlation of feline coronavirus shedding in faeces with serum coronavirus antibody
titre
12.35‐12.50
ISCAID‐O‐6
Dandrieux
A retrospective multi‐centre study on treatment and outcome in disseminated aspergillosis
in 41 dogs
14.25‐14.40
ISCAID‐O‐7
Cervone
Canine Trichuris vulpis infection: a retrospective study of 45 cases
14.40‐14.55
ISCAID‐O‐8
Lutz
Patterns of antimicrobial use for selected canine diseases in Switzerland in 2016
14.55‐15.10
ISCAID‐O‐9
Hubbuch
Comparison of antimicrobial prescription in selected diseases in cats in Switzerland
between 2016 and 2018: a trend towards more prudent antimicrobial use
15.10‐15.25
ISCAID‐O‐10
Schmidt
Evaluation of hand hygiene compliance in small animal clinics and practices in Switzerland
using the CleanHands application
15.25‐15.40
ISCAID‐O‐11
Schmidt
Evaluation of infection prevention and control standards and carriage of multidrug‐resistant
organisms in working staff in small animal clinics and practices in Switzerland
15.40‐15.55
ISCAID‐O‐12
Schuller
Prevalence, acquisition and persistence of rectal and naso‐/oropharyngeal carriage
of multidrug‐resistant organisms in dogs and cats presented to veterinary practices
and their owners
ESCG – European Society of Comparative Gastroenterology
Friday 20 September
09.45‐10.00
ESCG‐O‐1
Ruggerone
The fecal microbiota and unconjugated fecal bile acids in dogs with diabetes mellitus
10.00‐10.15
ESCG‐O‐2
Stavroulaki
Impact of antibiotic administration on fecal bacterial groups potentially associated
with dysbiosis in kittens
10.15‐10.30
ESCG‐O‐3
Bermudez Sanchez
Fecal microbial metabolism is altered in dogs with chronic enteropathy
11.20‐11.35
ESCG‐O‐4
Swales
The pug breed demonstrates a worse response to treatment of protein‐losing enteropathy
than other breeds of dog
11.35‐11.50
ESCG‐O‐5
Petrelli
Is measuring serum folate pointless? Retrospective analysis of prevalence and clinical
significance of hypo‐ or hyperfolataemia in dogs with chronic enteropathies
11.50‐12.05
ESCG‐O‐6
Moberg
Dogs with acute haemorrhagic diarrhoea syndrome not receiving antibiotics have a good
prognosis despite initial high AHDS‐score and systemic inflammation
12.05‐12.20
ESCG‐O‐7
Ziese
Faecal bile acid profiles in dogs with acute haemorrhagic diarrhoea syndrome over
time and compared to healthy dogs
12.20‐12.35
ESCG‐O‐8
Kaufmann
Long‐term consequences of acute hemorrhagic diarrhea syndrome in dogs
ESVIM – European Society of Veterinary Internal Medicine
Friday 20 September
16.30‐16.45
ESVIM‐O‐1
Hirt
Pulmonary deposition of nebulized 99mTc‐DTPA after pharmacologically induced airway
narrowing in healthy dogs
16.45‐17.00
ESVIM‐O‐2
Fastrès
Assessment of lung microbiota in healthy dogs: impact of breed and living conditions
17.00‐17.15
ESVIM‐O‐3
Grobman
Protein biomarkers in regurgitation, vomiting, and cough: proteomic characterization
of canine gastric fluid by liquid chromatography mass spectrometry (LCMS)
17.15‐17.30
ESVIM‐O‐4
Jaffey
Serum 25‐hydroxyvitamin D in dogs with sinonasal aspergillosis
17.30‐17.45
ESVIM‐O‐5
Jaffey
Plasma mRNA cathelicidin expression in hospitalized critically ill dogs
17.45‐18.00
ESVIM‐O‐6
Jaffey
Hereditary methemoglobinemia in dogs caused by cytochrome b5 reductase deficiency
associated with variants in CYB5R3
Saturday 21 September
16.30‐16.45
ESVIM‐O‐7
Jones
Differences in clinical presentation of common dog breeds diagnosed with primary IMHA
16.45‐17.00
ESVIM‐O‐8
de Laet
Diagnostic imaging findings in a referral population of dogs diagnosed with immune‐mediated
haemolytic anaemia
17.00‐17.15
ESVIM‐O‐9
Ebelt
Determination of Blood Groups DEA 1, DEA 4, DEA 5, Dal, and Kai 1/2 in Different Canine
Breeds
17.15‐17.30
ESVIM‐O‐10
Ferri
Systemic AA‐amyloidosis in shelter cats and shedding of amyloid fibrils
17.30‐17.45
ESVIM‐O‐11
Rabozzi
Treatment of non‐lactate metabolic acidosis in hypovolemic and normovolemic dogs:
chloride‐free iso‐osmolar solution with elevated Strong Ion Difference versus Ringer’s
Lactate solution
ESVONC – European Society of Veterinary Oncology
Friday 20 September
14.25‐14.40
ESVONC‐O‐1
Aupperle‐Lellbach
BRAF‐mutation in carcinomas of various sites in the canine urinary tract
14.40‐14.55
ESVONC‐O‐2
Kleiter
Re‐irradiation is a valuable treatment option for dogs and cats with cancer after
failing first line therapy
14.55‐15.10
ESVONC‐O‐3
Borgatti
Impact of Repeated Cycles of EGF Bispecific Angiotoxin (eBAT) Administered at a Reduced
Interval from Doxorubicin Chemotherapy on Tolerability and Survival of Dogs with Splenic
Hemangiosarcoma
15.10‐15.25
ESVONC‐O‐4
Škor
Humoral hypercalcemia of malignancy in canine lymphoma WHO types and its impact on
survival
15.25‐15.40
ESVONC‐O‐5
Rigas
High risk mast cell tumours with favourable outcome in 16 young dogs
15.40‐15.55
ESVONC‐O‐6
Willcox
Diphenhydramine Does Not Reduce Infusion‐Related Ventricular Arrhythmias in Dogs Treated
with Doxorubicin
16.30‐16.45
ESVONC‐O‐7
Škor
Time to change from WHO staging to Ann‐Arbor system in canine nodal diffuse large
B‐cell lymphoma?
16.45‐17.00
ESVONC‐O‐8
Willcox
Accuracy of PET for Detection of Lymph Node Metastasis in Canine Oral Malignant Melanoma
17.00‐17.15
ESVONC‐O‐9
Fournier
Efficacy of diosmectite in the management of chemotherapy‐induced diarrhoea in dogs:
an open‐label randomised clinical trial
17.15‐17.30
ESVONC‐O‐10
Fournier
Contrast‐enhanced ultrasound for sentinel lymph node identification in the routine
staging of canine mast cell tumours: a feasibility study
17.30‐17.45
ESVONC‐O‐11
Ossowska
Dorsal rhinotomy in 18 dogs with intranasal tumors
17.45‐18.00
ESVONC‐O‐12
Wood
The Use of Low‐dose Radiation Therapy for the Treatment of Small & Intermediate Cell
Gastrointestinal Lymphoma in Cats
ESVE – European Society of Veterinary Endocrinology
Saturday 21 September
09.00‐09.15
ESVE‐O‐1
Mack
The Relationship of SDMA and Creatinine in Cats with Subnormal Total T4 After Hyperthyroidism
Treatment
09.15‐09.30
ESVE‐O‐2
Kelly
Prevalence of ‘Atypical’ Addison’s disease among a population of dogs diagnosed with
hypoadrenocorticism
09.30‐09.45
ESVE‐O‐3
Petini
The predictive role of the transtubular potassium gradient (TTKG) for Addison syndrome
in hyperkaliemic dogs: a cross‐sectional study
09.45‐10.00
ESVE‐O‐4
Golinelli
Comparison of different monitoring methods in dogs with hypercortisolism treated with
trilostane
10.00‐10.15
ESVE‐O‐5
Tardo
Feline plasma adrenocorticotropic hormone: validation of a chemiluminescent assay
and concentrations in cats with hypercortisolism, primary hypoadrenocorticism and
other diseases
10.15‐10.30
ESVE‐O‐6
Denyer
Major Histocompatibility Complex (MHC) class II haplotypes associated with increased
risk of canine diabetes mellitus – a breed‐specific study
10.30‐10.45
ESVE‐O‐7
Copley
Comparison of nine canine serum thyroxine measurement methods and impact of T4 cross‐reacting
autoantibodies
11.20‐11.35
ESVE‐O‐8
Hazuchova
Analysis of GWAS data in Domestic Shorthair and Burmese cats identifies diabetes‐associated
loci near the DPP9 and within the DPP10 gene
11.35‐11.50
ESVE‐O‐9
Kraemer
Glycemic variability in newly diagnosed diabetic cats treated with the GLP‐1 analogue
exenatide extended‐release
11.50‐12.05
ESVE‐O‐10
del Baldo
Clinical perfrormances of flash glucose monitoring system in diabetic dogs
12.05‐12.20
ESVE‐O‐11
Davison
Whole Genome Sequencing to explore genetic risk factors in canine diabetes mellitus
12.20‐12.35
ESVE‐O‐12
Linari
Evaluation of 1,2‐o‐dilauryl‐rac‐glycero glutaric acid ‐ (6’‐methylresorufin) ester
(DGGR) lipase assay in dogs with naturally occurring hypercortisolism
12.35‐12.50
ESVE‐O‐13
Bennaim
Comparison of measurement of free thyroxine concentration by a chemiluminescent analogue
immunoassay to equilibrium dialysis in dogs with non‐thyroidal illness
12.50‐13.05
ESVE‐O‐14
Tièche
Organoid cultures of follicular‐cell thyroid carcinoma: a novel canine model for translational
thyroid cancer research
ESVCN – European Society of Veterinary Comparative Nutrition
Saturday 21 September
14.25‐14.40
ESVCN‐O‐1
Jeusette
Dietary lemon balm and fish peptides enhance the efficacy of L‐tryptophan to reduce
urinary cortisol, a stress marker in cats
14.40‐14.55
ESVCN‐O‐2
Nybroe
Metabolic effects of a diet with Enterococcus faecium NCIMB 10415 for healthy adult
dogs
LIST OF POSTER RESEARCH COMMUNICATIONS
ESVC – European Society of Veterinary Cardiology
ESVC‐P‐1
Baisan
Heart rate variability of dogs in various stages of degenerative mitral valve disease
ESVC‐P‐2
van Israel
Comparison of serum digoxin concentrations from blood collected in Vacutainer® tubes
with or without gel
ESVC‐P‐3
Caivano
Transverse right ventricle strain and strain rate assessed by 2‐dimensional speckle
tracking echocardiography in dogs with pulmonary hypertension
ESVC‐P‐4
Lee
Potential renoprotective effect of angiotensin‐receptor antagonists in dogs with myxomatous
mitral valve disease
ESVC‐P‐5
Takamura
Perioperative management with peripheral arteries in dogs undergoing open heart surgery
ESVC‐P‐6
Martinelli
Effects of in‐hospital diuretic therapy on electrolytes concentration, renal function
and survival in 85 dogs with acute congestive heart failure
ESVC‐P‐7
Yilmaz
Platelet proteomic profile in dogs with heart failure
ESVC‐P‐8
Ware
Vitamin D Status in Cats with Cardiomyopathy compared to Normal Cats
ESVC‐P‐9
Cheng
Identification of increased desmin aggregates consistent with intermediate filament
dysfunction in feline hypertrophic cardiomyopathy
ESVC‐P‐10
Guglielmini
Prevalence and risk factors for atrial fibrillation in dogs with myxomatous mitral
valve disease
ESVC‐P‐11
Poissonnier
Left atrial volume assessment in 160 Cavalier King Charles Spaniels with and without
degenerative mitral valve disease (2017‐2019)
ESVC‐P‐12
Passavin
Hematological abnormalities in dogs with congenital arterial stenosis: a prospective
study of 56 cases (2017‐2019)
ESVC‐P‐13
Poissonnier
Use of torasemide in cats with congestive heart failure: 17 cases (2016‐2019)
ESVC‐P‐14
Guarnera
Use of torasemide as a second line diuretic in dogs with congestive heart failure
ESVC‐P‐15
Mazzoldi
Echocardiographic predictors of first onset of atrial fibrillation in dogs with myxomatous
mitral valve disease
ESVC‐P‐16
Romito
Usefulness of Holter‐derived Lorenz plots analysis to discriminate different cardiac
rhythms in dogs
ESVC‐P‐17
Adin
Visual Representations of Cardiac Arrhythmias in Dogs using Lorenz Plots
ESVC‐P‐18
Borenstein
First case of successful transcatheter pulmonary valve implantation in a dog with
severe pulmonary regurgitation
ESVC‐P‐19
Claretti
Normal aortic annulus dimensions in Boxer dogs according to sex and body weight
ESVC‐P‐20
Domanjko Petric
Inflammatory and oxidative stress markers are associated with survival in canine cardiovascular
patients
ESVC‐P‐21
Domanjko Petric
Right heart remodelling in brachycephalic obstructive airway syndrome
ESVC‐P‐22
Baron Toaldo
Effect of a single dose of Pimobendan on right ventricular and atrial function in
healthy cats
ESVC‐P‐23
Harjen
Ambulatory electrocardiography and serial cardiac specific troponin I measurement
in twenty‐two dogs envenomated by the European Adder (Vipera berus)
ESVC‐P‐24
Parmentola
E point to septal separation (EPSS): difference of measurement from the right parasternal
long axis and short axis view in dogs
ESVC‐P‐25
Takahashi
Investigation report of the effect of long flightprolonged air travel on dogs with
heart mitral valve disease
ESVC‐P‐26
Lekane
Clinical, ECG and echocardiographic findings in a canine case series of presumptive
myocardial infarction
SCH – Society of Comparative Hepatology
SCH‐P‐1
Borusewicz
The use of MRI and gadoxetic acid to differentiate hepatic parenchymal hyperplastic
lesions in dogs
ESVCP – European Society of Veterinary Clinical Pathology
ESVCP‐P‐1
Martín
Serological and molecular detection of Leishmania infantum in stray cats in an endemic
region of Spain
ESVCP‐P‐2
Franco‐Martínez
Serum and salivary adiponectin dynamics in dogs before and after ovariohysterectomy
ESVCP‐P‐3
Baxarias
Effect of storage on nitroblue tetrazolium reduction test in dogs
ESVCP‐P‐4
Kocaturk
Identification of serum proteins in dogs naturally infected with Anaplasma phagocytophilum
and Borrelia burgdorferi
ESVCP‐P‐5
Tulone
Hypergammaglobulinemia as a marker of hepato‐pancreatic involvement in enteropathic
cats
ESVCP‐P‐6
Gori
C‐Reactive Protein/Albumin ratio in canine acute pancreatitis
ESVCP‐P‐7
Navarro Martínez
Urine capillary electrophoresis reference intervals for healthy dogs
ESVCP‐P‐8
Cantos Barreda
Does the time at sampling influence the measurement of anti‐Leishmania antibodies
in serum and saliva of dogs with clinical leishmaniosis?
ESVCP‐P‐9
Pierini
Platelet abnormalities and platelet‐to‐lymphocyte ratio (PLR) in canine immunosuppressant‐responsive
enteropathy (IRE): a retrospective study on 41 patients
ESVCP‐P‐10
Galizzi
The urine aldosterone to creatinine ratio (UAldo:C) determined by enzyme‐linked immunosorbent
assay (ELISA) in healthy dogs and dogs with myxomatous mitral valve disease
ESVNU – European Society of Veterinary Nephrology and Urology
ESVNU‐P‐1
Breu
Uroliths in dogs from Europe and China ‐ a comparative study
ESVNU‐P‐2
Fidalgo
Significant Feline Proteinuria: a retrospective study of its aetiology in 61 cats
ESVNU‐P‐3
Paz
The role of vector‐borne diseases in the aetiology of overt canine proteinuria: a
retrospective study in 106 dogs
ESVNU‐P‐4
Falus
Evaluation of the diagnostic value of urinary albumin to protein ratio in proteinuric
dogs
ESVNU‐P‐5
Neagu
N‐acetil‐ß‐D‐glucozaminidase index as an early renal tubular damage marker in male
cats with obstructive lower urinary tract disease
ESVNU‐P‐6
Pagnamenta
Non‐symptomatic bacteriuria is common in young female boxer dogs
ESVNU‐P‐7
Gori
Evaluation of symmetric dimethylarginine (SDMA) in canine acute pancreatitis
ESVNU‐P‐8
From
Evaluation of a point‐of‐care lateral flow immunoassay for detection of significant
bacteriuria in dogs and cats
ESVNU‐P‐9
Perondi
Antioxidant enzyme activity in dogs with acute uraemia managed with haemodialysis
ESVNU‐P‐10
Pantaleo
Risk factors for urinary tract infection in dogs with natural occurring leptospirosis:
a retrospective cohort study of 76 dogs
ESVNU‐P‐11
Manczur
Accuracy of refractometric urine specific gravity determination in cats
ESVNU‐P‐12
Duque
Early detection of tubular damage in dogs infected with Leishmania infantum: use of
N‐acetyl‐ß‐D‐glucosaminidase (NAG) and glutamyl transferase (GGT)
ESVNU‐P‐13
Duque
Usefulness of urine neutrophil gelatinase–associated lipocalin (NGAL) and Cystatin
C (CysC) in the diagnosis of renal disease in dogs affected with leishmaniasis
ESVNU‐P‐14
Zambarbieri
Complicated UTI in dogs: uropathogens, antimicrobial resistance and comorbidity
ESVNU‐P‐15
Scarpa
Cats at risk or with spontaneous CKD. What affects survival and prognosis?
ISCAID – International Society for Companion Animal Infectious Diseases
ISCAID‐P‐2
Carnés
Circulating immune complexes levels correlate with the progression of canine leishmaniosis
ISCAID‐P‐3
Cabré
Clinicopathological findings in canine leishmaniosis and its association with signalment
ISCAID‐P‐4
Su
Correlation between the molecular epidemiology of canine Babesia species and the distribution
of vector ticks on dogs in Taiwan
ISCAID‐P‐5
Liu
Risk factors of Babesia gibsoni infection from client‐owned dogs
ISCAID‐P‐6
Pacifico
Acantocheilonema reconditum in hunting dogs from Southern Italy: distribution, risk
factors and haemato‐biochemical findings
ISCAID‐P‐7
Sarpataki
Effect of human antiretroviral compound Tenofovir in the treatment of cats naturally
infected with feline immunodeficiency virus (FiV)
ISCAID‐P‐8
Gatellet
The many faces of Lyme borreliosis in dogs: a review of 29 suspected clinical cases
ISCAID‐P‐9
Piantedosi
Distribution and risk factors of canine hemotropic mycoplasmas in hunting dogs from
Southern Italy
ISCAID‐P‐10
Palerme
Prevalence of vector‐borne diseases in free‐roaming cats
ISCAID‐P‐11
Walker
Retrospective analysis of cases tested for leptospirosis at a university teaching
hospital
ISCAID‐P‐12
Guzmán Ramos
Canine urine culture and antimicrobial susceptibility patterns over an eight‐year
period: increasing antimicrobial and multidrug resistance
ESCG – European Society of Comparative Gastroenterology
ESCG‐P‐1
Benvenuti
Foxp3 and histopathological lesions in relation to outcomes in canine immunosuppressant‐responsive
enteropathy (Ire): prospective analysis in 57 dogs
ESCG‐P‐2
Tabar
Prevalence and significance of increased TLI concentrations in clinical practice
ESCG‐P‐3
Lyngby
Serum 25‐hydroxyvitamin D3 in dogs with acute gastrointestinal diseases
ESCG‐P‐4
Gori
Evaluation of abdominal ultrasound features in relation with canine Spec cPL, the
severity of disease and mortality in suspected canine acute pancreatitis
ESCG‐P‐5
Candido
Gastric mucosal pathology in Belgian Shepherd dogs with and without clinical signs
of gastric disease
ESCG‐P‐6
Cristóbal Verdejo
Effect of stem cell therapy on serum cobalamin levels in dogs diagnosed with chronic
enteritis without cobalamin supplementation
ESCG‐P‐7
Becher
Neutrophil‐to‐lymphocyte ratio (NLR) as a biomarker in dogs with chronic inflammatory
enteropathies
ESCG‐P‐8
Hanifeh
Calprotectin concentrations are increased in the intestinal mucosa of dogs with chronic
inflammatory enteropathies
ESCG‐P‐9
Benvenuti
Neutrophil‐to‐lymphocyte ratio (NLR) in canine patients with immunosuppressant‐responsive
enteropathy (IRE)
ESCG‐P‐10
Ambrosini
A Novel Canine‐Specific Model System to Study Intestinal P‐Glycoprotein‐Mediated Drug
Transport
ESCG‐P‐11
Johnsen
Investigation of the efficacy of a novel diet in the management of chronic enteropathies
in dogs
ESCG‐P‐12
Jergens
Effect of dietary fat content on mucosal microbiota and serum metabolome in healthy
beagles
ESCG‐P‐13
Crisi
The erythrocyte membrane lipidome in dogs with chronic enteropathy
ESCG‐P‐14
Da Riz
Hypercobalaminaemia and its possible association with disease severity in dogs: a
retrospective study of 47 cases
ESCG‐P‐15
Pignataro
In vitro model (SCIME) to study the intestinal microbiota in dog
ESCG‐P‐16
Hernandez
Expression and distribution of Toll‐Like Receptor (TLR)2, TLR4, TLR5 and TLR9 in the
colonic mucosa of dogs with Inflammatory Bowel Disease
ESCG‐P‐17
Weiß
Serum Vitamin A and E concentrations in dogs with pancreatitis
ESCG‐P‐18
Galiazzo
Water immersion vs gas insufflation in canine duodenal endoscopy: is the future underwater?
ESVIM – European Society of Veterinary Internal Medicine
ESVIM‐P‐2
Bottero
Retrospective study of 23 cases of canine nasal polyposis, of which 10 were treated
endoscopically
ESVIM‐P‐3
Keiner
Diagnostic utility of reticulocyte haemoglobin content (RETIC‐HGB) to detect iron‐limited
erythropoiesis in cats
ESVIM‐P‐4
Slawuta
A comparison of the diagnostic utility of the classic model, the value of the Anion
Gap (AG), corrected Anion Gap (AGcorr) and the chloride/sodium ratio in the diagnosis
of acid‐base basalnce disturbances in cats with chronic kidney disease (CKD)
ESVIM‐P‐5
Schulz
Evaluation of different cleaning methods for bacterial decontamination of feline aerosol
chambers
ESVIM‐P‐6
Lubas
Evaluation of clinico‐pathological alterations including some leukocyte ratios and
survival rate in dogs with IMHA transfused and not transfused: a retrospective study
ESVIM‐P‐7
di Loria
Expression of serum exosomal miRNA 122 in dogs naturally infected by Leishmania infantum
ESVIM‐P‐8
Tulone
Anemia and hypoferremia in cats with hepato‐pancreatic and intestinal involvement
ESVIM‐P‐10
Lam
Lung ultrasound findings in dogs using a regionally based protocol (Vet BLUE) versus
entire thorax scanning
ESVIM‐P‐11
Drut
Comparison of plasma metabolomic profiles of healthy adult cats with low or high plasma
homocysteine concentration
ESVIM‐P‐12
Gianesini
Association between immune‐mediated hemolytic anemia (IMHA) and acute pancreatitis
in dogs
ESVIM‐P‐13
Easley
Evaluation of Serum Procalcitonin in Dogs with Induced Endotoxemia as a Biomarker
for Sepsis
ESVIM‐P‐14
Cortese
Effect of a weight loss program on metabolic and immunological profile, blood leptin
level and cardiovascular parameters in obese dogs
ESVIM‐P‐15
Beaujard
Life expectancy and causes of mortality of dogs at the National Veterinary School
of Toulouse between September 2007 and September 2017 : retrospective study
ESVIM‐P‐16
Aromaa
Comparison of habitual physical activity levels in French Bulldogs and normocephalic
dogs – a pilot study
ESVIM‐P‐17
Canonne‐Guibert
Normal or mild increased C‐reactive protein values in 16 dogs with bronchial and pulmonary
infection with Bordetella bronchiseptica
ESVIM‐P‐18
Viitanen
Polycythemia is uncommon in dogs with chronic hypoxic pulmonary disease
ESVIM‐P‐19
Greci
A statistical analysis to predict persistence of canine sinonasal aspergillosis at
endoscopic follow‐up by comparing three different scoring systems: a retrospective
study of 47 cases treated with one hour 1% clotrimazole per‐endoscopic infusion and
undergoing endoscopic follow‐up
ESVIM‐P‐20
Spada
Evaluation of feline packed red blood cell units obtained by blood sedimentation and
stored for 42 days for transfusion purposes
ESVIM‐P‐21
Flageollet
Bronchoscopic findings in dogs with bronchial vegetal foreign bodies : a retrospective
study of 52 cases (2010‐2019)
ESVIM‐P‐22
Vangrinsven
Assessment of nasal microbiota in healthy dogs of different breeds
ESVIM‐P‐23
Peano
Canine sino‐nasal aspergillosis in Italy (38 cases)
ESVONC – European Society of Veterinary Oncology
ESVONC‐P‐1
Bottero
Multicentric and prospective study on 271 cases of endonasal neoformations in the
dog
ESVONC‐P‐2
Thumser‐Henner
Sensitivity of canine and human cancer cell lines towards thermoradiotherapy
ESVONC‐P‐3
Lanore
Interest of the association of abdominal ultrasound and alanine transaminase (ALT)
measurements in the determination of hepatic infiltration in case of nodal diffuse
large B‐cell lymphoma (DLBLCL)
ESVONC‐P‐5
Campigli
Pet owner feedback on psychological support service in an Italian veterinary hospital:
a survey data
ESVONC‐P‐6
Mosca
Evaluating the myelosupressive effects of a single dose of vincristine in dogs with
lymphoma
ESVE – European Society of Veterinary Endocrinology
ESVE‐P‐1
Codea
Hypothyroidism and its association with extra hepatic biliary diseases in dogs: a
retrospective case‐control study
ESVE‐P‐2
van den Berg
Planar and SPECT imaging of canine thyroid tumors: 68 cases
ESVE‐P‐4
Pérez‐López
Ultrasonographic evaluation of adrenal gland thickness in healthy dogs and in dogs
with hyperadrenocorticism
ESVE‐P‐5
Ledda
Ultrasonographic accuracy in primary adrenal insufficiency: a retrospective cohort
study of 182 dogs
ESVE‐P‐6
Graham
Effect of sample dilution on free T4 depends on physiological state and analytical
method
ESVE‐P‐7
Canonne‐Guibert
Survival in cats with diabetes mellitus and chronic pancreatitis: a preliminary study
of 36 cases
ESVE‐P‐8
Niessen
Efficacy of once daily Protamine Zinc Recombinant Human Insulin (ProZinc®) in canine
diabetes mellitus
ESVE‐P‐9
Garcia
Brachycephalic morphotype and pituitary tumor size in dogs with Cushing’s disease
ESVE‐P‐10
Pierini
Critical illness‐related corticosteroid insufficiency (CIRCI) in dogs with systemic
inflammatory response syndrome (SIRS)
ESVE‐P‐11
Nerhagen
Prednisolone induced hyperglycaemia and diabetes mellitus in cats
ESVE‐P‐12
Malerba
Accuracy and precision of insulin administration using human and veterinary pen‐injectors
and syringes
ESVE‐P‐13
Carotenuto
fractional excretion of electrolytes in dogs with primary hypoadrenocorticism before
and after treatment
ESVE‐P‐14
Kiss
Effects of bodyweight, age and pituitary hyperadrenocorticism on the adrenal gland
size of dogs, measured by ultrasonography
ESVCN – European Society of Veterinary Comparative Nutrition
ESVCN‐P‐1
Koizumi
Studies on estimation of ideal body weight by morphometry in dogs
ORAL RESEARCH COMMUNICATIONS
ESCG‐O‐1
The fecal microbiota and unconjugated fecal bile acids in dogs with diabetes mellitus
B. Ruggerone1, A.C. Manchester2, F. del Baldo3, F. Fracassi3, J.A. Lidbury2, J.M.
Steiner2, J.S. Suchodolski2, F. Procoli1
1Ospedale Veterinario i Portoni Rossi, Zola Predosa, Italy, 2Texas A&M University,
Gastrointestinal Laboratory, Tamu, United States of America, 3University of Bologna,
Dept. Veterinary Medical Sciences, Bologna, Italy
Alteration of intestinal and fecal microbiota (dysbiosis), together with changes in
fecal bile acid (BA) concentrations have been associated with type 1 diabetes mellitus
(DM) in people. DM in dogs resembles human type 1 DM. The aim of this study was to
evaluate changes in fecal microbiota and fecal unconjugated BAs profile in dogs with
naturally‐occurring DM during insulin therapy and compare them to healthy control
dogs (HC).
To this aim, naturally‐passed fecal samples and left over serum samples obtained for
diagnostic proposals from 17 adult dogs with DM were collected. Fecal samples from
16 clinically healthy dogs were used as a control population. In addition, serum folate,
cobalamin and cTLI were assessed in the DM group to exclude the presence of other
causes of dysbiosis; for each DM dog, the fed diet was known and the use of antibiotic
within the previous 12 months was excluded. DNA was extracted from each fecal sample
prior to quantitative PCR (qPCR) analysis. Data for 8 bacterial groups was compiled
to calculate a microbiota dysbiosis index (DI). Concentrations and proportions of
fecal unconjugated primary (cholic/chenodeoxycholic) and secondary (litho/deoxy/ursodeoxycholic)
BAs were measured using a gas chromatography mass spectrometry platform. Unpaired
t test and Mann‐Whitney U test compared median values between HC and DM dogs with
significance set at P < 0.05.
Median DI was statistically different between HC and DM dogs (HD −5.3 vs DM ‐1,5;
P = 0.0019;). A negative dysbiosis index (DI), indicative of normobiosis, was present
in 82% of DM dogs. Four dogs in the DM were dysbiotic (DI index >0). TLI, folate and
cobalamin concentrations were normal in all dogs with DM, though two dogs had cobalamin
levels <350 ng/L. There was no significant difference between groups for total BAs
and proportion of secondary BAs (respectively P = 0.1124 and P = 0.5814).
The results of this preliminary study did not confirm the association between intestinal
dysbiosis, fecal bile acids dysmetabolism and DM in dogs under insulin therapy. Fecal
unconjugated BA profiles of DM dogs mimicked those seen in healthy dogs. Further studies
are needed to evaluate the possible role of intestinal microbiota in the pathogenesis
of canine DM.
Disclosures
No disclosures to report.
ESCG‐O‐2
Impact of antibiotic administration on fecal bacterial groups potentially associated
with dysbiosis in kittens
E.M. Stavroulaki1, J.S. Suchodolski2, J.A. Lidbury2, J.M. Steiner2, P.G. Xenoulis1
1University of Thessaly, Karditsa, Greece, 2Gastrointestinal laboratory, Texas A&M
University, College Station, United States of America
In humans, antibiotic use results in long‐lasting changes of the bacterial constituents
of the gastrointestinal (GI) tract. Antibiotic‐induced microbial shifts are associated
with predisposition to certain diseases such as chronic GI diseases, obesity, and
allergies. No studies exist in kittens investigating the effect of antibiotic administration
on the GI microbiota and the duration of this effect. The study aim was to determine
the effect of antibiotic administration in kittens on certain bacterial groups that
are potentially associated with dysbiosis.
Naturally passed feces were collected from 17 healthy kittens that did not receive
antibiotics (Group 1), 14 kittens that received amoxicillin/clavulanic acid for 20 days
(Group 2), and 13 kittens that received doxycycline for 28 days (Group 3) as part
for standard treatment of upper respiratory tract infection. Kittens were approximately
2 months of age, on the same diet and the same antiparasitic treatment prior to sample
collection. Fecal samples were collected on days 0 (before antibiotic treatment),
20 or 28 (Group 2 and Group 3, respectively; after the end of antibiotic administration),
and 60. DNA was extracted from each sample and qPCRs were performed for total bacteria,
Turicibacter spp., Faecalibacterium spp., Streptococcus spp., Escherichia coli (E.
coli), Blautia spp., Fusobacterium spp., Clostridium hiranonis (C. hiranonis), and
Bifidobacterium spp. The data were tested for normal distribution and appropriate
statistical analyses were used for either repeated or independent measurements. Statistical
significance was set at p < 0.05 and correction for multiple comparisons was used
where appropriate.
On day 0, no significant differences were identified among the 3 groups. On day 20,
there were significant increases in E. coli (p = 0.003) and decreases in total bacteria
(p = 0.002), Blautia (P = 0.0038), C. hiranonis (P = 0.026), and Faecalibacterium
(p = 0.031) in group 2 compared to group 1. On day 60, E.coli (P = 0.012) was significantly
increased in group 3 compared to group 1. In group 1 E. coli significantly decreased
(P < 0.0001) and Faecalibacterium significantly increased (P = 0.023) over time. In
group 2, total bacteria (P = 0.014) and Blautia (P = 0.008) significantly decreased
on day 20 and C. hiranonis (p = 0.001) on day 60. Blautia (P = 0.017) remained decreased
on day 60. E.coli remained unchanged on day 20 (P = 0.999) but decreased on day 60
(P = 0.0001). Faecalibacterium remained unchanged on day 20 (P = 0.711) but increased
on day 60 (P = 0.0002). In group 3, no statistically significant differences were
identified.
Administration of amoxicillin/clavulanic acid or doxycycline had profound effects
on certain bacterial groups potentially associated with dysbiosis in these kittens.
Disclosures
No disclosures to report.
ESCG‐O‐3
Fecal microbial metabolism is altered in dogs with chronic enteropathy
S. Bermudez Sanchez1, R. Pilla1, A. Gramenzi2, F. Marsilio2, M. Steiner1, A. Lidbury1,
S. Suchodolski1
1Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, Texas,
College Station, United States of America, 2Veterinary Medicine. University of Teramo,
Teramo, Italy
Several studies have reported intestinal microbial dysbiosis in dogs with chronic
enteropathy. Limited data is available about the microbiota gene function in this
pathology in dogs. Determining the functional attributes of the microbiome is essential
for understanding their role on host metabolism and disease. The aim of this study
was to compare the functional roles of the fecal microbiota in healthy dogs and dogs
with CE by fecal DNA shotgun sequencing.
Fecal samples were collected from 14 healthy dogs and 20 dogs with chronic enteropathy
(CE). Fecal DNA was extracted using a commercial kit (PowerSoil, QIAGEN). Functional
characterization of the shotgun sequence reads in the KEGG database was performed
using next generation sequencing, in order to identify the relative abundance of specific
metabolic pathways. A Wilcoxon test was used for comparison of the gene abundance
between groups. Significance was set at q < 0.05.
At phylum level, low abundance of Bacteroidetes was observed in dog with CE, compared
to healthy control dogs (48.5 vs 1.6%; q = 0.0006). Fusobacteria was also significantly
increased in healthy controls (0.25 vs 0.04%; q = 0.0111). The pathway enrichment
analysis of the bacterial metagenomes showed that 130 of 360 (36.1%) total metabolic
modules were differentially abundant between studied groups. Genes for carbohydrate
metabolism, biosynthesis of amino acids (lysine, threonine, histidine, isoleucine,
tryptophan, leucine and serine) and vitamins (ascorbate, thiamine and riboflavin)
were decreased in dogs with CE, while genes involved in transport of molecules and
homeostasis maintenance during oxidative stress (glutathione biosynthesis) were increased
in CE.
Our data presents, as previous reported, an intestinal microbial dysbiosis in dogs
with CE. As new finding, our results show an altered microbial metabolism in dogs
with CE compared to healthy dogs, characterized by reduction of amino acid biosynthesis
and carbohydrate metabolism. Further studies including transcriptomic analysis are
warranted to define the consequences of this microbiota dysfunction on dogs with CE.
Disclosures
No disclosures to report.
ESCG‐O‐4
The pug breed demonstrates a worse response to treatment of protein‐losing enteropathy
than other breeds of dog
H. Swales1, D.J. Batchelor1, S. Campbell2, M. Kuijlaars3, R. Mellanby2, P.J.M. Noble1,
S. Palantzi4, P. Silvestrini1, J. Stallwood5, A.J. German1
1Institute of Veterinary Science, University of Liverpool, Neston, United Kingdom,
2The Royal (Dick) School of Veterinary Studies, Edinburgh, United Kingdom, 3Small
Animal Hospital, University of Glasgow, Glasgow, United Kingdom, 4Davies Veterinary
Specialists, Hitchin, United Kingdom, 5School of Veterinary Sciences, University of
Bristol, Bristol, United Kingdom
‘Protein‐losing‐enteropathy’ (PLE) is a syndrome caused by various diseases including
idiopathic inflammatory bowel disease, primary lymphangiectasia, lymphoma, and severe
acute gastroenteritis. Certain breed predispositions, such as the soft‐coated Wheaten
Terrier, are well known. Our clinical experience suggests that pugs with PLE respond
poorly to treatment, but this is not described in the literature. The aim of the current
study was to assess whether the pug breed demonstrates a worse response to treatment
for PLE than other breeds of dog.
This was a retrospective study comparing the response to treatment in all pugs diagnosed
with PLE between 2009 and 2018 in five referral centres in the United Kingdom. Approval
for the study was granted by the University of Liverpool Research Ethics Committee.
A group of non‐pug dogs, also diagnosed with PLE within the same period, was selected
for comparison. PLE was defined as any gastrointestinal disease resulting in serum
albumin below the laboratory reference interval that could not be explained by another
cause. Factors associated with survival were assessed using simple statistics (Mann‐Whitney
tests and chi‐square test as appropriate) and Cox's proportional hazards regression.
Initially, factors were tested individually using simple regression; a multiple regression
model was then created, subsequently refined by backwards stepwise elimination until
the best model was found.
A total of 35 pugs were diagnosed with a PLE between 2009 and 2018 and were compared
with 113 dogs from other breeds. On simple regression analysis, factors associated
with survival (at P < 0.1) were pug breed (P = 0.002), diet used for treatment (P
= 0.022), receiving immunosuppressive therapy (P = 0.089), and treatment with cobalamin
(P = 0.005). However, the only factors that remained in the final model were the pug
breed and the diet used for treatment. In this respect, dogs of the pug breed were
associated with a greater hazard of dying (compared with non‐pugs: hazards ratio [HR]
2.67 (CI 1.60‐4.47; P < 0.001), whilst being fed a hydrolysed diet was associated
with a lesser hazard risk of death than when fed other diets (compared with low‐fat
diets: HR 0.50, 95%‐CI: 0.26‐0.97; P = 0.042; compared with other diets including
highly‐digestible diets: HR 0.35, 95%‐CI: 0.17‐0.71; P = 0.004).
In conclusion, this study demonstrated an association between the pug breed and a
poorer response to treatment for PLE compared to other breeds. Further research should
be undertaken as to the underlying cause.
Disclosures
Disclosures to report.
AJG is an employee of the University of Liverpool, but his post is financially supported
by Royal Canin, which is also owned by Mars Petcare. AJG has also received financial
remuneration for providing educational material, speaking at conferences, and consultancy
work for Mars Petcare; all such remuneration has been for projects unrelated to the
work reported in this manuscript. All other authors declare no conflict of interest.
ESCG‐O‐5
Is measuring serum folate pointless? Retrospective analysis of prevalence and clinical
significance of hypo‐ or hyperfolataemia in dogs with chronic enteropathies
A. Petrelli, S. Salavati
Royal (Dick) School of Veterinary Studies and the Roslin Institute, Edinburgh, United
Kingdom
Assessment of serum folate (SF) is routinely performed in dogs with chronic enteropathies
(CE), most often in conjunction with serum cobalamin. Traditionally, their combination
has been used to differentiate intestinal malabsorption from dysbiosis. Despite the
fact that the diagnostic and prognostic value of serum cobalamin is well documented,
the prevalence of hypo‐ and hyperfolataemia and the clinical and prognostic value
of its assessment has not been scrutinised in dogs with CE. The aims of this study
were to determine the prevalence of SF abnormalities in dogs with CE, as well as its
relationship to other laboratory parameters and outcome. Files of dogs presented for
chronic gastrointestinal (GI) signs (> 3 weeks duration) between 2014 and 2017 were
retrospectively evaluated. Exclusion criteria were lack of SF assessment, and supplementation
of folate or cobalamin beforehand. 321 dogs (100 FN, 109 MN, 34 FE, 78 ME; median
age of 65 m, range 2‐171) were included. Hypofolataemia was present in 97/321 (30%),
hyperfolataemia in 86/321 (27%), with the remaining 138/321 dogs (43%) having normal
SF values. Initially, dogs were divided into groups according to the final diagnosis:
CE (n = 215), other GI disease (n = 76), non‐GI disease (n = 30). SF values were not
significantly different across those groups (Kruskal‐Wallis, P = 0.83). When dividing
CE dogs into different subgroups of food‐ (FRE), antibiotic‐ (ARE), steroid‐responsive
(SRE) or protein‐losing enteropathy (PLE), no difference in SF values was observed
(ANOVA, P = 0.92). When all dogs were grouped by their SF status (low, normal, high),
significant differences in serum cobalamin (P = 0.001), alkaline phosphatase (p =
0.01), cholesterol (p = 0.03) and total calcium (p = 0.01) were identified (ANOVA,
Dunn's post hoc test). Multivariate analysis confirmed the correlation between SF
and cobalamin (P = 0.009), as well as cholesterol (P = 0.028) and total calcium (p
= 0.038). However, none of these correlations were linear (Spearman, all P > 0.05).
Kaplan Maier analysis of follow‐up and survival times by SF status showed no significant
differences. In conclusion, SF was not associated with GI disease or subgroup of CE.
Improvement of clinical signs or survival was not associated with SF status. In this
study, no diagnostic or prognostic benefit of assessing SF in dogs with chronic GI
signs could be detected. Future prospective studies should assess if folate supplementation
in the 30% of CE dogs with hypofolataemia can accelerate clinical improvement or influence
outcome/ prognosis.
Disclosures
No disclosures to report.
ESCG‐O‐6
Dogs with acute haemorrhagic diarrhoea syndrome not receiving antibiotics have a good
prognosis despite initial high AHDS‐score and systemic inflammation
F.S. Moberg, C.R. Bjørnvad, C. Lorentzen, N.M. Zyskind, L.R. Jessen, N. Dupont
University of Copenhagen, Frederiksberg, Denmark
Acute haemorrhagic diarrhoea syndrome (AHDS) in dogs is often treated with antibiotics
due to the potential risk of bacterial translocation from the gastrointestinal tract
to the blood stream. However, recent studies indicate that antibiotics are not always
necessary. According to the Danish antibiotic use guidelines for companion animals
2012, antibiotics are not recommended for routine treatment of AHDS but only indicated
in hospitalized dogs with severely affected overall condition and signs of systemic
inflammation (SIRS)/sepsis.
The aim of this study was to evaluate severity of disease and outcome in hospitalized
dogs with acute haemorrhagic diarrhoea that did not receive antibiotics. The study
was performed as a retrospective, observational study based on information from medical
records for dogs with acute haemorrhagic diarrhoea of unknown aetiology, hospitalized
at the University Hospital for Companion Animals during the period 25/2‐2014 to 9/10‐2018.
Signalments, concurrent diseases, clinical disease at the time of hospitalization
and during each consecutive day, treatment prior to and during hospitalization, days
of hospitalization/euthanasia and laboratory results were registered for each patient.
Clinical disease was scored according to the AHDS‐scoring system from 0‐18 and the
number of SIRS criteria (tachycardia (HR > 120), tachypnea (RR > 40), hyper or hypothermia
(T > 39.0°C or < 37.5°C), leucocytosis (WBC > 18*109/L), leukopenia (WBC < 5*109/L,
band neutrophilia and/or hypoglycaemia [glucose <4 mmol/L]) were recorded.
One‐hundred and seventy‐two dogs were excluded from the analysis due to suspected
drug induced disease (vaccination(s) (N = 4), anaesthetics (N = 5), corticosteroids
or NSAIDs (N = 81)), alimentary foreign body (N = 5) or treatment with antibiotics
during hospitalization (N = 128).
Of the 128 dogs, where an obvious cause for the diarrhoea were not found and that
only received supportive treatment (intravenous fluid therapy N = 128; antiemetics
N = 98; gastroprotectants N = 107), 98% survived to discharge (125/128 dogs). Two
dogs were euthanized due to financial constraints and reluctance from the owner to
proceed with further treatment due to advanced age and one brachycephalic dog suffered
a respiratory crisis with respiratory arrest non‐responsive to resuscitation. The
surviving 125 dogs were hospitalized for an average of 1.7 days (range 1‐4 days) with
a mean AHDS‐score of 12 at hospitalization (range 4‐16). The mean AHDS‐score after
24 hours of hospitalization was 5.5 (range 0‐14). 29% (37/128) of the dogs met ≥2
SIRS criteria during hospitalization. None of the 128 dogs had a degenerative left‐shift.
These results suggest that antimicrobial therapy in dogs with acute haemorrhagic diarrhoea
may not always be necessary in dogs even when 2 or more SIRS‐criteria are met.
Disclosures
No disclosures to report.
ESCG‐O‐7
Faecal bile acid profiles in dogs with acute haemorrhagic diarrhoea syndrome over
time and compared to healthy dogs
A.L. Ziese1, B.C. Guard2, J.A. Lidbury2, J.M. Steiner2, A. Anderson1, N. Sindern1,
J.S. Suchodolski2, K. Hartmann1, S. Unterer1
1Clinic of Small Animal Medicine, Ludwig Maximilian University, Munich, Germany, 2Gastrointestinal
Laboratory, College of Veterinary Medicine, Texas A&M Univers, College Station, United
States of America
Recent studies have shown alterations in faecal bile acid (BA) profiles in dogs with
chronic enteropathy, potentially contributing to clinical signs. The study aim was
to assess faecal BA concentrations in dogs with acute haemorrhagic diarrhoea syndrome
(AHDS‐D) over time and to compare it to that of healthy control dogs (HC‐D).
Twenty‐five AHDS‐D and 53 HC‐D were enrolled. Faecal BA concentrations were measured
by gas chromatography‐mass spectrometry on days 0, 2, 7, and 14 in AHDS‐D, and on
day 0 in HC‐D. Statistical analysis was performed with Friedman test for comparison
of BA over time in AHDS‐D, and unpaired t‐test or Mann‐Whitney‐test for comparison
between AHDS‐D and HC‐D (P < 0.05).
On day 0, concentration of lithocholic acid was significantly lower in AHDS‐D than
in HC‐D (p < 0.001). On day 2, total faecal BA were significantly increased in AHDS‐D
(p < 0.001) compared to HC‐D. More precisely, primary BA were significantly increased
in AHDS‐D on day 2 (P = 0.034) with significantly higher concentration of cholic acid
(p = 0.004), while secondary BA were significantly decreased (p < 0.001) with significantly
lower concentrations of deoxycholic acid (p < 0.001) and ursodeoxycholic acid (UDCA)
(p < 0.001). Dogs in AHDS‐D showed a significant decrease in total primary BA concentrations
(P = 0.021) with significantly lower concentrations of cholic acid (P = 0.027) and
deoxycholic acid (p = 0.021) on day 14 compared to day 2.
In conclusion, AHDS‐D show alterations in faecal BA profiles compared to HC‐D. However,
faecal BA profiles normalize rapidly suggesting that BA dysmetabolism does not seem
to play a major role in the pathophysiology of AHDS.
Disclosures
No disclosures to report.
ESCG‐O‐8
Long‐term consequences of acute hemorrhagic diarrhea syndrome in dogs
E. Kaufmann1, K. Busch1, J.S. Suchodolski2, B.D. Ballhausen3, F. Neuerer3, K. Hartmann1,
S. Unterer1
1Clinic of Small Animal Medicine, Ludwig‐Maximilians‐Universitaet Munich, Munich,
Germany, 2College of Veterinary Medicine and Biomedical Sciences, Texas A&M University,
College Station, United States of America, 3Clinic of Small Animal Medicine, Haar,
Germany
Destruction of the intestinal barrier and microbiota dysbiosis especially around the
time of weaning represent important mechanisms for allergic sensitization. Consequently,
42% of young dogs surviving a canine parvovirus (CPV) infection develop chronic gastrointestinal
disorders later in their lives, but it is unknown if adult dogs with severe intestinal
lesions also have an increased risk for developing chronic gastrointestinal disorders.
The aim of this study was to evaluate, whether dogs with acute hemorrhagic diarrhea
syndrome (AHDS) have a higher prevalence of chronic enteropathies later in life.
Forty dogs diagnosed with AHDS, for which a follow‐up of at least 12 months was available,
were included in the study. A historical control group of 67 dogs without history
of gastroenteritis was included to enable risk assessment. Dog owners were asked to
complete a questionnaire. The percentage of dogs with signs of chronic enteropathies
in both groups were compared using Fisher's exact test.
There was no significant difference between AHDS and control dogs concerning development
of chronic enteropathies (AHDS 22.5%; controls 12.0%; P = 0.177) during their observation
time (AHDS: median 4 years, range 1‐12 years; controls: median 5 years, range 1‐12 years).
The results of this study suggest that dogs that experience an episode of AHDS do
not have an increased risk for developing chronic gastrointestinal disease later in
life, which is different to the risk of young dogs with CPV infection. Thus, timing
of the intestinal barrier dysfunction might represent one main risk factor.
Conflicts of interest: No conflicts of interest reported.
Disclosures
No disclosures to report.
ESVC‐O‐1
Acute effect of oral pimobendan on left atrial function and mitral valve regurgitation
severity in dogs with stage B2 myxomatous mitral valve disease ‐ A pilot study
O. Belachsen, J. Sargent, T. Wagner
Southern Counties Veterinary Specialists, Ringwood, United Kingdom
Myxomatous mitral valve disease (MMVD) is associated with failure of the mitral valve
(MV) apparatus. In a proportion of affected dogs, MV regurgitation is severe enough
to cause an increase in left atrial (LA) volume and pressure. LA function was reported
to decline with increased disease severity. Pimobendan, a phosphodiesterase III inhibitor
exerting positive inotropic and vasodilatory effects, was shown to decrease LA pressure,
although its effect on LA function is not well established. This study aimed to prospectively
evaluate the acute effect of pimobendan on LA function and mitral regurgitation fraction
in dogs with stage B2 MMVD.
Sixteen dogs in stage B2 MMVD were included in this prospective interventional study.
Echocardiograms were performed at presentation and 3 hours following a single‐dose
pimobendan. Two‐dimensional, M‐mode, and Doppler images were recorded from the right
parasternal and left apical standard views. In all dogs, left atrial volume was measured
using the biplane area‐length method at three time‐points: immediately before MV opening,
at onset of P‐wave, and at MV closure. Reservoir, conduit and active pump functions
were calculated, as previously described. In ten dogs, MV regurgitation volume was
calculated by subtracting the forward stroke volume (Aortic outflow velocity time
integral multiplied by the aortic cross‐sectional area) from the total left ventricular
(LV) stroke volume (End‐systolic LV volume subtracted from the end‐diastolic LV volume,
both measured using Simpson's method of discs). MV regurgitation fraction was calculated
as the percentage of regurgitation volume from the total stroke volume. Paired Student
t‐test and Wilcoxon Signed‐Rank Test were used to compare the results.
Compared with baseline, LA volume was significantly lower on post‐pimobendan measurements
immediately before MV opening (P < 0.01), at P‐wave onset (P < 0.01) and at MV closure
(p = 0.02). However, LA conduit, reservoir and active pump functions did not change
significantly. MV regurgitation fraction post‐pimobendan (27.7 +/− 5.3) was significantly
lower (p < 0.01) compared with baseline (43.7 +/− 4.7), forward stroke volume was
significantly increased (P = 0.015), while total stroke volume did not change significantly.
This study suggests that despite an acute reduction in LA volume, pimobendan may not
exert a measurable effect on LA function. The beneficial decrease in left atrial volume
appears to result from an acute reduction in MV regurgitation fraction. The mechanisms
by which pimobendan reduces regurgitation fraction are thought to be associated with
improved forward flow secondary to its inotropic and vasodilatory effects, in addition
to reduced end‐diastolic LV dimension, minimising secondary functional mitral regurgitation.
Disclosures
No disclosures to report.
ESVC‐O‐2
Retrospective evaluation of the safety and tolerability of pimobendan in cats with
obstructive versus nonobstructive hypertrophic cardiomyopathy
J.L. Ward1, E. Kussin2, M.A. Tropf1, S.P. Tou2, T.C. Defrancesco2, B.W. Keene2
1Iowa State University College of Veterinary Medicine, Ames, United States of America,
2North Carolina State University College of Veterinary Medicine, Raleigh, United States
of America
Pimobendan is frequently used off‐label for treatment of cats with congestive heart
failure (CHF) secondary hypertrophy cardiomyopathy (HCM). Concerns exist regarding
the safety of pimobendan in the subset of cats with HCM and dynamic outflow tract
obstruction (HOCM). The purpose of this study was to evaluate safety and tolerability
of pimobendan in cats with CHF secondary to HOCM compared with nonobstructive HCM.
Medical records from 94 cats with CHF (47 with HOCM, 47 with nonobstructive HCM) at
two tertiary referral hospitals were reviewed. Demographic, clinicopathologic, echocardiographic,
and treatment data were collected and compared between groups, including information
regarding possible adverse effects of pimobendan.
Average age of cats (9 +/− 4 years) did not differ between HOCM and HCM (P = 0.12).
Compared to cats with HCM, cats with HOCM were more likely to manifest CHF as pulmonary
edema (44/47 versus 32/47; P = 0.003) and less likely to have pleural effusion (13/47
versus 25/47; P = 0.02). Other than a higher incidence of heart murmurs in cats with
HOCM (P < 0.001), clinical variables did not differ between groups. Pimobendan was
typically initiated on the date of CHF diagnosis (median time from diagnosis of CHF
to initiation of pimobendan was 0 days). Initial dose of pimobendan was 0.25 +/− 0.07 mg/kg
every 12 hours; dose (or frequency) was escalated at some point during CHF management
in 31/94 (33%) of cases, with no difference between HOCM and HCM cats.
Clinical signs that could potentially represent adverse effects of pimobendan (vomiting,
diarrhea, anorexia, lethargy, new‐onset arrhythmias) were noted in 13/47 (28%) HCM
cats and 9/47 (19%) HOCM cats (P = 0.34). Based on patterns of timing and resolution,
these signs were generally ascribed to recurrence of CHF rather than pimobendan administration.
Pimobendan was discontinued due to adverse effects in only 1 cat with nonobstructive
HCM that experienced lethargy and nausea 2‐3 hours following pimobendan administration
(resolved when pimobendan discontinued). Pimobendan was discontinued in 7 additional
cats, either because owners were unable to administer the medication (n = 2) or because
CHF had resolved (n = 5 cases where CHF was precipitated by an acute external event,
such as fluid overload or injectable glucocorticoid administration). No cats experienced
acute adverse hemodynamic effects (hypotension, cardiovascular collapse) following
pimobendan administration.
Results of this study suggest that pimobendan is well‐tolerated in cats with cardiomyopathy
and CHF, regardless of presence of dynamic outflow tract obstruction.
Disclosures
Disclosures to report.
Drs. DeFranceso, Tou, and Keene have received consulting fees and/or honoraria from
Boehringer Ingelheim Vetmedica, Inc. and CEVA Animal Health.
ESVC‐O‐3
Aorto‐septal angle, isolated basal septal hypertrophy and systolic murmur in 122 cats
S. Crosara1, G. Allodi1, S. Guazzetti2, M. Borgarelli3, A. Corsini1, C. Quintavalla1
1University of Parma, Parma, Italy, 2Local Health Unit, Reggio Emilia, Italy, 3Department
of Small Animal Clinical Sciences, Virginia Maryland College, Blacksburg, United States
of America
Systolic heart murmurs (SM) are commonly diagnosed in healthy cats. The aim of this
study was to determine whether the aorto‐septal angle (AoSA) is associated with SM
in cats. More, we hypothesised that SM are related to the presence of septal bulge,
systolic anterior motion of the mitral valve (SAM) and increased aortic flow velocity
(AoV). Between November 2014 and February 2018, 316 client owned cats referred for
a cardiology evaluation were prospectively examined. Regardless the presence of a
systolic murmur, cats with a normal echocardiographic exam, normal blood pressure
(systolic pressure < 160 mmHg) and euthyroid were included in the study. Cats with
normal diastolic thickness of the left ventricle, but isolated basal septal hypertrophy
(IBSH) ≥6 mm or SAM, were also included. The AoSA was measured from the right parasternal
five chambers view, based on the published guidelines in the dog. A total of 316 cats
were examined, 122 fulfilled the inclusion criteria. A left parasternal SM was found
in 39 cats (32%). In 10 cats the murmur was audible only after stressed auscultation.
SM were associated with a narrower AoSA (P < 0.001), higher prevalence of IBSH (P
< 0.01) and higher AoV (P < 0.001), compare to cats without a murmur. The IBSH increases
with aging, with an increase of 0,11 mm per year. The AoSA decreases with aging (P < 0.001),
with a reduction of 0.55° per year. The AoSA was narrower in cats with IBSH (P < 0.001)
and IBSH was always present in cats with AoSA<120°. The AoSA did not differ between
cats with or without SAM (P = 0.853). There was a non‐linear correlation between AoSA
and AoV. In conclusion AoSA angle and the remodeling of the interventricular septum
may be correlated and can be a cause of systolic murmur in apparently healthy cats.
These findings resemble the sigmoid septum found in human, which can be considered
a morphologic variant of the ventricular septum, age related and associated with a
systolic murmur.
Disclosures
No disclosures to report.
ESVC‐O‐4
Accuracy of noninvasively determined pulmonary artery pressure in dogs with myxomatous
mitral valve disease (MMVD)
G. Menciotti1, M. Borgarelli1, M. Aherne2, J. Abbott1
1Virginia‐Maryland College of Veterinary Medicine, Blacksburg, United States of America,
2University of Florida College of Veterinary Medicine, Gainesville, United States
of America
Development of pulmonary hypertension is an independent predictor of poor outcome
in dogs affected by myxomatous valvular degeneration (MMVD). Pulmonary arterial pressure
is routinely estimated by applying the simplified Bernoulli equation to the velocity
of tricuspid regurgitation (PASP_D). The accuracy of this estimation is unknown in
dogs with MMVD, but experimental studies suggest that the method is imperfect. We
prospectively enrolled dogs affected by ACVIM stages B2 and C MMVD for which treatment
had been unchanged for at least one month. A flow‐directed thermodilution monitoring
catheter was percutaneously placed in the right jugular vein and advanced to the main
pulmonary artery. Pulmonary arterial systolic pressure was recorded (PASP_C). A second
operator simultaneously acquired tricuspid regurgitant velocity spectra to calculate
PASP_D. Each operator was blinded to the result of the other technique. Twenty dogs
were enrolled. Technical difficulties prevented catheterization in 2 dogs. Eighteen
measurement pairs were therefore used for comparison of PASP_C and PASP_D through
Bland‐Altman analysis and linear regression. A statistically significant bias between
PASP_C and PASP_D (mean difference = 0.5 mmHg; Confidence interval: −6.5 mmHg, +7.5 mmHg)
was not detected. The limits of agreement between the techniques were wide (−27.3 mmHg,
+28.2 mmHg). Regression analysis failed to identify a significant linear association
between the two techniques (r = 0.11, p = 0.17). In conclusion, PASP_D estimation
poorly agrees with PASP_C measurement in dogs affected by MMVD in ACVIM stages B2
and C. In these dogs, PASP_D could under‐ or over‐estimate PASP_C by more than 20 mmHg,
and therefore caution should be used when interpreting PASP_D.
Disclosures
Disclosures to report.
Michele Borgarelli receives financial support from Ceva Sante Animale for other work
not related to this abstract.
ESVC‐O‐5
Left atrial tear in dogs with myxomatous mitral valve disease ‐ clinical presentation,
echocardiographic features and long‐term survival
A.A. Ksiazek1, M.B. Toaldo2, F. Testa2, G. Romito2, M. Cipone2, A. Glaus1
1Vetsuisse Faculty, University of Zurich, Zurich, Switzerland, 2Alma Mater Studiorum
‐ University of Bologna, Bologna, Italy
Left atrial tear (LAT) is an acute, life‐threatening, rare complication in canine
myxomatous mitral valve disease (MMVD). This case‐control matched multicenter retrospective
study focussed on clinical manifestation and long‐term survival in LAT dogs compared
to control dogs with MMVD but without LAT.
Data were collected from the veterinary cardiology departments' databases, selecting
patients with advanced MMVD associated LAT. Signalment, clinical presentation, echocardiography,
selected laboratory findings, the cause of death and survival data were evaluated.
Parameters were assessed upon LAT diagnosis (time 0, T0) and at the resolution of
pericardial effusion (time 1, T1). Control dogs with similarly advanced MMVD were
selected based on quantitative echocardiographic parameters matching those of LAT
dogs at T1.
Thirty client‐owned dogs were included: 15 dogs with MMVD associated LAT and 15 control
dogs without LAT. In both groups, 9 dogs were in ACVIM congestive heart failure stage
C and 6 in B2 MMVD. Commonly observed clinical signs included dyspnoea, syncope and
weakness. No significant differences were found in age (both groups 10 ± 2 years,
P = 0.89), body weight (both groups 7 ± 5 kg, P > 0.99), gender distribution (LAT
group: 7 females, control group: 10 females, P = 0.46), serum creatinine concentration
(LAT group: 131 umol/L ± 72, control group: 108 umol/L ± 39, P = 0.42) or echocardiographic
variables between the groups. Mean left atrial to aortic diameter ratio was 2.24 ± 0.4
at T0, 2.53 ± 0.4 at T1 for dogs with LAT and 2.26 ± 0.4 for the controls. Left ventricular
internal diameter normalized to body weight at end diastole was 1.15 ± 0.3 at T0,
1.29 ± 0.2 at T1 for dogs with LAT and 1.25 ± 0.3 for the controls. Pericardiocentesis
was performed in 3/15 dogs. At study termination, all dogs in LAT and 10 in the control
group had died from cardiac causes. Five dogs with LAT had died in the first week
post admission as compared to 1 control dog. The mean survival time for LAT dogs was
53 days. When excluding the animals that died in the first week, survival times were
427 for dogs with LAT and 371 days for the control dogs (P = 0.617).
In conclusion, dogs with MMVD associated LAT bear a high mortality risk, especially
in the first week post the event. However, once survived this critical time, LAT does
not seem to significantly impact the long‐term survival.
Disclosures
No disclosures to report.
ESVC‐O‐6
Echocardiographic evaluation of left ventricular dimension and systolic function before
and 24 hours after percutaneous closure of patent ductus arteriosus in 120 dogs
M. Claretti1, D. Piantedosi2, A. Piscitelli2, B. Serrano Lopez1, E. Boz1, L. Mazzoni1,
A. de Rosa2, I. Navalon Calvo3, P. Ciaramella2, C. Bussadori1
1Clinica Veterinaria Gran Sasso, Milano, Italy, 2Department of Veterinary Medicine
and Animal Production, University Federico II, Napoli, Italy, 3Ars Veterinaria, Barcelona,
Spain
One hundred and twenty dogs were enrolled to value the effect of loading condition
changes on left ventricular volumes before and 24‐hours after the patent ductus arteriosus
(PDA) occlusion by ACDO using standard echocardiography. The animals were divided
in pure breed (n. 94) and mixed breed (n. 26); subsequently, the pure breed dogs were
divided on the basis of the size of the breed of belonging in 3 groups (small size
n. 36; medium size n. 8; large size n. 50). Moreover, the animals were divided in
three classes based on their age: until 6 months; 6‐12 months; over 12 months. A significant
reduction of all the examined parameters (LVIDd, LVIDs, EDV, ESV, EDVI, ESVI, FS)
was observed after ductal closure. The evaluation of the relative percentage difference
(RDP) of the echocardiographic parameters showed at 24‐hours after the closure, a
significant reduction higher in small size breed than in large size breed dogs. No
significant difference related to breed size was observed only for RPD_FS variable.
A significant interaction effect, between breed size and age classes, was observed
only for RPD_EDVI (F = 3.4; P = 0.039). Until six months of age there was no significant
difference in RPD_EDVI reduction, but over 6 months a significant reduction between
small size and large size breed dogs at 24‐hours from the occlusion was observed.
In conclusion, our data seem to indicate that small breed dogs show a greater tolerance
to congenital volume overload, and for this reason it could be possible to delay the
PDA closure of a few months allowing weight gain that makes easier the interventional
procedure. On the other hand, the large breed dogs should be submitted to ductal closure
as soon as possible, in order to avoid an excessive LV wall stress.
Disclosures
No disclosures to report.
ESVC‐O‐7
Delayed Electrolyte Depletion and Azotemia in a Furosemide Rate Continuous Infusion
Model
D. Adin1, C. Atkins2, H. Ru2, G. Wallace2
1University of Florida, Gainesville, United States of America, 2North Carolina State
University, Raleigh, United States of America
Intravenous furosemide is the mainstay of treatment for acute congestive heart failure
in dogs, however, the potential for delayed effects on hydration, electrolytes and
renal function have not been studied. This study sought to evaluate these parameters
in normal dogs receiving furosemide continuous rate infusion (CRI) with or without
renin‐angiotensin‐aldosterone system inhibitors.
Ten healthy dogs were studied in a 3‐way randomized, cross‐over design. Dogs orally
received either placebo, benazepril, or benazepril+spironolactone for 3 days prior
to 5‐hour furosemide CRI 0.66 mg/kg/hr. Body weight (BW), renal values, serum electrolytes,
packed cell volume and total protein were measured before oral medications, hour 0
and 5 of the furosemide CRI, and hour 24. Variables were compared between time‐points
and treatments.
Loss of BW during the CRI exceeded recovery at 24 hours and hemoconcentration occurred,
with incomplete return to baseline at 24 hours. Blood urea nitrogen and creatinine
were unchanged during the CRI but increased 24 ± 12% at 24 hours. Serum sodium did
not change during the CRI but decreased at 24 hours. Serum chloride decreased at hour
5 and did not return to baseline at 24 hours. Hypochloremic metabolic alkalosis and
increased anion gap present at hour 5 did not normalize at 24 hours. No differences
between treatments were found.
Some furosemide CRI‐related biochemical changes were delayed for 24 hours while others
evident at hour 5 only partially improved at hour 24 in these normal dogs. These findings
have implications for clinical patients with renal dysfunction, or receiving higher
doses or longer furosemide infusions.
Disclosures
Disclosures to report.
This study was funded by CEVA Sante Animale. Dr. Adin has received funding from the
American Kennel Club Canine Health Foundation for other (unrelated) studies.
ESVC‐O‐8
Changes in renal endothelin activity with cardiac, renal and other chronic diseases
in dogs
G.J. Culshaw1, N.X. Bommer1, D. Binnie1, P.M. Jamieson2, S.L. Dickson1, R.R. Blake1,
J. Bouvard1, G. Santarelli1, Y. Martinez‐Pereira1
1University of Edinburgh, Roslin, United Kingdom, 2ChesterGates Veterinary Specialists,
Chester, United Kingdom
Pathways that disrupt the cardiovascular‐renal axis in dogs are incompletely defined.
The renal endothelin (ET‐1) system may play a key role because it regulates blood
pressure and sodium homeostasis in the kidney, but also mediates vascular dysfunction
and pro‐fibrotic/inflammatory changes that increase cardiovascular risk in people.
Urinary ET‐1 (UET‐1) is a marker of renal vascular and tubular ET‐1 activity, and
so could provide insight into changes in renal ET‐1 signalling that contribute to
cardiovascular‐renal interactions in dogs. We hypothesised that renal ET‐1 activity
increases in advanced canine chronic cardiac and renal diseases.
In this pilot study, we compared UET‐1 and cystatin C (a marker of renal injury/dysfunction)
concentrations in surplus urine from four groups of dogs presented to the R(D)SVS:
healthy (n = 18), chronic kidney disease (CKD; IRIS stages 2‐4; serum creatinine 257 μmol/l,
IQR395; n = 11) cardiac disease (ACVIM classification B1‐C; n = 39) and non‐cardiorenal
chronic disease (n = 14). Urine was free‐catch and owner‐collected on the morning
of appointment. Samples were excluded if they contained active sediment, and were
stored at −80°C before batch analysis.
Both UET‐1 and cystatin C were measured by commercial ELISAs and indexed to urinary
creatinine concentration (enzymatic method). Comparisons by one‐way ANOVA yielded
non‐transformable residuals so Kruskal‐Wallis with Dunn's post hoc tests were used
(significance P < 0.05).
There was a marked increase in UET‐1 excretion in dogs with stage C heart disease
(0.69,IQR 1.61 pg/mg; n = 11) compared to healthy dogs (0.02 pg/mg, IQR 0.11; P =
0.02). UET‐1 excretion was also increased in stage B2 heart disease (0.25 pg/mg, IQR
1.70; P = 0.03; n = 19) although to a lesser degree. This was predominantly due to
increases in dogs with MMVD (0.38 pg/mg, IQR 1.75; P = 0.046; n = 7) rather than those
with non‐MMVD cardiac diseases (0.23 pg/mg, IQR 0.91). al increases in UET‐1 in CKD
and chronic disease groups were not statistically significant.
By contrast, CKD markedly increased urinary cystatin C excretion from below limits
of detection to (0.53 ng/mg, IQR 2.44; P < 0.0001), while only modest increases (P
= 0.03) were observed in dogs with chronic disease (0.02 ng/mg, IQR 0.07), and none
at all in heart disease stages B1‐C.
Renal ET‐1 activity increases with congestive heart failure, but surprisingly, also
increases in MMVD before congestion develops. Neither increase is associated with
renal injury or is a consequence of a chronic disease state. Renal ET‐1 may mediate
pathophysiological cardiovascular‐renal interactions in MMVD that are different to
those in isolated CKD and the development of congestive heart failure.
Disclosures
No disclosures to report.
ESVC‐O‐9
High grade AV Block and third degree AV Block in cats: a retrospective study of epicardial
pacemaker implantation (2006‐2018) focusing on signalment, presentation and survival
I. Spalla, G.A. Smith, D.J. Connolly
Royal Veterinary College, Potters Bar, United Kingdom
Third degree atrioventricular block (AVB) is characterised by complete atrioventricular
(AV) dissociation, causing independent atrial and ventricular rhythms. Persistent
third degree AVB (PAVB) is most commonly described. Another form of AVB, where AV
dissociation is intermittent (IAVB) is also recognised. In cats, AVB can be associated
with underlying cardiac or systemic diseases. When present, clinical signs associated
with these forms of AVB can include weakness, lethargy and syncope. If clinical signs
and in particular syncope are present, epicardial pacemaker implantation represents
an effective treatment. The aim of the study was to retrospectively assess presentation,
echocardiographic data, comorbidities and outcome from cats diagnosed with AVB (PAVB
or IAVB) in a single referral hospital, including those that underwent pacemaker implantation.
Non parametric testing and Kaplan Meier curves with log rank testing were performed.
Sixty‐four cats were included over a 12‐year period. Forty‐three cats had PAVB, 21
had IAVB. Median age of presentation was 13 years, with no difference between AVB
type (P = 0.752). Thirty‐five cats were male and 29 female. Forty‐four cats were referred
for cardiac complaints (syncope, arrhythmia or dyspnoea), 8 cats had non‐specific
signs (lethargy) and in 12 cats AVB was an incidental finding. Cats with IAVB were
more likely to present with syncopal events (p = 0.005). The median duration of clinical
signs prior to presentation was 21 days (1‐1138). Twenty‐nine cats had echocardiographic
changes, left ventricular hypertrophy (17), chamber dilation (12); 13 cats presented
with congestive heart failure (CHF). Forty‐five cats had one or more comorbidities,
the most common were hyperthyroidism (16), diabetes mellitus (9), azotaemia (8). Fifteen
cats underwent epicardial pacemaker implantation, mainly cats with IAVB (9/15). Five
cats had minor complications (lead dislodgement, pacemaker undersensing, exit block)
and 12 cats showed no further clinical signs since implantation. Forty‐seven cats
died; all‐cause mortality median survival time was 799 days (0‐2965) and no difference
in survival was observed in cats that presented with CHF (P = 0.052), IAVB (P = 0.082),
had comorbidities (P = 0.683) or pacemaker placement (p = 0.089). Death due to cardiac
cause occurred in fewer cats (17/47), with shorter survival than all‐cause mortality
(65 days, P = 0.003). CHF on presentation was associated with cardiac death (P < 0.001).
The results of this study showed a variable outcome in cats with AVB. Cardiac death
occurred in the minority of cat and was associated with CHF at presentation. Most
cats have comorbidities, which did not affect all‐cause mortality. Pacemaker implant
controlled clinical signs in the majority of cats.
Disclosures
No disclosures to report.
ESVC‐O‐10
Diet‐induced reduction of cardiac wall thickness, Troponin‐I and IGF‐1 in cats with
asymptomatic hypertrophic cardiomyopathy
I. van Hoek1, H. Hodgkiss‐Geere2, E. Bode2, P. Motskula3, V. Palermo4, Y. Martinez‐Pereira5,
J. Laxalde1, J. Dukes Mcewan2
1Royal Canin SAS, Aimargues, France, 2University of Liverpool, United Kingdom, 3Estonian
University of Life Sciences, Estonia, 4Anderson Moores Veterinary Specialists, United
Kingdom, 5University of Edinburgh, United Kingdom
Complete and balanced diets, one test and one control, were evaluated in this prospective,
randomized, double‐blind, multicenter study for effect on clinical, biochemical and
echocardiographic parameters in forty‐four client‐owned cats with asymptomatic hypertrophic
cardiomyopathy (aHCM).
Cats with diastolic interventricular septum (IVSd) and/or left ventricular wall (LVWd)
thickness ≥ 6 mm were included after informed owner‐consent. Examination of non‐sedated,
fasted cats before and after 6 and 12 months of test or control diet included auscultation,
bodyweight (BW), body condition score (BCS) and echocardiography. Wall thicknesses
measured by M‐ and 2D‐mode at basal, mid (LVWd, IVSd) and apical (IVSd) level were
recorded as maximum (max‐), sum‐ and number of areas ≥6 mm (n‐)). Blood analysis included
NT‐proBNP, ultra‐sensitive troponin‐I (c‐TnI), serum amyloid A (SAA), insulin, glucose
and IGF‐1. Linear and generalized mixed models analyzed diet, time and diet‐time interactions
with significance level of 5%.
There was a significant diet‐time interaction for heart‐rate (p = 0.032) and IGF‐1
(P = 0.020). Test but not control diet showed a significant decrease over time for
max‐IVSd (P = 0.011), n‐IVSd (P < 0.001), sum‐IVSd (P < 0.001), M‐IVSd (P = 0.023),
max‐LVWd (P = 0.002), n‐LVWd (P = 0.035), sum‐LVWd (P = 0.006), M‐LVWd (P < 0.001)
and n‐(IVSd + LVWd) (P = 0.001), IGF‐1 (P = 0.005) and cTnI (p = 0.001). No significant
changes in BW, BCS or effect of cardiac medication were observed. Cats with left atrium
remodeling separately had significantly decreased n‐IVSd (P = 0.014), sum‐IVSd (P
= 0.003) and M‐LVFWd (P < 0.001).
A reverse effect on primary echocardiographic parameters of aHCM, with decreased c‐TnI
and IGF‐1 was observed with the test diet. Further research is needed to evaluate
the effects on clinical outcome.
Disclosures
Disclosures to report.
Ingrid van Hoek and Jeremy Laxalde are employees of Royal Canin SAS.
The study described was financially supported by Royal Canin SAS.
ESVC‐O‐11
Biomarker discovery in cats with cardiomyopathy
V. Patata1, L. Carangiu2, S. Pisanu2, G.M.G. Puggioni2, V. Tedde2, S. Tore2, C. Parmentola1,
T. Vezzosi3, F. Marchesotti1, O. Domenech1, J.N. Matos4, V.L. Fuentes4, D. Connolly4,
H. Poser5, C. Guglielmini5, S. Uzzau2, D. Pagnozzi2, E. Zini5
1Istituto Veterinario di Novara, Novara, Italy, 2Porto Conte Ricerche, Alghero, Italy,
3University of Pisa, Department of Veterinary Sciences, Pisa, Italy, 4The Royal Veterinary
College, Queen Mother Hospital for Animals, London, United Kingdom, 5University of
Padua, Department of Veterinary Medicine, Padua, Italy
Cardiomyopathies are frequent in cats and their diagnosis relies on a combination
of physical examination, thoracic radiography, electrocardiography and echocardiography.
Additionally, in the last decade, assays to measure circulating biomarkers of heart
disease, such as cardiac troponin I and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP),
have become available for cats. These assays have been proven useful in the diagnosis
of feline cardiomyopathies, although in certain cases they may be less reliable. Therefore,
the aim of this study was to detect new circulating proteins that may improve the
identification of cats affected by cardiomyopathy using biomarker discovery. Client‐owned
cats were prospectively enrolled. Evaluation comprised complete blood count and biochemical
profile with T4 determination, blood pressure measurement, thoracic radiography and
echocardiography. Based on diagnosis, cats were allocated to 5 groups, namely symptomatic
cardiomyopathy with signs of congestive heart failure (group CM‐Sx), asymptomatic
cardiomyopathy (group CM‐aSx), respiratory diseases (group Resp‐Ds), systemic diseases
without systemic hypertension (group Sys‐Ds), and healthy controls (group Healthy).
Plasma samples were processed untreated or following enrichment in low‐abundant proteins,
submitted to mass spectrometry and their protein profiles compared with statistical
software. Putative biomarkers were evaluated by western immunoblotting experiments.
Eighty‐nine cats were included; 9 in CM‐Sx, 9 in CM‐aSx, 14 in Resp‐Ds, 30 in Sys‐Ds
and 27 in Healthy. In CM‐Sx, 7/9 cats had hypertrophic cardiomyopathy and 2/9 restrictive
cardiomyopathy; lung edema was identified in 7, pleural effusion and aortic thromboembolism
in 2. In CM‐aSx, all cats had hypertrophic cardiomyopathy. By mass spectrometry, several
differential proteins were identified among groups. Putative biomarkers were tested
by western immunoblotting and 2 of them (Protein 1 and Protein 2), were differentially
detected in CM‐Sx, compared to the others. In particular, Protein 1 was identified
in 6/9 (66.7%) cats in CM‐Sx, while plasma samples from cats in CM‐aSx, Resp‐Ds, Sys‐Ds
and Healthy had a visible band in 2/9 (22.2%), 2/14 (14.3%), 1/30 (3.3%) and 1/27
(3.7%), respectively (P < 0.001). Protein 2 was detected in the plasma of 4/9 (44.4%)
cats in CM‐Sx, 1/9 (11.1%) in CM‐aSx and 1/30 (3.3%) in Sys‐Ds, while no bands were
detected in Resp‐Ds and Healthy (P = 0.005). These data suggest 2 novel putative biomarkers
for differentiating cats with symptomatic cardiomyopathy. Further studies with a higher
number of cardiomyopathic cats and different symptomatic status are mandatory to optimize
the tests and evaluate sensitivity and specificity of the candidate biomarkers.
Disclosures
Disclosures to report.
Grant from Sardegna Ricerche. Incentive for Polaris research.
ESVC‐O‐12
Blood pressure measurement by High Definition Oscillometry in different clinical settings
in healthy cats
S. Hanås1, B.S. Holst2, I. Ljungvall2, U. Olsson3, J. Häggström2, A. Tidholm4, K.
Höglund5
1Evidensia Specialist Animal Hospital Strömsholm, Strömsholm, Sweden, 2Department
of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden,
3Unit of Applied Statistics and Mathematics, Swedish University of Agricultural S,
Uppsala, Sweden, 4Anicura Albano Animal Hospital, Stockholm, Sweden, 5Department of
Anatomy, Physiology and Biochemistry, Swedish University of Agricu, Uppsala, Sweden
Clinical environment can be stressful for cats, thereby affecting blood pressure (BP)
recordings.
The aim was to investigate how different clinical settings, and the order (sequence)
in which settings are performed, affect BP recordings in healthy cats.
Ninety‐six healthy cats were prospectively included. The health examination included
physical examination, echocardiography, hematology, and biochemistry. Blood pressure
was measured with a high‐definition oscillometric (HDO) device, with cuff on tail
in three clinical settings; (1) cat taken out of its carrier and placed on examination
table with veterinarian present, (2) cat in its own carrier with veterinarian present,
or (3) cat in its own carrier without veterinarian present. The owner was present
in all settings. The sequence of clinical settings was randomized and 4‐6 recordings
were made in each setting.
The combined effect of setting and sequence was associated with lower systolic (SBP),
mean arterial (MAP) and diastolic BP (DBP) when BP was measured by the owner with
the cat in its own carrier last in sequence (all; P < 0.0039). Heart rate was higher
when BP was measured with cat on examination table first in the sequence (P < 0.0006).
When measurements were made with the cat on the examination table, higher coefficients
of variation (CVs) were found for SBP, MAP, DBP and HR (all; P < 0.0001).
In conclusion, measuring BP with cat in its own carrier gave lower BP, HR and CVs,
compared to measurement on examination table. As sequence affected BP with lower values
when recordings were made last by owner, time might influence results.
Disclosures
No disclosures to report.
ESVC‐O‐13
Does pleural effusion protect against arterial thromboembolism in feline congestive
heart failure?
F. Busato1, A. Zoia1, M. Drigo2
1San Marco Veterinary Clinic, Veggiano, Italy, 2University of Padova, Padova, Italy
Aortic thromboembolism (ATE) is a frequently‐seen cardiac complication in cats and
left atrial (LA) enlargement is considered a risk factor. In dogs, activation of coagulation
followed by fibrinolysis occurs in all types of pleural effusions and dogs with pleural
effusion of any type or with ascites secondary to congestive heart failure (CHF) show
an enhanced systemic fibrinolysis, which may decreases clot formation. Therefore,
the aim of this study was to determine whether cardiopathic cats with pleural effusion
were less likely to develop aortic thromboembolism (ATE) than cats without pleural
effusion.
Cross‐sectional study retrospectively evaluating client‐owned cats with heart disease
presented between 2004 and 2018. All cats included underwent a full echocardiography
evaluation and thoracic radiographs. Cats were divided into 3 groups: without CHF
(group 1), with cardiogenic pulmonary edema (group 2) and with pleural effusion (group
3). Frequency of ATE among groups was compared by chi‐square test. The LA diameter
and the LA/aorta ratio (LA:Ao) were also compared between cats with and without ATE
(T‐test) and also among the 3 groups (Anova followed by Tamhane post‐hoc analysis).
In the study were included 629 cats (group 1 = 420, group 2 = 71, and group 3 = 138).
Sixty‐one cats at time of presentation had ATE, overall prevalence of 9.7%. LA in
cats with ATE (20.16 ± 4.48 mm) was significantly (t = 8.90, P < 0.001) bigger than
in cats without ATE (15.23 ± 4.7). LA:Ao in cats with ATE (2.25 ± 0.49) was significantly
(t = 8.16, P < 0.001) higher than in cats without ATE (1.68 ± 0.52). Frequency of
ATE was statistically (χ2 = 47.29, P < 0.001) different among the 3 groups (group
1, 30/420 [7.1%]; group 2, 23/71 [32.4%]; group 3, 8/138 [5.8%]). LA was significantly
(F = 79.3, P < 0.001) increased in cats of group 2 (19.80 ± 5.31 mm) and group 3 (18.17 ± 3.97 mm)
compared to group 1 (14.20 ± 3.38 mm), while no significant difference was present
between groups 2 and 3. LA:Ao was significantly (F = 66.6, P < 0.001) increased in
cats of group 2 (2.24 ± 0.55) and group 3 (2.10 ± 0.51) compared to group 1 (1.53 ± 0.43),
while no significant difference was present between groups 2 and 3.
As expected, cats with CHF (with edema or pleural effusion) had a bigger LA compared
to the cats without CHF. Moreover, also cats with ATE presented a larger LA atrium
compared to the cats without ATE. Nevertheless, when pleural effusion is present frequency
of ATE remains low despite an enlarged LA.
Disclosures
No disclosures to report.
ESVC‐O‐14
Iatrogenic heart murmur: a new cause of systolic murmurs in cats
L. Ferasin1, E. Kilkenny2, H. Ferasin1
1Specialist Veterinary Cardiology Consultancy Ltd, Alton, United Kingdom, 2Lumbry
Park Veterinary Specialists, Alton, United Kingdom
Heart murmurs are commonly detected in apparently healthy cats and Doppler echocardiographic
evaluation is ultimately required to identify the cause of blood flow turbulence responsible
for this clinical finding. However, even Doppler echocardiography can occasionally
fail to demonstrate the origin of murmurs in cats. Nevertheless, over the years, we
have observed that applying gentle pressure to the right side of the chest wall of
a cat with the ultrasound probe (“provocative testing”) can induce temporary narrowing
of the right ventricular infundibulum and dynamic right ventricular outflow obstruction,
subsequently causing blood flow turbulence. We have also observed that a similar phenomenon
can be reproduced by gently pressing the stethoscope head against the right wall of
the chest, inducing an audible murmur during auscultation. The aim of this study was
to evaluate the effect of increased pressure of the ultrasound probe against the chest
wall of cats undergoing echocardiographic examination in increasing right ventricular
outflow velocity and evoking blood flow turbulence in this anatomical area.
Clinical records of apparently healthy cats with dynamic right‐sided systolic heart
murmurs that underwent echocardiography between 2010 and 2018 were retrospectively
reviewed. Only cats that had blood flow turbulence in the infundibular tract induced
by provocative testing during image acquisition of the right parasternal short axis
view at the level of the heart base and did not have functional or structural abnormalities
during echocardiographic examination were included in this study (n = 61). Their median
age was 8.0 (6.0 to 9.3) years and mean body weight was 4.5 ± 1.22 Kg. The median
murmur grade was 2/6.
All cats included in the study presented a laminar blood flow on colour Doppler assessment
of the right infundibular tract; however, turbulence could subsequently be visualised
following provocative testing. Similarly, the provocative test caused increased peak
systolic velocity and a late‐peaking “scimitar‐like” profile, characteristic of dynamic
mid‐systolic obstruction.
Outflow peak systolic velocities were normally distributed both pre‐testing (1.05 ± 0.26 m/s)
and post‐testing (1.94 ± 0.51 m/s) and their difference (0.89 ± 0.40 m/s) was statistically
significant on paired samples t test (P < 0.0001).
The result of this study confirms that some murmurs in cats can be of iatrogenic origin,
being caused by pressure of the ultrasound probe against the chest wall. We postulate
that a similar phenomenon can be evoked by pressing the stethoscope head against the
chest wall.
Disclosures
No disclosures to report.
ESVC‐O‐15
Point Of Care Ultrasound of the Caudal Vena Cava in Canine Degenerative Mitral Valve
Disease
L. Giraud, K. Gommeren, A.C. Merveille
University of Liège, Liège, Belgium
In human medicine, caudal vena cava (CVC) diameter (CVCD) and collapsibility index
(CVCCI) evaluated via Point Of Care UltraSound (POCUS) are accepted markers of intravascular
volume status. In human chronic heart failure, CVC POCUS helps identifying patients
requiring hospitalization or at risk of decompensation. Degenerative mitral valve
disease (DMVD) is the most common acquired canine cardiac disease. It is typically
associated with RAAS‐activation and a subsequent hypervolemic state in advanced stages.
Intravascular volume status impacts treatment and is likely correlated with prognosis.
In dogs, CVC parameters obtained via POCUS are described markers of intravascular
volume status. The goal of this study was to investigate CVC parameters evaluated
via POCUS at different ACVIM stages of degenerative mitral valve disease in dogs.
Echocardiographic and CVC POCUS findings of dogs with DMVD presented between January
2017 and January 2019 were retrospectively reviewed. ACVIM stage and recent administration
of diuretics were recorded. Dogs with significant right sided heart disease or pericardial
effusion were excluded. POCUS CVC Cineloops were obtained during the echocardiographic
evaluation, using a longitudinal subxyphoid view with dogs placed in right lateral
recumbency. CVC maximal and minimal diameter were measured and indexed on aortic diameter
(CVCD‐max/Ao and CVCD‐min/Ao), and CVCCI was calculated. One single observer, unaware
of disease severity or ACVIM stage, performed all measurements, and subjectively assessed
the CVC as fat, flat or normal. CVC parameters were compared between ACVIM stages
using Fisher exact test and Kruskal‐Wallis. ANCOVA were used to assess the effect
of ACVIM stage and diuretic treatment on CVC parameters. Data are expressed as median
and range., 81 dogs with DMVD were included (ACVIM stage B1 (23), B2 (24), C (27),
D (7)), 28 had recently received diuretics. CVC parameters were associated with ACVIM
stage. CVCD‐min/Ao was significantly larger, whereas CVCCI was significantly reduced
in dogs with ACVIM stage C or D compared with ACVIM stage B1 or B2 (P‐value <0.01).
CVCD‐max/Ao differed in dogs with ACVIM stage D compared with other stages (p‐value
<0.01). There was a significant association between a subjectively fat CVC and advanced
DMVD stages (ACVIM C or D) (p‐value <0.0001). ANCOVA revealed that CVC parameters
were influenced by ACVIM stages and not by diuretic administration.
CVC POCUS parameters (CVCD‐min/Ao and CVCCI) were correlated with disease severity
in patients with DMVD, and could be useful to identify dogs in need of hospitalization
or at increased risk of decompensation.
Disclosures
No disclosures to report.
ESVC‐O‐16
Echocardiographically determined left ventricular volume indices obtained from two
views in dogs show good agreement
C. Bourguignon1, D. Caivano2, L. Vatne3, D. Dickson4, J. Harris5, M. Rishniw1
1Cornell University, Ithaca, United States of America, 2University of Perugia, Perugia,
Italy, 3Anicura, Oslo, Norway, 4HeartVets UK, Porthcawl, United Kingdom, 5HearVets
UK, Dursley, United Kingdom
Echocardiographic left ventricular (LV) volume estimates can help clinicians identify
and quantify cardiomegaly and cardiac function in dogs. Cardiologists can obtain these
estimates from different views and index them against body size to normalize them
for comparisons between individuals and to classify them into ranges of disease severity.
However, to‐date, studies comparing estimates obtained from different views have been
performed by only one group of investigators examining specific breeds. Therefore,
we examined the agreement between two methods of obtaining LV volume estimates in
dogs with a range of diseases and disease states. We also generated reference intervals
for LV volume indices.
Five investigators contributed echocardiographic data from 199 dogs; one dog was excluded
from the analyses. The LV of each dog was measured in triplicate using a Simpson's
single plane method, from either the right parasternal long axis view or the left
apical 4‐chamber view, in systole and diastole. The 3 measurements were averaged,
and the two methods were compared using limits‐of‐agreement analyses. Volumes were
indexed to bodyweight and to body surface area. Reference intervals were created from
measurements obtained on 73 healthy dogs. Indexed LV dimensions were regressed against
LA:Ao in 82 dogs with mitral valve disease.
Systolic and diastolic LV volume estimates obtained by the two methods agreed, showing
no fixed or proportional biases. Only 2 dogs showed markedly different LV volumes
between the two methods. The 95% limits of agreement were approximately 1.0 ml/kg
for diastolic LV volume index and 0.5 ml/kg for systolic LV volume index. Healthy
dogs had an upper limit of 4.8 ml/kg and 2.2 ml/kg (left apical view) or 4.3 ml/kg
and 2.0 ml/kg (right parasternal view) in diastole and systole, respectively. The
90% confidence intervals of each of these limits included the point estimate of the
complementary method. Diastolic, but not systolic, LV volume index increased with
increasing LA:Ao in dogs with mitral valve disease (r = 0.28). Data provided by all
investigators appeared similar with no investigator showing obvious bias.
Our study suggests that little difference exists in estimates of LV volume from the
two echocardiographic views, and that the estimates are interchangeable in dogs with
a range of cardiac diseases and disease severities. Additionally, our data provide
reference limits for volumes indexed to weight, which is both mathematically and physiologically
more appropriate than indexing to surface area.
Disclosures
No disclosures to report.
ESVC‐O‐17
Supraventricular tachycardia in 23 cats; comparison with 21 cats with atrial fibrillation
(2004‐2014)
V.F.J. Greet1, J.M.C. Sargent2, M. Brannick3, V. Luis Fuentes2
1Southern Counties Veterinary Specialists, Ringwood, United Kingdom, 2The Royal Veterinary
College, Department of Veterinary Clinical Sciences, Hatfield, United Kingdom, 3Companion
Care Vets, Ashford, United Kingdom
The causal mechanisms, predisposing factors and natural course of supraventricular
tachycardia (SVT) and atrial fibrillation (AF) are well described in people and to
a lesser extent in dogs. SVT has not been well‐described in cats, and reports of AF
are limited. The aim of this study was to describe the signalment, clinical findings
and outcome for cats with SVT versus cats with AF.
Forty‐four client‐owned cats were included in this retrospective study; 23 cats with
SVT and 21 with AF. Cats were examined between November 2004 and April 2014. Inclusion
criteria were availability of a 50 mm/s 6‐lead ECG and a concurrent echocardiographic
study. Continuous variables were compared between groups using a two‐sample t‐test
or Mann‐Whitney U test and categorical variables were summarised using Chi‐squared
or Fisher's exact test. Kaplan‐Meier survival curves were generated to assess for
impact of rhythm diagnosis, presence of ventricular arrhythmia, left atrial diameter,
heart rate and congestive heart failure status on cardiac death. Differences in survival
between groups were compared using Mantel‐Cox logrank comparison of Kaplan‐Meier survival
curves.
Overall, the most common presentation was respiratory distress, (10 of 44 cats), followed
by lethargy (n = 9) and collapse (n = 8). Cats with AF had a slower median heart rate
(220 [range 180‐260 bpm] compared to cats with SVT (300 [range 150‐380] bpm, P < 0.0001).
All cats with AF had cardiac chamber remodelling whereas 4 cats with SVT had no structural
abnormalities. Left atrial diameter was significantly larger in AF cats (23.7(16.2‐40.1)
mm, compared to 19.1 (12.8‐31.4) mm in SVT cats; P = 0.019)). Median survival was
58 days (1‐780) in cats with AF compared with 259 days (2‐2295) in cats with SVT (p
= 0.112). Cats presenting with signs of CHF had worse overall survival (P = 0.001);
rhythm diagnosis, ventricular arrhythmia, left atrial size and heart rate had no impact
on survival status.
Most cats with AF or SVT have advanced cardiac remodelling, and median left atrial
size was greater in cats with AF than SVT. Some cats with SVT had no evidence of cardiac
remodelling, suggesting that SVT in cats is not always a consequence of atrial enlargement.
Disclosures
No disclosures to report.
ESVC‐O‐18
Electrocardiographic patterns of ventricular pre‐excitation in the dog
M. Perego1, R. Pariaut2, N.S. Moise2, S. Lombardo1, M. Mateos Panero1, R. Santilli1
1Clinica Veterinaria Malpensa, Samarate, Italy, 2Department of Clinical sciences ‐
Cornell University, Ithaca, United States of America
Ventricular pre‐excitation (VPE) describes the activation of a portion of the ventricular
myocardium along an accessory pathway (AP), which occurs sooner than if an electrical
impulse only conducted along the normal His‐Purkinje system. Ventricular pre‐excitation
has been documented in 1/3 of the dogs with APs. The aims of our study were to explore
the electrocardiographic (ECG) features of VPE and identify ECG criteria to determine
AP location in this species.
Records of 26 privately‐owned dogs with documented AP were retrospectively reviewed.
For all dogs 12‐lead ECG and detailed electrophysiologic mapping were analyzed. The
dogs were classified in three groups according to the position of the AP: antero and
mid‐septal (6/26), right posterior and right lateral (9/26) and right postero‐septal
(11/26). For each ECG, measurements on 3 different beats were performed for the following
parameters: P‐delta wave (d) interval and segment duration, d duration, morphology
and axis (at 20 and 40 ms), d‐Q, d‐R, d‐R’ and d‐S duration, morphology and axis.
Descriptive statistics were performed and on quantitative variables normal distribution
of values was assessed by the Shapiro‐Wilk W‐test and mean, median, quartiles and
standard deviations were calculated. Kruskal‐Wallis one‐way analysis‐of‐variance‐by‐ranks
test was used to evaluate difference between position and delta wave measured on each
lead.
In 20 dogs VPE was manifest and in 6 intermittent. The most common d‐QRS complex morphology
in lead II was the multiple peak QRS (rR’, rRs) found in 18/26 dogs. Right posterior
and right lateral APs had a taller d‐R and d‐S respectively in lead I (P = 0.04) and
II (P = 0.01) Antero and mid‐septal APs had a taller d‐R’ in lead III (P = 0.04) and
a taller d‐S in lead V2 (P = 0.01).
The results of this study suggest that localization of APs using surface ECG criteria
is possible. Additional studies are needed to test the use of the d‐R, d‐S and dR’
amplitude to guide subsequent radiofrequency catheter ablation procedure.
Disclosures
No disclosures to report.
ESVC‐O‐19
Use of the cutting balloon technique for the treatment of subvalvular pulmonary stenosis
M. Perego, S. Lombardo, R. Santilli
Clinica Veterinaria Malpensa, Samarate, Italy
Subvalvular pulmonic stenosis (SPS) is classified into two subtypes: infundibular
(ISPS) and sub‐infundibular (SISPS). ISPS can be primary, due to fixed obstruction
of the right ventricular (RV) outflow tract, or secondary to right ventricular concentric
hypertrophy caused by pulmonic stenosis. Furthermore, SISPS is also defined as double
chambered right ventricle (DCRV), a high‐pressure superior chamber and a low‐pressure
inferior chamber. The aim of the study was to describe the treatment of ISPS and DCRV
in dogs and cats with a the cutting balloon (CB) technique.
This retrospective study included 7 patients (5 dogs and 2 cats) diagnosed with ISPS
or DCRV. All cases underwent dilation with a 8 mm in diameter (length 2 cm) CB followed
by dilation with an high pressure‐balloon. For each patient maximum outflow velocity
(Vmax), maximum pressure gradient (PGmax), tricuspidal regurgitation maximum velocity
(TRVmax), right atrial (RA) area, RV systolic function estimation were measured before
the procedure (T0) and then 24 hr (T1) and 1 month (T2) after the procedure and right
atrial and ventricular pressures during the procedure.
The mean diameter of the stenosis was 6,4 (±1,54) mm for the dogs and 2,1 (±0,14)
mm for the cats. At T0 mean Vmax was 5.3 ± 0.9 m/s, mean PGmax was 117.07 ± 40.3 mmHg,
mean TRV max was 5.23 ± 0,63 m/s, mean RA area was 599 ± 1225.5 mm2, mean TAPSE was
11.54 ± 4.39 mm, mean TDI was 0.11 ± 0.007 m/s and mean FAC was 42.16 ± 16.1%. Mean
pressure values measured by catheterisation before the procedure were: RA pressure
7.3 ± 1.8 mmHg, RV superior chamber 92.66 ± 40.45 mmHg; RV inferior chamber 34.33 ± 12.09 mmHg.
CB dilation could not be completed in 1/5 dogs and 2/2 cats. During the dilation mean
RV superior chamber pressure was 60.33 ± 13.42 mmHg. Follow‐up at T1 was available
for 4/4 treated dogs and at T2 was available for 3/4 treated dogs. Following CB dilation
mean RV superior chamber pressure was reduced by 31,5%, whilst mean PGmax was reduced
by 51.06%.
The present study described the successful treatment of ISPS and DCRV in 4 dogs by
CB dilation with a PGmax reduction of 51.06% and reverse right atrioventricular remodelling
at T1. The procedure could not be completed in 1 dog and 2 cats probably because of
their small body size and/or their severe RA remodelling which impeded us to advace
the stiff CB on the softer guide. These preliminary results indicate a possible application
of CB dilation in the treatment of ISIP and DCRV.
Disclosures
No disclosures to report.
ESVC‐O‐20
Imaging and clinical features of canine right atrial appendage aneurysm: a single‐centre
cross‐sectional study in 10886 dogs
A. Costa1, M. Caldin2, G. Ledda1, L. Angeloni1, G. Bertolini1
1San Marco Veterinary Clinic, Veggiano, Italy, 2San Marco Veterinary Laboratory, Veggiano,
Italy
Aim of this study was to describe the prevalence, morphology, and size of right appendage
aneurysm (RAA) in dogs. In this 13‐year single‐centre cross‐sectional study, CT reports
of dogs underwent thoracic CT examination for various reasons were reviewed. Patients'
characteristics were assessed for likely associations with RAA. Radiographic and echocardiographic
studies were also evaluated when available. Continuous data were assessed for normality
of distribution with the Shapiro‐Wilk test. Dogs with RAA were compared with dogs
without RAA for the variable gender and sexual status using Chi‐Square test. Wilcoxon‐Mann‐Whitney
test was used to analyse age and body weight of groups. The body condition score (five
points scoring system) was analyzed using the Fischer's exact test. Non‐normally distributed
data were reported as median, interquartile range (IQR), and range. For all statistical
analyses, the significance level was set to α = 0.05. CT data of dogs with RAA were
retrieved from archive and analyzed using various post‐processing techniques. RAA
location and shape were recorded. Oblique multiplanar views were used such that the
area to be measured was orthogonal to the long axis of the RAA. RAA measurements included
the neck, maximum height and width. Additional CT features of cardiac and extracardiac
structures were also recorded. RAA was detected in 23/10886 dogs having thoracic CT
in the selected period of time (0.21% prevalence). Radiographic and echocardiographic
studies were available for 10/23 dogs. A mediastinal mass were visible in 2/10 radiographs.
Echocardiographic examination disclosed RAA in 4/10 dogs with pulmonary hypertension.
The bodyweights of dogs with RAA were significantly lower than those of the remaining
10 836 dogs without RAA (median 8 kg [IQR 5; range 37.6] and median 16 kg [IQR 23;
range 116.9] respectively; P = 0.003). Female sex was also significantly associated
with RAA (P = 0.03). Four/23 dogs had also right atrial dilatation. Three different
RAA phenotypes were detected: sack‐like in 19/23 dogs, focal lump‐like in 3/23 dogs,
and fusiform in 1/23 dog. Results of CT measurements were: mean of the neck 1.48 cm
[IQR 1; range 2.6]; mean height 3.06 cm [IQR 1.39; range 4.85], and mean width 1.64 cm
[IQR 1; range 3.1]. RAA is an infrequent (0.21%) and often incidental condition that
can have different phenotypes. In this study, female sex and smaller size showed an
association with RAA. Further case‐control studies are necessary to assess a possible
relationship between RAA and pulmonary hypertension.
Disclosures
No disclosures to report.
ESVC‐O‐21
Predictors of reoccurrence of congestive signs in dogs with ACVIM‐Stage C myxomatous
mitral valve disease (MMVD)
A. Franchini1, J. Abbott1, B. Tyrrell2, S. Rosenthal2, S. Lahmers1, G. Menciotti1,
S. Crosara3, J. Häggström4, M. Borgarelli1
1Virginia‐Maryland College of Veterinary Medicine, Blacksburg, United States of America,
2CVCA Cardiac Care for Pets, Leesburg, United States of America, 3Department of Veterinary
Sciences, University of Parma, Parma, Italy, 4Department of Clinical Sciences, Swedish
University of Agricultural Science, Uppsala, Sweden
The aim of this study was to identify predictors of reoccurrence of congestive signs
(CS) in dogs with MMVD and clinically stable heart failure (HF). Congestive signs
were defined as tachypnea, dyspnea and cough that resolved with medical treatment
for HF.
Medical records of 5122 dogs enrolled in the LOOK‐Mitral registry from 1st November
2015 to 31st July 2018 were reviewed to identify dogs with stable ACVIM‐Stage C MMVD
defined as dogs with CS and unchanged medical treatment for at least four weeks since
the first identification of HF. The study population was composed by 186 dogs, subsequently
divided into two groups: reoccurrence group (RG, n = 66) and no reoccurrence group
(NRG, n = 120). Reoccurrence of CS was defined by resting respiratory rate > 40 breath/minute
and/or dyspnea, within the study period, that resolved after furosemide increase.
Baseline body weight (BW) (OR:1.11, 90%CI:1.06‐1.17), presence of cough (OR:1.98,
90%CI:1.05‐3.74), left atrial‐aortic ratio (LA/Ao)(OR: 3.08, 90%CI:1.38‐6.86), left
ventricular internal diameter at end‐diastole (OR: 3.41, 90%CI:1.22‐9.50) and end‐systole
(OR: 7.61, 90%CI:2.32‐24.90) indexed to body size, mitral valve peak E wave velocity
(OR: 3.44, 90%CI:1.63‐7.27), and furosemide daily dosage (OR:1.32, 90%CI:1.04‐1.67)
were associated with reoccurrence of CS in the univariate analysis. The BW (P = 0.0003)
and LA/Ao (P = 0.0196) remained significant in the multivariate analysis. Increment
of 0.1 of LA/Ao or of 1 kg in body weight were both associated with 1.1 increased
odds of reoccurrence.
This study suggests that BW and LA/Ao are independent predictors of reoccurrence of
CS in dogs with stable ACVIM‐Stage C MMVD.
Disclosures
Disclosures to report.
Dr. Michele Borgarelli receives financial support from Ceva Sante Animale for studies
unrelated to this Abstract.
Dr. Alessandra Franchini receives finical support form Ceva Sante Animale for her
PhD.
ESVCN‐O‐1
Dietary lemon balm and fish peptides enhance the efficacy of L‐tryptophan to reduce
urinary cortisol, a stress marker in cats
I.C. Jeusette1, G. Tami2, C. Torre1, A. Fernandez1, A. Tvarijonaviciute3, J. Ceron3,
A. Salas‐Mani1, J. Fatjó4
1Affinity Petcare SA, L'Hospitalet de Llobregat, Spain, 2Corbera de Llobregat, Spain,
3Interlab‐UMU, University of Murcia, Murcia, Spain, 4Psychiatry and Forensic Medicine,
Autonomous University of Barcelona, Bellaterra, Spain
The objective of this study was to test the efficacy of two diets supplemented either
with L‐tryptophan (diet U) or with L‐tryptophan, plus lemon balm (Melissa officinalis
L.) and fish peptides (diet US), on the reduction of urinary cortisol, a stress marker
in cats.
Ten colony cats firstly received a control adult cat diet (diet C) for five weeks
and then were randomly assigned to two groups to test diets U and US for five weeks,
in a cross over design, with two weeks wash‐out period. Twenty‐four‐hour naturally
voided urine was obtained at the end of each period, under routine conditions and
following the application of mild‐stressors (open‐field test, overnight fast and blood
sampling). Urinary cortisol and serum serotonin concentrations were measured and behaviour
tests were performed (open‐field test and reaction to the presence of and contact
with an unfamiliar person). Mixed models for repeated measurements (SPSS) were used
to analyse the data.
Compared with control diet, both supplemented diets were effective to reduce urinary
cortisol in almost all the tested situations (P < 0.05). Compared with diet U, diet
US resulted in a lower urinary cortisol concentration on average and after an overnight
fast (P < 0.05), difference for routine being marginal (P = 0.096). Diet US resulted
also in a marginal increase in serum serotonin (0.05 < P < 0.10) compared to the two
other diets (C and U). Diet U resulted in a higher average score for unfamiliar person
test while diet US mainly increased the tolerance to the presence of the unfamiliar
person compared to C.
In conclusion, both supplemented diets are effective to reduce stress markers in cats,
with an enhanced effect for lemon balm, fish peptides and L‐tryptophan supplementation
compared to L‐tryptophan alone. Supplemented diets may also help to improve interaction
with unfamiliar person. New trials should be conducted in cats suffering from stress‐related
disorders to confirm the clinical benefits of these dietary supplementations.
Disclosures
Disclosures to report.
All the study was funded by Affinity Petcare SA. I. Jeusette, A. Fernandez, C. Torre,
A. Salas‐Mani are employees of Affinity Petcare SA.
ESVCN‐O‐2
Metabolic effects of a diet with Enterococcus faecium NCIMB 10415 for healthy adult
dogs
S. Nybroe1, I.N. Kieler1, P.B. Rasmussen1, K. Krag1, T.G. Hosbjerg2, C.R. Bjørnvad1
1University of Copenhagen, Frederiksberg, Denmark, 2Bacterfield GmBH, Hamburg, Germany
The use of probiotics is believed to have health promoting effects such as stabilising
the gut microbiome, increase short‐chain fatty acid (SCFA) production and lower circulating
cholesterol levels. However, probiotic supplementation may also affect the vitamin
B metabolism and there are indications that circulating cobalamin may be depleted
to levels below reference levels in dogs. Yet, probiotic effects are highly strain
specific. The aim of this study was to investigate the effects of a commercial complete
diet containing Enterococcus faecium NCIMB 10415 on faecal quality, faecal SCFA (acetate,
butyrate and propionate) concentrations as well as serum folic acid, cobalamin, cholesterol
and triglycerides.
Ten healthy client owned dogs were included in this randomized prospective double‐blinded
crossover study. All dogs went through a 7 days acclimatisation period of gradual
transit from their regular diet to the control diet. The acclimatisation period was
followed by two study periods of each 35 days. In each study period, the dogs were
randomly assigned to start being fed the control diet (CD) or probiotic diet (PD)
(control diet supplemented with E. faecium NCIMB 10415, 109 cfu/kg). Blood samples
and rectal faecal samples were collected at inclusion (I) at day 0 and at the end
of each feeding period (day 42 and 77). The faecal quality was scored daily by the
owner. Results are presented as mean ± SD, and a difference of P < 0.05 was considered
significant.
A significant reduction in serum cholesterol (I: 6.5 ± 2.22 vs PD: 5.40 ± 1.71 mmol/L)
and increased faecal content of butyrate was found in the PD relative to I. For both
PD and CD, serum cobalamin was significantly reduced (I: 442 ± 110 vs CD: 381 ± 73
and PD: 359 ± 77 ng/L) but within the reference interval (235‐812 ng/L) and faecal
concentration of acetate was significantly increased compared to I. No changes were
found in serum concentration of triglycerides and folic acid or in the faecal concentration
of propionate or faecal quality.
Based on this study, E. faecium incorporated in a commercial diet, has a potentially
health promoting effect in dogs by reducing the serum concentration of cholesterol
and increasing the faecal concentration of butyrate. Circulating cobalamin decreased
following intervention irrespective of whether E. faecium NCIMB 10415 was included
or not, which could indicate that other dietary factors may significantly impact cobalamin
levels.
Disclosures
Disclosures to report.
The study was fonded and the study diets provided by Bacterfield GmBH, Hamburg, Germany,
who employs one of the authors, Therese G Hosbjerg.
ESVE‐O‐1
The Relationship of SDMA and Creatinine in Cats with Subnormal Total T4 After Hyperthyroidism
Treatment
R. Mack, D. Szlosek, C. Clements, M. Coyne
IDEXX, Westbrook, United States of America
Iatrogenic hypothyroidism in cats is associated with reduced glomerular filtration
rate, increased occurrence of azotemia, and shortened long term survival. Previous
studies have supported this conclusion but were limited by small sample sizes. Symmetric
dimethylarginine (SDMA) has been shown to be an earlier, more sensitive, and reliable
renal biomarker of decreased glomerular filtration rate than creatinine, which has
been found to be influenced by fluctuations in lean muscle mass. The purpose of this
study was to utilize big data to characterize the relationship of SDMA and creatinine
(Cr) to subnormal total T4 (TT4) post hyperthyroid treatment. Using the US IDEXX Reference
Laboratories database 2, 395 cats were identified with samples that were tested with
TT4, SDMA and Cr. From this dataset, a hyperthyroid treated group was identified,
from this treated population a total of 479 subnormal TT4 cats were identified, defined
as having a TT4 < 0.8 μg/dL post hyperthyroid treatment. The remaining cats were euthyroid
after treatment. A four‐to‐one comparative age‐matched control group of post treatment
euthyroid cats to subnormal TT4 cats was used to evaluate SDMA and Cr pre‐and post‐treatment.
A McNemar's paired test or Chi‐square test was used where appropriate. A significant
increase in the number of subnormal TT4 cats with an SDMA concentration above the
reference interval was found compared to euthyroid controls post‐treatment (39.6%
(190/479) vs. 32.1% (616/1916), P < 0.001). Cr concentrations were also increased
above the reference interval in a significantly greater number of subnormal TT4 cats
as compared to controls post‐treatment (25.9% (124/479) vs. 12.8% (246/1916), P < 0.001).
In the subnormal TT4 group increased SDMA concentrations identified 13.7% more cats
with potential decrease in GFR and reduction in renal function than Cr. This study
confirms that a significant percentage of cats with subnormal TT4 attributed to overtreatment
of hyperthyroidism have abnormal renal biomarkers as compared to those that are euthyroid
following therapy. The big data used for this study supports the importance of avoiding
iatrogenic hypothyroidism. The identified association of reduced renal function with
iatrogenic hypothyroidism emphasizes the importance of avoiding overtreatment. Comprehensive
renal monitoring including measurement of SDMA should be part of routine management
of hyperthyroid cats.
Disclosures
Disclosures to report.
All authors listed are employed full‐time for IDEXX laboratories.
ESVE‐O‐2
Prevalence of ‘Atypical’ Addison's disease among a population of dogs diagnosed with
hypoadrenocorticism
D. Kelly1, M. Garland2, V. Lamb1, F. Juvet1
1Southern Counties Veterinary Specialists, Ringwood, United Kingdom, 2TDDS, Exeter,
United Kingdom
A diagnosis of ‘Atypical’ Addison's disease is typically made in patients diagnosed
with hypoadrenocorticism with a Na:K ratio > 27 at presentation. The percentage of
patients with hypoadrenocorticism which have ‘atypical’ disease remains unknown. The
primary aim of this study was to determine the percentage of dogs diagnosed with atypical
disease within a general population of dogs diagnosed with hypoadrenocorticism and
to determine if this percentage differed between a population diagnosed in first opinion
practice and a population diagnosed at referral practice.
The database of a commercial laboratory in the United Kingdom was searched to find
dogs diagnosed with hypoadrenocorticism over a four year period (2015‐2018). Dogs
were included if an ACTH stimulation test was performed and post ACTH cortisol concentration
was <55 mmol/L. The results of serum or plasma sodium and potassium concentrations
at the time of initial presentation were also required for inclusion. Dogs were excluded
if they were receiving trilostane or any other medication known or expected to interfere
with adrenal function testing. Dogs were diagnosed with ‘atypical’ hypoadrenocorticism
if the Na:K ratio at the time of presentation was >27.
Forty‐seven dogs with newly diagnosed hypoadrenocorticism were identified and included.
Of the 47 cases included, 20 cases (43%) were diagnosed with ‘atypical’ hypoadrenocorticism.
Of the 33 cases diagnosed at referral practice, 16 (48%) were diagnosed with ‘atypical’
hypoadrenocorticism. Of the 14 cases diagnosed at first opinion practice, 4 (29%)
were diagnosed with ‘atypical’ hypoadrenocorticism.
The overall percentage of cases diagnosed with ‘atypical’ hypoadrenocorticism may
be higher than previous estimates. The percentage of newly diagnosed cases of hypoadrenocorticism
at referral practice which have ‘atypical’ disease appears higher than the percentage
of ‘atypical’ cases diagnosed at first opinion practice. In the absence of electrolyte
abnormalities classically associated with ‘typical’ cases of hypoadrenocorticism,
particularly a Na:K ratio < 27, the index of suspicion for the disease may be low.
The finding of a higher percentage of patients with ‘atypical’ disease when considering
the population diagnosed at referral practice raises concern that cases may go undiagnosed
at first opinion practice.
Disclosures
Disclosures to report.
One of the authors was employed by the commercial laboratory which allowed its databased
to be searched in order to identify cases. This commercial laboratory performed the
measurement of serum cortisol concentrations in all included cases.
ESVE‐O‐3
The predictive role of the transtubular potassium gradient (TTKG) for Addison syndrome
in hyperkaliemic dogs: a cross‐sectional study
M. Petini, A. Zoia, M. Caldin
San Marco Veterinary Clinic, Veggiano, Italy
Addison disease is characterized by a deficiency of both cortisol and aldosterone.
The lack of aldosterone results in renal sodium wasting and potassium retention leading
to hyponatriemia, hyperkalemia and a body volume depletion. The effect of aldosterone
on serum potassium excretion can be evaluated by comparing urine and serum potassium
concentrations after correcting the urine potassium concentration for reabsorption
of solute‐free water by the kidney. This estimation has been called TTKG. Thus, the
aim of this study was to evaluate the ability of TTKG in the identification of dogs
affected by Addison disease among a population of hyperkalemic dogs.
For this cross‐sectional study, we retrospectively search the data base for dogs with
a serum potassium concentration > 5.5 mmol/L (reference interval = 3.9‐5.1) presented
between December 2012 and February 2019. Inclusion criteria were a urine TTKG calculated
at hospital admission (which is routinely done in our laboratory) and a final diagnosis
available. Based on final diagnosis dogs were divided in newly diagnosed, naturally‐occurring
Addison's disease (diagnosed by an ACTH stimulation test) and other diseases. Dogs
were excluded from the study if they had an history of corticosteroid administration
and/or drugs having affecting potassium excretion (e.g., ace‐inhibitors, aldosterone‐receptor
blockers, diuretics, fludrocortisone, IV fluids). Moreover, hyperkalemic dogs were
also excluded if urine osmolality was ≤300 mOsm/Kg or urine sodium was ≤25 mmol/L,
precluding these values a correct TTKG calculation. TTKG was compared by T‐test between
dogs with Addison disease and sick hyperkalemic controls dogs. Finally, ROC curve
analysis was used to identify the best cutoff value (Youden index) for discriminating
dogs with Addison disease from sick hyperkalemic controls dogs without Addison disease.
For all analyses the significance was set to α = 0.05.
Eighty hyperkalemic dogs were included in this study, 41 with Addison disease and
39 without. TTKG in dogs with Addison disease was significantly (P < 0.0001) lower
(3.5 ± 1.73) than TTKG in control dogs (5.8 ± 2.07). The Youden index identified through
ROC curve analysis for TTKG was 4.55 (sensitivity = 75.6%, specificity = 74.3%; AUC
= 0.802, 95% CI, 0.707 to 0.898; p < 0.0001).
The present study showed that TTKG, in hyperkalemic patients can be used as a diagnostic
tool in the initial discrimination of dogs with Addison disease, from hyperkalemic
dogs without Addison disease. In a subset of hyperkalemic dogs, TTKG may be helpful
in patient management until confirmatory diagnosis with an ACTH stimulation test is
available.
Disclosures
No disclosures to report.
ESVE‐O‐4
Comparison of different monitoring methods in dogs with hypercortisolism treated with
trilostane
S. Golinelli1, G. Carotenuto1, V. de Marco2, R.O. Leal3, C. Aniballi1, F. Fracassi1
1University of Bologna, Bologna, Italy, 2Naya Especialidades, São Paolo, Brazil, 3University
of Lisbon, Lisbon, Portugal
The monitoring of trilostane treatment, the drug of choice for the medical therapy
of canine hypercortisolism (HC), is currently based on the evaluation of the clinical
signs and the results of the ACTH stimulation test. However, this method has many
limitations and recent data have shown a lack of correlation between ACTH stimulation
test results and the clinical signs of dogs with HC treated with trilostane. Over
the last years, many different studies investigated possible alternative methods with
conflicting results. A single study to compare all these methods in the same canine
population is lacking. The aim of this study was to evaluate which of the previous
investigated monitoring methods better correlate with a standardized and published
clinical score (CS) obtained by an owner questionnaire and could represent the best
method to monitor trilostane therapy.
We conducted a prospective multicentre study. Dogs with HC on treatment with trilostane
twice daily for at least two weeks were blood sampled and categorized as unwell (sick
or over‐treated dogs), well and under controlled (no dose or dose increase required
dogs, respectively) based on the CS. The results of the CS were compared with: serum
cortisol concentration pre‐trilostane (T0), 3 h‐post‐trilostane (T3) and 4 h‐post‐trilostane
(1 h‐post‐ACTH) (T4) administration, plasma ACTH concentration pre‐trilostane administration,
plasma ACTH/cortisol (T0) ratio, serum haptoglobin concentration (Hp), chemistry variables
(ALP, ALT, GGT), urinary cortisol/creatinine ratio and urine specific gravity (from
urine of the evaluation's day and from the morning of the day before). Plasma ACTH
and serum and urinary cortisol were measured with a chemilumescent assay (Immulite
2000)., 76 re‐evaluations of 37 dogs were included. Unwell dogs were excluded for
further analysis. Haptoglobin was the parameter that better correlated with the CS
(r = 0.47), followed by ALT (r = 0.34), T0 (r = 0.33) and the UCCR average of the
2 urinary samples(r = 0.33). ROC curve analysis identified a concentration of Hp of
150 mg/dl and a concentration of T0 of 4 μg/dl as useful value to discriminate well
and under controlled dogs with a specificity of 91% and 78% respectively.
Hp seems to be the best parameter to monitor trilostane therapy. However, Hp has likely
limited capability to identify over‐treated dogs; the concurrent evaluation of cortisol
pre‐trilostane may be useful in detecting an overdose of trilostane. The combined
evaluation of Hp and T0 correctly categorized 85% of the cases and can be used as
alternative monitoring method for dogs with HC under trilostane therapy.
Disclosures
Disclosures to report.
Federico Fracassi Financial support: Dechra, MSD Speaking & consultancies: Boehringer
Ingelheim, Dechra, MSD, Royal Canin, Hill's, Nestlé Purina, La Vallonea. Stefania
Golinelli Consultancies: Dechra Viviani De Marco Speaking: Royal Canin, Hill's, Nestlé
Purina Dechra pharmaceuticals supported this study providing Vetoryl for free.
ESVE‐O‐5
Feline plasma adrenocorticotropic hormone: validation of a chemiluminescent assay
and concentrations in cats with hypercortisolism, primary hypoadrenocorticism and
other diseases
A.M. Tardo1, C.E. Reusch2, S. Galac3, S. Fornetti1, L. Giacomelli1, A. Tirolo1, D.
Shehdula1, F. Fracassi1
1University of Bologna, Ozzano dell'Emilia ‐ Bologna, Italy, 2University of Zurich,
Switzerland, 3Utrecht University, Utrecht, Netherlands
Naturally occurring hypercortisolism (HC) and hypoadrenocorticism are rare conditions
in cats and their diagnosis can be challenging. Actually, there is a lack of validation
studies for the measurement of feline plasmatic adrenocorticotropic hormone (ACTH).
The aims of this study were to validate a commercially available chemiluminescent
assay to measure feline ACTH concentrations, determine the normal reference interval
(RI) and assess plasma endogenous ACTH concentrations in cats with primary hypoadrenocorticism
(PH), HC and cats with other diseases (OD).
Thirty‐three healthy cats and 25 cats with OD (9 cats with diabetes mellitus; 5 with
hyperthyroidism; 3 each with chronic kidney disease, or gastrointestinal disease;
2 with acute kidney injury; and 1 each with hypovolemic shock, septic shock, or hyperaldosteronism)
were included prospectively in the study. Data from 11 cats with PH and 9 with HC
(8 pituitary‐dependent hypercortisolism ‐ PDH ‐ and 1 adrenal‐dependent hypercortisolism
‐ ADH) were retrieved from medical records of three referral centers (University of
Bologna, Zurich and Utrecht) that use the same method of measurement (Immulite 2000).
Left over samples, collected for diagnostic purposes, were used. The intra‐assay coefficients
of variance (CVs) ranged from 2.6 to 3.6%, and interassay CVs from 6.6 to 13.2%, for
samples with high and low concentrations of ACTH, respectively. Dilution studies performed
on two samples with high concentrations of ACTH, using the diluent provided by the
manufacturer, showed excellent accuracy (R2 > 0.99). The RI for plasma endogenous
ACTH in healthy cats, established using the Robust Method, was 27‐390 pg/mL (median
96 pg/mL). Plasma ACTH concentrations ranged from 23.6 to 400 pg/mL, 21.6 to 355.5 pg/mL,
331 to >1250 pg/mL in healthy, OD and PDH cats, respectively; the only cat with ADH
showed an ACTH value of 5 pg/mL (detection limit of the assay). In all the cats with
PH the concentration of ACTH was >1250 pg/mL. ACTH concentrations did not show significant
differences between healthy and OD groups. Cats with PDH and PH had significantly
higher ACTH values than the other groups. There was only 1 PDH cat with a result in
the range of healthy and OD cats.
Immulite chemiluminescent assay is a valid technique for measurement ACTH in feline
plasma and the RI is quite wide. Due to the low overlap between healthy or OD cats
and those with PH or HC, measurement of endogenous ACTH seems useful and should be
included in the diagnostic workup when PH or HC are suspected.
Disclosures
Disclosures to report.
C.E. Reusch ‐ Financial support: Nestlé Purina, Hill's, Provet, Antlia SA, Glycemicon,
Novartis Animal Health, Clinical Studies fund of the ECVIM‐CA, Society of Comparative
Endocrinology. Speaking & consultancies: Boehringer Ingelheim, Dechra, Novartis Animal
Health, Waltham, Royal Canin. Sara Galac ‐ Financial support: Morris Animal Foundation,
Stichting D.O.G., AKC Canine Health foundation, Maria Naundorf‐van Gorkum fonds. Speaking:
Dechra. Federico Fracassi ‐ Financial support: Dechra, MSD. Speaking & consultancies:
Boehringer Ingelheim, Dechra, MSD, Royal Canin, Hill's, Nestlé Purina, La Vallonea.
ESVE‐O‐6
Major Histocompatibility Complex (MHC) class II haplotypes associated with increased
risk of canine diabetes mellitus ‐ a breed‐specific study
A. Denyer1, J.M. Massey2, L.J. Davison3, W.E.R. Ollier2, B. Catchpole3, L.J. Kennedy2
1Royal Veterinary College, University of London, London, United Kingdom, 2The University
of Manchester, Manchester, United Kingdom, 3Royal Veterinary College, London, United
Kingdom
Canine diabetes mellitus (DM) can be classified as insulin resistance or insulin deficiency
diabetes, with all cases requiring daily insulin injections to control hyperglycaemia.
A number of pathological mechanisms are thought to lead to the development of the
disease, including immune‐mediated destruction of beta cells. Disease risk differs
considerably between breeds, suggesting that genetic factors are involved, but environmental
triggers are also thought to play a role. In human Type 1 DM, the region of the genome
containing the human leucocyte antigen (HLA) MHC class II genes confers approximately
50% of the genetic risk. Associations with dog leucocyte antigen (DLA) class II haplotypes
have also been identified in diabetic dogs, but investigations to date have considered
all breeds together. This study aimed to identify breed‐specific diabetes‐associated
DLA haplotypes in an expanded data set. Taking the 18 most highly represented breeds
in our previous study, we increased the DLA‐typing data from 294 to 736 diabetic dogs
and from 501 to 1083 breed‐matched non‐diabetic controls to enable breed‐specific
statistical analysis.
Dogs were genotyped for DLA‐DRB1, −DQA1 and ‐DQB1 using sequence‐based typing of DNA
(extracted from blood surplus to diagnostic requirements). The study population only
included dogs from the UK. Female entire cases, expected to have dioestrus diabetes,
were excluded. In all breeds, there were at least ten cases and the number of controls
was equal to or greater than the number of cases. Genotypes from all three loci were
combined to identify DLA class II haplotypes affecting risk of DM across each breed
individually and all breeds together (P < 0.05 using Fisher's Exact test and an Odds
Ratio [OR] confidence interval entirely <1.0 or > 1.0).
Five breeds were identified as having one or more DLA haplotypes that were significantly
different between DM cases and controls. These breeds were Bichon Frise (one risk
haplotype, OR = 4.41); Labrador Retriever (one risk haplotype, OR = 1.60); Cavalier
King Charles Spaniel (one risk haplotype, OR = 2.73); Cocker Spaniel (one risk haplotype,
OR = 6.31 and one protective haplotype, OR = 0.30); Border Terrier (one protective
haplotype, OR = 0.21). Combined analysis of all samples identified four DM‐associated
haplotypes: one risk and three protective, including one protective DLA‐DQ haplotype
identified in the previous study.
These new DLA associations provide further evidence of a role for the adaptive immune
system in canine DM, and highlight potentially different aetiologies between breeds.
Disclosures
Disclosures to report.
Denyer A.L.: Dechra Ltd ‐ Partial sponsorship of PhD. The Kennel Club Charitable Trust
‐ prize grant in support of research and career development. Catchpole B.: Dechra
Ltd & MSD Animal Health ‐ Financial support of research. Davison L.J.: Dechra Ltd
‐ Financial support of research.
ESVE‐O‐7
Comparison of nine canine serum thyroxine measurement methods and impact of T4 cross‐reacting
autoantibodies
L. Copley1, K. Refsal2, P.A. Graham1
1University Of Nottingham, Sutton Bonington, United Kingdom, 2Michigan State University,
East Lansing, United States of America
Serum thyroxine (T4) concentration is commonly measured to assess canine thyroid function
or monitor therapy. Several reference laboratory and in‐clinic immunoassays are commonly
used. The pathogenesis of hypothyroidism may result in endogenous T4 cross‐reacting
antibodies (T4AA) in the sera of a proportion of cases. T4AA may interfere with T4
analysis.
The aims of this study were to compare results between seven total‐ and two free‐thyroxine
methods and to investigate the in‐vitro effect of T4AA on them.
Five serum pools of predictably equidistant T4 concentration covering the reference
interval were created using sequential 50:50 mixing of 2 initial pools of low and
high T4 concentration surplus canine serum and analysed by 7 TT4 (Radioimmunoassay
(RIA); Immulite Total T4 (ImmTT4); Immulite Canine Total T4 (ImmKT4); Thermo‐Microgenics
Total T4 (DRI‐T4); IDEXX Catalyst T4 (CataT4); IDEXX Snapshot T4 (SnapT4) and Tosoh
AIA T4 (TosT4)) and two Free T4 methods (Antech Free T4 by dialysis (FT4d) and Immulite
Veterinary Free T4 (ImmVF4)). The mixed pools approach allowed for assessment of internal
agreement within each method (linearity) as well as comparison between methods. To
determine the impact of T4AA, the same 5 pools were additionally analysed after mixing
50:50 with a T4AA positive canine surplus serum pool.
Total T4 methods did not agree with one another; e.g., highest pool varied between
39 and 59.5 nmol/L. Two TT4 methods (RIA and ImmKT4) demonstrated good linearity with
all points agreeing with predicted concentrations. Of 5 methods that demonstrated
less good internal agreement, three were linear but with results that did not match
predictions across the range (DRI‐T4, TosT4, SnapT4) and two were non‐linear (ImmTT4,
CataT4). ImmVF4 and FT4d were linear, although one data point by FT4d was not as predicted.
An in‐vitro effect of T4AA was seen in all methods (including FT4d) causing false
low results by ImmKT4, DRI‐T4, CataT4, SnapT4, TosT4 and FT4d and false high by RIA
and ImmVF4. ImmTT4 generated mid‐range (21‐24 nmol/l) results across all concentrations
in the presence of T4AA.
The choice of analytical method for canine serum T4 is likely to have an impact patient
management decisions. Commonly available methods do not agree with one another and
several do not agree within themselves. The effect of T4AA varies by method and a
combination of false high and false low methods within thyroid test panels could help
detect the likely presence of interfering T4AA if they are not measured directly.
Disclosures
Disclosures to report.
Graham: NationWide Laboratories (Consultancy) and Dechra Veterinary Products (Consultancy).
ESVE‐O‐8
Analysis of GWAS data in Domestic Shorthair and Burmese cats identifies diabetes‐associated
loci near the DPP9 and within the DPP10 gene
K. Hazuchova1, M. Wallace1, D.B. Church1, B. Catchpole1, Y. Forcada2
1The Royal Veterinary College, Hatfield, United Kingdom, 2VetCT, Cambridge, United
Kingdom
Diabetes mellitus (DM) in cats resembles human type 2 DM, a complex disease involving
a combination of genetic and environmental factors. In a previous genome‐wide association
study (GWAS), 4 single nucleotide polymorphisms (SNPs) were found to be associated
with DM in lean Domestic Shorthair (DSH) cats, and a polymorphism in the MC4R gene
was associated with DM in overweight DSH cats in a candidate gene study. Susceptibility
genes in Burmese cats, a breed predisposed to DM, had not been identified in the initial
GWAS study.
In an attempt to overcome some of the limitations present in the Burmese breed due
to inbreeding, data from the previous GWAS of DM in DSH and Burmese cats was combined
for analysis. Genotyping was performed using Illumina Infinium 63 k iSelect DNA array,
and after quality filtering, 390 diabetic and 390 non‐diabetic control DSH cats, as
well as 19 diabetic and 21 control Burmese cats were included in the analysis. Controls
were significantly older than diabetic cats (P < 0.0001). Body condition score (BCS)
was known for 718 cats, 62% of these were lean and 38% were obese. Stratified analysis
using a Cochran‐Mantel‐Haenszel (CMH) test within strata defined in the multidimensional
scaling (MDS), and logistic regression with MDS coordinates, using BCS and breed as
covariates, were conducted for case:control association testing. P‐values from the
CMH test were adjusted for genomic inflation (λ = 1.187), and feline standard genome‐wide
significance was set at P < 10e‐5. Max(T) permutations were used to generate corrected
empirical P‐values following logistic regression; significance was set at P < 0.05.
A single significant SNP (chrC1:125033967; Praw [adjusted for genomic inflation] =
9.58x10e‐6) was identified in the stratified analysis, and a single significant SNP
(chrA2:3535683; Pgenome [100000 permutations] = 2.75x10e‐3) was identified in logistic
regression. The SNP in chromosome A2 was associated with DM in the previously reported
GWAS of DM in lean DSH, but the association with the SNP in chromosome C1 in both
breeds is new. These SNPs are located within and close to DPP10 and DPP9 genes, respectively,
which are related to DPP4, an enzyme involved in degradation of incretins. This further
analysis has revealed new potential candidate genes in both breeds, highlighting the
usefulness of this alternative approach to the GWAS analysis. Both DPP9 and DPP10
have been implicated in metabolic and immune functions, suggesting that further investigation
of these genes in the pathogenesis of feline DM is warranted.
Disclosures
Disclosures to report.
SNP chips for the GWAS were provided by the Morris Animal Foundation. Katarina Hazuchova's
PhD studentship is supported by Boehringer Ingelheim and Beryl Evetts and Robert Luff
Welfare Trust.
ESVE‐O‐9
Glycemic variability in newly diagnosed diabetic cats treated with the GLP‐1 analogue
exenatide extended‐release
A.L. Kraemer1, A. Riederer2, F. Fracassi3, F.S. Boretti1, N. Sieber‐Ruckstuhl1, T.A.
Lutz4, B. Contiero5, E. Zini1, C.E. Reusch1
1Clinic for Small Animal Internal Medicine,Vetsuisse Faculty,University of Zurich,
Zurich, Switzerland, 2Swiss Veterinary Association, Berne, Switzerland, 3Department
of Veterinary Medical Sciences, University of Bologna, Bologna, Italy, 4Institute
of Veterinary Physiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland,
5Department of Animal Medicine, Production and Health, University of Padova, Legnaro
(PD), Italy
Glycemic variability (GV) refers to glycemic excursions with episodes of hypoglycemia
and hyperglycemia throughout the day or on different days with no apparent causal
link and is considered to be an indicator of glycemic control.
In humans with diabetes mellitus (DM), adding a glucagon‐like peptide‐1 (GLP‐1) analogue
to the conventional therapy results in significant reduction in GV. In cats knowledge
on GV is scarce and the influence of different treatment modalities has not been studied.
The objective of this study was to evaluate GV in cats receiving the GLP‐1 analogue
exenatide extended‐release (EER) additionally to insulin therapy. Blood glucose curves
from a recent prospective placebo‐controlled clinical trial were evaluated for GV
1, 3, 6, 10 and 16 weeks after starting therapy. Cats were treated with EER (200 μg/kg)
or 0.9% saline, administered subcutaneously, once weekly. Both groups received insulin
glargine twice daily and a low‐carbohydrate diet.
To assess GV, mean glucose concentrations and standard deviations (SD) were calculated
and compared between treatment groups and, in the EER group, between cats achieving
or not achieving remission. Both dependent variables (mean and SD) were analyzed using
a repeated mixed linear model which included the fixed effects of treatment, week,
their interaction and repeated animal effect. Data were reported as least‐squares
means and SE. Thirty cats with newly diagnosed DM were included, 15 of which received
EER and 15 received placebo. Six of 15 (40%) cats and 3 of 15 (20%) achieved remission
in the EER and placebo group, respectively (P = 0.427). The mean of the whole study
period was lower in the EER group compared to placebo (9.6 ± 0.8 vs. 12.4 ± 0.8 mmol/L;
P = 0.024); by considering the single time points, the mean was lower at week 6 (5.0 ± 1.7
vs. 12.9 ± 1.6 mmol/L; P = 0.003). The GV‐SD of the whole study period was lower in
the EER group compared to placebo (2.4 ± 0.3 vs. 3.3 ± 0.3 mmol/L; P = 0.035).
In the EER group, cats achieving remission had lower mean (7.6 ± 1.1 vs. 10.9 ± 0.8 mmol/L;
P = 0.026) and lower GV‐SD (1.7 ± 0.4 vs. 2.9 ± 0.3 mmol/L; P = 0.032) than those
not achieving remission.
In conclusion, the GLP‐1 analogue EER leads to a reduction in GV and better glycemic
control in cats with DM. Furthermore, lower GV is associated with higher remission
rates in cats treated with EER. The results of this study therefore suggest that adding
a GLP‐1 analogue to the conventional therapy may be advantageous in the treatment
of cats with DM.
Disclosures
Disclosures to report.
Federico Fracassi: Financial support: Dechra, MSD Speaking & consultancies: Boehringer
Ingelheim, Dechra, MSD, Royal Canin, Hill's, Nestlé Purina, La Vallonea. Claudia Reusch:
Financial support: Nestlé Purina, Hill's, Provet, Antlia SA, Glycemicon, Novartis
Animal Health, Clinical Studies fund of the ECVIM‐CA, Society of Comparative Endocrinology
Speaking & consultancies: Boehringer Ingelheim, Dechra, Novartis Animal Health, Waltham,
Royal Canin. Nadja Sieber‐Ruckstuhl: member of the Vetoryl novel monitoring meeting
2017 organized by Dechra Veterinary Products Ltd.
ESVE‐O‐10
Clinical performances of flash glucose monitoring system in diabetic dogs
F. del Baldo, C. Canton, S. Testa, S. Golinelli, F. Fracassi
University of Bologna, Ozzano dell'Emilia, Italy
Flash glucose monitoring system (FGMS, FreeStyle Libre®) was recently validated for
use in diabetic dogs (DD). It continuously measures the interstitial glucose concentrations
for up to 14 days. The aim of this study was to evaluate the clinical usefulness of
FGMS in monitoring DD.
Twenty DD on insulin treatment were prospectively enrolled in the study. The FGMS
was placed on the neck for up to 14 days. Duringthe 1st‐7th‐14thdays, blood glucose
curves (BGCs) have been performed simultaneously in the hospital with FGMS and a validated
portable blood glucose meter (PBGM) (OptiumXceed, Abbott®). During the 5th‐6th and
12th‐13thdays the owners performed a BGC using the FGMS at home. The BGCs performed
with PBGM and FGMS in hospital and those performed with FGMS at home and in hospital
were compared. Each BGCs has been evaluated as optimal considering: 1) 50% of the
values between 90‐250 mg/dL or 2) glucose nadir between 90‐180 mg/dL. The glucose
nadirs obtained from the data downloaded by the software (DDS), the FGMS scans and
the PBGM were compared. Moreover, the glucose day‐time (GDTNs) and night‐time nadirs
(GNTNs) were compared.
The evaluation of the BGCs performed in hospital with FGMS and PBGM, led to the same
decision on insulin adjustment in 77% and 80% of cases considering the percentage
of values in the range 90‐250 mg/dL and the glucose nadir, respectively.
The evaluation of the BGCs performed at home and the following day in the hospital
with the FGMS, led to the same decision of insulin adjustment in 68% and 64% of cases
considering the percentage of values in the range 90‐250 mg/dL and the glucose nadir,
respectively.
The glucose nadirs were identified in 81% of cases by the DDS and in 65% and 35% of
cases using FGMS scans and PBGM, respectively.
The medians of GNTNs were significantly higher than the GDTNs.
The hypoglycemic episodes obtained from the DDS were 39% more than those immediately
showed on the display of the FGMS.
In conclusion, adjustments in insulin dose based on BGCs obtained with FGMS and with
PBGM are similar. The FGMS detects the nadirs and the hypoglycemic episodes more frequently
than PBGM and it allows the assessment of glucose variations also during different
consecutive days. Therefore, FGMS is a potentially valuable tool in the monitoring
of canine diabetes mellitus.
Disclosures
Disclosures to report.
Federico Fracassi Financial support: Dechra, MSD. Speaking & consultancies: Boehringer
Ingelheim, Dechra, MSD, Royal Canin, Hill's, Nestlé Purina, La Vallonea. Stefania
Golinelli Consultancies: Dechra.
ESVE‐O‐11
Whole Genome Sequencing to explore genetic risk factors in canine diabetes mellitus
L.J. Davison1, M.D. Wallace1, A. Denyer1, C. Mellersh2, K. Hughes3, D. Xia1, A. Psifidi1,
P.J. Watson3, E. Schofield2, I. Ramsey4, L.J. Kennedy5, N. Zimmerman6, G. Williams6,
M.E. Herrtage3, B. Catchpole1, C.A. O'Callaghan7
1Royal Veterinary College, London, United Kingdom, 2Animal Health Trust, Newmarket,
United Kingdom, 3University of Cambridge, Cambridge, United Kingdom, 4University of
Glasgow, Glasgow, United Kingdom, 5University of Manchester, Manchester, United Kingdom,
6Dechra Veterinary Products, United States of America, 7University of Oxford, United
Kingdom
Canine diabetes mellitus (DM) is more prevalent in certain breeds, suggesting an underlying
genetic basis, although environmental factors may also be involved. Notably, dog breeds
with low DM risk are over‐represented in studies of neoplastic transformation of pancreatic
beta‐cells (insulinoma). This suggests that beta‐cell survival may be an important
contributing factor in canine DM, and that similar genes may be involved in canine
DM and insulinoma. Previous genetics work in canine diabetes mellitus (DM) has focused
on candidate genes and genome‐wide association studies, employing a case‐control design
within individual breeds. However, this design does not account for the fact that,
within high risk breeds, a fixed genetic risk of DM may exist, resulting in only minimal
genetic differences between cases and controls.
The aim of this study was to develop a new model for identification of genetic risk
variants in complex disease, in order to identify new canine DM genes. This was achieved
by exploring the genetic differences between dog breeds at very high risk of DM (Samoyed
‐ Odds Ratio 15.2) and exceptionally low risk of DM (Boxer ‐ Odds Ratio < 0.01), as
part of the Canine Diabetes Genetics Partnership initiative.
Whole genome sequencing (WGS) at 30X coverage was undertaken on 6 diabetic Samoyeds
and 6 Boxers with insulinoma, using Illumina HiSeqX technology. Six Samoyeds and 6
Boxers without DM or insulinoma underwent WGS as controls. DNA was extracted from
blood samples that were surplus to requirements for clinical purposes. A custom bioinformatics
pipeline was developed to annotate and prioritise variants for follow‐up, based on
the Genome Analysis ToolKit. Variants were annotated according to their minor allele
frequency (by breed or case‐control status), predicted impact on gene function and
location near a region with a plausible role in beta‐cell function or diabetes risk.
In Samoyeds, >4000 breed‐unique high or moderate impact variants were identified,
>3000 of which were present in more than one Samoyed, and 173 of which were found
exclusively in the diabetic group. In Boxers, >1500 breed‐unique high or moderate
impact variants were identified, >150 of which were present in more than one Boxer,
and 68 of which were found exclusively in the insulinoma group. Replication and functional
studies are in progress to validate candidates and investigate underlying mechanisms.
This study demonstrates that WGS offers a promising route for investigation of complex
diseases where genetic risk may be fixed at a high or low level within breeds.
Disclosures
Disclosures to report.
All authors are members of the Canine Diabetes Genetics Partnership, which is supported
by Dechra Veterinary Products (providing financial support for members' travel to
CDGP meetings three times a year, and acting as the industrial partner in a PhD studentship
for Alice Denyer). The CDGP is funded by the PetPlan Charitable Trust, and this funding
paid for the whole genome sequencing as well as the salary of the author (not attending
the congress) and bioinformatician Marsha Wallace. Brian Catchpole also receives funding
for a PhD student (unrelated to this project) from MSD Animal Health. Lucy Davison
(Senior Author and presenter) is funded by the UK Medical Research Council and also
has funding from BSAVA PetSavers for work unrelated to this abstract. She is also
already entitled to free registration to the meeting as Chair of the ECVIM exam committee
and wants to disclose that she is Vice‐president of ESVE and cannot be involved in
abstract review. We would be happy to provide any further details on request. Other
authors (CDGP members) are involved in a wide variety of other research projects at
their respective institutions, across a large number of fields with numerous funding
sources. None of their funding sources have access or potential to gain from the data
presented here. No CDGP members receive any salary or consultancy fee for their role
in the CDGP and none stand to make any direct financial gain from the data in this
abstract. All authors have seen the information presented in this abstract and have
been given the opportunity to comment on it. In the interests of full disclosure,
please note that a preliminary findings abstract on Whole Genome Sequencing in canine
diabetes (submitted by the Canine Diabetes Genetics Partnership) has been accepted
for poster presentation at the Canine and Feline Genetics and Genomics meeting in
Bern 2019. However the ECVIM abstract submitted here is based on screening variants
against a larger data set, so uses data from additional dogs and breeds. It also includes
bioinformatics improvements, allowing better quantification and annotation of candidate
genetics variants.
ESVE‐O‐12
Evaluation of 1,2‐o‐dilauryl‐rac‐glycero glutaric acid ‐ (6′‐methylresorufin) ester
(DGGR) lipase assay in dogs with naturally occurring hypercortisolism
G. Linari, F. Dondi, S. Segatore, K. Vasylyeva, F. Fracassi
University of Bologna, Bologna, Italy
Canine pancreatic‐specific lipase (ScPL) is considered the most sensitive and specific
test for the diagnosis of pancreatitis in dogs. However, relatively high costs and
long turnaround times can limit everyday clinical use. Other more accessible serum
assays are available for daily usage like 1,2diglyceride lipase assay (total lipase;
TL) and 1,2‐o‐dilauryl‐rac‐glycero glutaric acid‐(6′‐methylresorufin) ester (DGGR)
lipase assay (DGGRL). Recently a study compared ScPL to DGGRL obtaining a high agreement.
For this reason DGGRL is actually widely used. A recent study observed that in 35%
of dogs with hypercortisolism, ScPL concentrations were elevated (≥400 μg/L) resulting
in false positive results for pancreatitis.
The aim of the present study is to evaluate serum DGGRL and TL activity in dogs affected
by naturally occurring hypercortisolism. Dogs with acute pancreatitis (AP) and healthy
dogs (HD) were used as controls.
Left over samples used for diagnostic proposals and stored at −20°C were selected
retrospectively, following stability period recommendations, and analyzed from 19,
21 and 23 dogs with hypercortisolism, AP and HD, respectively. Serum DDGRL and TL
were measured using an automated analyzer. Diagnosis of hypercortisolism was performed
combining more than 2 typical clinical signs with a positive specific endocrine test
(ACTH stimulation test and/or LDDS test). Dogs with hypercortisolism were included
only if they had absence of clinical and ultrasonographic signs suggestive of AP.
The diagnosis of AP was based on the presence of suggestive clinical, clinicopathological
(excluding the study variable) and ultrasonographic findings. Data were expressed
as median and (range) and compared using nonparametric statistics (P < 0.05 considered
significant).
Median DGGRL concentration (U/L) was 234 (55‐874), 263 (37‐1768) and 44 (19‐209) in
dogs with hypercortisolism, AP and in HD, respectively. Median TL concentration (U/L)
was 416 (144‐1932), 469 (84‐3472) and 270 (58‐544) in dogs with hypercortisolism,
AP and in HD, respectively. DGGRL and TL concentrations were significantly different
among HD and the other two groups, but resulted not different between dogs with hypercortisolism
and AP (P = 0.58; P = 0.74). DGGRL concentrations were above the reference interval
(10‐130 U/L) in 63.2%, 66.6% and 8.7% dogs with hypercortisolism, AP and HD, respectively.
TL concentrations were above the reference interval (70‐700 U/L) in 26.3%, 33.3% and
0% dogs with hypercortisolism, AP and in HD, respectively.
Because of the high rate of false positive results, DGGRL concentrations should be
evaluated with caution when AP is suspected in dogs with hypercortisolism.
Disclosures
Disclosures to report.
Federico Fracassi Financial support: Dechra, MSD. Speaking & consultancies: Boehringer
Ingelheim, Dechra, MSD, Royal Canin, Hill's, Nestlé Purina, La Vallonea. Francesco
Dondi Financial support: Zoetis. Speaking & consultancies: Boehringer Ingelheim, La
Vallonea.
ESVE‐O‐13
Comparison of measurement of free thyroxine concentration by a chemiluminescent analogue
immunoassay to equilibrium dialysis in dogs with non‐thyroidal illness
M. Bennaim1, R.E. Shiel2, H. Evans3, C.T. Mooney2
1Aquivet Referrals, Eysines, France, 2School of Veterinary Medicine, University College
Dublin, Belfield, Ireland, 3NationWide Specialists Laboratories, Cambridge, United
Kingdom
Measurement of free thyroxine (T4) concentration by equilibrium dialysis (fT4d) is
technically demanding and expensive. An automated free T4 analogue (fT4a) immunoassay
(Immulite 2000 Veterinary Free T4, Siemens) has recently gained popularity. However,
there are concerns regarding its ability to differentiate hypothyroidism from non‐thyroidal
illness (NTI).
The aim of this study was to evaluate the changes in fT4a concentrations in dogs with
NTIs for comparison with simultaneous total T4 and fT4d concentrations. It was hypothesized
that fT4a would provide good and poor agreement with total T4 and fT4d concentrations,
respectively.
Initially fT4a concentrations were measured in surplus serum samples from 150 dogs
with various NTIs in which hypothyroidism was not suspected. Total T4 concentration
(Immulite Canine Total T4, Siemens) and fT4d (Free T4 by Equilibrium Dialysis, Antech
Laboratories) were subsequently measured in a subpopulation of 75 dogs selected with
a range of fT4a concentrations. Reference intervals were 7.7 to 47.6 PMol/L, 7.0 to
40.0 PMol/L and 15.0 to 50.0 nmol/L for fT4a, fT4d and total T4, respectively. The
Kruskal Wallis or chi‐squared tests were used for statistical analysis, as appropriate.
In 150 dogs with NTI, fT4a was significantly (P < 0.001 and P = 0.023, respectively)
lower in dogs with severe compared to mild and moderate NTI. The proportion of dogs
with values below the reference interval was significantly (P = 0.013 and 0.0032,
respectively) less for fT4d (n = 25 [33.3%]) compared to fT4a (n = 40 [53.3%]) and
total T4 (43 [57.3%]). The proportions did not differ significantly (P = 0.62) between
fT4a and total T4. Among the dogs with low total T4 concentration, fT4a and fT4d were
normal in 5 (11.6%) and 19 (44.2%) dogs, which was significantly (P < 0.001) different.
Among the 40 dogs with low fT4a, 15 (37.5%) dogs had normal fT4d values. Bland‐Altman
difference plot revealed that fT4a underestimated and overestimated free T4 concentration
as measured by fT4d at low and high concentrations, respectively.
Considering the lack of agreement observed, fT4a and fT4d cannot be used interchangeably.
As opposed to fT4d, fT4a provided no more diagnostic information than that gained
by measurement of total T4 in dogs with NTI. Based on these results, fT4a cannot be
recommended to differentiate NTI from hypothyroidism in dogs with a low total T4 concentration.
This represents the population in which measurement of free T4 concentration is most
commonly recommended.
Disclosures
Disclosures to report.
Carmel Mooney provides consultancy services for Dechra Veterinary Products. Helen
Evans is Veterinary Services Operation Manager at NationWide Specialist Laboratories.
ESVE‐O‐14
Organoid cultures of follicular‐cell thyroid carcinoma: a novel canine model for translational
thyroid cancer research
E. Tièche*1, K. Hahn*2, M. Dettwiler2, F. Massari3, S. Schallberger4, M. Kessler5,
S. Rottenberg2, M. Campos1
1Department of Clinical Veterinary Science, Vetsuisse Faculty, University of Bern,
Bern, Switzerland, 2Institute of Animal Pathology, Vetsuisse Faculty, University of
Bern, Bern, Switzerland, 3DOCVET, Nerviano, Italy, 4Tierklinik Thun, Thun, Switzerland,
5Tierklinik Hofheim, Hofheim, Germany
Growing patient‐derived tissue in 3‐dimensional cell culture systems (organoids) has
revolutionized in vitro cancer research. In contrast to 2‐D cell lines, organoids
can be grown more efficiently and conserve important features of the original tumor,
such as tissue architecture and cellular heterogeneity. In human medicine, organoid
cultures provide a unique platform for personalized cancer therapy. In this study,
we aimed to culture and characterize organoids derived from follicular‐cell thyroid
carcinoma (FTC) in dogs.
Tissue samples of follicular type (n = 1) and compact type (n = 1) FTCs derived from
two euthyroid dogs were frozen in DMSO‐containing freezing medium within 24 h of thyroidectomy
and stored at −150°C until processing. After thawing, the tissue was digested with
collagenase IV and dissociated mechanically. Cells were subsequently seeded in Cultrex®
Basement Membrane Extract and cultured to organoids in Advanced DMEM supplemented
with N‐acetylcysteine, B‐27 supplement, EGF, Noggin, Rspondin‐1 and Rock‐inhibitor.
Organoids were split and passaged every 9 to 14 days. After 15 to 24 days, organoids
were formalin‐fixed, pelleted in 2.5% agarose, paraffin‐embedded and processed for
hematoxylin‐eosin staining. Immunohistochemistry (IHC) for thyroid transcription factor‐1
(TTF‐1), thyroglobulin (Tg), calcitonin, vimentin and Ki‐67 was performed on sections
of the primary tumors and organoids.
Organoids of FTC were cultured efficiently using our protocol. Organoids of both tumors
formed follicle‐like structures composed of a single epithelial cell layer. These
epithelial cells were round to cuboidal, had variably distinct cell borders and abundant
eosinophilic to foamy cytoplasm. Anisocytosis and anisokaryosis were not observed
in either of the organoid lines but were present in the FTC of compact type.
Nuclear expression of TTF‐1 in both organoid lines confirmed thyroid origin. The organoids
derived from the compact FTC, which had approximately 30% of cells positive to Tg,
showed no Tg expression while the organoids derived from the follicular FTC, which
had Tg expression in >95% of cells, showed Tg expression in about 50% of the organoids.
Vimentin expression was observed in both organoid lines (30‐60% of cells) and was
higher than in the primary tumors, where only up to 10% of tumor cells were positive.
IHC for calcitonin and Ki‐67 was negative in both organoid lines.
Organoids derived from naturally occurring canine FTC are able to conserve histological
and immunohistochemical features of the primary tumors providing an interesting in
vitro model to better understand the pathogenesis and optimize treatment of thyroid
cancer in dogs. The culture protocol likely requires further optimization.
Disclosures
No disclosures to report.
*Both authors contributed equally to this work.
ESVIM‐O‐1
Pulmonary deposition of nebulized 99mTc‐DTPA after pharmacologically induced airway
narrowing in healthy dogs
R.A. Hirt1, A. Carranza1, A. Hiebl1, D. Kampner2, M. Pagitz1
1Vetmeduni Vienna, Vienna, Austria, 2Anicura Tierklinik Hollabrunn, Hollabrunn, Austria
In humans, airway narrowing due to asthma or COPD commonly results in heterogeneous
deposition of aerosols within the lung. Consequently, uneven distribution of inhaled
medications may lead to variable and inadequate drug levels in certain lung areas.
Currently it is not known if the same effects occur in dogs with lower airway disease.
The purpose of this study was to evaluate the effects of pharmacologically induced
airway narrowing on pulmonary deposition of a nebulized radiopharmaceutical (ie. the
amount and distribution) in healthy dogs.
The prospective study was conducted in ten healthy beagles. Radiopharmaceutical inhalation
was performed on 2 occasions with a wash out period of at least 1 week between both
experiments (ie. without and immediately after induction of airway narrowing). Narrowing
of the airways was achieved by nebulizing increasing concentrations of carbachol into
a barometric whole body plethysmography chamber harboring the animal until airway
narrowing was detected by the system (Buxco FinePoint®; endpoint: increase of PENH
>300% over baseline).
On both occasions dogs inhaled a dose of nebulized 99mtechnetium‐diethylenetriamine‐pentaacetic
acid (99mTc‐DTPA) through an Aerochamber® Medium attached to a customized nose‐muzzle
mask for 3 minutes. Immediately afterwards dogs were scanned with planar scintigraphy
in right lateral, left lateral and sternal recumbency. The deposition of 99mTc‐DTPA
in the head region, the lungs, the stomach, as well as the whole body distribution
were recorded and quantified by manual or isocontour region of interest (ROI) analysis.
Deposition calculated as percentage of delivered dose in the ROI was compared. The
distribution of deposition within the lungs was scored independently by 3 blinded
observers for the degree of asymmetry between right and left lung (0‐2) and patchiness
(0‐2) of individual images as well as possible differences in the scan image pairs
(ie. before and after airway narrowing; 0‐2) in random order. For analysis, individual
scores were averaged.
Mean percentage uptake of the delivered dose in the lungs was not significantly different
before and after airway narrowing. Before airway narrowing, the average asymmetry
score was 0.8 whereas none of the dogs had a patchy distribution (score 0). After
airway narrowing, the scores for asymmetry and patchiness significantly increased
(1.7 and 1.1, respectively). Comparison of the scan image pairs before and after airway
narrowing revealed a significant difference (score 1.8).
This study indicates that airway narrowing in dogs results in heterogeneous aerosol
deposition within the lungs, although the overall amount of drug deposition is not
affected.
Disclosures
Disclosures to report.
Lecturer for Improve (Hirt).
ESVIM‐O‐2
Assessment of lung microbiota in healthy dogs: impact of breed and living conditions
A. Fastrès, E. Vangrinsven, B. Taminiau, A.C. Tutunaru, H. Jabri, G. Daube, C. Clercx
University of Liège, Liège, Belgium
The lung has been recognized to host a diverse, low biomass bacterial population,
identified as the lung microbiota (LM). In human chronic lung diseases (CLDs), the
LM is altered compared with that of healthy patients. However, whether alterations
are a cause or a consequence of the disease is still unclear. In dogs, the LM has
been described mostly in healthy experimental beagles. However, in a previous work
from our team, an impact of the living conditions and/or of the breed was suspected
between healthy beagles and West Highland white terriers (WHWTs). Recent studies in
mice and horses showed modifications in the LM according to the living conditions.
These modifications in the LM could predispose individuals to certain CLDs. So, we
aimed to assess the breed impact and the influence of living conditions, either experimental
or domestic, on the LM, in healthy dogs.
Healthy dogs were sampled, for a total of 48 dogs, and categorized into 5 groups:
experimental Beagle (EB), Shepherd (S), Terrier (T), Brachycephalic (Br) and WHWT
dogs, a breed with high susceptibility for canine idiopathic pulmonary fibrosis (CIPF).
Bronchoalveolar lavage fluid (BALF) was obtained under anaesthesia in each dog. After
DNA extraction from BALFs, a PCR targeting the V1‐V3 region of the 16S rDNA was performed.
Amplicons were then sequenced on a MiSeq Illumina sequencer. Taxonomical assignation
and microbiota community analysis were done with MOTHUR V1.40 with an OTU clustering
distance of 0.03.
Results showed that the bacterial load was higher in EB dogs (P < 0.0001). The AMOVA
results indicated differences between EB group compared with S and T groups (P < 0.005).
Significant differences in relative abundances at the family and the genus level were
found. The genus Hydrogenophilus was higher in EB and the genera Brochothrix, Limnohabitans,
Parabacteroides and Curvibacter were higher in WHWT compared with other groups (P
< 0.05). In each group, specific genera were found as indicators of discrimination
(p < 0.05). Bacterial richness was higher in WHWT than in EB, S and T groups (P < 0.001),
but there were no significant differences for the evenness and the α‐diversity between
groups.
Our study demonstrated an effect of the living conditions on the LM. Breed differences
were also shown. This LM modifications might be related to breed susceptibility to
lower respiratory diseases, such as CIPF in WHWTs and need to be considered in future
analyses on the role of LM disturbances in diseases.
Disclosures
No disclosures to report.
ESVIM‐O‐3
Protein biomarkers in regurgitation, vomiting, and cough: proteomic characterization
of canine gastric fluid by liquid chromatography mass spectrometry (LCMS)
M.E. Grobman, C. Reinero
University of Missouri, Columbia, United States of America
Reflux and aspiration in people cause and exacerbate respiratory diseases. Protein
biomarkers in humans detect extra‐esophageal reflux (EER) in the absence of overt
dysphagia, regurgitation, or vomiting. In dogs, reflux likely contributes to respiratory
disease pathogenesis and progression.
Our study objectives were as follows: (1) Perform comprehensive analysis of the canine
gastric fluid (GF) proteome. (2) Compare the oropharyngeal (OP) proteome in normal,
vomiting/regurgitating and coughing dogs to identify potential biomarkers for EER
and aspiration. (3) Compare biologic function of proteins between sites.
Twenty‐three client‐owned dogs were prospectively enrolled. Canine GF samples (n =
5) and OP swabs in normal (n = 6), vomiting/regurgitating (n = 7), and coughing (n
= 5) dogs were evaluated. Protein digests were analyzed by liquid chromatography mass
spectrometry (LCMS). Data were searched against the NCBIMus database. Differential
abundance (DA) of proteins and functionality between groups was evaluated by Fisher
Exact test and ANOSIM respectively. A P < 0.0004 and p ≤ 0.01 respectively were considered
significant after correction for multiple comparisons.
Across sites, 504 individual proteins were identified. Normalized spectral abundance
demonstrated pancreatic proteins were increased compared to pepsin in GF. Significant
differences in DA between groups was noted (P < 0.0001): GF vs normal (n = 130), cough
vs. normal (n = 22), reflux/vomiting vs. normal (n = 20). Marked between‐dog variation
was observed for proteins with DA. Functional proteome was dissimilar between all
groups (P ≤ 0.01).
In conclusion, the proteomic composition of OP swabs varies between health and disease.
Variable abundance may impact utility of individual gastric proteins as disease biomarkers
and investigation into biomarker panels is warranted.
Disclosures
Disclosures to report.
Though unrelated to this project, a portion of my salary is provided by the the Boehringer
Ingelheim Post‐doctoral Fellow Program.
ESVIM‐O‐4
Serum 25‐hydroxyvitamin D in dogs with sinonasal aspergillosis
J. Jaffey1, C. Clercx2, F. Billen2, N. Fernandes2, R.C. Backus3
1Midwestern University, Phoenix, United States of America, 2Faculty of Veterinary
Medicine, University of Liege, Belgium, 3University of Missouri Veterinary Health
Center, Columbia, United States of America
Vitamin D has important roles in both innate and adaptive immune responses. Hypovitaminosis
D in people has been associated with increased susceptibility and severity of illness
with a variety of inhaled respiratory pathogens. Sinonasal aspergillosis (SNA) is
a common cause of chronic nasal disease that remains a challenge to treat and is associated
with substantial morbidity and non‐survival in dogs. There is a lack of biomarkers
that can predict the development of SNA and treatment outcome in dogs. Therefore,
the 2 objectives of this study were 1) to compare serum 25(OH)D concentrations in
dogs with SNA and healthy control dogs and 2) to determine if serum 25(OH)D concentrations
can predict first time treatment outcome.
Nine dogs with SNA and 8 healthy control dogs were in included in the retrospective
arm of this study. Serum samples were obtained from these 17 dogs between 2017 and
2019 and stored at −80° C until analysis. Diagnosis of SNA was based on presence of
compatible clinical signs and per‐endoscopic identification of fungal plaques with
turbinate destruction and fungal culture. Treatment was deemed successful if there
was resolution of clinical signs and absence of fungal plaques on follow‐up rhinoscopy.
Serum 25(OH)D was measured using HPLC.
Seventy‐eight percent of dogs with SNA had complete fungal debridement. Seven dogs
had follow‐up available of which 57% (4/7) had first time treatment success. Dogs
with SNA had significantly decreased serum 25(OH)D concentrations (mean, SD; 26.7 ng/ml,
15.3 ng/ml) compared to healthy control dogs (40.2 ng/ml, 7.4, p = 0.03), two‐tailed
t‐test). Serum 25(OH)D concentrations was not associated with first time treatment
outcome (P = 0.33, logistic regression).
These results suggest that serum 25(OH)D is significantly decreased in dogs with SNA
as well as a potential immunologic contributory role in the disease. In addition,
these results support pursuit of the prospective arm of the study that will investigate
potential mechanisms for decreased serum 25(OH)D in dogs with SNA and its role in
treatment outcome.
Disclosures
No disclosures to report.
ESVIM‐O‐5
Plasma mRNA cathelicidin expression in hospitalized critically ill dogs
J.A. Jaffey1,2, O. Okwumabua2, Z. Tao2, S. Manam2, R.C. Backus1, A.E. DeClue1
1Departments of Veterinary Medicine and Surgery, Veterinary Health Center, University
of Missouri, Columbia, Missouri, United States of America, 2Midwestern University
College of Veterinary Medicine, Glendale, Arizona, United States of America
Cathelicidin is an antimicrobial peptide essential to the innate immune system and
whose circulating concentrations are well documented to have a positive association
with 25‐hydroxyvitamin (OH) D in people. Decreased 25(OH)D concentrations are predictive
of survival in people and dogs with critical illness. Decreased production of cathelicidin
has been proposed to be an important mechanism linking decreased 25(OH)D concentrations
with survival in critically ill people. Therefore, we aimed to evaluate the association
between plasma cathelicidin mRNA expression and serum 25(OH)D concentration and survival
in critically ill dogs.
Nineteen dogs (sepsis, n = 7, critically ill without sepsis n = 5, healthy controls
n = 7) from a cohort (n = 99) with previously measured 25(OH)D concentrations were
randomly selected. Plasma mRNA was extracted, reverse transcribed and resulting cDNA
was used as template for real‐time PCR using specific primers for canine cathelicidin.
There was not a significant difference in cathelicidin concentrations between dogs
with sepsis (mean, SD; 8.29, 0.47), critically ill without sepsis (8.90, 0.82), and
healthy controls (8.52, 0.62; P = 0.32; one‐way ANOVA). There was not a significant
correlation between 25(OH)D and cathelicidin expression (rs = −0.14, P = 0.55; spearman
correlation). Thirty‐three percent (4/12) of critically ill dogs did not survive to
discharge. Cathelicidin concentrations were not predictive of survival to discharge
(P = 0.64; logistic regression). Dogs with sepsis (mean, SD; 26.1 ng/ml, 9.2, P = 0.001),
and critically ill dogs without sepsis (18.7 ng/mL, 9.4, P < 0.001) had significantly
decreased serum 25(OH)D compared to healthy controls (53.9 ng/ml, 15.7, one‐way ANOVA).
Severity of illness defined by APPLEfast scores (P = 0.22), serum 25(OH)D concentration
(P = 0.25), and presence of sepsis (P = 0.42; logistic regression) were not predictive
of survival.
Based on this small cohort, there was no association between plasma cathelicidin mRNA
expression and serum 25(OH)D concentrations or outcome in critically ill dogs. The
negative results from this preliminary investigation should be interpreted with caution
as the number of dogs enrolled was small and type II error might have been a contributing
factor to a lack of association.
Disclosures
No disclosures to report.
ESVIM‐O‐6
Hereditary methemoglobinemia in dogs caused by cytochrome b5 reductase deficiency
associated with variants in CYB5R3
J. Jaffey1, G. Johnson2, G. Bullock2, N. Villani2, T.M. Tendai2, S. Reading3, L. Cohn2,
A. Wiest4, O. Abdulmalik4, J.W. Harvey5, U. Giger4
1Midwestern University, Phoenix, United States of America, 2University of Missouri
Veterinary Health Center, Columbia, United States of America, 3ARUP Laboratories,
Salt Lake City, United States of America, 4University of Pennsylvania, Philadelphia,
United States of America, 5University of Florida College of Veterinary Medicine, Gainesville,
United States of America
Methemoglobin forms when hemoglobin iron is oxidized from ferrous iron (Fe2+) to ferric
iron (Fe3+), which is incapable of binding O2. Hereditary methemoglobinemia in dogs
is most commonly caused by cytochrome b5 reductase (CYB5R) deficiency. We recently
reported on 2 likely‐causal CYB5R3 variants in 1 dog. Scattered case reports show
varied clinical consequences of hereditary methemoglobinemia in dogs. Therefore, the
objectives of this study were to determine the metabolic and molecular bases and characterize
clinicopathological features of canine CYB5R deficiency.
Twenty‐five dogs from various breeds were investigated for unexplained mild to severe
non‐cardiopulmonary cyanosis. EDTA blood was used to determine methemoglobin concentrations
(methb%) and CYB5R enzyme activities, and analyze CYB5R3 gene for disease‐causing
mutations. The previously documented nonsynonymous Ile190Leu CYB5R3 variant was homozygous
in 16 of the dogs and heterozygous in 3 dogs. The other previously identified variant
was not found in any other dogs. Whole genome sequencing analysis identified 2 novel
nonsynonymous CYB5R3 variants: Arg219Pro (homozygous in 7 dogs) and Thr202Ala (homozygous
in 1 dog).
The mean methb% was 23.8% (±11.5 [SD]) and median CYB5R activity was 10.9% (Q1, Q3;5.8,24.1).
Dogs homozygous for the Arg219Pro variant had significantly greater methb% (36.2± 9.9%)
and more clinical signs than those homozygous for Ile190Leu variant (15.7%, 6.0, P
< 0.001). Beside cyanosis, 70% of dogs exhibited ≥1 other clinical sign.
In conclusion, this study reveals the clinical, metabolic, and molecular genetic variation
seen in CYB5R deficiency in dogs. The Arg219Pro variant appeared to cause a more severe
phenotype than the Ile190Leu variant. The 4 DNA variants identified can been readily
used as genetic screening tests.
Disclosures
No disclosures to report.
ESVIM‐O‐7
Differences in clinical presentation of common dog breeds diagnosed with primary IMHA
B. Jones1, B. Glanemann1, J.W. Swann2
1Royal Veterinary College, University of London, North Mymms, United Kingdom, 2Kennedy
Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Canine primary immune‐mediated haemolytic anaemia (IMHA) is a common haematological
emergency and the incidence differs among breeds. It is unknown whether dogs of predisposed
breeds present with different degrees of disease severity, different clinical signs
or differences in clinicopathological findings. This information could be used in
the clinic to guide treatment and provide prognostic advice for owners. The primary
aim of this retrospective study was to identify any differences in these findings
and outcomes in some of the commonly‐affected breeds. We hypothesised that spaniel
breeds would have findings associated with more severe disease and poorer outcomes
compared to other breeds.
Electronic records of canine patients of a tertiary referral centre were searched
over a 10 year period for IMHA‐related keywords. A recently‐published algorithm was
used to assess the confidence of diagnosis of IMHA. Cases with sufficient features
of IMHA were analysed further but were excluded if investigations revealed possible
underlying disease or were incomplete. Cases were also excluded if they had received
immunosuppressive or blood transfusion therapy more than 48 hours prior to presentation.
For cases fulfilling inclusion criteria, the most frequent five breeds were selected
for analysis, as well as ‘cross breeds’ to serve as a control group. Data were collected
on the historical and clinical signs, clinicopathological findings and outcomes.
For continuous variables, one‐way ANOVA with a Dunnett's multiple comparisons test
was performed to compare each breed to the control group. For categorical variables,
z‐tests were used to compare proportions.
689 records were identified containing IMHA keywords, of which 253 fulfilled all inclusion
criteria. Cocker Spaniels (n = 36), Springer Spaniels (n = 25), Labradors (n = 15),
Jack Russell Terriers (n = 13) and Shih‐tzus (n = 11) were selected for final analysis,
alongside crossbreeds (n = 24) as a control group. Labradors were significantly older
when compared to the control group (mean 8.6 v. 5.9 years, P = 0.029). Surviving Cocker
Spaniels had significantly shorter hospitalisation periods when compared to the control
group (mean 5.97 v. 8.91 days, P = 0.031). Compared to cross breeds, a greater proportion
of Jack Russell terriers survived to discharge (100% v. 75%, P < 0.05).
Spaniel breeds did not appear to be affected more severely, with surviving Cocker
Spaniels requiring shorter hospitalisation periods. Jack Russell Terriers may have
a more favourable outcome but this finding could be confounded by the effect of treatment
and requires confirmation.
Disclosures
No disclosures to report.
ESVIM‐O‐8
Diagnostic imaging findings in a referral population of dogs diagnosed with immune‐mediated
haemolytic anaemia
N. de Laet, C. Fina, M.P. Dhumeaux, A. Hrovat
Pride Veterinary Centre, Derby, United Kingdom
Diagnostic imaging in dogs diagnosed with immune‐mediated haemolytic anaemia (IMHA)
is indicated to rule out systemic diseases mimicking or triggering the IMHA. However,
studies, providing descriptions of thoracic and abdominal abnormalities, supporting
a clinical decision making in dogs with IMHA are lacking.
The aim of this study was to describe changes documented on thoracic and abdominal
imaging of dogs with confirmed IMHA.
Medical records from a referral hospital were searched from 2015 and 2018 for all
dogs that were diagnosed with IMHA and underwent thoracic and abdominal imaging by
radiography, ultrasound or computed tomography (CT). To be included, a complete history,
clinical and routine laboratory examination findings had to be available as well.
A total of 51 client owned dogs fulfilled the inclusion criteria and were included
in this retrospective study. The median age of dogs was 6.4 years (range, 7 months
to 11.4 years). There were 9 sexually intact females, 26 spayed females, 8 sexually
intact and neutered males, respectively. CT of thorax and abdomen were performed in
7 and radiographs of the thorax and abdominal ultrasound in 44 dogs. Fine needle aspirates
(FNAs) were collected in 28 dogs.
CT and radiographs of the thorax revealed abnormalities in 11/51 dogs. Sternal lymphadenopathy
and cardiomegaly were documented in 4 dogs respectively and pleural effusion in 2
dogs.
CT and ultrasound of the abdomen revealed abnormalities in 44/51 dogs. Hepatomegaly
and peritoneal effusion were present in 20 dogs respectively, gallbladder wall thickening
in 17, gallbladder sludge in 15, splenic nodule in 13, diffuse steatitis in 11, enlarged
pancreas and abdominal lymphadenopathy in 8 and splenomegaly in 7 dogs.
Hepatomegaly and splenomegaly were further investigated via FNA in 19/20 dogs and
revealed extramedullary haematopoiesis in 12 hepatic and 14 splenic samples. Cholestasis,
vacuolar hepatopathy and reactive lymphoid hyperplasia were documented in less than
50% of samples collected from both organs. Round cell neoplasia was documented via
FNA of liver, spleen and abdominal lymph nodes in one dog. Cholecystocentesis was
performed in 10/17 dogs with gallbladder wall thickening and revealed positive bile
culture in 3 dogs.
In this population of dogs with IMHA thoracic imaging abnormalities were uncommon.
Hepatomegaly with gallbladder wall thickening and peritoneal effusion were the most
common abdominal imaging findings with bactibilia confirmed in one third of collected
bile samples. Hepatosplenomegaly and abdominal lymphadenopathy were uncommonly associated
with neoplasia.
Disclosures
No disclosures to report.
ESVIM‐O‐9
Determination of Blood Groups DEA 1, DEA 4, DEA 5, Dal, and Kai 1/2 in Different Canine
Breeds
A. Ebelt1, S. Fuchs1, C. Weber1, E. Müller1, U. Giger2
1Laboklin GmbH, Bad Kissingen and Radolfzell, Germany, 2University of Pennsylvania,
Philadelphia, United States of America
Dogs have >12 blood group systems, but little is known about their frequency in Europe.
Here we report on an extensive typing survey with available reagents and established
or new clinical kits in purebred dogs.
Leftover EDTA blood samples were examined using an immunochromatographic strip method
for DEA 1, a gel column technique for Dal and Kai 1/2, and new agglutination card
test for DEA 4 and DEA 5 (and partially compared with gel column). Monoclonal antibodies
were used for DEA 1 and Kai 1/2 typing and polyclonals for all other types.
Among the 164 examined dogs, 62% were DEA 1+, 100% DEA 4+, 11% (card)/14% (gel) DEA
5+, 97% Kai 1+ and 2% Kai 2+. Blood from most DEA 1+ dogs bound strongly positive
on the strips. Agglutination reactions for card and gel tests were concordant for
DEA 4+ samples. In contrast, the reactions for DEA 5 were generally less in the agglutination
test than in the gel column test with some discordant reactions. None of the dogs
were Kai 1+/2+, and only one was Kai 1−/2‐. Dal‐ dogs were found in Cane Corso, Dalmatian,
Doberman, Maltese, Mastiff, Shih Tzu, and Pug dogs. Various blood group patterns were
observed in other breeds.
In this first extensive blood typing survey of purebred dogs from Europe, the proportion
of positive and negative blood types were similar to those in US. The newer typing
techniques seem to work well (DEA 5 cards are being improved) and will be useful to
detect and prevent specific blood type incompatibilities in clinics.
Disclosures
Disclosures to report.
This study was part of A. Ebelt's doctoral thesis and was supported by Laboklin. The
authors are associated with either the Laboklin (Ebelt, Fuchs, Weber, Müller) or PennGen
(Giger) diagnostic laboratories which are offering blood typing. Reagents and kits
were generously supplied for this survey by Alvedia (France) and DMS Laboratories
(Flemington, US).
ESVIM‐O‐10
Systemic AA‐amyloidosis in shelter cats and shedding of amyloid fibrils
F. Ferri1, C. Guglielmetti2, S. Ferro3, P.L. Acutis2, E. Gallo3, V. Fiore4, F. Iavazzo1,
F. Folatti1, C. Callegari1, F. Porporato1, M. Mazza2, E. Zini5
1Istituto Veterinario di Novara, Granozzo con Monticello (Novara), Italy, 2Istituto
Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Turin, Italy,
3Department of Comparative Biomedicine and Food Sciences, University of Padua, Padua,
Italy, 4La Cincia, Avigliana (Turin), Italy, 5Department of Animal Medicine, Production
and Health, University of Padua, Padua, Italy
Systemic AA‐amyloidosis is a protein misfolding disease of humans and animals arising
from the formation of amyloid fibrils from the acute phase protein serum amyloid A.
In animals it is common in chickens and cheetahs kept in captivity. Latest studies
showed that transmission of systemic AA‐amyloidosis occurs in cheetahs and involves
fecal shedding of amyloid fibrils. Client‐owned domestic shorthair cats are rarely
affected by systemic AA‐amyloidosis. Whether systemic AA‐amyloidosis is common in
domestic shorthair cats living in shelters and shedding of amyloid fibrils occurs
is unknown. Thus, aims of the study were to determine the frequency of systemic AA‐amyloidosis
in different cat shelters and to investigate excretion of amyloid fibrils.
Any cat from 3 shelters was included if necropsy was performed within 6 hours from
death. Liver, kidney, spleen and bile were obtained during necropsy. Clinical and
laboratory results were retrieved from available medical archives. AA‐amyloid was
identified in tissues by hematoxylin‐eosin and Congo‐red staining, and confirmed by
immunoblotting. Shedding of amyloid fibrils was investigated with immunoblotting in
bile samples. Descriptive statistics and non‐parametric tests were used.
Deposition of AA‐amyloid was observed in the liver, kidney or spleen of cats that
died in each of the 3 shelters; in particular, the prevalence was 40% (8/20 cats),
50% (8/16 cats) and 85.7% (6/7 cats), respectively. In 13 cats all 3 organs were involved,
in 4 cats 2 organs, and in 5 cats 1 organ. In cats with any of the 3 organs being
AA‐amyloid‐positive, sensitivity and specificity of AA‐amyloid identification in the
bile was 83.3% and 58.3%, respectively; in those with only the liver involved, 87.5%
and 50%. Of note, semiquantitative analysis of AA‐amyloid in the bile showed that
none of 12 cats without organ deposition of AA‐amyloid had a score > 1+, while scores
2+ or 3+ were identified in 66.7% (8/12 cats) of those with any of the 3 organs involved
(P = 0.001). In 18 cats with AA‐amyloid‐positive organs medical records showed that
9 had kidney or liver involvement: 4 had azotemia, 3 proteinuria, and 3 hemoabdomen
due to spontaneous hepatic rupture.
In conclusion, the prevalence of systemic AA‐amyloidosis appears to be elevated in
shelter cats and shedding of amyloid fibrils occurs in the bile. Cats with systemic
AA‐amyloidosis are more likely to shed higher amounts of AA‐amyloid. Whether bile
excretion of AA‐amyloid indicates that horizontal transmission is relevant to the
disease in shelter cats remains undefined.
Disclosures
No disclosures to report.
ESVIM‐O‐11
Treatment of non‐lactate metabolic acidosis in hypovolemic and normovolemic dogs:
chloride‐free iso‐osmolar solution with elevated Strong Ion Difference versus Ringer's
Lactate solution
R. Rabozzi1, S. Oricco2, C. Odoardi1, C. Meneghini1, P. Iacobellis1, A. Accardi1,
P. Franci3
1CVRS ‐ Policlinico Veterinario Roma Sud, Roma, Italy, 2Centro Veterinario Imperiese,
Imperia, Italy, 3Università degli Studi di Torino, Torino, Italy
The use of sodium bicarbonate‐based solutions for treating metabolic acidosis is currently
debated. The alkalizing effect of solutions with elevated Strong Ion Difference (SID)
has recently been described. The primary aim of the study was to evaluate the safety
and efficacy of a chloride‐free iso‐osmolar solution with elevated SID (Hyper‐SID),
compared to Ringer's lactate used for the treatment of metabolic acidosis.
Hyper‐SID solution was prepared by adding 145 mEq/L of sodium, 145 mEq/L of lactate,
10 mEq/L of potassium and 10 mEq/L of aspartate to the sterile water for injections.
The calculated SID was 155 mEq/L.
This prospective, multicenter, randomized study evaluating the efficacy and safety
was authorized from the Ethical Committee. Hospitalized dogs with an excess of bases
≤ −10 mEq/L were enrolled in the study if the baseline lactate level was not greater
than 4 mEq/L. Patients were classified by ultrasonographic methods as hypovolemic
or normovolemic and randomized with random number generation in the type of fluid
to be received (Ringer's Lactate in the RL group and Hyper‐SID in the H‐SID group).
Normovolemic and hypovolemic dogs received 4 hours infusion at the rate of 4 or 10 mL kg−1
hr−1 respectively. Blood gas analysis, before fluid infusion (T0) and after 4 hours
(T4), were compared for the following parameters: Be‐ecf, pH, PCO2, Sodium, Potassium,
Chloride, Lactate, SID3, SID4. After normality distribution analysis, variables were
described and evaluated using non‐parametric statistics (significance level set to
5%).
Forty dogs were included in the analysis, median age was 110 months (12‐192) and median
weight 16 kg (3‐39). Dogs classified as hypovolemic were 9/40 in the RL group and
13/40 in H‐SID group, while dogs classified as normovolemic were 8/40 in the RL group
and 10/40 in the H‐SID group. The basal Be‐ecf was not different between the treatment
groups (P > 0.05). In normovolemic patients the median increase in Be‐ecf at T4 in
the RL and H‐SID group was 0.8 mEq/L and 4.5 mEq/L (P = 0.004) respectively, whereas
in hypovolemic patients was respectively of 1.3 mEq/L and 11,5 mEq/L (P = 0.0001).
Lactate value greater than 5 mEq/L was not documented in any patient during the study.
The Hyper‐SID solution proved to be effective and superior to the RL solution in the
treatment of non‐lactate metabolic acidosis in hospitalized dogs. In the sample of
subjects belonging to the H‐SID group, no side effects or raising lactatemia was reported
during the infusion period.
Disclosures
No disclosures to report.
ESVNU‐O‐1
Serum symmetric dimethylarginine in dogs and cats with acute kidney injury treated
with intermittent hemofiltration
C. Amram1, F. Ferri1, F. Iavazzo1, F. Folatti1, F. Porporato1, M. Pesaresi1, E. Zini2
1Istituto Veterinario Novara, Granozzo con Monticello (NO), Italy, 2Università degli
studi di Padova, Padova (PD), Italy
Serum symmetric dimethylarginine (SDMA) concentration has been shown to be a marker
of renal dysfunction in dogs and cats. In humans, dialysis lowers SDMA but less efficiently
than urea because the former has a larger distribution volume. Information concerning
SDMA in animals undergoing extracorporeal renal replacement therapy is yet lacking.
The aim of this study was to describe the dynamic of SDMA concentration in dogs and
cats with acute kidney injury treated with intermittent hemofiltration (IHF).
Reports of IHF performed between October 2017 and 2018 were collected. Medical records
were reviewed and cases with pre‐ and post‐IHF biochemical profiles were included.
IHF was performed according to standard methods. Urea, creatinine and SDMA reduction‐ratio
(URR, CreaRR, SDMARR) was calculated for each IHF. In dogs and cats separately, first
sessions of IHF were included in group A, second sessions in group B and third sessions
in group C. URR, CreaRR and SDMARR were compared within each group with non‐parametric
tests.
Overall, 39 IHF sessions were performed in 14 dogs and 8 cats; specifically, 13 dogs
and 8 cats in group A, 9 dogs and 5 cats in group B, 3 dogs and 1 cat in group C.
Five (35.7%) dogs and 3 (37.5%) cats survived. Median SDMA concentration pre‐IHF was
62 μg/dl in dogs (range: 15‐ > 100) and 78 μg/dl in cats (range: 41‐ > 100). In dogs,
median values of URR, CreaRR and SDMARR were 37.1% (range: 12.0‐66.3), 35.6% (range:
12.0‐67.7) and 16.7% (range: −86.7‐42.6), respectively; in cats, their median values
were 38.6% (range: 20.4‐52.4), 41.5% (range: 21.2‐54.1) and 33.8% (range: 7.1‐50.0).
In 8 of 25 (32%) IHF sessions in dogs, SDMARR was either negative (n = 5) or 0 (n
= 3). These 8 sessions were performed in 6 dogs: 4 had leptospirosis and 2 poisoning
(grape and ethylene glycol), 4 died. The median SDMARR was lower than URR in groups
A and B in dogs (P = 0.021, P = 0.008) and not different in cats. In group A in dogs,
SDMARR was also lower than CreaRR (P = 0.007). No other differences were observed
in both species.
In conclusion, SDMARR did not represent an accurate marker to assess efficiency of
IHF in dogs. The partial inability of IHF to clear SDMA, the large distribution volume
of SDMA or other unknown conditions affecting post‐IHF SDMA concentration might have
contributed to this result. Differently, SDMARR may be reliable to evaluate IHF efficiency
in cats.
Disclosures
No disclosures to report.
ESVNU‐O‐2
Non‐obstructive ‘acute on chronic’ kidney disease in the cat: is it possible to predict
survival?
M.R. Faucher1, J. Renard1, A. Combes1, D. Concordet2, B.S. Reynolds2
1Alliance Clinic, Bordeaux, France, 2INTHERES, Toulouse University, Toulouse, France
Cats with chronic kidney disease (CKD) are often presented when a superimposed acute
uremic crisis happens and any prognostic indicator would be of relevance to feline
practitioners.
The aim of this study was to determine if some variables commonly assessed in azotemic
cats in that particular context could be accurate predictors of survival.
Medical records over 4 years from azotemic cats hospitalized for at least two days
with acute signs and confirmed CKD based on ultrasonographic findings and/or previously
documented azotemia were retrospectively reviewed. Cats with potential toxic, neoplastic
or obstructive cause of azotemia were not included. Signalment, clinical signs (combined
into a clinical severity score [CSS]), selected laboratory and diagnostic imaging
results and outcome were registered. A machine learning‐based classification and regression
trees method was used to assess predictors of survival at 7, 30, 90 and 180 days.
Thirty‐two cats were included in this study. Overall median survival time was 28 days
(range: 0 to 1566 days). Plasma creatinine concentration after 2 days of hospitalization
(Crea48) was the best predictor of survival. A Crea48 of less than 64 mg/L best predicted
survival at 7, 30 (Se = 0.87; Sp = 0.77) and 90 days. A Crea48 of less than 38 mg/L
best predicted survival at 180 days. When Crea48 was censored from the analysis a
lower CSS and a younger age were also predictive of survival up to 90 days.
This study confirms that Crea48 is a good predictor of short and medium‐term survival
in cats with CKD presented in uremic crisis.
Disclosures
Disclosures to report.
M.Faucher: Webconference for Boehringer Ingelheim A.Combes: Speaker for Veterinarius.
ESVNU‐O‐3
Effect of measurement location on systolic blood pressure (SBP) readings in out‐patient
and in‐patient dogs
A.C.C. Ferreira, A. Mcbrearty
Glasgow University Veterinary School, Glasgow, United Kingdom
Non‐invasive blood pressure (BP) measurement is widely used to diagnose hypertension,
yet many factors affect measurement accuracy. ACVIM guidelines propose a standard
protocol which suggests BP should be performed with the owner present. Studies have
not been performed to evaluate this in dogs nor to evaluate whether SBP varies in
different hospital locations.
The aims were: 1) to determine whether SBP was different in out‐patient dogs when
measured in the consult room with the owner or a quiet room away from the owner and
2) to determine whether SBP measured in in‐patient dogs was different when measured
in their kennel or in a quiet room away from other dogs.
Each dog had their BP measured using high definition oscillometry in 2 locations consecutively;
for the 25 out‐patients, in the consult room with the owner and in a quiet room and
for the 25 in‐patients, in their kennel and in a quiet room. The measurement location
order was randomized. Blood pressure measurement methods were standardized and based
on the ACVIM consensus statement and instrument manufacturer recommendations. The
BP cuff was placed on the tail. All measurements were taken by a single veterinary
surgeon using the same cuff and body position for each dog in both locations. The
pulse waveform was visualized during measurement and 5 valid readings were collected
and averaged in each location. Descriptive statistics were performed and the number
of dogs with >20% difference between locations was calculated. In addition, SBP was
classified using ACVIM consensus statement hypertension categories.
For out‐patients, SBP was a mean of 6 mmHg (SD: 20) higher in a quiet room. In 6 dogs
(24%), SBP was >20 mmHg different between the locations (3 were higher in the consult
room). Fourteen out‐patients (56%) changed hypertension category when the location
changed (9 were higher away from the client).
For in‐patients, the mean difference in SBP between the locations was 0 mmHg (SD:
18), however there was >20 mmHg difference in SBP in 7 dogs (28%) (4 were higher in
kennels). Eleven in‐patients (44%) changed hypertension category when the location
changed (6 were higher in kennels).
Although the mean difference in SBP in both locations was small for both in‐ and out‐patients,
approximately a quarter of dogs in both groups had >20% differences between locations
and approximately half changed hypertension category. This suggests that to measure
changing trends in any individual animal, the location of measurement should be kept
constant.
Disclosures
Disclosures to report.
The HDO device was bought with money from the University of Glasgow Veterinary Fund
Small Grant Scheme.
ESVNU‐O‐4
Immune‐complex glomerulonephritis in cats: a retrospective study based on clinico‐pathological
data and morphological features
F. rossi
1, L. Aresu2, V. Martini3, D. Trez4, R. Zanetti4, L.M. Coppola5, F. Ferri1, E. Zini6
1Istituto Veterinario di Novara, Granozzo con Monticello, Italy, 2Department of Veterinary
Science, University of Turin, Grugliasco (TO), Italy, 3Department of Veterinary Medicine,
University of Milan, via dell'Università, Lodi, Italy, 4Department of Comparative
Biomedicine and Food Science, University of Padova, Vi, Agripolis Legnaro (PD), Italy,
5Department of Animal Medicine, Production and Health, viale dell'Università 16, Agripolis
Legnaro (PD), Italy, 6Clinic for Small Animal Internal Medicine, Vetsuisse Faculty,
University of Zuri, Zurich, Switzerland
Chronic kidney disease (CKD) has typically a non‐immune mediated origin in cats and
immune‐complex glomerulonephritis (ICGN) has been scarcely described. To date, few
descriptions of ICGN have been published in cats, with membranous glomerulonephropathy
(MGN) being most commonly reported. Therefore, aims of this study were to characterize
morphological diagnoses of ICGN by light and electron microscopy in a large cohort
of cats and to identify associations with clinical and laboratory findings. Additionally,
comparisons were performed with cats affected by non immune‐complex glomerulonephritis
(non‐ICGN).
Renal biopsies of cats with ICGN and non‐ICGN examined between 2010 and 2019 were
considered if both light and electron microscopy were available. Data collected for
analysis included breed, sex, age, feline immunodeficiency virus (FIV) and feline
leukemia virus (FeLV) status, serum creatinine concentration, urine protein‐to‐creatinine
(UPC) ratio and systolic blood pressure (SBP). Differences between morphological diagnoses
of ICGN and non‐ICGN, including tubulointerstitial damage score, were investigated
with Kruskal‐Wallis and chi‐squared tests. The likelihood of diagnosing ICGN versus
non‐ICGN was explored with logistic regression.
Sixty‐eight cats were included, 37 (54.4%) with ICGN and 31 (45.6%) with non‐ICGN.
In cats affected by ICGN, 18 (48.6%) had MGN, 14 (37.8%) membranoproliferative glomerulonephritis
(MPGN) and 5 (13.5%) mesangioproliferative glomerulonephritis. Breed, sex, age, FIV
and FeLV status, creatinine, UPC ratio and SBP were not different among morphological
diagnoses. In cats with non‐ICGN, 11 (35.5%) had end‐stage CKD, 9 (29%) focal and
segmental glomerulosclerosis, 6 (19.4%) global mesangiosclerosis, 2 glomerular atrophy
and renal dysplasia (6.5%) and 1 (3.1%) amyloidosis. Eight (25.8%) cats with non‐ICGN
had grade 1 tubulointerstitial damage, 13 (41.9%) grade 2 and 10 (32.3%) grade 3;
creatinine and UPC ratio were positively associated with grades (P = 0.001, P < 0.001).
Cats with ICGN were more likely to have FIV or FeLV infection than those with non‐ICGN
(13/37 vs. 0/21; P = 0.002) and had higher mean UPC ratio (7 ± 3.2 vs. 3.6 ± 2.3;
P < 0.001). Mean age of cats with ICGN was lower than those with non‐ICGN (9.2 ± 3.3
vs. 10.9 ± 3.3 years; p = 0.042).
In conclusion, MGN and MPGN were the two most common morphological diagnoses of ICGN
in cats, but clinical and laboratory findings did not allow their differentiation.
In cats with non‐ICGN, serum creatinine concentration and UPC ratio were associated
with the degree of tubulointerstitial damage confirming previous literature. Cats
with retrovirus infections, higher UPC ratio and younger age were more likely affected
by ICGN than non‐ICGN.
Disclosures
No disclosures to report.
ESVNU‐O‐5
Short course of immune‐suppressive doses of prednisolone is associated with renal
hyperfiltration and changes in hydration and electrolyte status in healthy beagle
dogs
M.I.I.Y. Mantelli1, B.B. Roques1, T. Blanchard1, M. Mounier1, M. Quincey1, F. Jolivet1,
N. Jousserand1, A. Marchand1, A. Diquélou1, B.S. Reynolds1, M. Coyne2, R. Murphy2,
H.P. Lefebvre1, R. Lavoué1
1National Veterinary School of Toulouse, Toulouse, France, 2IDEXX Laboratories, Inc.,
Westbrook, United States of America
Glucocorticoids influence renal function and are frequently prescribed in dogs. The
extent and duration of their effects is scarcely described. Our objectives were to
assess prednisolone effects on renal, electrolytic and hydration status in healthy
dogs.
24‐hours urine collection, total body water content (tBWC) using pharmacokinetic equation,
glomerular filtration rate (GFR) using plasma exogenous creatinine clearance, serum
symmetric dimethylarginine (SDMA), complete plasma biochemistry and urinalysis (including
urine protein‐to‐creatinine ratio) were obtained in 14 beagles dogs in a 2x2 blinded
against placebo cross‐over design. One group received a 7‐days course of immune‐suppressive
prednisolone while the second received the placebo. After a 4‐weeks wash‐out period,
groups were switched. Blood and urine were collected before and after each treatment
period and during wash‐out. A general linear model was used to test period, sequence,
treatment, dog and weight effects. A Dunnett test was used to evaluate the effect
of steroid with day 0 serving as control. Correlations were assessed using Pearson's
coefficient.
Prednisolone significantly affected body weight (P < 0.001; mean difference − 1.1 kg),
GFR (p = 0.01; +0.6 mL/kg/min), SDMA (P < 0.001; −2.4 μg/dL), creatinine (P < 0.001;
−14.4 μmol/L), urea (P < 0.001; +1.53 mmol/L), chlorides (P < 0.001; −8.9 mmol/L),
bicarbonates (P = 0.006; +1.4 mmol/L), magnesium (P < 0.001; +0.19 mmol/L), total
proteins (P < 0.001; +6.3 g/L), albumin (P < 0.001; +8.7 g/L), tBWC (p = 0.022; −43 mL/kg),
urine specific gravity (P < 0.007; −0.015) and voided urine (P < 0.001; +274 mL).
SDMA (r = −0,51) and creatinine (r = −0,74) correlated significantly (p = 0,001) with
GFR. All variations became non‐significant after the wash‐out.
Prednisolone at immune‐suppressive dosage rapidly decreases tBWC and body weight and
induces relevant reversible renal hyperfiltration and clinically significant variations
of several analytes.
Disclosures
Disclosures to report.
SDMA dosages provided by IDEXX laboratories (Inc.,Westbrook, Maine,United States of
America).
ESVNU‐O‐6
Characterization and in vitro susceptibility of clinical feline UPEC isolates to an
E. coli probiotic as a potential therapeutic for urinary tract infection
C. Snell1, J. Gibson1, C. Zumpetta1, J. Byron1, J. Quimby1, A. Harrison2, S. Justice2,
A. Rudinsky1
1The Ohio State University, Columbus, United States of America, 2Nationwide Children's
Hospital, Columbus, United States of America
The rise in antibiotic resistance amongst urinary tract infections (UTIs) in both
cats and dogs underscores the need for non‐antibiotic approaches to UTIs. The probiotic
Escherichia coli Nissle‐1917 (EcN) has many benefits including antimicrobial activity
against many human pathogens including uropathogenic E. coli (UPEC). The aim of this
study was to phylogenetically characterize UPEC in feline UTI cases and investigate
the in vitro susceptibility of these isolates to EcN.
Twenty‐two cats with positive E. coli urine cultures were included in the study. Samples
used in this study were obtained from surplus urine collected for routine evaluation
of possible urinary tract infections. Characterization of UPEC isolates was performed
by clade analysis, serotyping and virulence factor analysis by multiplex PCR testing.
EcN effectiveness against UPEC isolates was tested in vitro using microcidin plate
analysis.
Clinical signs were consistent with lower urinary tract infection in all cats. Serogroup
and virulence factors correlated with clade analysis as reported in human UPEC studies.
Fifty‐nine percent of UPEC isolates were susceptible to the EcN probiotic in vitro.
Average zone of growth inhibition from the EcN probiotic was 5.54 mm (Range 2.33‐10.61 mm).
UPEC isolates from feline patients were similar to isolates in human patients in pathogenicity,
susceptibility, and genetic background. in vitro susceptibility of feline UPEC isolates
were frequently susceptible to the EcN probiotic through growth rate characteristics
and/or microcin production. These findings suggest the potential use of Nissle as
a novel therapeutic to treat feline urinary tract infections.
Disclosures
Disclosures to report.
Funding for this study was provided by the ACVIM Resident Research Grant. The authors
declare no other conflicts of interest.
ESVNU‐O‐7
Prognostic factors in dogs with common causes of proteinuria
F. Baumgartner, F. Boretti, B. Gerber
Vetsuisse Faculty, University of Zurich, Switzerland, Zürich, Switzerland
Little is known about the impact of increased urine protein:creatinine ratios (UPC)
on survival of dogs with different underlying diseases, and associated risk factors
for death are not established. Therefore, the aim of this study was to assess dogs
with severe proteinuria (UPC at least once during the disease measured >2.0) for their
survival time, underlying diseases and possible prognostic factors like UPC at time
of diagnosis, creatinine, urine specific gravity, albumin and haematocrit.
Between 2014 and 2015, 89 dogs with severe proteinuria were retrospectively analysed.
Among them, 46 dogs were diagnosed with glomerulopathy (median UPC: 6.0; range: 1.4‐21.2),
16 dogs with Cushing's disease (median UPC: 4.4; range 2.1‐14.1), 11 dogs with leishmaniosis
(median UPC: 4.7; range 2.1‐19.8) and 16 dogs with various diseases (median UPC 3.1;
range 1.9‐9.5).
Over all dogs, increased UPC was identified as a risk factor for death (P < 0.01).
Median time of survival was 42 days. UPC and time of survival did not differ significantly
between the groups. Among dogs with glomerulopathy, identified significant risk factors
for death included increased UPC (P = 0.03), increased creatinine (P < 0.01), low
haematocrit (P = 0.04) and low urine specific gravity (P = 0.03). In dogs with Cushing's
disease, only urine specific gravity was a significant risk factor for death (p =
0.05). In dogs with leishmaniosis, increased UPC and creatinine were significant risk
factors for death (P < 0.01; p < 0.01).
Increased UPC is a risk factor for death in dogs with glomerulopathy and leishmaniosis,
but not with Cushing's disease. This can be explained by different pathogenesis leading
to proteinuria.
Disclosures
Disclosures to report.
B Gerber was a speaker for Boehringer Ingelheim.
ESVNU‐O‐8
The effect of dietary sodium on urinary calcium and calcium oxalate relative supersaturation
(CaOx RSS) in dogs
E.S. Bijsmans, Y. Quéau, V. Biourge
Royal Canin, Aimargues, France
Calcium oxalate (CaOx) recurrence is challenging to manage in dogs. Relative supersaturation
(RSS) is a measure of crystallization risk, and lower urinary concentration of CaOx
precursors can decrease CaOx RSS. Urinary dilution is the primary strategy to decrease
CaOx RSS, and can be achieved by increased sodium content of pet food to drive water
intake. However, humans with CaOx renoliths are advised to decrease sodium intake
because of the potential increase in renal calcium excretion, which could increase
the risk of the disease.
The aim of this study was to compare the effect of two dry pet foods differing only
in sodium chloride content on urinary volume, urinary calcium excretion and concentration,
and CaOx RSS in a cross‐over study using 8 healthy colony dogs. A base diet was produced
with a sodium content of 0.3% as fed (LSD). This formula was supplemented with NaCl
to achieve high‐sodium diet (HSD) (1% sodium as fed ‐ comparable to commercially available
high‐salt urinary diet). The dogs were fed each diet for 7 days followed by 3 days
of urine collection. Urinary minerals were measured on pooled 3‐day samples using
ionic chromatography. CaOx RSS was calculated using SUPERSAT software. The impact
of diet on urinary volume, calcium excretion and concentration, oxalate concentration,
and CaOx RSS was evaluated using the Wilcoxon Rank‐Sum test (significance set at P < 0.05).
Data are presented as median[25th,75th percentile].
The HSD led to an increase in urine volume (LSD: 19.1[15.0, 23.3] vs HSD: 37.0[33.7,
46.9] ml/kg BW/day, P < 0.05). Urinary calcium excretion was not significantly different
between diets (LSD: 78.6[72.5104.9] vs HSD: 88.8[79.3,96.4] μmol/kg BW/day, P = 0.84),
but urinary calcium concentration was lower in HSD (LSD: 4.8[3.2,6.0] vs HSD: 2.5[2.0,2.9]
mmol/L, P < 0.05). Urinary oxalate concentration was lower in HSD (LSD: 1.4[1.1, 1.8]
vs HSD 0.9[0.7, 1.2] mmol/L, P < 0.01). CaOx RSS was significantly lower with the
HSD (LSD: 24.1[13.1, 32.7] vs HSD: 12.7[10.4, 12.4], P < 0.01).
The results of this study do not support an increase in urinary calcium excretion
with an increase in dietary sodium at commercially relevant levels. The increase in
urine volume seen with the high salt diet decreased the urinary calcium and oxalate
concentrations, and could explain the decrease in CaOx RSS. An increase in dietary
sodium therefore decreases the risk of CaOx urolithiasis in short‐term feeding trials.
Further studies are required to assess the effect of increased dietary sodium when
diets are fed for a longer period of time.
Disclosures
Disclosures to report.
All authors are current employees of Royal Canin, Mars Petcare.
ESVNU‐O‐9
Proliferative urethritis in dogs: long‐term follow up and prognosis
R. Caccamo1, A. Foglia2, E. Benvenuti3, E. Bottero3, D. Cattaneo3, M. Pietra2, F.
Dondi2
1Endovet ‐ Professional Association, Roma, Italy, Turin, Italy, 2Department of veterinary
medical sciences, University of Bologna, Italy, 3Endovet ‐ Professional Association,
Rome, Italy
Proliferative urethritis (PU) is an uncommon inflammatory disease with unknown etiology.
Data on prognosis of affected dogs are currently lacking. The aim of this study was
to describe clinical, endoscopic and histopathological findings and investigate their
influence on long‐term outcome in dogs with PU.
Medical records of dogs that underwent cystoscopy and were diagnosed with PU by histopathology
were retrospectively reviewed (2015‐2019). Dogs with a documented follow up period
of at least 12 months after diagnosis were included. Results regarding signalment,
clinical, cystoscopic, microbiological and histopathological findings were collected.
An endoscopic score (ES) for grading urethral lesions was used: mild localized lesions
(ES = 1), complete involvement without stenosis (ES = 2), urethral stenosis (ES =
3), and urethral obstruction (UO, ES = 4). Treatments, short‐term complications (<6 months),
survival time after diagnosis and variables associated with survival (12 months) were
investigated. Data were analyzed using descriptive statistics and reported as median
and (range). Survival analysis was performed using Cox proportional hazard regression
analysis (P value <.05 considered significant).
Thirteen female dogs (5/13 spayed) met the inclusion criteria. Median age was 96 months
(72‐168), while median body weight was 15.2 kg (10.2‐35). Main clinical signs were
dysuria (11/13) and stranguria (8/13); urethral obstruction was detected in 5/13 dogs.
In 7/8 dogs for which results were available, urine microbial cultures were positive.
All dogs had endoscopic evidence of irregular tissue projections into urethral lumen
that extended along the entire urethra in 6/13 dog (ES = 2); urethral strictures were
noted in 3/13 cases (ES = 3); 4/13 dogs had UO (ES = 4). At histopathology, lymphoplasmacytic
(8/13), lymphoplasmacytic and neutrophilic (3/13), and granulomatous (2/13) inflammation
was detected. Medical treatment was started in all dogs after diagnosis and included
antimicrobials (10/13), glucocorticoids (5/13), nonsteroidal anti‐inflammatories (9/13)
and immune‐suppressive medications (2/13). Median survival time was 12 months (5‐36).
Short‐term complications included relapsing of clinical signs (11/13) and recurrent
UTI (11/13); 5/13 dogs required additional interventional or surgical treatments to
restore urethral patency. Variables associated with survival were age (HR 1.037, 95%
CI 1.0068‐1.068, P = .016), body weight (HR 0.858, 95% CI 0.746‐0.987, P = .03), and
developing of UO within 6 months after diagnosis (HR 6.050, 95% CI 1.065‐34.481, P
= .04).
The severity of ES at time of diagnosis did not affect long‐term outcome of dogs with
PU; however small size older dogs that developed UO after diagnosis were more likely
to have a worst prognosis.
Disclosures
No disclosures to report.
ISCAID‐O‐1
Detection of canine and feline parvovirus shedding in asymptomatic shelter cats in
Australia using a minor groove binder probe real‐time PCR assay
M. Carrai1, J. Liu2, J.A. Beatty2, K. van Brussel2, J. Slapeta2, N. Decaro3, V.R.
Barrs2
1The University of Sydney, Camperdown, Australia, 2University of Sydney, Camperdown,
Australia, 3University of Bari, Valenzano, Bari, Italy
Canine parvovirus (CPV) and feline parvovirus (FPV) cause severe, often fatal, enteritis
in their hosts. A UK study reported faecal shedding of CPV, but not FPV, by 1 in 3
asymptomatic shelter cats. In contrast, an Australian study, utilizing a similar conventional
PCR (cPCR) assay reported no CPV shedding and FPV shedding in 1.8% asymptomatic shelter
cats.
The aim of this longitudinal study was to determine whether low‐level parvoviral shedding,
undetectable by cPCR, occurs in Australian shelter cats. Residual faecal samples from
the previous Australian study (n = 152), collected from asymptomatic shelter cats
on three sampling days (SD1 n = 47, SD2 n = 84, SD3 n = 21) over 12 months, were tested.
SD3 occurred during an FPV outbreak.
Parvoviral DNA was detected using quantitative PCR (qPCR), then a minor groove binder
real‐time PCR assay differentiated FPV, CPV2, CPV2a, CPV2b and CPV2c. Parvoviral DNA
was detected in 25 (16.4%) faecal samples (SD1 0/47, SD2, 5/84, SD3 20/21). All positive
samples from SD2 and SD3 were CPV2b, and FPV, respectively. Viral loads of CPV2b (1.85‐1.18
x 105; median 4.62 x 102 copies/μL template DNA) were lower than those of FPV (1.26
x 103‐8.96 x 109; median 9.7 x 105 copies/μL template DNA). Quantitative PCR was more
sensitive than cPCR to detect low‐level parvoviral shedding. FPV was shed by 95% asymptomatic
shelter‐housed cats during an FPV outbreak. A low prevalence of CPV shedding was detected
(3.3%). The potential role of cats as a reservoir of CPV infection in dogs varies
between populations tested.
Disclosures
Disclosures to report.
The authors receive funding support for other unrelated research projects from the
Australian Research Council (VB), Boehringer Ingelheim (VB), Morris Animal Foundation
(VB, JB), Winn Feline Foundation (VB, JB) and partnership collaboration awards from
the Universities of Sydney (VB, JB), University of Glasgow (VB) and University of
California, Davis (JB). The senior author (VB) is a member of the Australian Infectious
Diseases Advisory Panel (AIDAP), funded by Zoetis.
ISCAID‐O‐2
Prognostic value of systemic inflammatory response syndrome (SIRS) presence, serum
acute phase proteins, cholesterol and total thyroxine concentrations in cats with
feline panleukopenia: a retrospective cohort study in 70 cats (2010‐2018)
M. Petini1, M. Drigo2, A. Zoia1
1San Marco Veterinary Clinic, Veggiano, Italy, 2University of Padova, Padova, Italy
Feline parvovirus (FPV) is a common infectious agent and can be lethal. The aim of
this study was to assess the prognostic value of SIRS presence, serum concentrations
of serum amyloid A (SAA), haptoglobin, cholesterol and total thyroxine (tT4) in feline
panleukopenia.
Retrospective cohort study enrolling cats with feline panleukopenia presented between
January 2010 and January 2018. Definitive diagnosis of feline panleukopenia required
a positive direct ELISA assay on feces and/or a positive PCR on feces and/or blood.
According to their survival status at 28‐days from presentation cats were divided
into survivors and nonsurvivors. The prognostic importance at presentation of the
variables age, sex and reproductive status, presence of SIRS, serum concentrations
of SAA, haptoglobin, cholesterol and tT4 (measured on left over serum sample) was
investigated univariately and by multivariabile Cox proportional‐hazards regression
model. Finally, ROC curve analysis was used to identify the best cutoff value (Youden
index) for discriminating survivors from nonsurvivors for the prognostic variables
resulted statistically significant in multivariable analysis. For all analyses the
significance was set to α = 0.05.
Seventy cats were eligible for the study, 47 (67%) survivors and 23 (33%) nonsurvivors.
At presentation, nonsurvivors were significantly (U = 314.5, P = 0.005) younger than
survivors, while no difference in reproductive status was found. There was a significant
difference (χ2 = 8.02; P = 0.005) in the number of cats fulfilling SIRS criteria between
survivors (9/47, 19%) and nonsurvivor (12/23, 52%). SAA concentrations were significantly
lower (U = 749, P = 0.009) in survivors (median = 83.3 μg/dL; range, 0.1″‘248.4 μg/dL)
compared with nonsurvivors (median = 138.3 μg/dL; range, 3.2″‘235.8 μg/dL). Serum
haptoglobin concentrations were significantly lower (t = −3.24, P = 0.002) in survivors
(mean = 136.13 ± 69.80 mg/dL) compared with nonsurvivors (mean = 190.09 ± 55.25 mg/dL),
while no difference in serum cholesterol concentrations were found. Finally, serum
tT4 concentrations were significantly higher (t = 3.546, P = 0.001) in survivors (mean
= 1.38 ± 0.66 μg/dL) compared with nonsurvivors. In the Cox proportional‐hazards regression
model only serum tT4 concentration was significantly associated with survival (HR
= 0.26, P = 0.014). The Youden index identified through ROC curve analysis for serum
tT4 concentration was 0.82 μg/dL (sensitivity = 73.9%, specificity = 82.9%; AUC =
0.783, 95% CI, 0.668 to 0.873; P < 0.0001).
The present study showed that serum tT4 at presentation in cats with FPV could be
use as prognostic factors in predicting the disease outcome.
Disclosures
No disclosures to report.
ISCAID‐O‐3
Clinical and epidemiological features of the first reported outbreaks of feline calicivirus
virulent systemic disease in Australia and in vitro efficacy of three antiviral compounds:
nitazoxanide, 2’‐C‐methylcytidine and NITD‐008
M. Bordicchia1, T.M. Fumian2, M. Shi1, J.A. Beatty1, J.M. Norris1, E.C. Holmes2, P.A.
White2, V.R. Barrs1
1University of Sydney, Camperdown, Australia, 2University of New South Wales, Sydney,
Australia
Feline caliciviruses (FCV) are common feline pathogens causing “flu”‐like signs. Rarely,
FCVs cause virulent systemic disease (FCV‐VSD) characterised by jaundice, facial/limb
oedema, skin ulceration and death. The pathogenesis of FCV‐VSD is poorly understood.
The aims of this study were to 1) characterise clinical and virological features of
two nosocomial outbreaks of FCV‐VSD in Australia in 2015 and 2018, 2) assess efficacy
of three antivirals against representative outbreak strains in vitro.
Cats presenting with ≥1 sign consistent with FCV‐VSD during the outbreaks were included.
Viral isolation and whole genome sequencing were performed on residual diagnostic
oropharyngeal swabs and/or necropsy tissue. One virus from each outbreak was tested
in plaque reduction assays against nitazoxanide (NTZ), 2’‐C‐methylcytidine (2CMC)
and NITD‐008. For each antiviral, EC50 was determined. Therapeutic index (TI) was
derived from the EC50 and half maximal cytotoxic concentration in CRFK cells.
Twenty cases (NSW n = 8, QLD n = 12) were identified (age: 1‐72 months, median 16.7).
Onset of signs was ≤10 days after hospital admission for surgery in 19/20 cases. FCV
vaccination status, where known, was current in 15/16 cases. Overall mortality was
45%. Phylogenetic analysis of full FCV genomes revealed co‐infections of two FCV lineages
in NSW and a separate lineage in QLD. Dose‐response inhibition of both FCV‐VSD strains
was obtained with all antivirals; NTZ EC50, 0.4‐0.6 μM, TI 21, 2CMC EC50, 2.7‐5.3 μM,
TI >18, NITD‐008, EC50 0.5 to 0.9 μM, TI >111.
FCV‐VSD outbreaks continue to occur in vaccinated cats and are associated with high
mortality. Three antivirals were potent inhibitors of FCV‐VSD outbreak strains tested.
Disclosures
Disclosures to report.
Statement of disclosures This study was supported financially by the Australian Companion
Animal Health Foundation, by a philanthropic donation to the Sydney School of Veterinary
Science, University of Sydney, and by a research donation from Virbac Australia Pty
Ltd. Virbac were not involved in the study design including selection of antiviral
drugs, or testing or analysis. The authors receive funding support for other unrelated
research projects from the Australian Research Council (VB, ECH, MS), Boehringer Ingelheim
(VB), Morris Animal Foundation (VB, JB), Winn Feline Foundation (VB, JB) and partnership
collaboration awards from the Universities of Sydney (VB, JB, MB), University of Glasgow
(VB, MB) and University of California, Davis (JB). The senior author (VB) is a member
of the Australian Infectious Diseases Advisory Panel (AIDAP), funded by Zoetis.
ISCAID‐O‐4
Antibody response to feline calicivirus vaccination in healthy adult cats
M. Bergmann1, S. Speck2, A. Rieger1, H. Poulet3, U. Truyen2, K. Hartmann1
1LMU Munich, Munich, Germany, 2University of Leipzig, Leipzig, Germany, 3Boehringer
Ingelheim Animal Health, Lyon, France
It is unknown how cats in the field react to feline calicivirus (FCV) vaccination.
This study evaluated prevalence of FCV antibodies in healthy adult cats and their
antibody response to FCV vaccination.
Cats >1 year (n = 111) that had not received vaccinations within 12 months received
a vaccine containing inactivated FCV antigen strains 431 and G1.
On day 0, 7, 28, FCV antibodies were determined in leftover samples by virus neutralization
(VN) using isolate KS20, and by p66 antigen ELISA.
Factors associated with presence of antibodies and response to vaccination were determined
by uni‐ and multivariate statistical analysis.
Pre‐vaccination antibodies were detected in 62.7% (69/111) of cats (95%CI: 52.9‐70.1)
by VN and 77.2% (71/92; 95%CI: 67.5‐84.6) by ELISA.
A ≥ 4‐fold titre increase after vaccination was observed in 13.6% (15/110; 95%CI:
8.3‐21.4) by VN and 33.7% (28/83; 95%CI: 24.5‐44.5) by ELISA.
Cats ≥2 years were more likely to have pre‐vaccination VN antibodies than cats <2 years
(OR: = 7.194; P = 0.021). Presence of VN antibodies was also correlated with the cats'
vaccination status (OR: 3.472; P = 0.014).
Presence of pre‐vaccination ELISA antibodies was associated with time since last vaccination
(OR: 5.672; P = 0.043).
Outdoor cats were more likely to have a ≥ 4‐fold titre increase in ELISA (OR: 5.556;
P = 0.005).
Many cats have pre‐vaccination FCV antibodies even if vaccination was performed >1 year
ago.
Prevalence of antibodies depends on previous vaccinations and seems to increase with
age.
A ≥ 4‐fold titre increase after vaccination was rarely observed and influenced by
the cat's lifestyle.
Disclosures
Disclosures to report.
Hervé Poulet is Global Head of Companion Animals and Equine Biologicals R&D at Boehringer
Ingelheim who provided antibody testing by ELISA. Boehringer Ingelheim played no role
in the collection and interpretation of data, or in the decision to submit the manuscript
for publication. Katrin Hartmann has given talks for MSD, Merial, Boehringer Ingelheim,
Idexx. She participated in research funded by or using products from MSD, Merial,
Boehringer, Zoetis, Megacor, Biogal, Scil. Michèle Bergmann has given talks for Merial.
She participated in research funded by or using products from MSD, Merial, Boehringer,
Zoetis, Megacor, Biogal, Scil. There is no commercial conflict of interest as the
information generated here is solely for scientific dissemination. The authors declare
that they have no competing interests.
ISCAID‐O‐5
Correlation of feline coronavirus shedding in faeces with serum coronavirus antibody
titre
S. Felten1, U. Klein‐Richers1, R. Hofmann‐Lehmann2, M. Bergmann1, S. Unterer1, N.
Pantchev3, C.M. Leutenegger4, K. Hartmann1
1Clinic of Small Animal Medicine, LMU Munich, Munich, Germany, 2Clinical Laboratory,
Vetsuisse Faculty, University of Zurich, Switzerland, 3IDEXX Vet Med Labor GmbH, Ludwigsburg,
Germany, 4IDEXX Laboratories, Inc., West Sacramento, United States of America
Feline coronavirus (FCoV) infection is very common in multi‐cat households. It has
been proposed that cats with higher antibody titres are more likely to shed FCoV in
their faeces. Aim of the study was to determine a possible correlation between FCoV
serum antibody titres and faecal FCoV shedding.
Four faecal samples from 72 cats originating from 18 German catteries were examined
for FCoV by quantitative reverse transcriptase polymerase chain reaction (RT‐PCR).
Serum antibody titres were determined by immunofluorescence assay.
There was a weak positive correlation between height of antibody titre and mean faecal
virus load (Spearman r = 0.3394; P = 0.0035). Antibody titres were significantly higher
if cats shed FCoV more frequently (Kruskal Wallis test P = 0.0042). Twenty‐two cats
were RT‐PCR‐negative in all four faecal samples. Those cats had significantly lower
antibody titres than cats shedding continuously (in all four samples) (Dunn's test;
P < 0.05). When analysing FCoV‐shedding cats (shedding at least once), cats that were
FCoV RT‐PCR‐positive continuously in all four samples had significantly higher antibody
titres (Mann‐Whitney U test P = 0.0026) and significantly higher mean faecal virus
loads (Mann‐Whitney U test P = 0.0383) than cats that were FCoV RT‐PCR‐positive in
only one, two, or three samples. Eight cats had no detectable antibodies but were
shedding FCoV.
Height of antibody titre was correlated to faecal virus load. Chronic FCoV shedders
had higher antibody titres and shed more virus. This knowledge can be of importance
for the management of FCoV infection in multi‐cat environments. However, measurement
of serum antibodies cannot replace faecal RT‐PCR.
Disclosures
Disclosures to report.
Dr. Christian Leutenegger was the Head of Molecular Diagnostics at IDEXX Laboratories,
Inc. Dr. Nikola Pantchev is employed at IDEXX Laboratories, Ludwigsburg. This laboratory
offers the FCoV real‐time RT‐PCR on a commercial basis and performed the RT‐PCR‐testing
in this study.
ISCAID‐O‐6
A retrospective multi‐centre study on treatment and outcome in disseminated aspergillosis
in 41 dogs
J.R.S. Dandrieux1, C.S. Mansfield1, M. Stevenson2, A. Lim1
1The University of Melbourne, Werribee, Australia, 2Asia‐Pacific Centre for Animal
Health, Melbourne, Australia
Disseminated aspergillosis (DA) in dogs has a guarded prognosis. The aim of this study
is to describe DA treatment regimens and their association with post diagnosis survival
times.
This retrospective study evaluated dogs diagnosed with DA from 13 veterinary referral
centres (private and University) from around Australia over a 10‐year period (January
2007 to June 2017). Inclusion criteria included consistent diagnostic findings and
a positive culture for Aspergillus from a sterile site or a positive serum galactomannan
assay.
The data were analysed using survival analysis. The outcome of interest was the length
of time (in days) between the date of diagnosis and the date of death or euthanasia
due to DA. Factors influencing survival time post diagnosis were quantified using
a Cox proportional hazards regression model. Here the data were organised into counting
process format which allowed us to quantify the effect of each antifungal agent on
survival time.
A total of 41 dogs were included in the study. The most common breed was German shepherd
dogs (n = 24, 59%). The most common organism cultured was A. terreus (n = 24 out of
31 positive cultures, 77%).
Treatment was started in 27 dogs, whereas 9 dogs received no specific treatment, and
5 dogs were lost to follow up. Twenty‐four dogs (89%) were treated with itraconazole
as first‐line treatment (single agent in 12 dogs). A total of nine dogs (33%) were
treated concurrently with terbinafine. Median survival time post diagnosis was 273 days.
Age at diagnosis had no significant effect on survival time. The daily hazard of death
from DA for dogs with an elevated serum creatinine concentration at diagnosis was
18 (95% CI 3.8 to 83) times that of dogs with normal serum creatinine concentration.
The daily hazard of death from DA for dogs treated with itraconazole was 5.7 (95%
CI 1.7 to 19) times that of dogs that were treated with other anti‐fungal treatment.
The daily hazard of death from DA for dogs treated with terbinafine was 0.21 (95%
CI 0.05 to 0.97) times that of dogs that were not treated with terbinafine.
Consistent with previous studies, we found that most DA cases were German Shepherds.
A. terreus was the most commonly isolated organism. Although itraconazole has previously
been the drug of choice to treat DA, our findings show that combination therapy with
terbinafine or newer anti‐fungal treatment improves survival times. Serum creatinine
is a useful prognostic indicator of survival time.
Disclosures
No disclosures to report.
ISCAID‐O‐7
Canine Trichuris vulpis infection: a retrospective study of 45 cases
M. Cervone, M. Hugonnard, G. Bourdoiseau, L. Chabanne, J.L. Cadoré, E. Krafft
VetAgro Sup, Marcy l'Étoile, France
Trichuris vulpis (Tv) is a parasite of canids large intestine with a worldwide distribution.
Despite its well‐known epidemiology, its pathogenic impact in dogs remains controversial.
The aim of the current retrospective study was to describe clinical and biological
signs and treatment response in dogs naturally infected with Tv.
Our medical database was searched for cases with Tv eggs identified on fecal analysis
between 2002 and 2018. Dogs were classified as mono‐infected by Tv (G1) or poly‐infected
(Tv and other parasitic species; G2) and the intensity of Tv fecal excretion (FE)
was quantified (number of Tv eggs/5 g of feces). Dogs diagnosed with other comorbidities
potentially contributing to systemic or digestive signs, or to biological abnormalities
such as anemia or hypoalbuminemia, were excluded. Clinical signs, biological abnormalities
and course of the disease were recorded and compared between groups. Associations
between these variables and the FE were statistically evaluated and the level of significance
was set at P < 0.05.
Forty‐nine dogs were positive for Tv on fecal analysis and 45 were included in the
study (25 dogs in G1 and 20 dogs in G2). In G2, concurrent isolated parasites were
Toxocara canis (47,8%), Ankylostomatidae (43,5%), Capillaria spp (13%), Tænidae (4,3%),
Isospora spp (34,8%) and Giardia duodenalis (21,7%). The median age of infected dogs
was 4 years. Overall, clinical signs included diarrhea (49%), weight loss (38%), hematochezia
(29%), inappetence (24%), vomiting (18%) and polyphagia (13%). Intussusception was
diagnosed in 2 dogs, only in G1. Two dogs showed lethargy as the only clinical sign,
likely due to a moderate to severe anemia. Digestive signs were acute (less than 10 days)
in 34% of dogs and chronic in the remaining dogs. Biological abnormalities included
anemia (23%), eosinophilia (30%), hypoalbuminemia (60%) and Na/K ratio < 24 with normal
ACTH‐stimulation test (12%). Four percent of dogs had neither clinical nor biological
signs. The only difference between G1 and G2 was that weight loss was more frequent
in G2 (P < 0.05). No significant association was found between clinical signs or biological
abnormalities and FE. However, a Na/K ratio < 24 with normal ACTH‐stimulation test
was only found among dogs with massive FE. Complete recovery after antiparasitic treatment
was obtained in 94% of dogs with available follow‐up (n = 18). One dog died of intussusception.
Our results suggest that Tv is pathogenic in dogs, leading to both acute and chronic
digestive clinical signs, hypoalbuminemia, anemia and electrolytes disorders.
Disclosures
No disclosures to report.
ISCAID‐O‐8
Patterns of antimicrobial use for selected canine diseases in Switzerland in 2016
B. Lutz1, C. Lehner1, K. Schmitt2, B. Willi2, G. Schuepbach‐Regula3, M. Mevissen4,
R. Peter5, C.R. Muentener5, H. Naegeli5, S. Schuller1
1Department of Clinical Veterinary Medicine,Vetsuisse Faculty, University of Bern,
Bern, Switzerland, 2Clinic for Small Animal Internal Medicine, Vetsuisse, University
of Zurich, Zürich, Switzerland, 3Veterinary Public Health Institute, Vetsuisse, University
of Bern, Bern, Switzerland, 4Division of Pharmacology and Toxicology, Vetsuisse, University
of Bern, Bern, Switzerland, 5Institute of Pharmacology and Toxicology, Vetsuisse,
University of Zurich, Zürich, Switzerland
Antimicrobial resistance is an increasing threat for human and animal health. Both
over‐ and misuse of antimicrobials can foster resistance. The objective of this retrospective
study was to investigate patterns of antimicrobial use for selected canine diseases
in Switzerland in 2016.
Antimicrobial prescriptions for respiratory and urinary tract infections (UTI) and
acute diarrhea from two Swiss university hospitals and 14 private practices during
2016 were reviewed. Classes of antimicrobials, dosage and treatment duration were
assessed. A justification score (JS) was applied, where sufficient clinical information
was available, to define the appropriateness of antimicrobial therapy based on current
guidelines (1 = appropriate, 2 = incorrect dosage and/or duration, 3 = inappropriate
antimicrobial choice, 4 = overall wrong treatment decision).
Of 274 dogs with proven or suspected upper or lower respiratory tract infections,
171 (62%) were treated with antimicrobials of the following classes: potentiated aminopenicillins
(68.4%), fluoroquinolones (15.8%), non‐potentiated (NP) aminopenicillins (20.4%),
tetracyclines (22.2%), first‐generation cephalosporins (2%), third‐generation cephalosporins,
lincosamides, macrolides and nitroimidazoles (0.8% each). In 48.2% (132/274), therapeutic
decisions regarding antimicrobial therapy were judged appropriate (JS‐1), in 23.3%
(64/274) inappropriate (JS‐2 n = 4; JS‐3 n = 26).
Of 245 dogs with proven or suspected UTI, 215 (87.8%) received antimicrobials. In
only 36.3% of these, a bacterial etiology was confirmed via culture and/or sediment
examination. Antimicrobial classes used were potentiated aminopenicillins (61%), fluoroquinolones
(22%), NP‐aminopenicillins (11%), first‐generation cephalosporins (5%), third‐generation
cephalosporins (1%), lincosamides (0.8%), amphenicols and potentiated sulfonamides
(0.4% each). Antimicrobial susceptibility testing was performed in 73/85 (86%) of
the cases where bacterial culture was performed. In 20% (49/245), antimicrobial therapy
was judged appropriate (JS‐1), in 16% (39/245) inappropriate (JS‐2n = 5; JS‐3 n =
30).
Antimicrobials were prescribed in 89.5% (247/276) of the dogs with acute diarrhea.
Classes used were nitroimidazoles (72.1%), potentiated aminopenicillins (29.1%), fluoroquinolones
(7.6%), NP‐aminopenicillins (3.6%), tetracyclines (1%) and third‐generation cephalosporins
(1%). Antimicrobial therapy was significantly associated with the presence of bloody
diarrhea (P < 0.001). It complied in 43.5% (120/276; JS‐1) with current guidelines
restricting therapy to the use of aminopenicillins in suspected sepsis.
The results of this study show that antimicrobial use commonly does not comply with
current treatment guidelines in dogs with respiratory or urinary tract infections
and acute diarrhea. Consequently, there is an urgent need for antimicrobial stewardship
initiatives.To support the prudent use of antimicrobials in animals, antibioticscout.ch,
a comprehensive online tool based on current guidelines was launched in December 2016.
The impact of this tool on veterinary prescribing habits will be assessed in future
studies.
Disclosures
Disclosures to report.
This research project was supported by Swiss National Science Foundation (NRP72 project
407240_167054), accorded to Hanspeter Naegeli.
ISCAID‐O‐9
Comparison of antimicrobial prescription in selected diseases in cats in Switzerland
between 2016 and 2018: a trend towards more prudent antimicrobial use
A. Hubbuch1, H. Naegeli1, K. Schmitt2, C. Lehner1, G. Schüpbach‐Regula3, M. Mevissen4,
S. Schuller5, B. Willi2
1Institute of Veterinary Pharmacology and Toxicology, Vetsuisse Faculty, Zurich, Switzerland,
2Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, Zurich, Switzerland,
3Veterinary Public Health Institute (VPHI), Vetsuisse Faculty, Bern, Switzerland,
4Division of Pharmacology and Toxicology, Vetsuisse Faculty, Bern, Switzerland, 5Division
of Small Animal Internal Medicine, Vetsuisse Faculty, Bern, Switzerland
Overuse of antibiotics is a common problem in veterinary medicine contributing to
the development of antimicrobial resistance. To foster prudent antimicrobial use by
veterinarians, a freely accessible online tool containing Swiss consensus guidelines
for prudent antimicrobial use was launched in December 2016 (http://www.antibioticscout.ch).
The aim of this study was to compare antimicrobial prescription in cats in Switzerland
before and after the introduction of antibioticscout.ch.
Cats presented to one university clinic and eight private practices/clinics in 2018
with acute upper respiratory tract disease (aURTD), feline lower urinary tract disease
(FLUTD) and abscesses (only in private practices/clinics) were included. Signalment,
clinical symptoms, diagnostic work‐up, diagnosis and antimicrobial therapy were assessed
and the data compared to published data from cases belonging to the same disease categories
presented to the same practice/clinic in 2016 (Schmitt et al., 2019). A justification
score was applied to evaluate accordance of prescription with the guidelines (JS1
= complete accordance, JS2 = different dosage/duration, JS3 = different antimicrobial
choice, JS4 = antimicrobial use/non‐use in disagreement with the guidelines, JS5 =
prudent use not assessable).
Data from 485 cats (aURTD, n = 152; FLUTD, n = 205; abscesses, n = 128) presented
in 2018 were compared with data from 2016 (469 cases). The frequency of antimicrobial
prescription decreased from 72% (2016) to 61% (2018; P < 0.001); this decline was
found at the university clinic (68% to 48%, P = 0.003) as well as in private practices/clinics
(73% to 64%, P = 0.010) and in each disease category (aURTD, 72% to 61% P = 0.030;
FLUTD, 56% to 44%, P = 0.012; abscesses, 97% to 88%, P = 0.008). More specifically,
the prescription of critically important 3rd generation cephalosporins decreased (2016,
18%; 2018, 13%; P = 0.017). Urine analyses were more frequently performed in private
practice/clinic in cats with FLUTD (2016, 26%; 2018, 48%; P < 0.001). Despite this,
the number of prescriptions in accordance with the guidelines (JS1) did not significantly
increase from 2016 to 2018 (aURTD, 25% and 31%; FLUTD, 21% and 28%; abscesses, 18%
for both years).
The present study reports a reduction in antimicrobial prescription and use of 3rd
generation cephalosporins in cats in Switzerland which coincided with antibiotic stewardship
activities including the launch of antibioticscout.ch. However, the adherence to consensus
guidelines was still poor. An oral preparation of a non‐potentiated aminopenicillin
for cats was not available in 2018 in Switzerland and could have hampered compliance
with the guidelines. Thus, although the present study indicates a trend towards less
frequent prescription of antimicrobials in cats, further efforts are necessary to
promote antimicrobial stewardship in small animal medicine.
Disclosures
Disclosures to report.
This study was supported by the Swiss National Science Foundation (NRP72 project 407240_167054).
ISCAID‐O‐10
Evaluation of hand hygiene compliance in small animal clinics and practices in Switzerland
using the CleanHands application
J.S. Schmidt1, S.P. Kuster2, S. Hartnack3, A. Ebert2, S. Schuller4, B. Willi1
1Clinic for Small Animal Internal Medicine, Vetsuisse Faculty Zurich, Zürich, Switzerland,
2Division of Infectious Diseases and Hospital Epidemiology, University of Zurich,
Zurich, Switzerland, 3Section of Epidemiology, Vetsuisse Faculty Zurich, University
of Zurich, Zurich, Switzerland, 4Division of Small Animal Internal Medicine, Vetsuisse
Faculty Bern, Bern, Switzerland
Small animal veterinarians are commonly faced with contagious or zoonotic diseases
and infections with multidrug resistant organisms. Hand hygiene (HH) is considered
one of the most important infection control measures in healthcare. Recent studies
suggest that HH compliance in small animal veterinary institutions is poor, but comprehensive
data from small animal clinics and practices in Europe is lacking.
The present study evaluated HH compliance according to the World Health Organization
(WHO) five moments for HH in small animal clinics and practices in Switzerland using
the CleanHands application.
Three small animal clinics (A‐C), one medium‐sized (D) and one small primary opinion
practice (D) were included. A minimum of 500 observations in clinics A‐C (100 observations
per study area: pre‐operative preparation area, intensive care unit [ICU], animal
housing area, examination area, consultation area) and 130 observations in practices
D‐E (consultation area and animal housing area) were obtained. The WHO five moments
for HH included: before touching a patient, before clean/aseptic procedures, after
body fluid exposure/risk, after touching a patient and after touching patient surroundings.
Hand disinfection with alcohol‐based handrubs or hand washing with water and soap
were considered successful HH procedures. Frequency of HH [95% confidence intervals]
based on Jeffreys approach were estimated using the software R version 3.4.4.
A total of 1772 observations revealed an overall HH compliance across all institutions
of 32% [29‐34], ranging from 26‐47%. Highest compliance was observed in the consultation
area (45% [40‐49]), followed by ICU (32% [27‐37]), examination area (29% [24‐34]),
animal housing area (26% [22‐31]) and pre‐operative preparation area (20% [15‐24]).
HH was most commonly performed after contact to body fluids (42% [36‐47]) and after
patient contact (37% [34‐41]), and was least common prior to clean/aseptic procedures
(12% [8‐15]). Veterinarians showed a higher adherence to HH (37% [34‐40]) than veterinary
assistants (25% [22‐29]).
The study indicates an overall poor adherence to HH in small animal clinics and practices
in Switzerland. HH was remarkably poor in critical areas such as the pre‐operative
preparation area and before clean/aseptic procedures. In contrast to observations
in human hospitals, adherence to HH was lower in nursing staff than in doctors. In
conclusion, the study highlights the need to promote HH in small animal medicine,
with special emphasis on training of nursing staff and personnel in pre‐operative
preparation areas.
Disclosures
Disclosures to report.
The study was supported by the Swiss Federal Food Safety and Veterinary Office (FSVO
project no. 1.18.10).
ISCAID‐O‐11
Evaluation of infection prevention and control standards and carriage of multidrug‐resistant
organisms in working staff in small animal clinics and practices in Switzerland
J.S. Schmidt1, S.P. Kuster2, A. Nigg3, V. Dazio4, M. Brilhante3, M. Clément5, S. Schuller4,
A. Endimiani5, V. Perreten3, B. Willi1
1Clinic for Small Animal Internal Medicine, Vetsuisse Faculty Zurich, Zurich, Switzerland,
2Division of Infectious Diseases and Hospital Epidemiology, University of Zurich,
Zurich, Switzerland, 3Institute of Veterinary Bacteriology, Vetsuisse Faculty Bern,
Bern, Switzerland, 4Division of Small Animal Internal Medicine, Vetsuisse Faculty
Bern, Bern, Switzerland, 5Institute for Infectious Diseases, Faculty of Medicine,
University of Bern, Bern, Switzerland
Intensive medical care of companion animals and their close contact to people pose
a risk for the selection and zoonotic transmission of multidrug‐resistant organisms
(MDROs). Infection prevention and control (IPC) concepts are key measures to reduce
the spread of MDROs, but data on IPC standards in small animal clinics and practices
is sparse. The goals of the study were to assess IPC standards, environmental MDRO
contamination and prevalence of MDRO carriage in veterinary personnel in small animal
clinics/practices in Switzerland.
Three large clinics (A‐C), two medium‐sized clinics (D‐E) and two primary opinion
practices (F‐G) were included. Structured one‐day IPC audits were performed and environmental
samples collected from high‐touch surfaces. Nasal and faecal MDRO carriage in veterinary
staff (institutions A‐C, G) was assessed by providing kits for sampling. The samples
were analysed for methicillin‐resistant (MR) Staphylococcus aureus (MRSA), MR S. pseudintermedius
(MRSP), MR coagulase‐negative staphylococci (MRCoNS), MR Macrococcus spp., colistin‐resistant
Enterobacteriaceae, and extended‐spectrum beta‐lactamase (ESBL)‐ and carbapenemase‐producing
Enterobacteriaceae (CPE) using enrichment and selective procedures. Species identification
was performed by MALDI‐TOF MS analysis. Antibiotic resistance genes were identified
by PCR and sequencing. Genetic relatedness was assessed by rep‐PCR (for Enterobacteriaceae)
and multilocus sequence typing (for MRSP).
Frequency of MDRO detection on high‐touch surfaces in clinics/practices A‐G was 3%,
27%, 28%, 0%, 26%, 4% and 6%, respectively. In clinics with high environmental contamination,
CP‐E. coli (bla
OXA‐48, bla
OXA‐181), CP‐K. pneumoniae (bla
OXA‐48
) and MRSP (mecA, ST551)(clinic B), MRCoNS (mecA)(clinic C), and Macrococcus spp.
(mecB, mecD) and MRCoNS (mecA)(clinic E) predominated. IPC audits revealed deficits
in IPC organization, cleaning/disinfection, hand/personal hygiene, medication preparation
and antimicrobial use guidelines in these clinics.
In veterinary personnel, faecal carriage of colistin‐resistant E. coli (6%), ESBL‐producing
E. coli (6%) and CP‐E. coli (1%), and nasal carriage of MRSA (7%), MRSP (1%) and MRCoNS
(5%) were found. MDRO carriage was not associated with work place or profession of
the person. The CP‐E. coli (bla
OXA‐181) from a staff member of clinic B was related to environmental isolates.
This study documents major deficits in IPC standards in small animal clinics in Switzerland
and extensive, but variable, environmental contamination with MDRO. We report for
the first time the detection of CPE in environmental samples in a small animal clinic
and the faecal carriage of a related CPE isolate in a staff member. The present study
highlights the potential of small animal clinics to spread MDRO and the need to promote
IPC concepts in these institutions.
Disclosures
Disclosures to report.
The study was supported by the Swiss Federal Food Safety and Veterinary Office (FSVO
project no. 1.18.10).
ISCAID‐O‐12
Prevalence, acquisition and persistence of rectal and naso−/oropharyngeal carriage
of multidrug‐resistant organisms in dogs and cats presented to veterinary practices
and their owners
S. Schuller1, V. Dazio2, A. Nigg3, J.S. Schmidt4, M. Brilhante3, M. Clément5, A. Collaud3,
S.P. Kuster6, S. Gobeli Brawand7, B. Willi4, A. Endimiani5, V. Perreten3
1University of Bern, Bern, Switzerland, 2Department of clinical veterinary medicine,
University of Bern, Bern, Switzerland, 3Institute of Veterinary Bacteriology, University
of Bern, Bern, Switzerland, 4Clinic for Small Animal Internal Medicine, University
of Zürich, Zürich, Switzerland, 5Institute for Infectious Diseases, University of
Bern, Bern, Switzerland, 6Division of infectious Diseases and Hospital Epidemiology,
University Hospital, Zürich, Switzerland, 7Federal Food Safety and Veterinary Office,
Bern, Switzerland
Multidrug‐resistant organisms (MDRO) represent a significant threat to human and animal
health. Extended‐spectrum β‐lactamase (ESBL), extended‐spectrum cephalosporinase (3CG)
and carbapenemase‐producing (CP) Enterobacteriaceae are of particular importance as
their easily transmitted resistance genes mediate resistance to many antimicrobial
classes. The aims of this study were: to assess the prevalence of MDRO carriage in
dogs and cats at presentation to veterinary clinics/practices, to monitor MDRO acquisition
during hospitalization, to study MDRO transmission among pets and owners and to determine
the duration of carriage.
For this prospective, longitudinal, observational study, rectal and nasal/oropharyngeal
swabs were collected from 88 cats and 183 dogs presented to 5 veterinary care facilities
and 187/271 animals were resampled at discharge. Participating owners sampled themselves
(nasal swab/stool sample). Carriers were resampled for up to 8 months. Nasal/oropharyngeal
swabs were analysed for the presence of methicillin‐resistant (MR) Staphylococcus
aureus (MRSA), MR S. pseudintermedius (MRSP), MR coagulase‐negative staphylococci
(MRCoNS), MR Macrococcus spp. and rectal swabs/stool for ESBL‐producing and CP Enterobacteriaceae.
After enrichment, isolates were selected on CHROMID ESBL, OXA‐48 and CARBA plates
or MRSA selective agar. Isolates were identified via MALDI‐TOF MS. Antibiotic susceptibility
was tested by measurement of MICs and clonality determined using rep‐PCR, ERIC‐PCR
and whole genome sequencing (WGS).
The overall admission prevalence of MDRO carriage was 15.5% (95%CI 11.4‐20.4) with
ESBL‐producing E.coli (5.5%) and MRCoNS (8.5%) predominating. The overall discharge
prevalence was 32.6% (95%CI 26‐39.8; range 17.2‐42.7%). In the institution with the
highest discharge prevalence predominant hospital‐acquired isolates were: ESBL‐producing
K. pneumoniae (13.7%) and ESBL‐producing E.coli (16.7%). E.coli isolates commonly
displayed CP‐encoding genes (bla
oxa‐181,
bla
oxa‐48,
bla
NDM‐5) and showed clonality (ST410, bla
oxa181), suggesting transmission from a common source rather than de novo selection.
Persistence of ESBL‐producing or CP E.coli or K. pneumoniae was shown in 7/34 MDRO
positive animals for up to 138 days. Resistant bacteria were isolated from 10/46 owners
(6/10 ESBL‐producing E.coli; 3/10 MRCoNS; 2/10 MRSA); carriage persisted in one owner
for 68 days. Transfer of ESBL‐producing E.coli between owner and dog was suspected
in one case. Further analysis is ongoing to determine the relatedness of the isolates.
In this cohort, the acquisition rate of 3CG‐resistant and/or CP Enterobacteriaceae
was high, but varied between institutions. MDRO carriage was observed in 22% of owners
and carriage persisted for several months. These findings show that veterinary hospitals
play a significant role in the selection and transmission of MDRO amongst veterinary
patients, including bacteria with very problematic resistance profiles.
Disclosures
Disclosures to report.
This project was funded by a grant from the Swiss Federal Food Safety and Veterinary
Office (BLV 1.18.k).
SCH‐O‐1
Lactulose drives a reversible reduction and qualitative modulation of the faecal microbiota
diversity in healthy dogs
M.F. Ferreira, S. Salavati Schmitz, J.J. Schoenebeck, D.N. Clements, S.M. Campbell,
D.E. Gaylor, R.J. Mellanby, A. Gow, M. Salavati
The University of Edinburgh, Roslin, Scotland
Hepatic encephalopathy (HE) is a syndrome of neurologic dysfunction and an important
contributor to patient morbidity in dogs with liver diseases. The prebiotic lactulose,
a nonabsorbable synthetic disaccharide, is a frequently employed treatment for canine
HE, yet with incompletely understood mechanisms of action. In humans, HE is linked
with dysbiosis, which has been associated with worsened morbidity and mortality. The
impact of lactulose in ameliorating this HE‐associated dysbiosis or general modulation
of the intestinal microbiota is controversial. It is unknown if dysbiosis is present
in canine HE and the influence of lactulose on the intestinal microbiota has also
not been assessed in dogs. The aims of this study were therefore to examine the changes
in faecal microbiota composition before, during and after lactulose treatment in healthy
dogs.
A total of 21 healthy privately owned dogs were enrolled in a prospective cohort study
(12 females, 9 males, median age 5 years [range 2‐10]) with 18 completing the study
fully. Faecal samples were collected weekly, while dogs were either on their usual
diet (week 1), followed by a standardised commercial diet (weeks 2‐9), with added
oral lactulose (0.5 mL/kg every 12 hours) in weeks 6‐7. Faecal bacterial DNA extraction
was followed by PCR amplification of the V4 region of the 16S rRNA gene. Illumina
standard 16S library prep and sequencing was performed on the MiSeq platform and data
analysed using the QIIME2™ pipeline.
After 2 weeks of lactulose treatment (week 7) significantly lower faecal microbiota
richness/diversity was observed based on the alpha diversity metrics: observed operational
taxonomic units, Shannon/ Chao1 indexes and Pielou's evenness. Beta diversity, based
on UniFrac distances, was also significantly different in week 7 compared to weeks
1, 5 and 9. At the bacterial phylum and family levels, week 7 was associated with
a significant increase of Firmicutes and Actinobacteria (Veillonellaceae and Bifidobacteriaceae),
and decrease of Bacteroidetes and Fusobacteria (Bacteroidaceae, Fusobacteriaceae,
Ruminococcaceae and Alcaligenaceae), when compared to weeks 5 and 9. Finally, an extrapolated
cirrhosis dysbiosis ratio (CDR) was calculated, for which lower values are associated
with dysbiosis and linked with worse outcomes in humans. CDR was increased in week
7 compared to weeks 1, 5 and 9.
In conclusion, lactulose induced a reversible qualitative and quantitative change
of the faecal microbiota in healthy dogs, possibly explaining its potential benefit
in the management of HE.
Disclosures
Disclosures to report.
This study was supported by a Royal (Dick) School of Veterinary Studies Clinical Research
Grant. The funding source had no involvement in: the study design; the collection,
analysis and interpretation of data; the writing of the manuscript; or the decision
to submit the manuscript for publication. J.J.S. is a University of Edinburgh Chancellor's
Fellow based at the Roslin Institute. He is supported by strategic funding from the
Biotechnology and Biosciences Research Council (BB/P013759/1 and BB/P013732/1). R.J.M.
and M.S. were supported by BBSRC through the Institute Strategic Programme funding
(BB/J004235/1 and BB/P013740/1). Edinburgh Genomics, The University of Edinburgh,
performed the DNA sequencing and generated the raw data. Edinburgh Genomics is partly
supported through core grants from NERC (R8/H10/56), MRC (MR/K001744/1) and BBSRC
(BB/J004243/1).
SCH‐O‐2
Prevalence of bactibilia in apparently healthy dogs
E. Verwey1, A. Gal2, F. Kettner1, W.J. Botha3, P. Pazzi4
1Tygerberg Animal Hospital, Cape town, South Africa, 2University of Illinois at Urbana‐Champaign,
Urbana, United States of America, 3Panorama Veterinary Clinic and Specialist Centre,
Cape town, South Africa, 4University of Pretoria, Pretoria, South Africa
Bacterial cholecystitis is a debilitating disease in dogs. The presence of bacteria
in bile in ill dogs would be significant if bile was considered sterile; however,
the prevalence of bactibilia in healthy dogs is unknown. The primary purpose of this
study was to determine the prevalence of bactibilia in healthy dogs. Secondary aims
were to determine if differences between bactibillic and non‐bactibillic healthy dogs
occur with regards to serum liver enzymes activities; and liver and gallbladder histopathology.
Fifty‐five healthy, abandoned dogs euthanased for non‐medical reasons were included
in this cross‐sectional, prospective study. Dogs were deemed healthy based on clinical
and necropsy examinations. Whole blood, bile, gallbladder wall and liver samples were
collected aseptically from all dogs within 30 minutes of euthanasia and submitted
for bacterial culture, cytological, biochemical (alkaline phosphatase (ALP), alanine
aminotransferase (ALT) and gamma‐glutamyl transferase (GGT)) and histopathological
analyses. Agreement between cytology and culture was assessed with Cohen κ analysis
and analysis of variance of serum liver enzymes activities between dogs with bactibilia
and without was performed using the Mann‐Whitney test.
The prevalence of bactibilia was 16.36% (9/55), with 10.91% (6/55) of dogs diagnosed
on cytology and 10.91% (6/55) on bile culture. There was poor agreement between bile
cytology and culture (0.439, Cohens kappa; P = 0.001). No significant differences
in liver enzyme concentrations were found between bactibilic and non‐bactibilic dogs.
No significant hepatobiliary histopathological abnormalities were present in bactibilic
dogs.
The prevalence of bactibilia in asymptomatic dogs was 16.36%, with no significant
elevation in liver enzymes or histopathological changes.
Disclosures
Disclosures to report.
Co‐author F. Kettner has a financial relationship with and indirectly benefits from
the laboratory service (Vetdiagnostix) used in this study to perform the bacterial
culture, cytological, biochemical and histopathological analyses discussed in the
abstract. He has indirect shareholding in Vetdiagnostix and is involved in managing
the Vetdiagnostix Cape Town branch.
SCH‐O‐3
Hyaluronic acid as a liver function test to asses extrahepatic portosystemic shunt
closure in dogs after surgical attenuation
N. Devriendt, G. Serrano, E. Meyer, D. Paepe, H. de Rooster
Ghent University, Ghent, Belgium
Liver function tests do not always normalize after successful surgical attenuation
of portosystemic shunts (PSS). Currently the gold standard to demonstrate absence
of portosystemic shunting is portal scintigraphy. Serum hyaluronic acid concentrations
(sHA) in dogs with PSS are increased compared to those in healthy dogs. A preliminary
study reported that sHA decreased 2 weeks after surgical attenuation of extrahepatic
PSS (EHPSS).
The aims of the current study were: 1/ to serially evaluate sHA in dogs with surgically
attenuated EHPSS and to determine differences in sHA in dogs with closed versus open
(persistent or multiple acquired) PSS; 2/ to compare sHA in patients with EHPSS versus
other liver diseases.
Twenty dogs with surgically treated EHPSS and 10 dogs with other liver diseases were
included. Dogs with EHPSS had a blood sample taken at diagnosis, 1, 3 and 6 months
postoperatively. At the 3‐month control visit a transsplenic portal scintigraphy was
performed to determine shunt closure status. Dogs with other liver diseases were only
sampled at a single time point and comprised of: Maltese dogs with moderately increased
postprandial bile acids and no liver disease based on imaging (n = 3), dogs with histologically
confirmed portal vein hypoplasia (n = 4) or histologically confirmed chronic hepatitis
(n = 3). All samples were analysed in batch using a commercially available ELISA kit
(Hyaluronan Quantikine, R&D systems, Minneapolis).
At EHPSS diagnosis, median sHA was 337.20 ng/mL (158.02‐790.66 ng/mL). After successful
surgery (closed PSS), sHA dropped to 36.62 ng/mL (13.51‐92.24 ng/mL) whereas in dogs
with persistent portosystemic shunting, sHA remained higher (median 135.70 ng/mL;
56.44‐312.04 ng/mL). Kruskal‐Wallis tests revealed a significant difference between
sHA in dogs with closed versus open EHPSS (P = 0.008, P = 0.005 and P = 0.025 at 1,
3, and 6 months postoperatively, respectively). The median sHA of dogs with other
liver diseases was 119.64 ng/mL (48.44‐160.00 ng/mL), which was significantly lower
compared to dogs at the moment of EHPSS diagnosis (P = 0.009).
In dogs with EHPSS, sHA seems to be a promising non‐invasive biomarker to determine
EHPSS closure after surgical attenuation. In addition, it might also be valuable to
differentiate dogs with EHPSS from dogs with other liver diseases.
Disclosures
No disclosures to report.
ESVONC‐O‐1
BRAF‐mutation in carcinomas of various sites in the canine urinary tract
H. Aupperle‐Lellbach1, J. Grassinger1, H. Erhard1, L. Kempker1, S. Merz2, P. Pantke3
1LABOKLIN, Bad Kissingen, Germany, 2Institute of Veterinary Pathology, Berlin, Germany,
3AniCura Bielefeld, Tierärztliche Klinik für Kleintiere, Bielefeld, Germany
The oncogenic mutation of the BRAF‐gene is well described in canine transitional cell
carcinomas (TCC) of the urinary bladder and urethra (Mochizuki et al. 2015, Aupperle‐Lellbach
et al. 2018, 2019). This study investigates the prevalence of BRAF‐mutation in carcinomas
distributed over the whole canine urinary tract.
Dogs included in this study were 23 terriers (7 Scottish, 7 Jack Russel, 3 West Highland
White, 2 Airedale, 3 Fox, 2 Yorkshire, 1 Welsh, 1 Irish Soft Coated Wheaten) and 108
dogs of other breeds (eg, 40 mongrels, 6 Beagle, 5 Bearnaise Mountain Dogs, 4 Cocker
Spaniel) in the age of median 11 years. Formalin fixed samples from carcinomas of
the urinary tract (renal tubular carcinoma (RCa, n = 10), TCC of renal pelvis (RPCa,
n = 6), TCC of urinary bladder (ubTCC, n = 78), TCC in urethra (uTCC, n = 28), and
TCC simultaneously in urethra and urinary bladder (sTCC, n = 9) were histopathologically
diagnosed. DNA‐isolation was performed by using a QIAamp DNA FFPE Tissue Kit. Exon
15 of chromosome 16 was examined for the presence of BRAF‐mutation c.1799 T > A by
TaqMan SNP assay. Statistical analyses were performed using GraphPad Prism version
7.03.
Histological diagnosis showed tubulopapilliform RC and solid high‐malignant PRCa in
all cases. Most TCC were high‐malignant (55/78 ubTC, 28/28 uTC, 8/9 sTCC). BRAF‐mutation
was detected in 0/10 RCa, 1/6 RPCa, 36/78 ubTCC, 16/28 uTCC, 6/9 sTCC. It was significantly
(P ≤ 0.05) more often found in neoplasms of the lower urinary tract than in the kidney.
However, there was no significant difference in the prevalence of BRAF‐mutation between
the different sites of TCC in urinary bladder and/or urethra. Statistical correlation
of histological degree of TCC in LUT and BRAF‐mutation was not obvious. BRAF‐mutation
was identified significantly more frequent in ubTcc of terriers (20/25, 75%) than
in other breeds (21/57, 35%) (P < 0.005). In uTCC the breed differences in BRAF‐mutation
were not significant, probably due to the small number of terrier cases (2/28 dogs
with BRAF mutation).
In conclusion, renal carcinomas are mostly not caused by BRAF‐mutation. Thus, tubular
and pelvic carcinomas of the kidney cannot be detected by BRAF‐mutation analysis of
cells excreted within urine. In contrast, BRAF‐mutation is often involved in pathogenesis
of TCC in urinary bladder and/or urethra, and can be used as an excellent diagnostic
tool with enormous specify for malignancy and site of carcinomas in lower urinary
tract.
Disclosures
Disclosures to report.
The authors H. Aupperle‐Lellbach, J. Grassinger, L. Kempker and H. Erhard are employed
at LABOKLIN GmbH & Co KG, who provides the BRAF‐test.
ESVONC‐O‐2
Re‐irradiation is a valuable treatment option for dogs and cats with cancer after
failing first line therapy
M. Kleiter1, L. Reinhalter1, A. Tichy2, M. Pagitz1, T. Kreilmeier‐Berger1, B. Wolfesberger1
1VetMedUni Vienna, Department for Companion Animals and Horses, Vienna, Austria, 2VetMedUni
Vienna, Department for Biomedical Sciences, Austria
Re‐irradiation is getting a more recognized treatment option in patients with recurrent
neoplastic disease. However, information about efficacy and risk for chronic side
effects is limited in veterinary medicine. The aim of this study was to evaluate outcome
and reported late side effects in dogs and cats receiving re‐irradiation because of
progressive tumor recurrence. Small animal cancer patients treated with re‐irradiation
between 2006‐2017 were included into this retrospective study. Patient characteristics,
tumor type and localization, pretreatment, time interval between initial radiotherapy
and re‐irradiation, radiation protocols, late side effects, cause of death and survival
times were analyzed. Forty‐nine patients (27 dogs, 22 cats) were included into this
study and the majority of them suffered from head‐and neck tumors (61%). Re‐irradiation
protocols were ‐ with one exception ‐palliative and five animals received a second
course of re‐irradiation. Fifteen patients were initially radiated definitively and
34 animals with palliative intent. Mean time interval between initial radiotherapy
and first re‐irradiation was 264 days and between first and second re‐irradiation
207 days. Mean total biologic‐effective‐dose for late responding tissue (BED3) was
126 Gy for initial radiotherapy and re‐irradiation. Late side effects were most commonly
observed in skin/hair but always scored as mild (score 1, VRTOG). Chronic ocular side
effects were reported in seven patients (score 1‐3). Median tumor‐specific survival
time of all patients was 529 days. In conclusion, this study demonstrate that palliative
re‐irradiation can be offered as treatment option for incurable recurrent tumors.
Late side effects were mostly mild and not life‐threatening.
Disclosures
No disclosures to report.
ESVONC‐O‐3
Impact of Repeated Cycles of EGF Bispecific Angiotoxin (eBAT) Administered at a Reduced
Interval from Doxorubicin Chemotherapy on Tolerability and Survival of Dogs with Splenic
Hemangiosarcoma
A. Borgatti1, A. Fieberg2, J.S. Koopmeiners3, A.L. Winter4, K. Stuebner4, E. Taras5,
A. Masyr6, A. Rendhal7, D.A. Vallera5, J.F. Modiano6
1College of Veterinary Medicine, University of Minnesota, St. Paul, United States
of America, 2Coordinating Center for Biometric Research, University of Minnesota,
Minneapolis, United States of America, 3Division of Biostatistics, School of Public
Health, University of Minnesota, Minneapolis, United States of America, 4Clinical
Investigation Center, College of Vet Med, University of Minnesota, St. Paul, United
States of America, 5Department of Radiation Oncology, School of Medicine, University
of Minnesota, Minneapolis, United States of America, 6Department of Vet Clin Sciences,
College of Vet Med, University of Minnesota, St. Paul, United States of America, 7Department
of Veterinary and Biomedical Sciences, CVM, University of Minnesota, St. Paul, United
States of America
Targeted toxins are promising agents designed to target receptors that are uniquely
or highly expressed by cancer cells, improving tumor specificity with reduced adverse
events (AEs). As their name implies, bispecific ligand‐targeted toxins have dual targeting
ability that confers greater binding affinity and killing ability compared to monospecific
counterparts. eBAT is a bispecific epidermal growth factor (EGF) angiotoxin developed
as a second generation biologic drug to specifically target tumor cells and associated
vascular and inflammatory stroma for sarcoma therapy. It consists of human EGF, targeting
the EGF receptor (EGFR), human amino terminal transferase (ATF) of urokinase, targeting
the urokinase plasminogen activator receptor (uPAR), and a genetically modified, de‐immunized
Pseudomonas exotoxin, leading to inhibition of protein synthesis. We previously reported
that eBAT was safe and improved overall survival for dogs with splenic hemangiosarcoma
(HSA) in the minimal residual disease setting when added to standard of care (SOC)
therapy in a single cycle of three treatments. Studies with Pseudomonas exotoxin in
humans have suggested that repeat cycles of administration may prolong remissions
whereas the optimal timing between administration of targeted toxins and chemotherapy
is unclear. The SRCBST‐2 (sarcoma bispecific toxin trial‐2) study described herein
was undertaken to prospectively determine if multiple cycles of eBAT at the biologically
active dose (50 ug/kg) given intravenously, concomitant with a reduced interval between
administration of the targeted toxin and doxorubicin chemotherapy would be well‐tolerated
and further improve outcomes of dogs with splenic HSA. Eligibility was expanded to
dogs with stage‐3 HSA, provided that macroscopic lesions could be surgically excised.
Treatment included three planned cycles of eBAT, each administered on a Monday/Wednesday/Friday
schedule starting upon recovery from splenectomy, and continuing one week prior to
the 1st, 2nd, and 5th doxorubicin events. The interval between first eBAT (given on
day 1) and first doxorubicin was reduced compared to the previous trial using a single
cycle of eBAT (with doxorubicin starting on day 8 instead of day 21). Twenty‐five
dogs were enrolled; six experienced acute hypotension with two requiring hospitalization.
Self‐limiting elevation of ALT was observed in one dog. A survival benefit was not
seen in this study: overall survival was comparable to that of a contemporary control
group of dogs with stages 1‐3 hemangiosarcoma treated with SOC alone. Repeated dosing
cycles of eBAT led to greater incidence and severity of AEs and reduced efficacy as
compared to a single cycle of eBAT with delayed commencement of chemotherapy.
Disclosures
Disclosures to report.
This work was supported by grant K01OD017242 from the Office of The Director, National
Institutes of Health, grant AB15MN‐002 from the National Canine Cancer Foundation,
a grant from the Masonic Cancer Center, University of Minnesota Sarcoma Translational
Working Group, grant 1889‐G from the AKC Canine Health Foundation, the US Public Health
Service Grant R01 CA36725 awarded by the NCI and the NIAID, DHHS, the Randy Shaver
Cancer Research and Community Foundation, the Atwater Cancer Drug Development Award,
a CETI Translational Award from the University of Minnesota Masonic Cancer Center,
and a grant from GREYlong. The authors gratefully acknowledge generous support from
the Angiosarcoma Awareness Foundation and donations to the Animal Cancer Care and
Research Program of the University of Minnesota that helped support this project.
The authors declare that patent „Reduction of EGFR therapeutic toxicity,„ related
to this work has been filed by the Office of Technology Commercialization. Anivive
Lifesciences has purchased the license for therapeutic use of eBAT for all non‐human
species and applications.
ESVONC‐O‐4
Humoral hypercalcemia of malignancy in canine lymphoma WHO types and its impact on
survival
O.P. Skor1, B. Wolfesberger1, A. Fuchs‐Baumgartinger1, K. Reháková2, L. Bicanová1,
M. Faldyna3, I. Schwendenwein1, M. Kleiter1
1Vetmeduni Vienna, Vienna, Austria, 2University of Veterinary and Pharmaceutical Sciences
Brno, Brno, Czech Republic, 3Veterinary Research Institute, Brno, Czech Republic
Humoral hypercalcemia of malignancy (HHM) is a common paraneoplastic syndrome in canine
lymphoma and has always been considered a negative prognostic factor. However, studies
analyzing the role of HHM in WHO lymphoma types are lacking. The aim of this study
was to evaluate the incidence of HHM among different lymphoma types and its prognostic
impact on survival. In a retrospective study data of dogs diagnosed with untreated
lymphoma between 2008 and 2019 were analyzed. Inclusion criteria were availability
of WHO type and serum/plasma calcium concentration.
139 cases were included. HHM was present in 14/139 (10%) patients. Most notably only
patients with T‐lymphomas were affected. 9/14 (64%) suffered from peripheral T‐cell
lymphoma (PTLC) and 5/14 (36%) from T‐lymphoblastic lymphoma (T‐LBL). HHM occurred
in 43% (9/21) of PTLC and 38% (5/13) of T‐LBL cases. 86% of patients with HHM showed
symptoms attributable to hypercalcemia, predominantly polyuria/polydipsia, neurological
(somnolence, weakness), and gastrointestinal manifestation (inappetence). In dogs
with HHM, median total and ionized calcium were 3.81 mmol/l (reference interval 2.4‐3.0)
and 1.8 mmol/l (reference interval 1.25‐1.5), respectively. Under chemotherapy calcium
concentration returned to normal in 93% of cases. No significant differences in progression
free survival (150 vs. 60 days, P = 0.29) or lymphoma specific survival (170 vs. 135 days,
P = 0.42) were observed between hypercalcemic and normocalcemic dogs of both subtypes.
According to our results, HHM is not an unfavorable prognostic factor but it is associated
with aggressive T‐cell lymphoma types. Prospective studies assessing the role of vitamin
D3, PTHrP and PTH in HHM are warranted.
Disclosures
No disclosures to report.
ESVONC‐O‐5
High risk mast cell tumours with favourable outcome in 16 young dogs
K. Rigas1, D. Biasoli2, S. Murphy3, G. Polton4, R. Finotello1, M. Starkey2, S. Verganti5
1University of Liverpool,Department of small animal clinical sciences, Neston, United
Kingdom, 2Animal Health Trust, Molecular Oncology Group, Newmarket, United Kingdom,
3’Centre for Small Animal Studies, Animal Health Trust, Lanwades Park, Newmarket,
Suffolk, United Kingdom, 4North Downs Specialist Referrals, Bletchingley, United Kingdom,
5Animal Health Trust,Centre for Small Animal Studies, Newmarket, United Kingdom
Mast cell tumour (MCT) represents the most common canine skin neoplasia and typically
affects adult‐geriatric dogs (median age 9 years). MCTs are rarely reported in puppies
and junior dogs, and therefore little information exists about their biologic behaviour
and treatment requirements. The aim of this retrospective study was to describe clinical
and histopathological features, proliferation markers, c‐kit mutations and outcome
of MCTs in dogs less than 1 year‐old.
Sixteen dogs were included in the study: 13 with cutaneous MCT and 3 with subcutaneous
MCT. The median age at first presentation and diagnosis was 7.6 months (range 2‐11.9)
and 9 months (range 2‐36.1), respectively. There were 5 males (4 entire, 1 neutered)
and 11 females (6 entire, 5 neutered) and the most common breeds were Labrador (5)
and Golden Retriever (2). Of the thirteen cutaneous MCTs, 3 were grade II (Patnaik),
6 were grade II/low‐grade (Patnaik/Kiupel), 2 were grade II/high‐grade (Patnaik/Kiupel),
and 1 was high‐grade (Kiupel); 3had mitotic index >5/10HPFs(median mitotic index 7/10HPFs).
Of the three subcutaneous MCTs, two had an infiltrative growth pattern and 1 had mitotic
index of 10/10HPFs.
The regional lymph nodes were assessed in 13/16 cases by means of cytology or histopathology;
metastases were identified in 4 dogs (2 cutaneous, 2 subcutaneous).Ki‐67 was assessed
in 10 cases and it was above the cut‐off in 9 (8 cutaneous, 1 subcutaneous MCT).Of
the 9 cases screened, a c‐Kit mutation was identified in 6 (all cutaneous, exons 9,11,12).
Patients underwent different treatment modalities: surgery +/− corticosteroids(8),
surgery + chemotherapy (5) + radiotherapy (2) and radiotherapy/chemotherapy(1). Recurrence
was identified in 3 cases after a median time of 632 days (range 15‐730): one patient
received only corticosteroids following recurrence (15 days after the initial surgery),
achieving complete and durable clinical remission (1013 days); the other 2 dogs received
surgery, which was followed by chemotherapy in one case.The median follow‐up time
for this cohort of dogs was 1115 days (range 282‐2655). All patients were alive, and
with no evidence of MCT at the end of the study period.
This study suggests that MCTs in puppies and junior dogs might have a more favourable
outcome despite the presence of clinical, pathological or genetic characteristics
that would predict an aggressive biological behaviour in adult‐geriatric dogs. Based
on this, prognostic factors might need to be stratified for life stages.
Disclosures
Disclosures to report.
Funding of the project by Animal Health Trust.
ESVONC‐O‐6
Diphenhydramine Does Not Reduce Infusion‐Related Ventricular Arrhythmias in Dogs Treated
with Doxorubicin
J.L. Willcox, L.F. Yu, Y. Ueda, C. Belanger, K.A. Skorupski, J.H. Burton, J.A. Stern
University of California, Davis, Davis, United States of America
Doxorubicin (DOX) is one of the most effective chemotherapeutics for canine high‐grade
lymphoma. Besides dose‐dependent chronic cardiotoxicity, DOX can trigger acute cardiac
arrhythmias during drug infusion. Diphenhydramine premedication is commonly used,
as histamine release is a proposed mechanism for DOX‐associated arrhythmogenesis.
The study objectives were to evaluate the incidence and severity of DOX infusion‐related
cardiac arrhythmias in dogs with high‐grade lymphoma, and the effect of diphenhydramine
premedication on arrhythmia number and severity during and after DOX infusion.
Dogs with cytologically/histopathologically confirmed high‐grade lymphoma were screened
with an echocardiogram and concurrent electrocardiogram for this randomized prospective
cross‐over study. Group‐A received no premedication for DOX#1 and was premedicated
with diphenhydramine for DOX#2; Group‐B received diphenhydramine with DOX#1 and no
premedication for DOX#2. For both visits, Holter monitor data was collected 1 hour
before DOX and 3 hours post‐administration and analyzed by Burdick Holter Analysis
Software. Commercially available software (Prism7.0) was used for normality testing
and paired‐sample analysis with each individual acting as its own control.
Seventeen dogs were enrolled and 10 dogs [Group‐A(6), Group‐B(4)] completed the protocol.
There was no statistical difference between groups A and B when evaluating total ventricular
premature complex (VPC) numbers (P = 0.34), change of VPCs/hour (P = 0.25), total
atrial premature complex (APC) numbers (P = 0.5), change of APCs/hour (P = 0.06),
or arrhythmia severity score (P > 0.99).
This study demonstrates that in dogs with appropriate pretreatment cardiovascular
screening, DOX infusion does not induce significant arrhythmias. Furthermore, these
data suggest diphenhydramine may not alter arrhythmia number or severity in canine
DOX recipients.
Disclosures
No disclosures to report.
ESVONC‐O‐7
Time to change from WHO staging to Ann‐Arbor system in canine nodal diffuse large
B‐cell lymphoma?
O.P. Škor1, K. Hittmair1, A. Fuchs‐Baumgartinger1, L. Bicanová1,
A. guija
de Arespacochaga1, J. Pfeifr2, M. Pagitz1, B. Wolfesberger1, M. Kleiter1
1Vetmeduni Vienna, Vienna, Austria, 2Animed Clinic, Brno, Czech Republic
Ann Arbor system (AAS) remains the best anatomic staging of human diffuse large B‐cell
lymphoma (DLBCL). AAS divides patients into four stages based on localized disease
(I), multiple nodal sites on one side (II), disseminated nodal disease on both sides
of diaphragm (III), and in other extranodal sites (IV). In comparison to the veterinary
WHO staging system (WHOS) AAS considers a splenic infiltration as nodal involvement,
but not as a higher stage.
The aim of this retrospective study was to compare WHOS and AAS to predict treatment
response and survival in 54 canine nodal DLBCL treated with CHOP between 2008‐2019.
Because of low number of stage I/II patients (n = 3) in both systems, these were excluded.
There were nine stage III, 28 stage IV, and 17 stage V cases in WHOS, and 23 stage
III, and 31 stage IV cases in AAS. No association between WHOS and grade, substage,
B‐symptoms and treatment response were found. Higher AAS stage was associated with
substage B (P = 0.03) and B‐symptoms (P = 0.002) and negatively with treatment response
(P = 0.001). Higher AAS decreased progression free survival (PFS) (116 vs. 332 days,
P = 0.001) and lymphoma specific survival (LSS) (180 vs. 489 days, P = 0.001). Higher
WHOS showed a tendency toward shorter PFS (135 vs. 180 vs. 380 days, P = 0.36) and
LSS (194 vs. 250 vs. 396 days, P = 0.43). In conclusion, AAS could predict more accurately
prognosis in canine nodal DLBCL. Prospective studies assessing AAS in larger cohort
of patients with standardized staging and in other lymphoma types are warranted.
Disclosures
No disclosures to report.
ESVONC‐O‐8
Accuracy of PET for Detection of Lymph Node Metastasis in Canine Oral Malignant Melanoma
J.L. Willcox, K.A. Skorupski, J.H. Burton, K.D. Woolard, V.K. Affolter, K.S. Hansen,
M.A. Giuffrida, M. Spriet
University of California, Davis, Davis, United States of America
Positron emission tomography (PET) is commonly used for lymph node (LN) metastasis
detection in human medicine. Studies report a range of accuracy depending on tumor
type and grading system. Species and tumor‐specific studies are needed to define the
role of PET in staging veterinary oncologic patients. The aim of this study was to
evaluate the accuracy of PET for metastasis detection in canine oral malignant melanoma
(OMM).
Client‐owned dogs with cytologically/histologically diagnosed OMM were eligible for
this prospective study. A PET scan of the head/neck using 18Fluorine‐fluorodeoxyglucose
(18F‐FDG) was performed followed by computed tomography. Bilateral mandibular lymphadenectomy
was performed for histopathologic assessment. Scans were evaluated by two independent
observers. First, observers were blinded to primary tumor laterality and graded subjectively
comparing 18F‐FDG uptake to background. Subsequently, observers were unblinded to
primary tumor information and utilized standard uptake value (SUV) quantification
for evaluation. Interobserver agreement and receiver operating characteristics (ROC)
analysis were performed.
Twelve dogs were enrolled, and metastatic melanoma was identified in 6 mandibular
lymph nodes in 5 dogs. The interobserver agreement was higher when SUV quantification
was employed (K = 0.58 versus 0.54). The area under the curve improved for both observers
using this method (0.92 and 0.97 vs 0.86 and 0.90). The ROC analysis identified the
SUVmax value of 3.3 as a cutoff leading to a sensitivity of 100% and a specificity
of 83%.
In conclusion, including assessment of the oral cavity and use of quantification improves
the accuracy of PET for metastasis detection in canine patients with OMM.
Disclosures
No disclosures to report.
ESVONC‐O‐9
Efficacy of diosmectite in the management of chemotherapy‐induced diarrhoea in dogs:
an open‐label randomised clinical trial
Q. Fournier, J.C. Serra, C.W. Williams, S. Bavcar
University of Edinburgh, Roslin, United Kingdom
Chemotherapy‐induced diarrhoea (CID) is one of the most frequent adverse events associated
with chemotherapy in dogs. Yet, there is currently no consensus regarding its management.
Metronidazole is frequently prescribed, however there is no evidence supporting its
use, which could actually be associated with concerning gastrointestinal dysbiosis.
Diosmectite is a natural medical clay, which is widely used for the treatment of acute
diarrhoea in humans. There is strong evidence, both in vivo and in vitro, and in multiple
species, supporting the use of diosmectite as an antidiarrheal.
The aim of this prospective study was to investigate the efficacy of diosmectite for
the management of CID in dogs. We hypothesised that diosmectite would decrease the
duration of CID compared to our standard management.
Dogs diagnosed with non‐gastrointestinal neoplasia and undergoing maximum‐tolerated
dose chemotherapy between June 2017 and January 2019 were randomised into 2 groups
(“diosmectite” and “standard” groups), and were randomly re‐allocated if they developed
another CID event. Diosmectite was administered at 0.5 g/kg/day PO divided in 2‐3
doses to be initiated at the start of CID. “Standard” management consisted of a course
of metronidazole at 10‐15 mg/kg PO q12h to be initiated if the diarrhoea was not improved
after 48 hours. Dogs were assessed weekly with standard quality of life (QOL) and
diarrhoea diary forms filled by the owner, and physical examination performed by the
clinician. The Waltham faeces scoring system was used to grade diarrhoea.
Sixty‐one dogs were recruited during the study period. Twenty‐three and 20 grade ≥ 4
diarrhoea events were recorded among the “diosmectite” and “standard “groups, respectively.
Median duration of diarrhoea was significantly shorter (12h versus 96h) in the “diosmectite”
group compared to the “standard” group (P < 0.001). Median QOL score was significantly
higher (9/10 versus 7.5/10) in the “diosmectite” group compared to the “standard”
group (P = 0.0032).
Management of CID in dogs with early administration of diosmectite was associated
with a faster resolution of diarrhoea compared to our standard management with metronidazole,
confirming our initial hypothesis. Diosmectite appears to be effective in the first‐line
management of CID in dogs, leading to an improved quality of life whilst decreasing
antiobiotic usage.
Disclosures
Disclosures to report.
The diosmectite used for this study was kindly provided by VBS Direct LTD in the form
of VBS Clay 100 g powder pots. VBS Direct LTD had no involvement in the design or
performance of the study, writing the abstract, or the decision to submit it for presentation.
ESVONC‐O‐10
Contrast‐enhanced ultrasound for sentinel lymph node identification in the routine
staging of canine mast cell tumours: a feasibility study
Q. Fournier, F. Thierry, M. Longo, J. Bisson, S. Woods, T. Liuti, S. Bavcar
University of Edinburgh, Roslin, United Kingdom
Regional lymph node (LN) assessment is part of the routine staging of canine mast
cell tumours (MCTs). However, regional LNs are often determined based on their anatomical
location and the draining LN(s) may not be accurately identified. In order to overcome
this issue, different techniques of sentinel lymph node (SLN) detection have been
reported. Contrast‐enhanced ultrasound (CEUS) has been described to be a sensitive
and specific technique in human patients, but has not been widely used in veterinary
medicine.
The primary objective of this prospective study was to report the SLN detection rate
of CEUS in dogs diagnosed with a cutaneous/subcutaneous MCT. A secondary objective
was to assess the safety of this technique. We hypothesised that CEUS will identify
at least one SLN in >80% of dogs, and that adverse reactions would occur in <5% of
cases.
Dogs undergoing routine staging of cutaneous/subcutaneous MCT between June 2017 and
March 2019 were recruited. Routine staging included bloodwork, urinalysis, fine‐needle
aspirate (FNA) of regional LN(s), thoracic radiographs, and abdominal ultrasound with
FNA of liver and spleen. Regional LN assessment was completed with CEUS for identification
of SLN(s). Premedication with intramuscular chlorpheniramine was administered, and
1‐2 mL of sulfure hexafluoride microbubbles (SonoVue™) was injected around the tumour,
followed by a local massage. A resident in training in diagnostic imaging examined
with ultrasound the anatomical regions with potential draining LNs recommended by
a resident in training in oncology. The injection site was checked following the procedure
and before the discharge of the dog, and the owners were recommended to monitor the
site for any local reaction for the following couple of days.
Sixty‐five dogs diagnosed with a cutaneous/subcutaneous MCT were recruited. At least
one SLN was identified in 61 (94%) of the dogs. Sixteen dogs (26%) had 2 SLNs and
one dog (1.6%) had 3 SLNs identified. No adverse reaction to the procedure was recorded.
Among the 30 dogs that had histopathological assessment of all the SLN(s) identified,
18 (60%) were diagnosed with nodal metastasis.
CEUS is a sensitive and safe technique for the identification of SLNs in dogs with
MCTs, confirming our initial hypothesis. This technique may easily be incorporated
to the routine staging of canine MCT, but additional studies are warranted to confirm
its clinical benefit.
Disclosures
No disclosures to report.
ESVONC‐O‐11
Dorsal rhinotomy in 18 dogs with intranasal tumors
M.A. Ossowska, T. Emmerson, C. Lopez Jimenez,
A. Anna
, G. Polton
North Downs Specialist Referrals, Bletchingley, United Kingdom
Tumours of the nasal cavity and paranasal sinuses account for approximately 1% of
all canine neoplasms. The treatment of choice for intranasal tumors is radiotherapy.
Rhinotomy is associated with morbidity and a shorter survival than radiotherapy. The
objective of this study was to retrospectively analyze the outcome of dogs with nasal
tumours treated surgically. Patients with clinically low‐grade nasal tumours, defined
by clinical signs persistent for more than 6 months and no signs beyond local disease,
were treated with surgery.
Eighteen dogs were included. Twelve had carcinomas (9 adenocarcinomas, 2 transitional
type carcinomas and 1 adenosquamous) and 6 sarcomas (1 chondrosarcoma, 1 peripheral
nerve sheath tumour and 1 haemangiosarcoma). The main complains were sneezing, nasal
discharge and epistaxis. Fifty‐five percent (n = 10) of dogs presented with epistaxis.
Clinical signs were reported 2 months to 3 years (mean 8 months) prior to the surgery.
Surgery was the sole treatment for 83% of dogs while 3 had radiotherapy and surgery.
All dogs had blood analysis before surgery including haematology, biochemistry and
coagulation times. One dog had planned auto‐transfusion after surgery. CT imaging
was performed in 94% (n = 17) of dogs, one had rhinoscopy. Dorsal rhinotomy was performed
in all dogs without serious complications excluding one dog that required blood transfusiion
after surgery. Nasal packing was placed and left for 24 hours. Most of the dogs developed
mild to moderate facial emphysema and nasal discharge which resolved within two or
three weeks.
Thirteen dogs died (72%) of which 11 died of local tumour progression. One each died
from GI bleeding and renal carcinoma. Two dogs had a second surgery following relapse.
At the time of data submission, three dogs were still alive at 900, 723 and 141 days
and two dogs were lost to follow up 564 and 856 days after surgery. Overall median
survival time was 893 days. There was no significant difference between the survival
outcomes according to carcinoma or sarcoma diagnoses.
Historically, canine nasal tumours treated surgically achieved a median surival time
of 7‐9 months which is inferior to the outcome reported using radiotherapy. In our
case series severe surgical complications were infrequent. This study reveals that
some patients experience prolonged survival following surgery for intranasal tumours.
More studies are necessary to better define this patient group.
Disclosures
No disclosures to report.
ESVONC‐O‐12
The Use of Low‐dose Radiation Therapy for the Treatment of Small & Intermediate Cell
Gastrointestinal Lymphoma in Cats
C. Wood1, H. Wilson‐Robles2, M. Deveau2
1IndyVet Emergency & Specialty Hospital, Indianapolis, United States of America, 2Department
of Small Animal Clinical Sciences, College of Veterinary Medicine & B, College Station,
United States of America
Alimentary lymphoma is one of the most common forms of neoplasia in feline patients.
Chemotherapy has been the main stay of therapy for decades for feline alimentary lymphoma.
Overall response rates reported from 50‐92% and overall survival times range from
days to >3 years depending on the protocol utilized and the histologic form. For small
cell lymphoma, treatment generally has involved the use of glucocorticoids in combination
with chlorambucil (Leukeran). There is currently no standardized protocol for the
use of these drugs with some clinicians choosing to continue the therapy for a defined
period of time (6‐12 months) or indefinitely until disease progression in the patient.
The aim of this study is to establish a foundation for use of low‐dose radiation therapy
for feline intermediate and small cell alimentary lymphoma as an alternative to chronic
chemotherapy or in patient's refractory to medical management.
TAMU medical records searched 2012 to 2018 for cases utilizing helical tomotherapy
for treatment of intermediate and small cell alimentary lymphoma in feline patients.
Exclusion criteria, disease extension beyond intestines and liver. Recorded information
included patient signalment, baseline bloodwork, date, method of diagnosis, staging
diagnostics, date of treatment initiation with chemotherapy and radiation therapy,
any hematological abnormalities, first response duration to radiation therapy, and
date of progression and/or death if available for the patient.
Ten cats diagnosed with alimentary lymphoma were treated with low‐dose radiation.
Seven cats diagnosed with small cell lymphoma were treated with 3 Gy total and three
diagnosed with intermediate cell lymphoma were treated with 4 Gy total. Acute effects
associated with radiation therapy were not observed. Median overall survival time
for cats treated with radiation therapy was 1368 days, the median overall survival
time for the control population receiving chemotherapy alone was 1161 days.
Radiation therapy appears to be efficacious and well tolerated with no clinically
relevant adverse effects reported. In addition to the favorable adverse event profile,
low‐dose radiation was extremely convenient for the patients and clients as a number
of these clients have to travel long distances for treatment, monitoring and follow‐up.
Client compliance and satisfaction improved due to a variety of factors such as reduced
number of at‐home medications, hospital visits and financial burden. Further investigation
into the potential use of low‐dose radiation therapy for intermediate and small cell
alimentary lymphoma as a salvage or an alternative to oral chemotherapy for feline
patients is warranted.
Disclosures
No disclosures to report.
POSTER RESEARCH COMMUNICATIONS
ESCG‐P‐1
Foxp3 and histopathological lesions in relation to outcomes in canine immunosuppressant‐responsive
enteropathy (Ire): prospective analysis in 57 dogs
E. Benvenuti1, A. Pierini1, S.L. Benali2, E. Gori1, F. Abramo1, E. Bottero3, M. Pietra4,
P. Ruggiero3, V. Merchetti1
1University of Pisa, San Piero a Grado, Pisa, Italy, 2Laboratory MyLav La Vallonea,
Milan, Italy, 3Associazione Professionale Endovet Italia, Rome, Italy, 4Department
of Veterinary Medical Sciences, University of Bologna, Bologna, Italy
Canine immunosuppressant‐responsive enteropathy (IRE) is an intestinal idiopathic
inflammation, in which diet and antibiotic trials failed and immunosuppressants are
needed. The number of transcription factor forkhead box P3 (Foxp3)‐Positive Regulatory
T lymphocytes have been investigated in IBD dogs in association with mortality. The
aim of the study was to evaluate the clinical significance and prognostic role of
histopathological changes and Foxp3‐positive T cell in the clinical response and relapse.
CCECAI and CIBDAI scores have been assessed at presentation (T0) and 1 (T1), 3 (T3),
6 (T6) and 12 months (T12) from diagnosis. Endoscopic biopsies histopathology and
features were classified using WSAVA guidelines score. Moreover four morphologic features
were evaluated: presence of crypt distension (CD), lacteal dilation (LD), mucosal
fibrosis (MF) and intraepithelial lymphocytes (IL). Immunohistochemistry for Foxp3
were performed in all cases. Dogs were classified as responders (decreased CCECAI
and CIBDAI scores >25% at T1 compared to T0) and non‐responders (decreased CCECAI
and CIBDAI <25% at T1 compared to T0). Relapse was evaluated as follows: from T3,
if clinical scores was >3, differences (D) between CCECAI and CIBDAI at T3, T6 and
T12 and the previous closest time point were calculated obtaining DCCECAI and CIBDAI
T3‐T1, T6‐T3, T12‐T6. A DCCECAI and CIBDAI 32 were considered relapse. Associations
between response or relapse and categorical data were evaluated using Fisher's exact
test and chi‐square test. Fifty‐seven dogs were prospectively enrolled. At T1, 9 and
8 dogs belongs to non‐responders according to CIBDAI and CCECAI score, respectively.
CIBDAI and CCECAI scores at T0 were not associated with T1 clinical response. Patients
who relapsed were 5 (T3 and T6) and 4 dogs at T12, respectively. CIBDAI and CCECAI
at T1, T3 and T6 were not associated with relapse. Dogs with histological WSAVA moderate
had a higher response rate than severe dogs (P = 0.009, OR 6.5). However, histological
scores were not associated with relapse rate. The 4 histological features were not
associated neither with response nor with relapse rate. Presence of IL was associated
with higher CIBDAI scores (P = 0.022). The percentage of Foxp3‐positive cells was
not associated with T0 CCECAI and CIBDAI or histological scores and morphologic features.
The number of Foxp3‐positive cells were not different between responders and non‐responders
and not related with relapse. Between the evaluated parameters, only histological
grade seems to predict clinical response at T1. Furthermore, none of the clinical
or histological parameters, including Foxp3, seems to predict relapse in IRE dogs.
Disclosures
No disclosures to report.
ESCG‐P‐2
Prevalence and significance of increased TLI concentrations in clinical practice
M.D. Tabar1, C. Bertolani2, A. Climent1, N. Guilà2
1Hospital Veterinario San Vicente, San Vicente del Raspeig‐Alicante, Spain, 2Hospital
Veterinario Canis, Mallorca, Spain
TLI lacks specificity in individuals with certain gastrointestinal conditions, as
has been previously reported in cats with intestinal and/or hepatic disease. In humans
with chronic enteropathies, it has been suggested that enterocytes can synthetize
small amounts of trypsin but is has not been verified for other species.
The aim of the present study was to evaluate the prevalence and significance of increased
TLI in cats and dogs from clinical practice.
Results of serum TLI measurements were retrospectively reviewed from samples from
animals evaluated for different diseases from two Veterinary Hospitals, performed
in an outside laboratory (Idexx Barcelona) using a radioimmunoassay (feline) and chemiluminescent‐assay
(canine). Clinical records from patients with elevated TLI levels (>45 ng/L for dogs
and > 82 μg/L for cats) were reviewed.
383 samples from 317 dogs and 66 cats were evaluated, and TLI was increased in 19.8%
(70 dogs and 6 cats). Cobalamin was available for review in 181 of total patients,
without correlation between cobalamin and TLI results (P = 0.143).
In 38 of the 76 patients with increased TLI, cPLI was also determined (semi‐quantitative
and/or quantitative analyses) with results consistent with pancreatitis in 50%(19/38).
Among patients with normal cPLI results, pancreatitis was suspected in 2 based on
pancreatic histology (n = 1) and abdominal ultrasound (n = 1), and non‐cirrhotic portal
hypertension (n = 1) and gastrointestinal disease (n = 16) were diagnosed in the other
17 patients. Gastrointestinal disease was confirmed in 11 cases [food‐responsive enteropathy
(5), IBD (4), gastrointestinal neoplasia (2)] and pressumptive in 5 patients (chronic
enteropathy).
Pancreatitis was not suspected in any of the 38 patients with elevated TLI without
cPLI analyses. In 30 patients underlying disease was confirmed: gastrointestinal disease
(15), hepatopathy (4), renal disease (3), hypoadrenocorticism (1), insulinoma (1),
neoplasia (2) and poliartritis (1). In the 11 patients with presumptive diagnosis,
the most likely underlying disease was chronic enteropathy (n = 9).
In the present study 76,9% (40/52) of cases with increased TLI and without pancreatitis
or azotemia had confirmed or suspected underlying gastrointestinal disease, coincident
with previous feline and human findings. In fact TLI was performed in those cases
to rule out exocrine pancreatic insufficiency. Although cobalamin deficiency has been
linked to increased feline TLI (that normalized after supplementation), this study
didn't detect a significant correlation between cobalamin and TLI levels. Other yet
undefined mechanisms likely explain the production of TLI in absence of pancreatic
inflammation, and TLI levels must be carefully interpreted in animals with gastrointestinal
disease.
Disclosures
No disclosures to report.
ESCG‐P‐3
Serum 25‐hydroxyvitamin D3 in dogs with acute gastrointestinal diseases
J.G. Lyngby, F.K. Nielsen, C. Piper, C.R. Bjørnvad, L.N. Nielsen
University of Copenhagen, Frederiksberg, Denmark
Hypovitaminosis D has been linked to systemic inflammation, chronic enteropathy (CE)
and cancer in dogs. It is unknown if changes in serum 25‐hydroxyvitamin D3 [25(OH)D3]
are seen in dogs with acute enteropathy (AE).
This study aimed to investigate [25(OH)D3] in dogs with AE and compare these to normal
dogs and dogs with CE. It was hypothesized that dogs with AE had significantly different
concentrations of [25(OH)D3] compared to healthy dogs while similar concentrations
to dogs with CE.
The study was approved by the local ethics committee. Twenty‐eight client owned adult
dogs were recruited prospectively. Ten healthy, 10 diagnosed with AE (clinical signs
<72 hours) and 8 diagnosed with CE (clinical signs >3 weeks). Serum 25‐hydroxyvitamin
D3, ionized calcium, total calcium, phosphorus, magnesium and C‐ reactive protein
(CRP) were measured in all dogs. Dietary vitamin D3 was calculated. Comparisons between
groups and correlations were performed using appropriate parametric and non‐parametric
statistics. P < 0.05 was significant.
Descriptive statistics revealed comparable groups apart from an overweight of small
medium breed dogs (P = 0.01) in the CE group. The mean ± SD [25(OH)D3] was 271.4 ± 95.2 nmol/L
for healthy dogs, 205.9 ± 62.1 nmol/L for AE and 196.5 ± 76.7 nmol/L for CE and not
statistically different between groups (P = 0.1). A negative correlation between [25(OH)D3]
and CRP (P < 0.05) in dogs with AE was observed. No significant difference in electrolytes
were found between groups. There was no correlation between [25(OH)D3] and dietary
Vitamin D3.
In conclusion, in this pilot study, no statistical significant difference in [25(OH)D3]
was detected between groups.
Disclosures
No disclosures to report.
ESCG‐P‐4
Evaluation of abdominal ultrasound features in relation with canine Spec cPL, the
severity of disease and mortality in suspected canine acute pancreatitis
E. Gori, A. Pierini, I. Lippi, S. Citi, T. Mannucci, V. Marchetti
University of Pisa, Pisa, Italy
In canine acute pancreatitis (AP) abdominal ultrasound (US) is a widely‐used non‐invasive
diagnostic tool involved in the diagnosis. Although, no specific recent studies about
the relationship between US and clinicopathological features and severity of canine
AP are available.
The aim of the study was to evaluate abdominal ultrasound features in relation with
canine Spec cPL, severity of disease and outcome in suspected canine AP.
Dogs with suspected AP hospitalized between 2017 and 2019 were prospectively enrolled.
AP was suspected based on compatible clinical and laboratory parameters, abnormal
SNAP cPL test (Idexx Laboratories) at admission. Data regarding abdominal pain were
recorded and serum samples for Spec cPL were sent to a commercial laboratory (Idexx
Laboratories). US was performed at presentation, and every 24 h until 2 days from
hospitalization. US was considered consistent with AP if there were hypoechoic and
enlarged pancreas, irregular shape and margins, surrounded by hyperechoic mesentery
and/or abdominal effusion. Recently developed Canine Acute Pancreatitis Severity (CAPS)
score was calculated and dogs were divided into groups (CAPS <11 and > 11. Mortality
rate was assessed at hospital discharge. US positivity at presentation was compared
with the presence of abdominal pain, mortality rate and CAPS using Fisher's exact
test. OR was also calculated. Spec cPL values were compared in positive/negative US
at presentation using Mann‐Whitney U‐test. Forty‐seven client‐owned dogs were prospectively
enrolled with owners' informed consent. Seventeen dogs (36%) died during hospitalization.
Twenty‐four dogs (51%) had US suggestive of AP at presentation, while other 10 US
became positive within 2 days from hospitalization (US+ group, n = 34). Thirteen dogs
(27%) remained US negative (US‐ group). No association between mortality and US positivity
was found. Twenty‐two dogs (47%) presented with abdominal pain. Dogs showing abdominal
pain had significantly higher prevalence (88%) of positive US than dogs without abdominal
pain (P = 0.0014; OR 10.22). CAPS and US positivity were not associated, although
CAPS was associated with mortality (P = 0.0021; OR 9.3). Spec cPL were not significantly
different between positive or negative US at presentation, and 8 dogs had negative
US at admission, which became positive afterwards with Spec cPL < 400 mg/L. Interestingly,
4 dogs were in US‐ group, despite a Spec cPL > 400 mg/L.
In dogs with AP, changes in US could occur later during hospitalization, although
the presence of abdominal pain at presentation may suggest US positivity. Furthermore,
US positivity seems to be related neither with Spec cPL nor to the prognosis or the
severity of the disease.
Disclosures
No disclosures to report.
ESCG‐P‐5
Gastric mucosal pathology in Belgian Shepherd dogs with and without clinical signs
of gastric disease
M.V. Candido, P. Syrjä, M. Hanifeh, S. Kilpinen, T. Spillmann
University of Helsinki, Helsinki, Finland
Belgian Shepherd dogs (BSD) are considered at increased risk for gastric carcinoma
(GC), mucous metaplasia and glandular dysplasia. In humans, gastric mucosal atrophy,
metaplasia and dysplasia are all linked to GC. We performed a prospective clinical
trial exploring early diagnosis of such conditions. Gastroscopy with histology of
mucosal biopsies was conducted to investigate possible associations of clinical signs,
atrophy, metaplasia, dysplasia and GC.
After an online survey for recruitment, anamnesis and laboratory minimal database
were performed. Canine chronic enteropathy clinical activity index (CCECAI) and signs
of gastroesophageal reflux (GER) were used to ascribe dogs in two groups: with or
without signs of gastric disease (Group A: CCECAI >1 and/or GER; Group B: CCECAI =
0 and no GER). Gastric inflammation, including mucosal fibrosis and glandular atrophy,
was histologically assessed according to standardization guidelines by the World Small
Animal Veterinary Association. Mucous metaplasia and glandular dysplasia were rated
as present or absent.
Group A included 20 dogs (median age 9 years [5.5‐11.6], mean CCECAI = 3.4 ± 2.1),
and Group B included 11 dogs (median age 9.8 years [7.6‐11.3]). Logistic regression
analysis detected no statistical difference in histological findings between Groups
A and B concerning mucosal atrophy (A: 14/20; B: 10/11), metaplasia (A: 5/20; B: 3/11),
dysplasia (A: 11/20; B: 3/11) or GC (A: 4/20; B: 2/11). Independent of grouping, numerous
BSD had atrophy (25/31), followed by dysplasia (15/31), metaplasia (8/31), and GC
(6/31). Out of the six dogs with GC, five had also atrophy, four metaplasia, and six
dysplasia. Fisher's exact test revealed a significant association of GC with metaplasia
(P = 0.026) and dysplasia (P = 0.004), but not with atrophy (P = 1). All neoplasms
were gastric adenocarcinomas: 1/6 tubular type and 5/6 partly or completely of the
diffuse, non‐cohesive type, including four signet‐ring‐cell carcinomas and one mucinous
adenocarcinoma.
This study in BSD showed a high proportion of gastric mucosal pathological changes,
regardless of clinical signs of gastric disease; even GC presented repeatedly as an
occult entity. The significant association of both metaplasia and dysplasia with GC
supports an indication for endoscopic follow‐up of affected BSD. Extensive endoscopic
screening seems, however, unrealistic for early diagnosis due to the occurrence of
occult disease. To address this problem, research on serum biomarkers for GC should
be pursued. Future studies should also revise the diagnostic criteria for atrophy.
Keywords: gastric, carcinoma, atrophic gastritis, metaplasia, dysplasia, dog.
Disclosures
Disclosures to report.
Statement of Disclosures ‐ Marcus Vinicius Candido The author has the following disclosures
related to their presentation: Employee/salary: Marcus Vinicius Candido has worked
in zoos in southern Brazil, having researched on various topics. He has been a teacher
of anatomy and exotic animal medicine between 2009 and 2012. He has worked as a private
practitioner with companion animal endoscopy since 2012. He is currently a PhD student
working with endoscopy and also treating patients at the exotic animal clinic at the
Small Animal Hospital at University of Helsinki. Grants/research: As a PhD student
at University of Helsinki, Finland, Candido has received research grants from the
National Research Council / Ciencia Sem Fronteiras (CNPq ‐ Brazil, personal funding),
from the Finnish Foundation of Veterinary Research (research material grant), and
from the Finnish Veterinary Foundation and the Doctoral Program ‐ Clinical Veterinary
Sciences, University of Helsinki, Finland (travel grants). Speaking & consultancies:
He has given lectures on wild, zoo and exotic pet animal husbandry, medicine and welfare,
in events held by several veterinary faculties in Brazil, as well as congresses and
meetings such as Grupo Fowler (Wild Animal Veterinary Association, Brazil), CONBRAVET
(Brazilian Congress of Veterinary Medicine) and others. Investments/commercial interests:
None Gifts, hospitality, travel support: Marcus Vinicius Candido will have travel
support from the Finnish Veterinary Foundation and the Doctoral Program ‐ Clinical
Veterinary Sciences, University of Helsinki, Finland to participate in 26th ECVIM.
Other, including indirect benefits: None. Statement of Disclosures ‐ Pernilla Syrjä
The authors have the following disclosures related to their co‐authorship: Employee/salary:
Syrjä is employed by University of Helsinki, Faculty of Veterinary Medicine, Section
of Veterinary Pathology, which is partially funded through diagnostic income from
client biopsies, among them biopsies related to the submitted abstract. Grants/research:
Syrjä has received research grants, for topics not related to the submitted abstract,
from the Finnish Foundation of Veterinary Research, the Finnish Veterinary Foundation
and Svenska Kulturfonden. Speaking & consultancies: None Investments/commercial interests:
None Gifts, hospitality, travel support: None Other, including indirect benefits:
None Thomas Spillmann The authors have the following disclosures related to their
presentation: Employee/salary: Thomas Spillmann was Hill's professor of small animal
clinical nutrition at the Veterinary University, Hannover, Germany from 2004‐05. Since
2005 he has been employed as professor of small animal internal medicine at the Veterinary
Faculty, University of Helsinki, Finland Grants/research: Thomas Spillmann has received
research grants from the German Research Society, the Finnish Foundation of Veterinary
Research, and the Finnish Veterinary Foundation. His PhD students received grants
from the Doctoral Program ‐ Clinical Veterinary Sciences, University of Helsinki,
Finland; the Center of International Mobility (CIMO)/Finland; the Finnish Foundation
of Veterinary Research; the Finnish Veterinary Foundation; the Finnish Culture Foundation;
the Emil Aaltonen Foundation/Finland; the Alfred Kordelin Foundation/Finland; Agria/Sweden;
the Swedish Kennel Club Research Foundation; the Ulla Yard Foundation/Sweden; Ciencia
Sem Fronteiras/Brazil; and the Archimedes Foundation/Estonia. Speaking & consultancies:
Thomas Spillmann has been a consultant for IPSAT, Finland. He has given lectures on
behalf of Royal Canin, Hill's, Iams, Purina, Triolab/Finland, zoetis/Finland, the
Finnish Association of Veterinary Practitioners, the German Small Animal Veterinary
Association, the British Small Animal Veterinary Association, the Estonian Small Animal
Veterinary Association, the World Small Animal Veterinary Association, the Federation
of European Companion Animal Veterinary Associations, and the European College of
Small Animal Internal Medicine ‐ Companion Animals. Investments/commercial interests:
None Gifts, hospitality, travel support: Thomas Spillmann has had travel support for
attending congresses and for research and teaching visits at other universities by
Iams, Royal Canin, Hill's, the Finnish Veterinary Foundation, and the European Erasmus
program. Equipment and material donations for clinical research have been received
from the Endoscopy Unit of the Hospital District of Helsinki and Uusimaa/Finland;
Olympus/Finland; Pulsion, Munich/Germany; and Biophysics Assay Lab (biopal), Worcester
MA/USA. Other, including indirect benefits: Resident salary for Residency Program
ECVIM‐CA by Royal Canin 2013‐18.
ESCG‐P‐6
Effect of stem cell therapy on serum cobalamin levels in dogs diagnosed with chronic
enteritis without cobalamin supplementation
J.I. Cristóbal Verdejo, F.J. Duque Carrasco, C. Zaragoza Bayle, R. Barrera Chacón,
P. Ruiz Tapia, B. Macías García, J. Usón Casaús, E.M. Pérez Merino
Hospital Clínico Veterinario de la Universidad de Extremadura, Cáceres, Spain
Cobalamin deficiency is a common finding in dogs diagnosed with chronic enteropathy
(CE) due to low absorption and/or bacterial competition. It has been described the
importance of hypocobalaminaemia in the long‐term prognosis of these patients being
cobalamin supplementation highly recommended. Treatment of CE constitutes a therapeutic
challenge and new approaches include stem cell therapy.
Our aim was to evaluate serum concentration of cobalamin in dogs diagnosed with CE
in which stem cells were used in the absence of cobalamin administration.
Twenty dogs diagnosed with CE were included in this study; all showed persistent gastrointestinal
signs, no response to conventional treatment (diet, antibiotics and/or immunosupressors/immunomodulators
administration) and histopathological evidence of intestinal inflammation. The study
was approved by the Ethical Committee of the University of Extremadura. A single dose
of canine mesenchymal stem cells (MSCs) of allogeneic adipose origin at 2‐4 x 106
cells per kilogram of weight was parenterally administered. A blood sample was obtained
prior MSCs administration and subsequent cobalamin checkups were performed at 1, 3,
6 and 12 months; blood samples were submitted to a reference laboratory (Laboklin,
Madrid, Spain). Clinical improvement was assessed at the same time points by the Clinical
Activity Index (CIBDAI; clinically normal <3). The data were analyzed using a Saphiro‐Wilk
test and a repeated measures One‐Way ANOVA followed by a Dunns or a Holm Sidak post‐hoc
test; P < 0.05 was considered as significant and results are expressed as mean ± SE
of the mean. At the beginning of the study, 75% of dogs (15/20) presented hypocobalaminaemia
(<300 pg/ml; laboratorial reference value). Statistically significant differences
were observed between pre‐treatment cobalamin values (225.3 ± 26 pg/ml) and those
analyzed at 3 (360.7 ± 33.5 pg/ml), 6 (423 ± 55.7 pg/ml) and 12 (602.6 ± 54 pg/ml)
months of treatment (P < 0.001). No significant differences were observed between
pretreatment values and those obtained after one month of MSCs administration (299.2 ± 41 pg/ml).
The CIBDAI significantly improved at all the checkups ranging from 8.2 ± 0.6 (pre‐treatment)
to 0.7 ± 0.3 (twelve months). CIBDAI was <3 for all groups treated with MSCs.
Our results demonstrate that administration of MSCs leads to an increase in serum
cobalamin in dogs diagnosed with CE. This increase is associated with an improvement
of their clinical status and therefore, MSCs therapy should be considered for the
treatment of dogs affected with CE due to their positive impact on the long‐term prognosis.
Funded by: IB16133 and FEDER/FSE.
Disclosures
Disclosures to report.
Mr. José Ignacio Cristóbal Verdejo, as first author and on behalf of all the authors
declares that the present work was exclusively funded by the project IB16133 of the
Junta de Extremadura and co‐funded by FEDER/FSE funds. The authors declare no commercial
interest or any other conflicts of interest. The veterinary laboratory Laboklin has
not participated in the design, writing or funding of the present work.
ESCG‐P‐7
Neutrophil‐to‐lymphocyte ratio (NLR) as a biomarker in dogs with chronic inflammatory
enteropathies
A. Becher1, J.S. Suchodolski2, J.M. Steiner2, R.M. Heilmann3
1College of Veterinary Medicine, University of Leipzig, Leipzig, Germany, 2Texas A&M
University, College Station, United States of America, 3University of Leipzig, College
of Veterinary Medic, Leipzig, Germany
Chronic inflammatory enteropathies (CIE) comprise an important group of diseases in
dogs. Only few biomarkers that can be routinely measured (eg, serum cobalamin and
albumin, fecal calprotectin) appear to be of clinical utility in dogs with CIE and
can potentially aid in CIE subclassification based on the response to treatment (ie,
diagnosis of food‐responsive enteropathy [FRE] vs. steroid−/immunosuppressant‐responsive
enteropathy [IRE]). The neutrophil‐to‐lymphocyte ratio (NLR) was recently shown to
have diagnostic and prognostic potential in humans with inflammatory bowel disease
(IBD). NLR also appears to be useful in the diagnosis of dogs with hypoadrenocorticism,
but the NLR has not been evaluated or reported in dogs with CIE.
Data from 91 dogs diagnosed with CIE (that had not received steroids for ≥2 weeks
prior to diagnostic evaluation) at 2 veterinary centers were used for this study.
NLR was calculated as [neutrophil count/lymphocyte count] and was evaluated for a
potential relationship with the severity of clinical signs (CCECAI scoring system,
n = 65), serum albumin and cobalamin concentrations (n = 65), histologic lesion severity
(4‐point semi‐quantitative grading system, n = 36), serum and fecal concentrations
of other inflammatory markers (n = 60), and the response to treatment (FRE vs. IRE,
n = 39). Statistical significance was set at P < 0.05.
NLR ranged from 0.23‐54.0 (median: 5.69) in all dogs with CIE. NLR was significantly
higher in dogs with very severe clinical signs compared to dogs with mild (P = 0.014)
or moderate (P = 0.026) clinical disease. NLR was not correlated with the overall
histologic score (P > 0.05), but was significantly higher in dogs with histologic
lesions compatible with protein‐losing enteropathy (P = 0.006). Hypoalbuminemia (P
< 0.001), but not hypocobalaminemia, was significantly associated with a higher NLR.
NLR correlated significantly with serum S100A12 (P = 0.032), C‐reactive protein (P
= 0.046), decoy receptor for advanced glycation end products (P = 0.034), and fecal
alpha1‐proteinase inhibitor (P < 0.001), but not with serum or fecal calprotectin
concentrations. Dogs with IRE (n = 26) had significantly higher NLRs (median: 8.41)
than dogs with FRE (median: 3.09; n = 13; P = 0.008), and an NLR ≥4.60 best distinguished
dogs with IRE from those with FRE (sensitivity: 77%, specificity: 69%).
Our findings suggest that neutrophils play a role in the systemic inflammatory response
associated with CIE in dogs. NLR (ie., leukogram changes) in canine CIE are of similar
magnitude as in human IBD. NLR can be easily obtained during routine hematology, and
can potentially aid in the subclassification of dogs with CIE. The potential utility
of NLR in the monitoring of dogs with CIE requires further investigation.
Disclosures
No disclosures to report.
Not applicable.
ESCG‐P‐8
Calprotectin concentrations are increased in the intestinal mucosa of dogs with chronic
inflammatory enteropathies
M. Hanifeh1, R. Heilmann2, P. Syrjä1, S. Kilpinen1, C.A. Moniz3, K. Kock3, C. Niederberger3,
T. Spillmann1
1Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland, 2Veterinary
Teaching Hospital, University of Leipzig, Germany, 3Bühlmann Laboratories, Schönenbuch,
Switzerland
Calprotectin, a Ca2+ − binding protein of the S100/calgranulin family, has potential
as a marker of inflammation in dogs and mainly originating from granulocytes. Increased
canine calprotectin concentrations have been detected in feces and serum samples from
dogs with chronic inflammatory enteropathy (CIE). However, intestinal mucosal calprotectin
concentrations have not been extensively investigated in canine CIE.
We evaluated the mucosal concentrations of calprotectin in dogs with CIE in comparison
with healthy Beagle dogs using a particle‐enhanced turbidimetric immunoassay (PETIA)
method on a clinical chemistry analyzer. Additionally, we assessed the association
of mucosal calprotectin levels with the canine clinical IBD activity index (CIBDAI),
histopathologic findings, clinical outcome, and serum albumin concentrations. Intestinal
mucosal biopsies were collected from 38 dogs with CIE (duodenum [n = 34], ileum [n
= 10], colon [n = 14], and caecum [n = 7]). Archived intestinal tissue samples from
18 healthy Beagle dogs served as controls (duodenum [n = 17], ileum [n = 18], colon
[n = 18], and caecum [n = 6]). Data are presented as medians (interquartile ranges).
In comparison to healthy Beagles, mucosal calprotectin concentrations of CIE‐dogs
were higher in the duodenum (332 [91‐639] vs. 94 [24‐137] μg/L; P = 0.001) and colon
(380 [187‐542] vs. 112 [36‐196] μg/L; P = 0.002). Histologic severity was significantly
associated with mucosal calprotectin levels (P < 0.05) for total histopathology score,
lymphoplasmacytic infiltration in the duodenum, and epithelial injury in the colon.
Duodenal calprotectin concentrations were higher in hypoalbuminemic dogs than normoalbuminemic
dogs (1441 [1098‐1748] μg/L vs. 227 [74‐506] μg/L), but because of the small number
of hypoalbuminemic dogs (n = 4) the results were only descriptively reported. There
was no significant association of mucosal calprotectin levels with CIBDAI scores or
with the clinical outcome.
This study showed that mucosal calprotectin concentrations are increased in the duodenum
and colon of dogs with CIE. The results provide supporting evidence for the potential
diagnostic value of mucosal (or fecal) calprotectin concentrations in dogs with CIE.
Further prospective research is needed to assess the value of measuring mucosal calprotectin
concentrations in clinical practice, the relationship between mucosal and fecal calprotectin,
and other inflammatory markers in dogs with CIE.
Disclosures
No disclosures to report.
ESCG‐P‐9
Neutrophil‐to‐lymphocyte ratio (NLR) in canine patients with immunosuppressant‐responsive
enteropathy (IRE)
E. Benvenuti1, E. Gori1, A. Pierini1, C. Lucarelli1, P. Ruggiero2, G. Lubas1, V. Marchetti1
1University of Pisa, San Piero a Grado, Pisa, Italy, 2Associazione Professionale Endovet
Italia, Rome, Italy
In human IBD, neutrophil‐to‐lymphocyte ratio (NLR) was associated with active bowel
inflammation and correlated with clinical and laboratory indices. So far, NLR in dogs
has been only evaluated in oncologic patients and in septic peritonitis.
The aim of the study was to evaluate the NLR in canine immunosuppressant‐responsive
enteropathy (IRE).
Forty‐one dogs presented to two veterinary facilities (Veterinary Teaching Hospital
and Private Veterinary Center) with a final diagnosis of IRE were retrospectively
included. The Canine Chronic Enteropathy Clinical Activity Index (CCECAI) score was
assessed for each dog at presentation. The diagnosis of IRE was set on histopathology
performed on endoscopic biopsies and classified using the current WSAVA guidelines.
Lacteal dilatation (LD) and crypts abscesses (CD) were also recorded. NLR was calculated
for each dog. Serum total protein, albumin, cholesterol and C‐reactive protein (CRP)
were also recorded. Kruskal‐Wallis test was performed to evaluate NLR between different
CCECAI category (0‐3, 4‐5, 6‐8, 9‐11 and > 12) and different histological grading.
Spearman's correlation tests were performed between NLR and total protein, albumin,
cholesterol and CRP. Mann‐Whitney U‐test was used to compare NLR in dogs with or without
LD and CD. A receiving operator characteristic curve (ROC) was built to obtain an
optimal cut‐off value of NLR to differentiate dogs with or without LD. A Fisher's
exact test was then performed between the presence of LD and NLR groups.
NLR was significantly different between CCECAI score categories (P = 0.004). NLR was
negatively correlated with total protein (P = 0.022, r = −0.35), albumin (P = 0.007,
r = −0.41) and cholesterol (P = 0.03, r = −0.33). No significant correlation between
CRP and NLR was found. NLR was not different between histological grading and dogs
with or without CD. Contrarily, NLR was higher in dogs with LD (P = 0.004). The cut‐off
value of NLR for the detection of LD was 3.96 (sensitivity 82.4% and specificity 58.3%).
So far, this is the first report evaluating the NLR in IRE dogs. Our results suggest
that NLR could be an easy, feasible and economic additional tool to evaluate the disease
severity in IRE dogs. Moreover, NLR seem to have a good correlation with other essential
biochemistry parameters in the evaluation of dogs with protein‐losing enteropathy.
Furthermore, the most interesting data was the association between NLR and histologic
lymphangectasia.
Disclosures
No disclosures to report.
ESCG‐P‐10
A Novel Canine‐Specific Model System to Study Intestinal P‐Glycoprotein‐Mediated Drug
Transport
Y.M. Ambrosini1, D.C. Borcherding1, T. Atherly1, W.J. Shin2, H.J. Kim2, A. Jergens1,
J.P. Mochel1, K. Allenspach1
1Iowa State University College of Veterinary Medicine, Ames, United States of America,
2University of Texas at Austin, Austin, United States of America
P‐Glycoprotein (P‐gp) modulates oral absorption of therapeutic drugs in the small
intestine. Many drugs serve as substrates for P ‐ gp including chemotherapeutic agents
(vincristine, doxorubicin), parasiticides (macrocyclic lactones) and antidiarrheal
agents (loperamide). Due to its significant influence on drug disposition and the
risk of severe adverse drug reactions seen with defective P ‐ gp function, routine
screening of drug candidates for P‐gp transport is common practice in human drug discovery.
However, there is currently no canine‐specific in vitro system for evaluating P‐gp‐mediated
drug transport in veterinary medicine available. Our laboratory has recently developed
an ex vivo 3D canine enteroid (ENT) system, which accurately mimics the cellular and
molecular features of the intestinal epithelium in vivo. The aim of this research
was to evaluate P‐gp functional activity and expression in canine ENT vs. intestinal
tissues.
P‐gp expression was assessed using qPCR of intestinal tissues and ENT from the ileum
of 3 healthy and diseased dogs. Immunofluorescence (IF) staining of canine ileal ENT
in transwell culture was performed to assess the localization of P‐gp transporters.
Functional assays were performed using 10 μM rhodamine123 (Rh123), a fluorescent dye
substrate for P‐gp, with or without 20 μM verapamil (P‐gp inhibitor). An un‐paired
t‐tests was used to compare the mean luminal fluorescence intensity obtained with
ImageJ. Kruskal‐Wallis test was used to compare the mean quantitation cycle obtained
with qPCR, and P = 0.05 was considered as statistically significant.
P‐gp gene expression was not significantly different between ENT and the epithelial
layer of the intestinal mucosa (quantitation cycle values expressed in Mean ± S.D):
Organoid: PLE M = 24.5 ± 1.0; RW M = 24.7 ± 0.3; HC M = 25.7 ± 0.3; Tissue: PLE M
= 25.4 ± 0.6; RW M = 26.3 ± 0.7; HC M = 24.1 ± 0.5; P = 0.06), confirming that ENT
express P‐pg in comparable amounts as reported in vivo tissues from the same dogs.
The culture of primary canine ENT in Transwell showed apical expression of P‐gp, which
is again consistent with in vivo observations. Co‐incubation with verapamil significantly
reduced Rh123 fluorescence in the lumen of ENT at 30 min (P < 0.0001) and 60 min (P
< 0.001), indicating that P‐gp‐mediated transport was successfully blocked.
In summary, P‐gp gene expression, localization, and function in canine ENT were similar
to those of intestinal tissues they were originally derived from. Our novel ENT model
can serve as a useful ex vivo system for oral drug transport and related safety studies
in veterinary medicine.
Disclosures
No disclosures to report.
ESCG‐P‐11
Investigation of the efficacy of a novel diet in the management of chronic enteropathies
in dogs
C.T. Johnsen, A. Gow, S. Campbell, S. Salavati, N. Bommer, R. Richard
University of Edinburgh, Midlothian, United Kingdom
Chronic Enteropathies (CE) are a common cause of morbidity in dogs. Chronic enteropathies
are diagnosed in dogs with chronic gastrointestinal clinical signs (>3 weeks), inflammatory
changes on intestinal biopsies and where no other underlying cause is determined based
on a thorough, standardised diagnostic workup. Based on response to therapy, CE are
sub‐classified into food‐responsive, antibiotic‐responsive or steroid‐responsive enteropathies.
A significant proportion of dogs with a CE are food‐responsive; however, there are
limited peer‐reviewed publications describing the clinical efficacy of the commercially
available food used to treat CE.
In this study, we evaluated the response of 15 dogs with a CE to a commercially available
dietetic food (Hill's Prescription Diet i/d Sensitive Canine Dry). The dogs underwent
a standard diagnostic evaluation, and did not receive concurrent anthelmintics, antibiotic,
glucocorticoid or gastroprotectant therapies. The clinical efficacy of the dietary
treatment was assessed by comparing the Canine Inflammatory Bowel Disease Activity
Index (CIBDAI) before and a median of 13 days after dietary therapy.
We found that the CIBDAI significantly decreased following the introduction of the
dietetic food (median CIBDAI score pre treatment 9, post treatment 2 [P < 0.0005]).
Our study demonstrates that this dietetic food can be used to successfully manage
CE in dogs.
Disclosures
Disclosures to report.
Although the study was not funded, owners got the food from Hills for free during
the trial.
ESCG‐P‐12
Effect of dietary fat content on mucosal microbiota and serum metabolome in healthy
beagles
A. Jergens, J. Mochel, L. Kilburn, T. Atherly, S. Vandewalle, A. Mochel, D. Borcherding,
Y. Ambrosini, Y.J. Seo, N. Serao, M. Rossoni‐Serao, K. Allenspach
Iowa State University, Ames, United States of America
Dietary fat composition has been shown to modulate fecal microbiota composition and
impact host health. High‐fat diets have been linked to reduced fecal microbial diversity,
increased Firmicutes to Bacteroidetes ratio, and low‐grade systemic (LPS) inflammation.
While high‐fat diets may modulate the fecal microbiota, there is no data available
on the impact of high‐fat diets on the canine mucosal microbiota. The aim of the study
was to investigate changes in composition of the mucosal microbiota and serum metabolome
in Beagle dogs fed two rations varying in their content of dietary fat.
Eight healthy adult Beagle dogs were fed a control diet (13% fat), followed by low‐carbohydrate
diet (1% starch) containing either 32% fat (T1) or 46.5% fat (T2) for 2 weeks each
in randomized order. Endoscopic biopsies of the small and large intestines and sera
were collected for analysis of mucosal microbiota and metabolomic profiles, respectively,
before and during dietary intervention. Fluorescence in situ hybridization (FISH)
using a 4‐probe array (ie, total bacteria, Firmicutes [Clostridium cluster XIVa],
Bacteroides‐Prevotella and Enterobacteriaceae) quantified colonic mucosal bacteria
into distinct compartments. Serum metabolomic profiles resulting from the different
diets were quantified by a targeted approach to analyze samples using mass spectrometry
and the Biocrates AbsoluteIDQ p400 HR Kit. Metabolite changes between diets were analyzed
by PCA, PLS‐DA, HCA and univariate statistics. P values <0.05 were considered statistically
significant.
Analysis by FISH showed that most mucosal bacteria (EUB‐338) were located within the
adherent mucus. There was no difference in the total number and spatial distribution
of bacteria within the mucosa of dogs fed control diet versus T1. For the different
bacterial groups, sub‐populations of Clostridium spp. were significantly (P < 0.05)
increased in adherent mucus of dogs fed T2 versus T1. Changes in mucosal bacteria
were accompanied by altered serum metabolomes of dogs fed either T1 or T2. Perturbations
in lipid metabolism predominated and primarily involved different glycerophospholipids
(GPL), including the phosphatidylcholines (PC) and acylcarnitines (AC). Most GPLs
were significantly (P < 0.05) reduced in dogs fed T2 but not T1 when compared to control
ration. Conversely, T2 also resulted in lower (P < 0.05) concentrations of other lipid
metabolites and select amino acids.
Our results indicate that enhanced dietary fat modified the mucosal microbiota and
the serum metabolome of healthy dogs. Consumption of high fat diets has implications
for canine health by modulating host immune responses in association with changes
in gut microbial composition.
Disclosures
No disclosures to report.
ESCG‐P‐13
The erythrocyte membrane lipidome in dogs with chronic enteropathy
P.E. Crisi1, P. Prasinou1,
C. ferreri
2, C. Chatgilialoglu2, F. Procoli4, A. Luciani1, A. Gramenzi1, A. Sansone2, M. Pietra3,
M.V. Giordano1, F. de Santis1, A. Boari1
1University of Teramo, Isola del Gran Sasso, Italy, 2Consiglio Nazionale delle Ricerche,
ISOF, Area della Ricerca, Bologna, Italy, 3Alma Mater Studiorum University of Bologna,
Bologna, Italy, 4Ospedale Veterinario i Portoni Rossi, Zola Predosa, Italy
Chronic enteropathies (CE) are common cause for persistent or recurrent gastrointestinal
signs in dogs. Food‐responsive enteropathy (FRE), antimicrobial‐responsive enteropathy
(ARE), and immunosuppressive‐responsive enteropathy (IRE) have different etiologies
however clinical signs overlap and distinguishing among these disorders may be challenging
with the most reliable diagnostic tool represented by sequential treatment using diet,
antimicrobials, and immunosuppressive drugs.
Analysis of erythrocyte membrane lipidome represents a powerful tool in humans for
assessing the quantity and quality of fatty acids (FA) and the follow‐up of the membrane
FA remodeling under physiological and pathological conditions. The aim of this study
was to compare the FA membrane profile of healthy dogs (HD, n = 68) with 29 dogs with
CE (ie, >3 weeks). Dogs receiving dietary ω3 supplementation were excluded from the
study.
Erythrocyte membranes were isolated from EDTA‐treated blood and a cluster of 10 FA,
that is, saturated [SFA (palmitic; stearic)], mono‐unsaturated [MUFA (palmitoleic;
oleic; vaccenic)], polyunsaturated [ω‐6 (PUFA‐ω6): linoleic, dihomo‐gamma‐linolenic,
arachidonic and ω‐3 (PUFA‐ω3): eicosapentaenoic and docosahexaenoic] FA, was determined
by Gas‐Chromatography. Results are referred as % of one FA in the cluster. Relevant
lipid parameters (SFA/MUFA, SFA/PUFA, ω6/ω3, PUFA balance, unsaturation and peroxidation
indexes) were calculated.
HD dogs were 30 males (6 neutered) and 38 females (12 sterilized) with a median age
of 41 months (2‐156), while CE dogs were 20 males and 9 females (4 sterilized) with
a median age of 43 months (10‐114). Among CE dogs 11 were diagnosed with FRE, 1 ARE,
6 IRE, while 11 are undergoing diagnostic trials or were lost to follow‐up. Diminished
value of palmitic acid (P < 0.0001) and increased value of stearic acid (P < 0.0001),
with decreased total SFA (P < 0.05) were observed in CE group. Among PUFA‐ω6, CE dogs
showed increased values of dihomo‐gamma‐linolenic (P < 0.001) and arachidonic (P < 0.05)
acids, while no differences were observed in PUFA‐ω3 levels between the two groups.
Unsaturation (P < 0.05) and peroxidation (P < 0.05) indexes were found significantly
increased in CE dogs. Interestingly, dogs with FRE and IRE dogs had similar erythrocyte
membrane lipidome profiles; ARE was not object of statistical analysis, due to the
low number of dogs in this group.
These results point out the importance of the balance between pro‐inflammatory arachidonic
acid and the anti‐inflammatory dihomo‐gamma‐linolenic acid levels in the inflammatory
conditions of CE.
The erythrocyte membrane lipidome of dogs may be successfully applied in dogs with
CE, providing important information leading to personalized intervention targeted
to decrease inflammation and increase protective components.
Disclosures
No disclosures to report.
ESCG‐P‐14
Hypercobalaminaemia and its possible association with disease severity in dogs: a
retrospective study of 47 cases
F. Da Riz, P. Higgs, G. Ruiz
Highcroft Veterinary Referrals, Bristol, United Kingdom
Serum cobalamin concentration is frequently assessed in companion animals, especially
when facing a patient with chronic gastrointestinal signs. Although the clinician's
attention is mainly focused on patients with hypocobalaminaemia, recent studies in
humans and cats suggest that high serum cobalamin concentration could be associated
with specific conditions such as neoplasia and liver disease and, in addition, may
be a marker of severity. The aims of this retrospective, cross‐sectional study were
therefore to identify the conditions associated with hypercobalaminaemia in dogs and
to determine whether it could be used as a marker of disease severity in these patients.
Medical records of dogs having serum cobalamin measured between November 2016 and
December 2018 in 14 practices in the United Kingdom were reviewed. Dogs were excluded
if they had received cobalamin supplementation at any time prior to analysis. Signalment,
clinical signs, laboratory & imaging findings were recorded for each case. The cases
were then classified into different disease categories by consensus depending on the
final diagnosis. Values were expressed as percentages and medians and variables were
compared between groups using a Kruskal‐Wallis, Chi‐2 or Fischer's exact test.
One hundred‐and‐sixty dogs were included in the study and divided into three groups:
hypocobalaminaemia (39 dogs), normal serum cobalamin concentration (74 dogs) and hypercobalaminaemia
(47 dogs). The age distribution was significantly different between groups (P = 0.0214),
with hypercobalaminaemic dogs being significantly younger (median age 79 months, range
[2‐207]). Dogs with hypercobalaminaemia presented with diarrhoea (49%), vomiting (47%),
inappetence (38%), lethargy (40%) and/or weight loss (38%); this was not significantly
different from the other groups. Conditions associated with hypercobalaminaemia included
gastrointestinal (57%), hepatic (11%), neurological (11%), endocrine (9%), renal (4%),
pancreatic (2%) and miscellaneous (6%) diseases. Among all, 11% had neoplasia. This
distribution was not significantly different from hypocobalaminaemic and normocobalaminaemic
dogs.
There were significantly more dogs with high serum folate concentration in the hypercobalaminaemia
group, as compared to the other groups (P = 0.009). Dogs with hypoalbuminaemia, anaemia,
high ALT activity and/or hypocholesterolaemia were also compared between the three
cobalamin groups and no statistical difference was identified. There was no association
found between hypercobalaminaemia and the parameters tested for disease severity.
Our results suggest that hypercobalaminaemia in dogs is most commonly seen with gastrointestinal
and hepatic disease as with other species, but can also be seen with endocrine and
neurological conditions. Interestingly, hyperfolataemia was most commonly seen with
hypercobalaminaemia; it is unknown whether this reflects or not active dysbiosis.
Disclosures
No disclosures to report.
ESCG‐P‐15
In vitro model (SCIME) to study the intestinal microbiota in dog
G.P. Pignataro1, P. van den Abbeele2, B. Guimaraes2, A. Gramenzi1, B. Belà1, C. Ribecco3,
M. Marzorati2, B. Bachetti3, M. Massimini3, E. Dalle Vedove3
1University of Teramo, Teramo, Italy, 2Prodigest, Gent, Belgium, 3CIAM srl, Ascoli
Piceno, Italy
In vivo studies on the physiology of the gastrointestinal tract (GIT) in living animals
meet with serious technical difficulties and ethical question. Therefore, much attention
has been given recent years to the development of in vitro models which mimic metabolic
process of the GIT.
The aim of the present work is the validation of the SCIME (Simulator of the Canine
Intestinal Microbiome) above the SHIME model (Simulator of Human Intestinal Microbiome
Ecosystem) considering the physiological parameters of the dog, the different diet
and the different microbiological populations comparatively to the in vivo microbial
population from the faecal samples of donor dogs.
Fresh faeces collected from four healthy dogs were inoculated in the SCIME system,
the experiment lasted 14 days and was conducted in duplicate by giving two different
types of feeds to each donor. Model validation was evaluated through analysis of microbial
activity by the quantification of SCFA, lactate, and ammonium. The composition of
the colonic microbiota was studied through qPCR using primers targeting the Firmicutes,
Bacteroidetes, Bifidobacteria, Lactobacilli, and Enterobacteriaceae and through 16S‐targeted
Illuminates sequencing of the total bacterial population.
Different effects on the composition of the canine intestinal microflora during the
experiment time were promoted. Among Firmicutes, the results obtained highlighted
the ability to a significant increase (P < 0,005)in the amount of Acidaminococcaceae
(OTU 0022:0.8 ± 0.9% at lumen level) and Enterococcaceae (P < 0,0005). The Bacteroidetes
displayed a decrease (P < 0,05) in species that belong to the family of Bacteroidaceae
(OTU 0002:5.2 ± 0.2% at lumen level). In addition, there is a significant growth (P < 0,05)
in the family of Coriobacteriacaee. The Akkermansiaceae family (OTU 0010:4.2 ± 0.4%
at lumen level) is absent in the inoculum but there is a little increase during the
experiment. Enterobacteriaceae (OTU 0008:23.2% ± 0.4) recorded a significant increase
(P < 0.05).
Interesting is the result regarding the SCFAs where is promoted a significant increase
(P < 0.05) in their concentration; especially in the amount of butyrate (average:
2.05 ± 2.19 mmoL/L), acetate (average: 7.41 ± 5.34 mmoL/L) and branched fatty acids
(average: 1.37 ± 0.58 mmoL/L).
Finally, the study highlighted the ability of the SCIME model to increase also the
ammonium levels showing an average concentration of 461.37 ± 63.80 mg/L for the proximal
colon and 580.79 ± 68.25 mg/L for the distal colon.
It followed that the novel model allowed the growth of the bacteria present in the
original inoculum, offering a relevant technology platform to simulate the intestinal
ecosystem for evaluation of pharmaceutical and nutraceutical effects on dog microbiota.
Disclosures
No disclosures to report.
ESCG‐P‐16
Expression and distribution of Toll‐Like Receptor (TLR)2, TLR4, TLR5 and TLR9 in the
colonic mucosa of dogs with Inflammatory Bowel Disease
J.L. Hernandez1, F. Chocteau2, E. Rouillé2, J. Hervé3, J.M. Bach3, B. Lieubeau3, J.
Abadie2
1Oniris, Nantes, France, 2Animal Histopathology Laboratory, Nantes‐Atlantic College
of Veterinary Medicin, Nantes, France, 3Cellular and Molecular Immuno‐Endocrinology
Unit, INRA, Nantes‐Atlantic College, Nantes, France
Inflammatory bowel disease (IBD) is a common cause of chronic gastrointestinal disease
in dogs. The current paradigm of IBD involves complex interactions between environmental
factors, such as the intestinal microbiota, and dysregulated host responses. Toll‐Like
receptor (TLR) 2, TLR4, TLR5 and TLR9 recognize bacterial Pathogen‐Associated Molecular
Patterns (PAMPs). In a previous study, TLR2, TLR4, and TLR9 mRNAs were reported to
be up‐regulated in the inflamed duodenal and colonic mucosa of IBD dogs compared to
asymptomatic healthy Beagles. The aim of this study was to evaluate the expression
of these receptors by immunohistochemistry in colon biopsies isolated from dogs with
IBD compared to asymptomatic controls.
Ten dogs with IBD were included in this study. Diagnosis was based on clinical signs
of at least 3 weeks' duration, the presence of a lymphocytic and plasmacytic and/or
eosinophilic inflammation on colon biopsies and exclusion of other causes of chronic
gastrointestinal signs. Nine dogs were included in the control group. Colon paraffin‐embedded
biopsies were processed for immunohistochemistry using anti‐human TLR2, TLR4, TLR5
and TLR9 antibodies. The expression of TLRs in the different samples was graded from
0 (no expression) to 3 (strong expression) by a board‐certified pathologist in a blinded
fashion.
TLR5 and TLR9 were detected both in the epithelial cells and in the lamina propria
cells. In contrast, TLR2 was detected only in the epithelial cells while TLR4 staining
was restricted to the leucocytes of the lamina propria. No statistical differences
were found in TLRs expression when comparing IBD dogs with asymptomatic dogs although
epithelial TLR9 expression tended to be higher in the IBD group (P = 0,054).
To our knowledge, our study describes for the first time the pattern of expression
of TLR2, TLR4, TLR5 and TLR9 in the colon of dogs and suggests that their expression
is poorly affected by IBD. Further experiments are warranted in a larger number of
patients and in other intestinal segments (duodenum and ileum) to analyze whether
epithelial TLR9 expression might be correlated with clinical activity or histopathology
score.
Disclosures
Disclosures to report.
This work was funded by Hill's Pet Nutrition.
ESCG‐P‐17
Serum Vitamin A and E concentrations in dogs with pancreatitis
M. Weiβ, K. Törner, H. Aupperle‐Lellbach, E. Müller
Laboklin GmbH und Co KG, Bad Kissingen, Germany
Acute and chronic pancreatitis in humans results in significantly lower levels of
serum Vitamin A and Vitamin E due to antioxidative stress and as part of the inflammatory
response. To our knowledge no studies about Vitamin A and E levels in serum of dogs
with pancreatitis have been performed so far.
The aim of this retrospective study was to evaluate the level of serum vitamin A and
E from routine diagnostic left‐over samples in dogs with pancreatitis compared to
a control group of dogs with other diseases.
40 dogs with pancreatitis were included in this study. These dogs all had serum pancreatic
lipase concentrations >600 μg/L and clinical symptoms of pancreatitis like vomiting,
abdominal pain or inappetence and had received no medical treatment so far. Additionally,
in 3 dogs pancreatitis was diagnosed by histology of pancreatic tissue biopsies.
The 45 dogs of the control group had serum pancreatic lipase values <40 μg/l and had
clinical symptoms concurrent with other diseases than pancreatitis.
Serum Vitamin A and E levels were measured by HPLC from cooled serum within 72 hours
of sampling. Dogs with pancreatitis had significantly higher (P < 0.001) levels of
serum Vitamin A (average 1701 μg/L, range: 405‐4448 μg/L) than dogs of the control
group (average: 978 μg/L, range: 139 μg/L ‐ 1904 μg/L). The study dogs also had significantly
higher (P < 0.001) serum Vitamin E levels (average: 36.0 μg/L, range: 15.3‐83.7 μg/L)
than the control group (average: 20.4 μg/L, range: 1,9‐54.6 μg/L).
This study suggests that dogs with pancreatitis have a different metabolism of Vitamin
A and E compared to dogs with other diseases and humans with pancreatitis. In the
course of pancreatitis a release of Vitamin A and E into the blood stream due to necrotic
processes of tissue may be discussed in this species.
Disclosures
Disclosures to report.
All authors are employees of the commerical laboratory LABOKLIN. This study was financed
by LABOKLIN.
ESCG‐P‐18
Water immersion vs gas insufflation in canine duodenal endoscopy: is the future underwater?
G. Galiazzo1, G. Bitelli2, A. Gaspardo1, N. Romagnoli1, C. Lambertini1, C. Francolini2,
F. Costantino1, R. Chiocchetti1, M. Pietra1
1University of Bologna, Ozzano dell'Emilia (BO), Italy, 2Department of Civil, Chemical,
Environmental, and Materials Engineering, Bologna, Italy
The endoscopy of the gastrointestinal tract is often part of the diagnostic protocol
for canine acute and chronic gastroenteropathy. To analyze properly the intestinal
wall, it is fundamental to distend the lumen, usually inflating it with air. In human
medicine, it is well known how the gas insufflation (GI) with air or carbonic dioxide
during colonscopy can induce pain in the patient. More and more frequently it is used
warm‐to touch water, instead of air, to distend the lumen. Randomized controlled trials
suggest that the introduction of water to distend the lumen of the colon decreases
spasm of the musculature of the bowel and pain, and significantly increases the visualization
of mucosal texture and the adenoma detection rate.
This study was the first in veterinary medicine to compare GI and water immersion
(WI) during duodenoscopy in anesthetized dogs, in order to evaluate eventual differences
in procedural nociception and in the quality of mucosal visualization.
Twenty‐five dogs, subjected to endoscopy under general anesthesia, were included in
the study. To evaluate differences in nociception during anesthesia, heart rate and
arterial blood pressure (sistolic, diastolic and mean) were measured throughout the
procedure and divided into four steps (baseline, water, air, outcome). A random sequence
of GI or WI was applied to dilate duodenal lumen and, in every condition, the same
mucosal image of the bowel was recorded. For every dog, two images (GI and WI) were
recorded and subjected to a texture analysis by using image processing approaches
like skeletonization and entropy evaluation, and to a subjective blind evaluation
by three expert endoscopists, considering the architecture and the intestinal texture.
No systematic significant differences were detected for the cardiovascular parameters
and the texture analysis between GI and WI, except for the subjective evaluation by
the endoscopists, who identified the WI images as qualitatively better.
The results of this study highlight how the algic answer does not change between the
two methods, maybe influenced by the drugs used during the endoscopy, which well control
nociception and give deep anesthesia. Based on the evaluation of the endoscopists,
the WI allows to get better quality images, with a detailed visualization of the intestinal
villi, while this is still not confirmed by objective texture analysis.
Disclosures
No disclosures to report.
ESVC‐P‐1
Heart rate variability of dogs in various stages of degenerative mitral valve disease
R.A. Baisan1, V. Vulpe1, D.G. Ohad2
1University of Agricultural Sciences and Veterinary Medicine, Iasi, Romania, 2Koret
School of Veterinary Medicine, Robert H. Smith Faculty of Agriculture, Jerusalem,
Israel
Hemodynamic changes associated with mitral valve degeneration (MVD) activate neurohumoral
mechanisms, to maintain adequate cardiac output and capillary perfusion pressure.
A predominant sympathetic and/or a diminished vagal tone are linked to disease progression.
Only scarce information about autonomic nervous system (ANS) dynamics during MVD progression
is available in the veterinary literature. To our knowledge, the ANS imbalance in
dogs with MVD prior to receiving cardiac pharmacotherapy has not been evaluated. We
sought to analyze heart rate variability (HRV) for assessing the ANS activity in dogs
with preclinical and yet untreated clinical MVD.
Seventy‐four client‐owned dogs with echocardiographically confirmed MVD were retrospectively
divided into three groups according to the 2009 ACVIM Consensus Statement: B1 (n =
20), B2 (n = 20) and C (n = 34). A control group, labeled N (n = 21) included healthy
normal dogs. All dogs received physical examination, five‐minute‐long six‐lead electrocardiography
(ECG), complete echocardiography, thoracic radiography and bloodwork. Short‐term heart
rate variability was evaluated using the time and frequency domains from the five‐minute‐long
ECG recordings.
A significant decrease in time domain parameters was shown in Group C when compared
to Groups N, B1 and B2. These parameters included the SD of all normal intervals (SDNN)
(P < 0.05), the root‐mean square of successive differences between normal heartbeats
(rMSSD) (P < 0.01), and the percentage of adjacent normal intervals that differ from
each other by more than 50 ms (pNN50) (P < 0.01).
In addition, significant increase in the low‐frequency (LF, P < 0.01) and a decrease
in high‐frequency (HF, P < 0.01) band was observed in Group C, compared to Groups
N, B1 and B2. The LF/HF ratio was significantly increased in Group C (P < 0.01) relative
to all other groups. When Group B2 was compared to B1, only SDNN showed significantly
lower values (P < 0.05).
This study shows that in dogs with aclinical MVD, both sympathetic and parasympathetic
tones might remain unchanged until only after clinical signs have developed, despite
the presence of structural remodeling. The onset of clinical signs is likely to trigger
an ANS imbalance due to both sympathetic tone activation and vagal tone withdrawal.
Moreover, SDNN, which is an independent marker for risk of mortality, may be the only
HRV‐related parameter able to distinguish between aclinical dogs with and without
cardiomegaly.
These findings may have future implications regarding choices made around the best
timing of pharmacotherapy onset, as well as around the most effective order of adding
specific medications to an on‐going pharmacotherapy regimen, administered to dogs
with MVD.
Disclosures
No disclosures to report.
ESVC‐P‐2
Comparison of serum digoxin concentrations from blood collected in Vacutainer® tubes
with or without gel
N. van Israel
ACAPULCO, Stavelot, Belgium
Therapeutic monitoring of serum digoxin levels to avoid digoxin intoxication is performed
at least 3 to 5 days after beginning therapy. Some labs discourage the use of blood
collection tubes containing gel because of potential absorption of digoxin by the
gel resulting in an underestimation of the serum digoxin concentration. The aim of
this study was to compare serum digoxin concentrations in blood collected in serum
tubes with and without gel. Blood samples were taken with a syringe and needle from
the jugular vein of 48 dogs treated with digoxin (Lanoxin®). For each dog, half of
the blood sample was put in a tube containing no gel (NGC) (Vacutainer Z) while the
other half of the sample was put in a gel containing (GC) tube (BD Vacutainer® STT
II Advance). NGC tubes were sent to the referral lab (Synlab, Belgium) for immediate
analysis. GC tubes were kept uncentrifuged and refrigerated for 5 days before analysis
was performed. All analyses were carried out by the same lab using the ARCHITECT ci
System (Abbott Diagnostics, US). Median digoxin concentration (quartile 1‐3) was 0.90 μg/L
(0.70‐1.10) for the NGC tubes and 1 μg/L (0.80‐1.10) for the GC tubes. Agreement between
the two methods was shown by a mean bias of 0.05 and a narrow range of agreement (lower
level of agreement: −0.09; upper level of agreement: 0.18). Mean bias (%) was 5.1%
and did not exceed the method quality specifications for total allowable error (14%).
Bland‐Altman plot of data did not show significant differences in data sets. Serum
digoxin concentrations do not decrease when collected in tubes containing gel and
kept refrigerated for 5 days before analysis. Blood collection serum tubes containing
gel can be used for therapeutic monitoring of serum digoxin levels.
Disclosures
No disclosures to report.
ESVC‐P‐3
Transverse right ventricle strain and strain rate assessed by 2‐dimensional speckle
tracking echocardiography in dogs with pulmonary hypertension
D. Caivano1, M. Rishniw2, F. Birettoni1, V.F. Petrescu1, F. Porciello1
1University of Perugia, Perugia, Italy, 2Veterinary Information Network, Davis, United
States of America
Right ventricular (RV) strain analysis using 2‐dimensional speckle tracking echocardiography
has focused on assessing longitudinal strain and strain rate variables in dogs. However,
RV contraction is also characterized by transverse deformation; this strain component
has not been investigated in dogs. Therefore, we evaluated the ability of transverse
RV strain and strain rate, obtained by 2‐dimensional speckle tracking echocardiography
in healthy dogs and dogs with pulmonary hypertension, to identify dogs with pulmonary
hypertension. Additionally, we examined relationships of transverse strain and strain
rate variables with heart rate, age and bodyweight in healthy dogs, and with tricuspid
regurgitation (TR) velocity and left atrial size in dogs with pulmonary hypertension.
We acquired 2D echocardiographic cineloops from the left apical 4‐chamber view optimized
for the right ventricle and analyzed transverse RV free wall strain and strain rate
in 74 dogs (40 healthy dogs and 34 dogs with pulmonary hypertension) using Xstrain®
software. Dogs were classified as having pulmonary hypertension based on the TR jet
velocity (> 3 m/sec). We classified dogs as having moderate pulmonary hypertension
if TR velocity > 3.5 m/sec, and severe pulmonary hypertension if TR velocity > 4.5 m/sec.
Seven dogs (3 healthy and 4 dogs with pulmonary hypertension) were excluded during
the analysis for low quality images. In healthy dogs, strain and strain rate showed
no relationship with heart rate, body weight or age. In dogs with pulmonary hypertension,
strain and strain rate showed weak negative relationships with TR velocity (r2 = 0.25),
but no relationship with left atrial size (r2 = 0.05). Although transverse RV strain
(but not strain rate) showed a negative relationship with class of pulmonary hypertension,
it was not useful in identifying dogs with pulmonary hypertension.
Transverse RV strain and strain rate using 2‐dimensional speckle tracking echocardiography
can be obtained in most dogs, but does not help in identifying dogs with pulmonary
hypertension.
Disclosures
No disclosures to report.
ESVC‐P‐4
Potential renoprotective effect of angiotensin‐receptor antagonists in dogs with myxomatous
mitral valve disease
J. Lee1, W. Kim2, H. Hwang1, S. Jeon1, C. Ahn3
1Korea Animal Speciality Medical Institute, Seongnam, South‐Korea, 2Columbia University,
New York, United States of America, 3Andante Animal Hospital, Seoul, South‐Korea
Blockade of renin‐angiotensin‐aldosterone system is a pivotal strategy to manage congestive
heart failure (CHF). Angiotensin‐receptor blockers (ARBs) are perceived to offer more
complete neurohormonal suppression in the treatment of CHF by directly occupying angiotensin
II receptor sites. However, whether the combination therapy of ARBs with current CHF
treatments has clinically incremental benefits, is unknown in dogs with myxomatous
mitral valve disease (MMVD).
This retrospective cohort study was conducted with client‐owned dogs with symptomatic
MMVD, which have been treated with a standard protocol (Controls, n = 43) and with
the addition of ARBs (Cases, n = 29; irbesartan 6~16 mg/kg/day, n = 20; telmisartan
2~4 mg/kg/day, n = 9) to the conventional treatment. For the initial analysis of homogeneity
between two groups, physical examination, comprehensive blood test profile (CBC, serum
biochemistry, NT‐proBNP, SDMA), radiographic, and echocardiographic data were collected.
Subsequently, the same clinical indices were compared at the time points when ARBs
were given for three to six months. In addition, survival analysis was also performed
using Kaplan‐Meier curves.
After 3~6 months treatment, the degree of increases in clinical parameters related
to renal function was significantly higher in the control than the case group (P < 0.01):
BUN (+11.3 ± 9.9 vs. ‐3.3 ± 7.9), creatinine (+0.5 ± 0.27 vs. +0.1 ± 0.19), SDMA (+5.1 ± 2.25
vs. +2.0 ± 5.78), sodium level (+3.5 ± 3.31 vs. ‐0.8 ± 3.81). The differences of heart
rate (+7.9 ± 12.2 vs. ‐1.5 ± 9.8) and blood pressure (+14.2 ± 14.6 vs. ‐3.8 ± 15.9)
between baseline and follow‐up were significantly lower in the case group (P < 0.01).
Furthermore, the increased level of NT‐proBNP (1621.4 ± 1274.2 vs. 444.3 ± 619.5)
was also greater in the controls (P = 0.04). However, no statistical differences were
found in thoracic radiographic and echocardiographic indices between the groups. Comparing
survival curves of two groups did not reveal an overall survival advantage with ARBs
treatment.
These results suggest that ARBs in combination with ongoing conventional CHF treatments
may provide an additional renoprotective effect in dogs with MMVD.
Disclosures
No disclosures to report.
ESVC‐P‐5
Perioperative management with peripheral arteries in dogs undergoing open heart surgery
K. Takamura, A. Takahashi, Y. Nii, M. Uechi
JASMINE Veterinary Cardiovascular Medical Center, Yokohama, Japan
Insertion of an arterial catheter is essential in open heart surgery. The femoral
artery is one of the most commonly used arteries in open heart surgery in dogs. Although
peripheral arteries, such as the dorsalis pedis, have been used in veterinary medicine
in recent years, little is known about their use for open heart surgery in dogs. Therefore,
we compared it with conventional management via the femoral artery.
We retrospectively reviewed cases involving mitral valve repair with cardiopulmonary
bypass between September 2018 and November 2018. We compared successful catheter placement,
catheter insertion, removal time, adverse events, and operation time in the femoral
and peripheral arteries.
The study included 104 dogs. Five (4.8%) underwent catheter insertion into the femoral
artery (group F), and 99 (95.2%), into either the dorsalis pedis (n = 96) or caudalis
median (n = 3) peripheral arteries (group P). Group F required a median 8 min (range
6‐13 min) for catheter insertion and a median 18 min (range 10‐29 min) for catheter
removal. Three dogs in group F bled after heparin infusion during surgery. There was
no bleeding in group P, and the pulse was palpable immediately after surgery. Good
pressure waveforms were obtained during all perioperative periods, and blood collection
was uneventful. There were no adverse events after surgery in both groups. Operation
time did not differ significantly between the two groups.
These results suggest that perioperative management with peripheral arteries in open
heart surgery is effective and safe.
Disclosures
No disclosures to report.
ESVC‐P‐6
Effects of in‐hospital diuretic therapy on electrolytes concentration, renal function
and survival in 85 dogs with acute congestive heart failure
E. Martinelli1, A. Galizzi1, R. Toschi Corneliani1, C. Locatelli2
1San Francesco Veterinary Hospital, Milano, Italy, 2Cardiology Service, Department
of Veterinary Medicine, University of Milan, Milano, Italy
Critically hill patients with acute congestive heart failure (CHF) may often show
haemoconcentration, dysnatremia, dyskalemia and increased azotemia, due to aggressive
diuretic therapy. Haemoconcentration is associated with lower risk of mortality, while
dysnatremia and dyskalemia are associated with higher mortality in human medicine.
The aim of this study was to retrospectively evaluate the impact of in‐hospital diuretic
therapy for CHF on selected laboratory parameters and long‐term mortality.
Dogs with clinical and radiological evidence of CHF confirmed by echocardiography
were included. Blood samples collected throughout the hospitalization at presentation
(T0) and discharge (T1) were: venous blood gas analysis (VBGA), serum creatinine (sCr),
blood urea nitrogen (BUN), microhematocrit (Htc) and total proteins (TP). Length of
hospital stay, ACVIM class and other clinical indices were recorded. Haemoconcentration
was defined as a simultaneous increase in Htc and total protein.
A total of 85 dogs (45 male and 40 female; mean age 11.07 ± 2.54 years; mean weight
8.86 ± 6.92 kg) were included. Thirty‐six dogs had previous episodes of CHF. Mean
length of in‐hospital stay was 31.15 ± 17.35 hours. Treatment protocol included a
single furosemide endovenous bolus at 2 mg/kg followed by multiple 1 mg/kg bolus/hour
until respiratory rate reach 40respiratory rate. Each dog received 8.6 ± 2.8 mg/kg
and 11.1 ± 2.9 mg/kg furosemide in 24 and 48 hours respectively. Ten dogs received
higher furosemide doses or torasemide bolus.
Haemoconcentration was reached in the 33% of dogs. Considering the VBGA and biochemistry
results, the number of dogs showing extra‐range values (T0‐T1) were respectively:
hyponatremia (10‐23), hypernatremia (13‐17), hypokalemia (18‐30), hyperkalemia (10‐10),
hypocloremia (46‐61), increased BUN (26‐34), increased sCr (3‐8). Fourty‐one dogs
experienced cardiac death, 12 during hospitalization, the remaining dogs between 3
and 721 days after admission.
Stepwise backward regression demonstrated haemoconcentration (HR 0.33) and disnatremia
(HR 2.85) influence over outcome. Statistically significant correlation (Pearson)
was seen between furosemide dose and kalemia (r = −0.32, P = 0.014) and between BUN
and sCr (r = 0.27, P = 0.021). No correlation was seen between furosemide dose and
the variables sCr, BUN, Htc and between sCr and Htc.
In conclusion, haemoconcentration and disnatremia affected the outcome in dogs with
CHF. Haemoconcentration was associated with lower risk of mortality and had to be
considered a target in CHF therapy. In‐hospital diuretic therapy increased electrolyte
disorder due to loop diuretics inhibition of the renal Na, K, Cl cotransporter in
the Henle's loop and disnatremia was a risk factor for adverse outcome. Diuretics
doses and haemoconcentration didn't play a direct role in inducing renal disfunction.
Disclosures
No disclosures to report.
ESVC‐P‐7
Platelet proteomic profile in dogs with heart failure
Z. Yilmaz1, P. Levent1, A. Saril1, M. Kocaturk1, A.T. Baykal2, E. Akgun2
1Bursa Uludag University, Veterinary Medicine, Internal Medicine, Bursa, Turkey, 2Acibadem
University, Medical Biochemistry Department, Istanbul, Turkey
Heart failure can cause haemostatic complications due to platelet over‐ activation
in human and veterinary medicine, especially in cats with hypertrophic cardiomyopathy.
There is not enough information on the molecular relationship between hemostasis and
cardiovascular diseases in dogs. Thus, in this study, it was aimed to elaborate hemostasis
(coagulation) changes with the platelet proteomic profile in dogs with naturally occurred
heart failure.
The material of this study consisted of totally 20 dogs with different breed, age,
and sexes. Two different group were designed; control (n = 10) and test groups (n
= 10). Based on the physical, laboratory and cardiologic examination results, dogs
were included into control (healthy) group, or dogs with stage C of heart failure
according to ACVIM classification were enrolled into test group. Platelet isolations
were performed from each dog, and platelet pellets were stored −80 C until analysed.
Platelet proteomes were identified by use of UPLC‐ ESI/QTOF/MS method. Global clotting
times (PT and aPTT) were measured, as well.
Platelet proteomes (n = 107) were matched with the previously described proteins for
Canis lupus familialis, and compared to the control, at least P < 0.05 level and 1.2‐fold
change of proteomes (n = 10) was considered statistically significant. Compared to
control group, of platelet proteomes, guanine nucleotide‐binding protein subunit alpha‐11,
apolipoprotein C‐III, apolipoprotein A‐II and clusterin levels increased whereas CXC‐motif
chemokine‐10, cytochrome‐C‐oxidase subunit‐2, cathepsin‐D, serine/threonine ‐ protein
phosphatase PP1‐gamma catalytic subunit, creatine kinase B‐type and myotrophin levels
decreased in testgroup. PT and aPTT values in the test group were longer than the
control values (P < 0.05).
As a result, each platelet protein identified in the present study could be a potential
biomarker in the diagnosis of heart failure and therefore these proteins need validation
with field studies. Also this proteomes provide detailed information of heart failure
process.
Disclosures
No disclosures to report.
ESVC‐P‐8
Vitamin D Status in Cats with Cardiomyopathy compared to Normal Cats
W. Ware1, L. Freeman2, J. Rush2, J. Ward1, A. Makowski3, M. Zhang1
1Iowa State University, Ames, United States of America, 2Tufts University, N. Grafton,
United States of America, 3Heartland Assays, Ames, United States of America
Low serum 25‐hydroxyvitamin D (25(OH)D3) has been associated with cardiovascular (CV)
disease in people and dogs. We aimed to determine if 25(OH)D3 and its metabolite,
3‐epi‐25(OH)D3 (3‐epi), are lower in cats with cardiomyopathy (CM) vs. normal cats,
or if associations with certain clinical variables exist. CM cats (n = 44) were enrolled
from patients at the Veterinary Medical Centers of Iowa State (ISU) and Tufts Universities;
38 CM cats had congestive heart failure. Exclusion criteria included hypertension,
hyperthyroidism, and clinically relevant systemic (including kidney) disease. Normal
cats (N) were recruited at ISU; 44 were age‐ and sex‐matched to CM cats, although
56 normal cats ultimately were enrolled. All cats were eating commercial cat foods.
CV exam, blood pressure and echocardiographic data were collected; collected serum
was frozen until analyzed.
25(OH)D3 and 3‐epi were positively correlated (correlation coefficient, 0.35; P = 0.004).
However, neither was significantly different between CM and matched‐N groups (paired
Wilcoxson rank‐sum). Linear regression analysis to assess impact of CM status, age,
and sex among all enrolled cats showed age was significant to 25(OH)D3 (P = 0.0028).
Statistical modeling including all variables was confounded by multicollinearity;
therefore, one‐by‐one simple linear regression tested for relationships between vitamin
D status and 18 clinical variables. Significant relationships were found between 25(OH)D3
and age, survival time, azotemia category, left atrial enlargement, and left ventricular
fractional shortening (FS). After accounting for age, only FS and survival time remained
significant with 25(OH)D3. We conclude that vitamin D status in cats is not significantly
associated with CM.
Disclosures
No disclosures to report.
ESVC‐P‐9
Identification of increased desmin aggregates consistent with intermediate filament
dysfunction in feline hypertrophic cardiomyopathy
W.C. Cheng1, M. Dobromylskyj2, L.J. Wilkie1, V. Luis Fuentes1, D.J. Connolly1
1The Royal Veterinary College, Hatfield, United Kingdom, 2Finn Pathologists, Harleston,
United Kingdom
Desmin, the intermediate filament (IF) in cardiomyocytes is critical for maintaining
architecture and mechanical integrity of the contracting cell. Aggregation of desmin
and impairment of protein quality control systems including heat shock proteins (HSP)
which governs correct IF protein folding are reported in humans and rodent models
with hypertrophic cardiomyopathy (HCM). Incorrect folding of desmin leads to its aberrant
accumulation within cardiomyocytes. This study aimed to characterise the expression
and localisation of desmin, and its chaperone the HSP αB‐crystallin in feline HCM.
Residual left ventricular (LV) tissues from necropsy (5 normal and 5 HCM cats) were
used for immunoblotting of desmin and αB‐crystallin normalised to GAPDH. Fluorescent
immunohistochemistry was performed on transverse sections of formalin‐fixed and paraffin‐embedded
LV from another 4 normal and 8 HCM cats. A minimum of 10 images were captured under
40x magnification (5 longitudinal and 5 transverse) were used for fluorescence quantification
and protein localisation. Diagnoses were made by histopathology ± clinical assessment.
Mann‐Whitney's U test, or Spearman's rho test were used and the results were expressed
as median (range).
On immunoblotting, only one control had a recorded age (5.8 yrs), the other controls
were documented as young adult. The median age of HCM cats was 8 yrs (1.7‐17). The
protein level of desmin was 0.54 (0.27‐0.69) in the controls and 1.41 (0.59‐2.19)
in the HCM group (P = 0.0159). The protein level of αB‐crystallin was 0.56 (0.18‐0.66)
in the controls and was 1.46 (0.63‐2.39) in the HCM group (P = 0.0317). The protein
expression of αB‐crystallin and desmin was highly correlated (R = 0.8788, P = 0.0016).
On immunohistochemistry, the median age was 3 yrs (1.6‐5.8) in control cats and 8.5
(2‐17.9) in the HCM group (P > 0.05). In controls, desmin appeared as stripes at Z‐bands
and intercalated discs and a scarce amount of perinuclear aggregates were observed
in the cross‐section of cardiomyocytes close to epicardium. In HCM cats, dissociation
of desmin from the intercalated discs was a frequent finding and clumps of aggregates
were seen in the transversely sectioned cardiomyocytes not limited to the periphery
of epicardium. Averaged mean intensity of fluorescence was 95.2 (76.6‐116.3) in the
HCM group and 70.7 (64.7‐81.1) in the control group (P = 0.0056).
In HCM cats, the IF desmin is structurally disorganised which might compromise the
integrity of contractile apparatus. The presence of desmin aggregates suggests that
the protein quality control measures failed to restore proteostasis in the HCM affected
heart despite the corresponding increase in the chaperone protein αB‐crystallin.
Disclosures
No disclosures to report.
ESVC‐P‐10
Prevalence and risk factors for atrial fibrillation in dogs with myxomatous mitral
valve disease
C. Guglielmini1, M.G. Sousa2, M. Baron Toaldo3, C. Valente1, V. Bentivoglio2, C. Mazzoldi3,
I. Bergamin1, M. Drigo1, H. Poser1
1University of Padua, Legnaro (PD), Italy, 2University of Paranà, Curitiba, Brazil,
3University of Bologna, Bologna, Italy
Atrial fibrillation (AF) is a common canine supraventricular arrhythmia usually observed
in large breed dogs with cardiac disease associated with left atrial enlargement.
Although some epidemiologic data and risk factors for AF have been reported, no study
has thoroughly examined the prevalence and risk factors for this arrhythmia in dogs
with myxomatous mitral valve disease (MMVD). The aims of this study were to estimate
the prevalence of AF in a large population of dogs with MMVD and to identify the risk
factors for AF development in these animals.
The medical databases of three Veterinary Teaching Hospitals were retrospectively
reviewed. Inclusion criteria were a diagnosis of MMVD after complete cardiovascular
assessment (ie., physical examination, thoracic radiography and trans‐thoracic echocardiography)
and cardiac rhythm assessment via routine 2 minutes ECG and/or good quality ECG tracing
during echocardiographic examination of at least 20 minutes' duration. For dogs with
multiple examinations during the observing period only data of the most recent exam
were considered. Selected clinical and echocardiographic parameters were compared
using univariable and different multivariable logistic regression models.
A total of 2194 dogs were enrolled, including 1280, 588, 290, and 36 dogs in ACVIM
stage B1, B2, C, and D, respectively. Pulmonary hypertension (PH) was diagnosed in
526 (23.9%) dogs. Atrial fibrillation was diagnosed in 59 dogs with a prevalence of
2.7%. Univariate analyses showed that mixed breed, male gender, decompensated ACVIM
stage, left atrial diameter‐to‐aortic ratio (LA/Ao) > 1.6, normalized left ventricular
diastolic diameter > 1.7, and presence of PH were significantly associated with the
development of AF. Also the continuous variables LA, body weight (BW), fractional
shortening (FS), and velocity of trans‐mitral E wave (E‐max) were significantly different
(P < 0.01) for AF cases. After evaluation of autocorrelation and/or interaction between
predictors, two multivariable models were obtained. LA/Ao (odds ratio [OR] 14.011,
7.463‐26.304), E‐max (OR 2.204, 1.192‐4.076), BW (OR 1.094, 1.058‐1.130), and FS (OR
0.899, 0.865‐0.934); and LA (OR 5.28, 3.377‐8.092), decompensated ACVIM stage (OR
4.922, 1.481‐16.353), and FS (OR 0.919, 0.881‐0.959) were significant predictors of
AF for model 1 and 2, respectively. An LA > 3.45 cm had sensitivity and specificity
of 98.3% and 89.8% to predict development of AF.
Atrial fibrillation is an uncommon complication of canine MMVD and is significantly
associated with the more advanced stages of the disease. Increased LA dimension and
BW, and decreased systolic function are associated with development of AF in dogs
with MMVD.
Disclosures
No disclosures to report.
ESVC‐P‐11
Left atrial volume assessment in 160 Cavalier King Charles Spaniels with and without
degenerative mitral valve disease (2017‐2019)
C. Poissonnier1, P. Foulex2, M.P. Alvarado2, E. Trehiou‐Sechi2, V. Saponaro2, P. Passavin2,
S. Ghazal2, S. Lefort2, L. Desquilbet2, V. Chetboul2
1École Nationale Vétérinaire d'Alfort, Maisons‐Alfort, France, 2Ecole Nationale Vétérinaire
d'Alfort, Maisons‐Alfort, France
Degenerative mitral valve disease (DMVD) is the most common acquired heart disease
in small‐sized dogs with a high predisposition of the Cavalier King Charles Spaniel
(CKC) breed. Echocardiographic assessment of the disease is based on the evaluation
of atrial and ventricular dimensions, with left atrial (LA) diameter measurement being
one of the strongest predictors of clinical outcome. The LA diameter is usually evaluated
on the right parasternal transaortic short‐axis view and compared to the aortic (Ao)
diameter (LA:Ao ratio). However, LA dilation can develop in medio‐lateral, cranio‐caudal,
or ventro‐dorsal directions. Therefore, the LA:Ao ratio may not be reliable for the
early detection of LA dilation. Measurements of LA volumes have been recently recommended
in the dog using monoplane and biplane Simpson's modified methods of discs (SMOD)
and area‐length methods (ALM). The objectives of this prospective study were therefore
to 1) compare different echocardiographic methods in evaluating LA volume in a large
population of CKCs and 2) to assess LA volume according to DMVD severity.
The study population consisted in 160 CKCs either healthy or affected by DMVD (median
weight = 9.15 kg [interquartile range (IQR) = 7.8‐10.3], male‐to‐female ratio = 0.95).
According to the ACVIM classification, 28/160 dogs (17.5%) had no identifiable DMVD
lesions (stage A), 86/160 (53.8%) and 22/160 (13.8%) were in stages B1 and B2, respectively,
23/160 (14.3%) had past or current congestive heart failure (CHF, stage C), and 1/160
(0.6%) had refractory CHF (stage D). Dogs for which mitral regurgitation (MR) was
adequate for quantification by the Proximal Isovelocity Surface Area method (n = 107)
had a median regurgitation fraction (RF) of 38% [23‐55].
The monoplane SMOD and ALM using the left apical 4‐chamber view overestimated LA volume
by comparison with the biplane ALM (+2.6% and + 10.8%, respectively), and the monoplane
ALM overestimated LA volume in comparison with the monoplane SMOD (+8.3%). Left atrial
volumes significantly increased with ACVIM stages. Among B1 dogs, end‐systolic LA
volume assessed by the biplane ALM was significantly lower in dogs with mild MR (RF < 30%,
median volume = 0.75 mL/kg [IQR = 0.59‐0.90]) than for dogs with higher MR (RF≥30%,
median volume = 1.39 mL/kg [IQR = 0.96‐1.56]; P < 0.01).
In conclusion, this study demonstrates the importance of LA volume measurement in
CKCs with DMVD, especially among B1 DMVD dogs. These results suggest that a category
of B1 dogs (with RF > 30%) actually show LA dilation, which is however not apparent
using the LA:Ao ratio calculation, thus potentially leading to a misdiagnosis between
DMVD B1 and B2 stages.
Disclosures
Disclosures to report.
Fondation Un Coeur/Vetoquinol sponsoring for a clinical research assistant position
in Alfort Cardiology Unit.
ESVC‐P‐12
Hematological abnormalities in dogs with congenital arterial stenosis: a prospective
study of 56 cases (2017‐2019)
P. Passavin, V. Chetboul, M. Lavennes, M. Roche‐Catholy, C. Poissonnier, V. Saponaro,
E. Trehiou‐Sechi, S. Ghazal, M.P. Alvarado, S. Lefort, C. Tilmant, L. Desquilbet,
I. Lagrange
Ecole Nationale Vétérinaire d'Alfort, Maisons‐Alfort, France
Intravascular hemolysis has been identified in human patients with moderate to severe
aortic stenosis. The underlying mechanism implies shear stress exerted on erythrocytes
by high velocity flows through the stenotic orifice. No similar data are currently
available in veterinary medicine. The aim of this prospective study was therefore
to 1) document hematological abnormalities in dogs with arterial stenosis (ie, aortic
stenosis [AS], pulmonic stenosis [PS]) between 2017 and 2019 and 2) evaluate if maximal
and mean Doppler‐derived trans‐stenotic pressure gradients (∆P), as well as features
of stenotic lesions (number and location), were associated with erythrocyte abnormalities.
The study sample consisted of 56 dogs (median age = 1.6 year [interquartile range
(IQR) = 0.7‐4.0 years], male‐to‐female ratio = 1.5). The most commonly recruited breeds
were French Bulldogs (n = 13), White Swiss Shepherds (n = 6), English Bulldogs (n
= 4), Boxers (n = 4), Golden retriever (n = 3), Chihuahua (n = 2), and 24 other breeds
(n = 1 for each). Among the study population, 44 dogs (79%) had PS and 12 (21%) had
AS. The median maximal ∆P values were 161 mmHg [110‐215 mmHg] and 144 mmHg [IQR =
125‐176 mmHg] for PS and AS, respectively. Included dogs showed 1 (34/56), 2 (16/56)
or 3 (6/56) obstructive lesions: subvalvular stenosis for 24/56 dogs (13/44 with PS,
11/12 with AS), valvular stenosis for 42/56 dogs (37/44 with PS, 5/12 with AS), and
supravalvular stenosis for 16/56 dog (only PS).
Hematological abnormalities were detected in most dogs (n = 49; 88%), with schizocytes
found in 28/56 (50%) dogs (median proportion = 1‰ cells [IQR = 0‐3‰]), acanthocytes
in 46/56 (82%) dogs (median proportion = 45‰ cells [IQR = 10‐226‰]), and hemolytic
anemia in 4 dogs with PS (hemoglobinemia <12.4 g/dL). No significant association was
identified between these abnormalities and the above‐mentioned echocardiographic parameters.
Three out of the 4 dogs with hemolytic anemia had a maximal ∆P > 200 mmHg (242 to
412 mmHg). Interestingly, the dog with the highest maximal ∆P also had the most severe
anemia and schizocytosis, and both abnormalities decreased, and then resolved, after
balloon valvuloplasty.
In conclusion, these results show that red blood cell abnormalities (acanthocytosis
and schizocytosis) are very common in dogs with congenital arterial stenosis, thus
suggesting that turbulent blood flows through stenotic orifices induce mechanical
erythrocyte damage. Further prospective studies are needed to better document these
findings and elucidate the precise mechanisms of red cell damage using other hematolytic
markers (eg, lactate dehydrogenase, hemosiderinuria, etc.), as performed in human
patients.
Disclosures
No disclosures to report.
ESVC‐P‐13
Use of torasemide in cats with congestive heart failure: 17 cases (2016‐2019)
C. Poissonnier1, S. Ghazal2, P. Passavin2, M.P. Alvarado2, S. Lefort2, E. Trehiou‐Sechi2,
V. Saponaro2, A. Barbarino2, J. Delle Cave2, C.R. Marchal2, B. Depré2, E. Vannucci2,
P. Verwaerde2, V. Chetboul2
1École Nationale Vétérinaire d'Alfort, Maisons‐Alfort, France, 2Ecole Nationale Vétérinaire
d'Alfort, Maisons‐Alfort, France
Torasemide is a loop diuretic whose safety and efficacy have been demonstrated in
dogs with congestive heart failure (CHF). Torasemide is characterized by a longer
duration of action, a more potent diuretic action, and a higher bioavailability than
furosemide. However, to the best of our knowledge, no study has focused on the efficacy
and safety of torasemide in cats with CHF. The objectives of this retrospective study
were therefore to 1) describe the clinical and echocardiographic characteristics and
document the clinical outcome of cats with CHF treated with oral torasemide, and 2)
identify potential adverse events related to torasemide administration in this feline
population.
The case records of cats treated with torasemide were reviewed. The study population
consisted of 17 cats (median age = 10.6 years [interquartile range (IQR) = 6.4‐11.0],
male‐to‐female ratio = 2.4), with a majority of Domestic shorthair cats (13/17). All
cats presented dyspnea related to CHF (pleural effusion [4/17], pulmonary edema [6/17]or
both [7/17]), associated with ascites in 2/17 cats. The cause of CHF was determined
in all cats by echocardiography: hypertrophic (8/17,47%), restrictive (3/17,18%),
dilated (3/17,18%) and arrhythmogenic right ventricular (2/17,12%) cardiomyopathy,
and aortic valve congenital abnormality (1/17,5%). The left atrium (LA) was dilated
in all cats, with a median end‐diastolic LA‐to‐aorta‐ratio of 1.97 [IQR = 1.80‐2.11,
normal values <1.2]. Median torasemide dosage at initiation was 0.20 mg/kg/day [IQR
= 0.17‐0.23].
Follow‐up was available for all cats. Torasemide dosage was increased for 41% (7/17)
cats due to the persistence of CHF signs (median time from treatment initiation to
dosage change = 7 days [7‐32]; median dosage = 0.26 mg/kg/day [0.19‐0.34]). Additionally,
furosemide was added 12 hours after torasemide intake for 29% (5/17) of cats (median
time from treatment initiation to furosemide initiation = 15 days [1‐44]; median dosage
= 1.13 mg/kg/day [1.09‐1.35]). Other treatments included benazepril (4/17), pimobendane
(4/17), clopidogrel (12/17), aspirin (3/17) and spironolactone (3/17). Regression
of clinical signs was observed in most cats (16/17), with no remarkable adverse events.
Death was reported in 8/17 cats, with 6/8 euthanized as a result of CHF worsening
(n = 4) or aortic thromboembolism (n = 2), and death related to CHF for 2/8 cats.
Median survival time after torasemide prescription was 96 days [19‐330].
In conclusion, to the best of our knowledge, this is the first description of torasemide
use in cats with CHF. This drug was well tolerated in all cases. This case series
illustrates the therapeutic interest of torasemide in cats, which needs to be confirmed
by further prospective clinical trials.
Disclosures
Disclosures to report.
Fondation Un Coeur/Vetoquinol sponsoring for a clinical research assistant position
in Alfort Cardiology Unit.
ESVC‐P‐14
Use of torasemide as a second line diuretic in dogs with congestive heart failure
I. Guarnera, G. Romito, P. Castagna, M. Cipone, M. Baron Toaldo
University of Bologna, Ozzano Emilia, Italy
Torasemide is a loop diuretic used in dogs with congestive heart failure (CHF) as
an alternative to furosemide. Studies comparing furosemide and torasemide in dogs
with refractory CHF are sparse.
Medical database of our Teaching Hospital has been reviewed searching for dogs with
myxomatous mitral valve disease who experienced CHF and received torasemide as a second
line diuretic after treatment failure with furosemide (study group: 25 dogs). Clinical,
echocardiographic, radiographic and laboratory findings have been annotated. Survival
time has also been reported and calculated from the first episode of CHF. A control
group (23 dogs) of dogs with similar cardiac disease, that never received torasemide
has also been selected. Data were collected at the time of first CHF (first examination)
and in concomitance with the last examination available.
Sex distribution was equal between the two groups (P = 0.250). In both groups the
mixed breed was overrepresented. Besides furosemide and torasemide, other medications
used to control the cardiac disease were comparable. At admission there was no difference
between groups regarding age (P = 0.956), body weight (P = 0.543), left ventricular
diastolic internal diameter normalized for body weight (LVIDDn) (P = 0.331), left
atrial to aortic ratio (LA:Ao) (P = 0.959), tricuspid regurgitation peak velocity
(P = 0.838), creatinine (P = 0.433) and potassium (P = 0.230) serum levels. There
was no difference in prevalence of atrial fibrillation between groups (P = 1.000).
The overall number of decompensations experienced by each dog was higher for the study
group (4.4 ± 1.9) compared to the control group (2.9 ± 1) (P = 0.001). At last examination
only LA:Ao was higher in the study group compared to controls (P = 0.035). The total
maximal dose of furosemide was 6.1 ± 3 mg/kg/day for the study group and 5.6 ± 2.1 mg/kg/day
for the control group (P = 0.475). While the initial dose of torasemide used was 0.7 ± 0.4 mg/kg/day.
When comparing the first and last examinations within the two groups, body weight
reduced in the study group (P < 0.001), while LA:Ao (P < 0.001), and creatinine (P < 0.001)
increased. The number of decompensations recorded before (2.9 ± 1.1) and after (1.5 ± 1.5)
torasemide initiation reduced significantly (P = 0.001). Within the control group
only creatinine increased (P = 0.013). Thirty‐six dogs died of cardiac related causes.
There was no difference in survival between the two groups (P = 0.413), with a median
survival of 523 days for the study group and of 383 days for the control group.
Torasemide appears effective as a second line diuretic for CHF control in dogs with
myxomatous mitral valve disease, offering a life expectance comparable if not superior
to furosemide alone.
Disclosures
No disclosures to report.
ESVC‐P‐15
Echocardiographic predictors of first onset of atrial fibrillation in dogs with myxomatous
mitral valve disease
C. Mazzoldi1, C. Guglielmini2, G. Romito1, H. Poser2, M. Baron Toaldo1
1University of Bologna, Ozzano Emilia, Italy, 2Departement of Animal Medicine, Production
and Health, University of Padova, Padova, Italy
Atrial fibrillation (AF) occurs in dogs with myxomatous mitral valve disease (MMVD)
as a consequence of left atrial (LA) dilatation. Predicting its occurrence might have
beneficial consequences. This is a retrospective study evaluating the usefulness of
echocardiography in predicting the first occurrence of AF in dogs with MMVD.
The medical databases of two Veterinary Teaching Hospitals were reviewed searching
for dogs with MMVD that developed AF during the following year (study group). The
last echocardiographic examination obtained during sinus rhythm was used to derive
selected variables used for successive statistical comparison. For each dog with AF
a control dog, matched for body weight (BW), class of heart failure, and LA dimension
as expressed by the ratio between LA and aortic diameters (LA:Ao), but never developing
AF over a comparable follow up period was selected. All echocardiographic exams were
reviewed by a single board certified cardiologist and several variables of LV and
LA dimension and function, and LA volumes were obtained. In particular LV internal
diameters in diastole and systole were obtained as absolute values and indexed to
BW. LA dimensions were expressed as absolute value and LA:Ao, moreover LA volumes
were measured during maximal and minimal LA expansion and at the peak of the P wave,
and then indexed to BW. Several indexes of LA function were then calculated from these
volumes. Peak trans‐mitral E and A waves velocities, E:A ratio, and A wave duration
were also measured. LA speckle tracking echocardiography (STE) was carried out and
peak atrial longitudinal strain (PALS), peak atrial contraction strain, and contraction
strain index were measured.
Forty‐four dogs with MMVD were included, 22 dogs developing AF and 22 dogs maintaining
a sinus rhythm. There was no difference in terms of BW (P = 0.803), sex distribution
(P = 0.393), and class of heart failure (P = 0.550). Among the tested echocardiographic
variables only LA diameter (P = 0.034), and LV internal diameter in diastole not indexed
for BW (P = 0.031) differed significantly between groups. There was no difference
in terms of LA:Ao (P = 0.097), LV internal diameters in diastole and systole indexed
for BW (P = 0.131 and P = 0.406, respectively), and LA volumes and volume‐derived
functional parameters. Among the STE‐derived variables, PALS values differed significantly
between AF group (mean value 23.8 ± 8.6) and control group (mean value 30.5 ± 9.6)
(P = 0.027).
Absolute cardiac dimensions as well as LA STE, and in particular PALS, are useful
echocardiographic predictors for the development of AF in dogs with MMVD.
Disclosures
No disclosures to report.
ESVC‐P‐16
Usefulness of Holter‐derived Lorenz plots analysis to discriminate different cardiac
rhythms in dogs
G. Romito1, C. Guglielmini2, H. Poser2, M. Berlanda2, M. Baron Toaldo1
1University of Bologna, Ozzano dell'Emilia, Italy, 2Department of Animal Medicine,
Production and Health, University of Padova, Padova, Italy
Lorenz plot (LP) is a representation of heart rate variability that summarizes graphically
the beat‐to‐beat intervals recorded during a Holter monitoring (HM). The use of LP
patterns (LPPs) to diagnose rhythm disturbances has been studied in people, but little
is known in animals. The aim of this study was to analyze the graphic features of
LPs and to evaluate the diagnostic value of LPPs for identifying arrhythmias in dogs.
HMs with >20 hours of valid data obtained from dogs with sinus rhythm (SR) or different
types of tachyarrhythmias were used. One operator blinded to the underlying rhythm
diagnosis reviewed the automated analyses in order to: assess HMs quality, manually
correct any software misinterpretation, and make the rhythm diagnosis. Cardiac rhythms
were classified as SR; SR with frequent (>100) premature ectopic complexes (SR + PEC),
either supraventricular or ventricular; atrial fibrillation (AF); and AF with frequent
ventricular premature complexes (AF + VPC). For each HM, a LP was generated by the
software using all RR intervals. LPs were studied qualitatively and quantitatively
and distinct LPPs were created by adapting previously recognized patterns in humans.
The diagnostic accuracy of LP analysis in predicting the underlying cardiac rhythm
was evaluated by calculating the corresponding sensitivity (Se) and specificity (Sp).
One hundred and nineteen HMs were analyzed including 48 SR, 49 SR + PEC, 4 AF, and
18 AF + VPC. Ten distinct LPPs were identified: comet (10 cases); torpedo (3 cases);
Y‐shaped (6 cases); diamond (12 cases); diamond with central silent zone (15 cases);
a combination of one of the above 5 patterns with a double side‐lobe (DSL) (46 cases),
a triple side‐lobe (2 cases), or a quadruple side‐lobe (3 cases); fan (19 cases);
and fan with DSL (3 cases). When pooled together as a single normal pattern, the comet,
torpedo, Y‐shaped, and diamonds, predicted presence of SR with Se and Sp of 91.7%
and 97.2%, respectively. Two LPs with a diamond pattern had a Holter diagnosis of
SR + PEC. The DSL pattern indicated presence of SR + PEC with Se and Sp of 85.7% and
94.3%, respectively. Triple and quadruple side lobe patterns were exclusively associated
to SR + VPC. The fan configuration (considering together the fan and fan with DSL
pattern) indicated AF with both Se and Sp of 100%. The three cases of fan with DSL
were associated with AF + VPC.
In conclusion, different cardiac rhythms are associated with peculiar LPPs and their
analysis holds relevant diagnostic value in dogs with SR and/or tachyarrhythmias.
Disclosures
No disclosures to report.
ESVC‐P‐17
Visual Representations of Cardiac Arrhythmias in Dogs using Lorenz Plots
D. Adin1, D. Deprospero2
1University of Florida, Gainesville, United States of America, 2North Carolina State
University, Raleigh, United States of America
Lorenz plots (LPs) can be generated from continuous electrocardiographic (ECG) recordings
to provide visual representations of rhythm patterning. This study sought to characterize
LP patterns for common rhythms of dogs.
Twenty Holter recordings free from pathologic arrhythmias and ten recordings each
of supraventricular premature complexes (SPVCs), complex supraventricular ectopy,
ventricular premature complexes (VPCs), complex ventricular ectopy, atrial fibrillation
(AF), high‐grade second degree atrioventricular block (AVB) and paced rhythms were
retrospectively evaluated and utilized for one‐hour LP generation. Beat origin was
color coded. Patterns found in each arrhythmia group were described, and arrhythmia
numbers and LP shape measurements were reported.
Normal Holter recordings uniformly showed a torch morphology with variable silent
zones. Premature beats were associated with double and triple side lobe patterns,
with variations resulting from multiple coupling intervals and variable post‐ectopic
pauses. Complex ectopic rhythms were evidenced by a small data point concentration
in the lower left corner of the LP. Recordings with AF uniformly showed a fan pattern
consistent with random atrioventricular nodal conduction, and recordings with AVB
showed island patterns consistent with variable atrioventricular nodal conduction.
Paced rhythms were torpedo shaped when the rhythm was completely controlled by the
pacemaker.
Specific LP patterns were identified for common cardiac rhythms in dogs which supports
non‐random mechanisms for most rhythms. Incorporation of LPs in arrhythmia interpretation
may aid mechanistic understanding, which in turn may advance the understanding of,
and approach to diagnosis and treatment of arrhythmias in dogs.
Disclosures
No disclosures to report.
ESVC‐P‐18
First case of successful transcatheter pulmonary valve implantation in a dog with
severe pulmonary regurgitation
N. Borenstein1, V.M. Saponaro2, P. Passavin2, A. Morlet1, R. Fernandez3, L.E. Carazo
Arias1, G. Giannettoni3, C. Poissonnier2, S. Ghazal2, S. Lefort2, E. Treiou‐Sechi2,
C.R. Marchal3, J. Delle Cave3, E. Vannucci3, L. Behr1, P. Verwaerde3, V. Chetboul2
1IMM Research, Paris, France, 2Cardiology Unit of Alfort School, Maisons‐Alfort, France,
3Unité de Réanimation, Anesthésie et Soins Intensifs d'Alfort, Maisons‐Alfort, France
Transcatheter pulmonary valve implantation is a therapeutic approach, approved by
the US Food and Drugs Administration in 2010 for human patients with failing pulmonary
conduits and for failing bioprosthetic surgical pulmonary valves in 2017. We report
here the first case of successful transcatheter implantation of a stented valve in
a pulmonary position in a dog with congenital pulmonary valve disease. A 3‐year‐old,
10.9 kg, client‐owned Beagle dog was referred for a follow‐up visit after a percutaneous
balloon valvuloplasty performed 22 months before for correcting a severe type A valvular
pulmonic stenosis (Doppler‐derived peak trans‐stenotic pressure gradient, DP = 348 mmHg
before the procedure, 66 mmHg 24 hours later). At time of presentation the dog was
lethargic, and echocardiography revealed a mild pulmonic stenosis (DP = 43 mmHg) associated
with severe pulmonary regurgitation (proximal width ratio assessed by color‐flow Doppler
mode of 100%), and secondary major right ventricular and right atrial dilation. Despite
medical therapy, worsening of right heart dilation was observed two months later,
and a transcatheter pulmonary valve implantation using a Melody™ valve with a pre‐stenting
system was decided. A contrast‐enhanced cardiac‐gated computed tomography 3D scan
was performed one week before surgery, to accurately assess the pulmonary and coronary
artery morphology, and perform measurements of the pulmonary annulus and the right
ventricular outflow tract maximal diameters. Aneurysm of the pulmonary trunk with
plications of the arterial wall was confirmed. The initial minimally invasive approach
via the left jugular vein with a Seldinger technique was unsuccessful due to the size
of the outer diameter of the delivery system and therefore was converted to a left
3rd intercostal thoracotomy and a trans‐ventricular delivery (the approach had been
prepped at the same time as the neck area in case of conversion). The dog recovered
uneventfully and was discharged 10 days after the procedure. Right heart dilation
disappeared within 15 days. The dog is still doing well three months after valve implantation.
This case illustrates that pulmonary transcatheter stented valve implantation is technically
feasible in the dog with severe pulmonary valve disease. Stented valves as an alternative
to open‐heart surgery is the source of tremendous development in human medicine and
it can be foreseen that veterinary cardiology will, in some way, benefit from this
revolution.
Disclosures
Disclosures to report.
The Melody valve was kindly offered by Medtronic, Minnesota, U.S.A.
ESVC‐P‐19
Normal aortic annulus dimensions in Boxer dogs according to sex and body weight
M. Claretti1, C. Quintavalla2, S. Crosara2, C. Bussadori1
1Clinica Veterinaria Gran Sasso, Milano, Italy, 2Università degli Studi di Parma,
Parma, Italy
Boxer dogs breeding in Italy is regulated by Boxer Clubs. The Boxer Club of Italy
(BCI) drafted the guidelines for the “selection” of dogs with morphological and attitudinal
standards. Given the high prevalence of congenital heart diseases in Boxer dogs the
BCI established a cardiovascular screening mandatory for the admission to the selection
process. Screening data have been collected by either board‐certified cardiologist
or operators, selected through a practical exam after a training. During this exam
different operators examined the same Boxer and their findings were compared with
those of the board‐certified (inter‐observer variability) and were compared also three
measurements of the same dogs performed by each operator (intra‐observer variability).
Current reference intervals for aortic annulus dimensions do not account for body
weight (BW).
The objective of this study is to analyse the aortic annulus dimensions based on sex
and BW of dogs.
Four thousand two hundred one Boxer dogs free from cardiovascular diseases were included
in the study.
Cardiovascular screening conducted between 12/11/1999 and 09/03/2018 were included.
Two‐dimensional, M‐Mode, spectral and color flow Doppler transthoracic echocardiography
(TTE) is performed following the published recommendations. Sixteen dogs were excluded
from the analysis due to the lack of data on sex and 119 for the annulus less than
15 mm, remaining for the analysis a sample of 4066 dogs. These dogs have been divided
into males and females and into weight quartiles. Subsequently the normal values and
confidence intervals for annulus were analysed for the entire sample, by gender, by
weight quartiles and by sex and weight interaction.
Regarding the results we have objectified that aortic annulus dimensions increased
with increasing BW. The values obtained were tested by sex using a t‐test while for
weight quartiles or by sex and weight interaction with the ANOVA test (with the Bonferroni
correction for multiple comparisons): in all cases the significance level p is lower
than 0.001.
As for the cases excluded from the analysis by measure of the annulus less than 15 mm,
they are mostly females (84.9%, P < 0.001) and an average weight lower than 4.1 kg
(SE 0.40, P < 0.001) compared to cases analysed.
In conclusion we can say that BW based 95% confidence interval may help in screening
dogs for heart disease, discriminating normal aortic annulus dimension.
Disclosures
No disclosures to report.
ESVC‐P‐20
Inflammatory and oxidative stress markers are associated with survival in canine cardiovascular
patients
A. Domanjko Petric1, B. Verk1, D. Manevski2, A. Nemec Svete1
1Veterinary Faculty, Ljubljana, Slovenia, 2Institute for Biostatistics and Medical
Informatics, University of Ljubljana, Slovenia
Various factors can influence survival of dogs with mitral valve disease (MVD) and
dilated cardiomyopathy (DCM). In canine cardiovascular patients, inflammatory and
antioxidant markers have not been investigated in terms of association with survival,
yet. Thus, we investigated the association of inflammatory (white blood cell (WBC),
neutrophil (NEUT) and monocyte (MONO) counts, C‐reactive protein (CRP), tumour necrosis
factor‐alpha (TNF‐α) and interleukin‐6 (Il‐6)) and oxidative stress (malondialdehyde),
vitamin E and glutathione peroxidase (GPX)) markers with survival in dogs with MVD
and DCM.
Thirty‐seven dogs with MVD (21) and DCM (16) (11 dogs in International Cardiac Health
Council Class [ISACHC] I, 7 dogs in ISACHC II and 19 dogs in ISACHC III) were included
in the study (2 dogs were censored). Survival time was counted from the day of admission
when the blood samples were collected to the day of death or euthanasia. Markers were
analysed using Cox proportional‐hazards models. Hazard ratios (HR), 95% confidence
intervals (CI) and corresponding P values were calculated. A value of P < 0.05 was
considered significant.
A log‐rank test was performed on survival time with respect to disease type (MVD or
DCM). No significance was found (P = 0.37), although dogs with MVD (median = 452 days)
had on average longer survival time than those with DCM (median = 184 days). Univariate
Cox proportional‐hazards models were performed for every marker. The following markers
were significantly associated with survival (HR; 95% CI; P value): WBC (1.139; 1.049,
1.237; 0.002), NEUT (1.184; 1.074, 1.305; 0.001), MONO (7.502; 2.044, 27.532; 0.002),
CRP (1.000; 1‐000, 1.000; 0.008), TNF‐α (1.078; 1.018, 1.142; 0.010), Il‐6 (1.009;
1.000, 1.017; 0.039) and GPX (0.992; 0.986,0.999; 0.025). If we interpret some of
the results: an increase of NEUT for 1 unit (x109/L) increased the risk of death by
18.4%, while an increase of GPX (U/g of haemoglobin) for 50 units decreased the risk
of death by 33%. Furthermore, Cox models were fitted, with ISACHC and an additional
marker as covariates, since survival was significant with respect to ISACHC class
(log‐rank test, P = 0.0004). In these models, the effect of the above markers decreased;
however, GPX (0.992; 0.985,0.999; 0.025) and NEUT (1.122; 1.007,1.249; 0.036) remained
significantly associated with survival.
These results suggest that increased inflammation and decreased activity of antioxidant
enzyme GPX are associated with decreased survival in canine MVD and DCM patients,
even when ISACHC is considered in the model. We may conclude that selected inflammatory
and oxidative stress markers predict survival.
Disclosures
No disclosures to report.
ESVC‐P‐21
Right heart remodelling in brachycephalic obstructive airway syndrome
A. Domanjko Petric, M. Brložnik, V. Erjavec, A. Nemec Svete
Veterinary Faculty, Ljubljana, Slovenia
Brachycephalic Obstructive Airway Syndrome (BOAS) is characterised by various upper
airway abnormalities that could potentially trigger remodelling of the right heart.
The aim of this study was to evaluate echocardiographic characteristics in symptomatic
(BOAS) and asymptomatic French Bulldogs (FB) and Pugs. Dogs were diagnosed as BOAS
according to clinical signs and anatomical abnormalities.
Fifteen FB (7 BOAS, 3F/4M, 8 asymptomatic, 8F) and 10 Pugs (7 BOAS, 2F/5M, 3 asymptomatic,
3F) underwent complete echocardiographic examination of the left and right heart according
to guidelines. In each breed, echocardiographic parameters of dogs with clinical signs
of BOAS were compared to asymptomatic dogs. Furthermore, BOAS FBs were compared to
BOAS Pugs. Weight‐depended variables were indexed (variable/weight1/3). Normally distributed
variables were compared with independent t‐test and for not normally distributed data
Mann‐Whitney test was used. Statistical significance was defined as P ≤ 0.1.
There were no significant differences in age and weight between BOAS FB and asymptomatic
FB. BOAS FB had significantly lower vena cava collapsibility index (P = 0.013), larger
right ventricular internal diameter in mid cavity (RVIDmid) (P = 0.056), larger indexed
RVIDmid (P = 0.098), higher tricuspid valve (TV) E wave velocity (P = 0.083), and
lower peak systolic tricuspid annular velocity (St) (P = 0.037) compared to asymptomatic
FB. There were no statistical differences between asymptomatic and BOAS Pugs in age,
weight and echocardiographic parameters. No significant difference in weight between
FB and Pugs was found; however BOAS FBs were younger (P = 0.067). BOAS FBs comparing
to BOAS Pugs showed lower collapsibility index (P = 0.002), larger indexed right ventricular
longitudinal internal diameter (RVIDlong) (P = 0.084), larger indexed right ventricular
area (RVA) in diastole (P = 0.022), larger indexed RVA in systole (P = 0.027), larger
indexed right atrial area (P = 0.023), larger indexed LVIDd (P = 0.048), higher mitral
annular plane excursion (MAPSE) (P = 0.011), higher mitral valve (MV) E velocity (P
= 0.013), higher MV A wave (P = 0.084), higher TV A (P = 0.099) and higher peak systolic
annular velocity of left free wall Em (P = 0.047).
In BOAS FB right ventricle was larger compared to asymptomatic FB, which suggests
remodelling of the right heart. Higher TV E velocity might suggest higher right atrial
pressure and lower St might suggest decreased right ventricular systolic function
in BOAS FB. Lower vena cava collapsibility index in BOAS FB compared to asymptomatic
FB, might be due to higher right atrial pressure in BOAS dogs. Breed specific reference
ranges are recommended for evaluation of the right heart. Echocardiographic differentiation
of BOAS and asymptomatic brachycephalic dogs seems challenging.
Disclosures
No disclosures to report.
ESVC‐P‐22
Effect of a single dose of Pimobendan on right ventricular and atrial function in
healthy cats
M. Baron Toaldo, M. Pollesel, M. Cipone, G. Romito
University of Bologna, Ozzano Emilia, Italy
Pimobendan is an inodilator widely used in canine cardiology. It increases life expectance
in dogs with heart failure. Moreover it is able to enhanced right ventricular (RV)
systolic function in healthy and diseased canine patients. Only a few studies are
focused in evaluating the effect of pimobendan in cats, and no report exist regarding
its effect on the right heart. The aim of the present study was to analyze the changes
of RV and right atrial (RA) echocardiographic parameters in healthy cats after a single
oral dose of pimobendan.
Eleven apparently healthy cats were used for this study. Cats were deemed to be healthy
on the basis of clinical examination, cardiac auscultation, non‐invasive blood pressure
measurement, blood work, and conventional echocardiography (including RV wall thickness
in diastole, RV internal diameters in diastole and systole from a short axis view,
RV fractional shortening (FS), RV areas in diastole and systole from an apical view,
fractional area change, tricuspid annular plane systolic excursion, tissue Doppler
imaging derived tricuspid annulus systolic wave velocity, RA maximal and minimal diameters,
and RA FS). Cats were scanned following standard techniques while gently manually
restrained. Each cat was scanned a total of eight times, at different time points
in two subsequent days. The first day cats were scanned at time 0, and after 1, 3,
and 6 hours. The following day, each cat received an echocardiography before (time
0), and 1, 3, and 6 hours after a single dose of 1.25 mg of pimobendan administered
orally.
None of the cats showed any adverse reaction to the drug. Data obtained from different
time points before (day 1 at time 0, 1, 3, and 6, and day 2 at time 0) and after (day
2 at time 1, 3 and 6) pimobendan administration were pooled together. The statistical
comparison was then performed between two global time points (before and after pimobendan
administration).
Among the tested variables, some differed before and after pimobendan administration.
In particular heart rate (P = 0.002), RV FS (P = 0.011), RV fractional area change
(P = 0.010), and tissue Doppler imaging derived tricuspid annulus systolic wave velocity
(P = 0.014) increased significantly. On the other side, RV internal diameter in diastole
(P = 0.019) and systole (P = 0.002), and RA maximal (P = 0.004) and minimal (P = 0.002)
diameters were reduced after pimobendan administration.
Pimobendan appears safe when administered to healthy cats and it is able to induce
a significant increase in RV and RA systolic properties.
Disclosures
No disclosures to report.
ESVC‐P‐23
Ambulatory electrocardiography and serial cardiac specific troponin I measurement
in twenty‐two dogs envenomated by the European Adder (Vipera berus)
H.J. Harjen1, A. Bjelland2, J. Harris3, T. Grøn1, K. Anfinsen1, E. Moldal1, R. Rørtveit1
1Norwegian University of Life Sciences (NMBU)/Faculty of Veterinary Medicine, Oslo,
Norway, 2The Norwegian Medicines Agency, Oslo, Norway, 3HeartVets, Dursley, United
Kingdom
Envenomation by the European adder (vipera berus), is a common seasonal presentation
in small animal practice in Norway. Cardiac arrhythmias are observed in patients but
studies describing their time course and severity are limited. Cardiac auscultation
and short in‐hospital electrocardiograms (ECGs) are insensitive for the detection
of arrhythmias and as such, many may go undetected.
The aim of this study was to describe the prevalence and nature of arrhythmias detected
in dogs during the first forty‐eight hours post envenomation and to investigate associations
between arrhythmia grade, serum cardiac specific troponin I (cTnI, a marker of myocardial
cell injury) and snakebite severity score (SS score) at presentation.
Twenty‐two dogs bitten by vipera berus were included in this prospective cohort study.
An ambulatory ECG (AECG) was placed on each dog at presentation, for 24‐54 hours.
Arrhythmia grades of 0‐3 were assigned based on frequency and severity of arrhythmia
during AECG recording (modified from previously described grading systems). Serum
was obtained at presentation, 12 h, 24 h, 36 h and 14 days post bite, for cTnI analysis.
An SS score of 1‐3 was recorded upon admission using a previously described grading
system.
Four dogs (18%) had an SS score of 1 (mild) while SS scores of 2 (moderate) and 3
(severe) were observed in fourteen (64%) and four dogs (18%), respectively. Seventeen
dogs (77%) had raised cTnI concentrations at a minimum of one time point. Ten dogs
(45%) had elevated cTnI at presentation, 12 h, 24 h and 36 h.
Nine dogs had arrhythmia grades of 0 (non‐pathological). Thirteen dogs (59%) developed
pathological arrhythmias (grades 1‐3). All arrhythmias were ventricular in origin.
Severe complex ventricular arrhythmias (grade 3) were observed in 6 dogs (27%). All
grade 3 arrhythmias persisted into day two.
Concentrations of cTnI at presentation were significantly higher in dogs that developed
pathological arrhythmias compared to those that did not (P < 0.05). One dog with a
pathological arrhythmia had normal cTnI concentrations at all time points. SS score
was not significantly associated with arrhythmia grade, initial cTnI concentrations
or peak cTnI on day one.
This study shows that raised cTnI concentration and ventricular arrhythmias are common
following vipera berus envenomation in dogs and highlights the value of prolonged
ECG monitoring of these patients. Dogs that developed pathological arrhythmias could
not be differentiated from those that did not, based on SS score. Normal cTnI concentrations
did not rule out the development of pathological arrhythmias, in this study.
Disclosures
Disclosures to report.
Unsure if this is relevant: Joanne Harris is a director at Heartvets who provide ECG
interpretation and Holter rental services.
ESVC‐P‐24
E point to septal separation (EPSS): difference of measurement from the right parasternal
long axis and short axis view in dogs
C.H. Parmentola1, V.A. Patata2, F.E. Marchesotti1, T.O. Vezzosi1, O.R. Domenech1
1Istituto Veterinario of Novara, Novara, Italy, 2Istituto veterinario of Novara, Novara,
Italy
E point to septal separation (EPSS) is the distance of the maximal early diastolic
motion of the septal mitral valve leaflet (E‐point) to the interventricular septum
measured using the M‐mode recordings. EPSS is an important index in the diagnosis
of occult and symptomatic dilated cardiomyopathy (DCM) as recently reported in the
European screening guidelines for DCM in Doberman Pinschers. EPSS can be measured
from the right parasternal long axis view (RPLA) or from the right parasternal short
axis view (RPSA). However, no previous studies assessed if the EPSS values are different
using different echocardiographic views. Therefore, the aim of this study was to compare
EPSS values obtained from the RPLA and RPSA views in different canine breeds.
This was a prospective observational study. Dogs were presented to the Istituto Veterinario
di Novara for routine screening purposes. All dogs underwent a complete clinical and
echocardiographic examination performed in right and left lateral recumbency with
a simultaneous ECG tracing. The measurement of the EPSS was obtained from both the
RPLA and RPSA views. All measurements were performed offline by the same operator
(OD) evaluating 3 cardiac cycles, and the mean values were calculated.
A total of 33 healthy dogs were included: 20 Golden Retriever, 7 Doberman Pinschers,
3 English Bulldogs, 2 Labrador Retriever and 1 Czechoslovakian Wolf. This study included
27 females and 12 males, with a median age of 3 years (range 1‐8 years) and a median
body weight of 29.5 kg (range 22‐42 kg). The mean EPSS measured from the RPLA and
RPSA view were 4.0 ± 0.92 mm and 4.8 ± 1.2 mm respectively. EPSS was significantly
higher when measured from RPSA than RPLA view (P < 0.0001) with a mean difference
of 0.85 ± 1 mm.
The EPSS measurement obtained from the RPLA and RPSA view might not be used interchangeably.
The greater lateral and torsional movements of the heart obtained from the short axis
view during respiratory phases and cardiac cycle, might be the reason for the higher
values of EPSS obtained from the RPSA view. This finding could be taken into account
for an adequate echocardiographic evaluation and diagnosis. Further study with a larger
canine population is warranted to confirm this result.
Disclosures
No disclosures to report.
ESVC‐P‐25
Investigation report of the effect of long flightprolonged air travel on dogs with
heart mitral valve disease
A. Takahashi, S. Takeuchi, M. Uechi
JASMINE veterinary cardiovascular medical center, Kanagawa, Japan
The effect of long air travel on animals with heart disease has not been investigated.
In this study, we assessed the changes in physical condition of animals with mitral
valve disease before and after flight.
Target case profile: 38 dogs with mitral valve disease who underwent air travel to
undergo mitral valve repair at the JASMINE Veterinary Cardiovascular Medical Center
between September 2017 and March 2019. Before and after flight events: changes in
exercise intolerance, appetite, respiratory rate and frequency of coughing, gastrointestinal
signs and presence of syncope were evaluated. Also presence or absence of events related
to heart disease post‐flying and post‐operative discharge rate were studied.
All cases boarded the cabin. Thirty‐five patients were able to return home (2 dogs
without surgery). Two dogs developed events related to mitral valve disease (1 left
atrium rupture and 1 pulmonary edema, respectively). The dog with left atrial rupture
died before surgery and she did not receive cardiac medications during the flight.
The dog that developed pulmonary edema post‐flight also missed a dose during the journey,
but responded to medical therapy after the landing. Both of the dogs were in ACVIM
classification stage D. About 20% of cases showed changes in physical condition (exercise
intolerance, appetite) before and after flight. None of the changes required treatment.
Two dogs showed gastrointestinal symptoms (vomiting, diarrhea) before flight. Three
patients developed diarrhea after the flight. Among patients who showed respiratory
symptoms before and after flight, 38% showed respiratory distress and 19% showed worseing
in coughing. There were 5 dogs with syncopal episodes before the flight; however,
none of the dogs fainted after the flight. One dog had post‐flight syncope..
Although dogs with mitral valve disease may show clinical changes related to air travel,
these are only transient and can be alleviated with symptomatic treatment. Post‐flight
cardiac disease related symptoms can be prevented by managing the medication time
with alarm clock or other devices when travelling across timezones. Avoidance of medication
errors that may be caused by inexperienced while moving and misreading of the clock
due to time difference may be sufficient to avert mitral valve disease related events
with sufficient alertness. In conclusion, long distance air travel of patients with
mitral valve disease can be safely performed by carrying out routine care and medication
adherence.
Disclosures
No disclosures to report.
ESVC‐P‐26
Clinical, ECG and echocardiographic findings in a canine case series of presumptive
myocardial infarction
M. Lekane1, D. Connolly2, P. Smets3, K. Borgeat4, D. Casamian‐Sorrosal5, A. Boswood2,
V. Luis Fuentes2, K. Gommeren1, A.C. Merveille1
1Department of Veterinary Clinical Sciences, University of Liège, Liège, Belgium,
2Department of Veterinary Clinical Sciences, Royal Veterinary College, London, United
Kingdom, 3Department of Medicine and Clinical Biology of Small Animals, Ghent University,
Ghent, Belgium, 4Langford Veterinary Services, University of Bristol, Bristol, United
Kingdom, 5Department of Cardiology and Cardiopulmonary, Southfields Veterinary Specialists,
Basildon, United Kingdom
Acute myocardial infarction (AMI) is the most common cause of human ischemic heart
disease. Its pathogenesis involves atherosclerosis of coronary arteries, platelet
activation, thrombosis and vasospasms. Only anecdotal information on canine AMI exists.
Postmortem descriptions of arteriosclerosis with myocardial ischemic injury and congestive
heart failure are available, but clinical data regarding ante‐mortem diagnosis of
AMI is lacking. This case series describes possible predisposing factors, clinical,
electrocardiographic and echocardiographic findings in dogs with a presumptive diagnosis
of myocardial infarction.
The database of 4 veterinary clinics were retrospectively screened for dogs with a
presumptive diagnosis of AMI. Suspicion was based on echocardiographic regional wall
motion abnormalities (hypokinesia, akinesia or dyskinesia at initial presentation
or follow‐up), and/or elevated serum cardiac troponin I (cTnI), without any other
obvious cause. Thirteen dogs with a presumptive diagnosis of AMI were identified.
History, clinical data, cTnI, electrocardiographic and echocardiographic findings
were reviewed. Data are expressed as median and range.
Three out of thirteen cases were West Higland White Terriers. Median age was 9 years
(1‐12) and body weight was 21,8 kg (6,1‐ 40,8). Factors predisposing to thrombosis
were identified in 9 dogs (4 postoperative, 3 neoplastic, 1 immune‐mediated hemolytic
anemia and 1 hypothyroidism). Common clinical findings were arrhythmia (13/13), 1
with normal heart rate, 9 tachycardic and 3 bradycardic; weakness (11/13); and syncope
(6/13). cTnI was severely elevated (50.000 ng/L, range: 8.960‐221.961) in all tested
cases (10/10).
Identified ECG abnormalities were ventricular arrhythmias (9/13), 3rd degree atrioventricular
block (4/13) or sinus rhythm with right axis deviation (1/13). ST segment abnormalities
were present in 6 dogs.
Regional wall motion abnormalities affecting various myocardial segments (left ventricular
free wall (4/11), apex (4/11) and interventricular septum (3/11)) were observed at
the first exam in 8/13 or at follow‐up visits in 9/10 dogs. Abnormal segments appeared
thin and hyperechoic in 7/10 dogs during follow‐up echocardiograms. Systolic dysfunction
was observed in 9/13 dogs (5/13 at presentation and 4/10 at follow‐up). Three dogs
did not survive to discharge. Postmortem exam was performed in 2 dogs, showing severe
extensive myocardial necrosis and hemorrhage and/or replacement of myocardial tissue
by fibrous tissue on histopathology.
This is the largest case series of dogs with a presumptive diagnosis of AMI. Although
AMI remains a rare condition, it should be considered a differential diagnosis in
dogs with a predisposing condition, arrhythmia, elevated cTnI and/or segmental wall
motion abnormalities. However, Findings may only become apparent after the acute phase.
Disclosures
No disclosures to report.
ESVCN‐P‐1
Studies on estimation of ideal body weight by morphometry in dogs
A. Koizumi1, T. Hirose2, N. Tsuchiya2, K. Otsuji2
1Teikyo University of Science, Tokyo, Japan, 2Teikyo University of Science, Tokyo,
Japan
Accurate clinical nutritional assessment by body condition scoring in dogs is not
easy because of subjective method. Therefore, to make an objective nutritional assessment,
we examined a morphometric method. As a result, a high correlation coefficient (r
= 0.945) occurred between the length from the sternal process to the sciatic process
and the ideal body weight (IBW). In this studies, we present a caliper that can estimate
the IBW by measuring the length by applying this finding.
A caliper was prepared on which the length and the IBW appeared simultaneously. The
ideal body weight on the caliper was the weight corresponding to either a body fat
percentage of 20% or 25%. The length between the sternal process and the sciatic process
was measured by clinical veterinarians using caliper. Ten dogs that visited the animal
hospital were used. The veterinarians were asked to assess how the IBW determined
by the callipers differed from that of the IBW based on their experience.
The correlation coefficient between body length and IBW was r = 0.208, when the IBW
corresponded to a body fat percentage of 20%. On the other hand, the correlation coefficient
between the two was r = 0.333 when the IBW corresponded to a body fat percentage of
25%. Clinical veterinarians also replied in the questionnaire survey that a body weight
that corresponded to a body fat percentage of 25% was closer to the IBW assessed by
their experience. Body fat percentage at a BCS of 3 on a 5‐point scale corresponds
to 15 to 25%, with a median of 20%. It is suggested that Japanese clinical veterinarians
are evaluating their nutritional assessments by setting their IBW higher. It is found
that life span can be extended by dietary restriction in dogs. From this point of
view, Veterinarians should set IBM lower than their assessment results. Also, there
was a large difference in the correlation coefficient between our measured body length
and that measured by the clinical veterinarians. The difference was caused by the
large variation in body length measurements by veterinarians. In this regard, it may
be necessary to create a manual for body length measurement in dogs to improve measurement
accuracy.
Disclosures
No disclosures to report.
ESVE‐P‐1
Hypothyroidism and its association with extra hepatic biliary diseases in dogs: a
retrospective case‐control study
A.R. Codea, C. Popovici, A. Mure?An, D. Neagu, A. Biris, D.I. Marcutan, R. Lacatu?,
I. Cimpoie?, O. Sarpataki, I.M. Cismaru, M.V. Mircean
UASVM Faculty of Veterinary Medicine, Cluj‐Napoca, Romania
Hypothyroidism may have a major implication in delayed gallbladder emptying. Its role
in the pathogenesis of gallbladder mucocele and other extrahepatic biliary diseases
merits investigation.
The aim of this study is to evaluate the incidence of extrahepatic biliary diseases
in hypothyroid dogs.
Records of 63 dogs diagnosed with hypothyroidism have been examined for the presence
or absence of extrahepatic biliary disease (mucocele, colecistitis, colelitiasis and
gallblader masses).
Forty nine dogs (77.7%) had serum elevation of gamma glutamyl transferase, alkaline
phosphatase, alanine aminotransferase and total bilirubine, enlarged gallbladders,
finely striated or immobile stellate bile patterns, thickened gallbladder walls, biliary
sludge or hyperechogenic gallbladder masses. Older dogs and small breeds were overrepresented.
Most dogs presented non‐specific clinical signs such as vomiting, anorexia and lethargy,
diarrhea and/or fever. Thirty four dogs (53.9%) were diagnosed with extrahepatic biliary
disease: gallbladder mucocele (n = 21 dogs), cholelitiasis (n = 8 dogs) and colecystitis
(n = 5 dogs) upon ultrasound examination, histologic/macroscopic evaluation and culture
and sensitivity tests. The incidence of gallbladder mucocele was found to be the highest
(33,3%) followed by cholelitiasis (12.6%) and colecystitis (7.9%).
This study suggests that hyporthiroid dogs that are presented for acute illness with
laboratory evidence of hepatobiliary disease should undergo evaluation for the presence
of extrahepatic biliary diseases such as biliary mucocele, cholelitiasis and colecystitis.
Disclosures
No disclosures to report.
ESVE‐P‐2
Planar and SPECT imaging of canine thyroid tumors: 68 cases
M.F. van den Berg, S. Daminet, E. Vandermeulen, S. Scheemaeker, K. Peremans
Ghent University, Merelbeke, Belgium
Thyroid scintigraphy is indispensable for the diagnosis, staging and treatment planning
of thyroid carcinoma. However, literature on pertechnetate (99mTcO4) and iodine‐123
(123I) scintigram findings in dogs is scarce, and nearly absent on single‐photon emission
computed tomography (SPECT). Similar to human medicine, the use of SPECT could increase
the sensitivity in detection of metastases.
The aim of this retrospective study was to describe planar and SPECT imaging results
in canine thyroid tumors, and to compare it with thoracic radiography for detection
of thoracic metastases.
Thyroid scintigraphy was available from 68 dogs presented at our clinic between 2008
and 2018, of which 6 presented after surgical resection. All dogs had a confirmed
diagnosis of thyroid neoplasia based on histopathology, cytology, and/or abnormal
radionuclide accumulation.
Thirty‐nine dogs had unilateral tumors, 14 bilateral, and 10 ectopic tumors. One dog
had an ectopic and unilateral tumor, and 1 dog had bilateral masses and an ectopic
tumor. For 3 dogs, tumor extent hindered accurate localization.
Uptake relative to the parotid salivary glands (thyroid/salivary (T/S) ratio) was
increased in 35 of 62 dogs (median T/S ratio 3.2 (1.1‐12)), decreased in 15 dogs (median
T/S ratio 0.73 (0.36‐0.90)), and comparable to that of the salivary glands (median
T/S ratio 0.96 (0.85‐1.0)) in 8 dogs. In 4 dogs with multiple masses, uptake extent
was different at the level of the various masses. A homogeneous, uniform uptake pattern
was present in 10 dogs and a heterogeneous uptake pattern in 45 dogs. In 7 dogs (all
with multiple masses), various uptake patterns were present.
Thirty‐one dogs were euthyroid, 12 were hyperthyroid, and 9 were hypothyroid. The
majority of hyperthyroid dogs (10 of 12 dogs) had increased radionuclide uptake.
SPECT imaging was available in 41 dogs. In 16 dogs, SPECT revealed tracer uptake at
the level of the thorax, suggestive of distant metastases. In 13 of these dogs, thoracic
radiographs were performed, and metastases were detected in only 2 of 13 dogs.
In the majority of dogs, scintigraphy was performed using 99mTcO4. In 5 dogs, both
99mTcO4 and 123I scintigrams were performed. In 1 of these dogs, 123I SPECT imaging
revealed a thoracic metastasis that was not clearly identified with 99mTcO4.
This study is the first to describe planar and SPECT imaging in a large number of
dogs with thyroid tumors. Our results suggest that SPECT imaging is superior to thoracic
radiography for detection of metastases.
Disclosures
No disclosures to report.
ESVE‐P‐4
Ultrasonographic evaluation of adrenal gland thickness in healthy dogs and in dogs
with hyperadrenocorticism
L. Pérez‐López1, J.R. Jaber2, A. Ravelo3, Y. Santos4, C. Melián4
1University Institute of Biomedical and Health Research, Las Palmas de Gran Canaria,
Spain, 2Deparment of Morphology of University of Las Palmas de Gran Canaria, Spain,
3Institute for Technological Development and Innovation in Communications, University
of Las Palmas de Gran Canaria, Spain, 4Department of Animal Pathology, Veterinary
Faculty, University of Las Palmas de Gran Canaria, Spain
Ultrasonography is commonly used in the diagnostic workup of dogs with hyperadrenocorticism
(HAC) to support its diagnosis, to rule out non‐adrenal diseases and to help differentiate
the type of HAC. Some studies have established reference ranges for ultrasonographic
adrenal gland thickness based on weight categories. However, the use of those ranges
in dogs with HAC, have not been evaluated. Therefore, four weight categories were
used in order to avoid large variations of weight within each group. The aims of this
study were to establish new reference ranges for adrenal gland thickness in healthy
dogs, to evaluate the sensitivity of those ranges to detect adrenomegaly in dogs with
HAC and to describe ultrasonographic adrenal findings in dogs with HAC.
A total of 86 clinically healthy dogs were prospectively included. Adrenal thickness
in a sagittal plane were measured in dogs using the following weight categories: 21
dogs ≥2.5‐5 kg, 22 dogs >5‐10 kg, 22 dogs >10‐20 kg, and 21 dogs >20‐40 kg. Reference
ranges (5‐95th percentile) for left adrenal gland maximum thickness were as follows:
3.4‐4.8 mm (dogs ≥2.5‐5 kg), 3.4‐5.6 mm (dogs >5‐10 kg), 3.9‐6.2 mm (dogs >10‐20 kg),
and 5.2‐7.4 mm (dogs >20‐40 kg); whereas for right adrenal gland maximum thickness
were as follows: 3.2‐5.5 mm (dogs ≥2.5‐5 kg), 3.8‐6.0 mm (dogs >5‐10 kg), 4.2‐7.7 mm
(dogs >10‐20 kg), and 5.4‐9.4 mm (dogs >20‐40 kg).
In addition, other 85 dogs with HAC were retrospectively included. These dogs were
classified into the same weight categories used for healthy dogs: 23 dogs ≥2.5‐5 kg;
37 dogs >5‐10 kg; 17 dogs >10‐20 kg, and 8 dogs >20‐40 kg. The overall sensitivity
for detection of unilateral or bilateral adrenomegaly on ultrasound examination was
97% (82/85 dogs). Dogs with HAC were ultrasonographically classified as: 41 (48%)
dogs with symmetrical adrenomegaly (consistent with pituitary‐dependent HAC), 11 (13%)
dogs with unilateral adrenomegaly and atrophy of the contralateral adrenal gland or
unilateral or bilateral adrenomegaly with malignancy features on the ultrasound examination
(consistent with adrenal‐dependent HAC), 30 (35%) dogs with equivocal adrenal asymmetry,
and 3 (4%) dogs with normal adrenal gland thickness.
The overall sensitivity of ultrasonography to detect adrenomegaly using four weight
categories for left and right adrenal gland thickness was 97%. Although, most dogs
with HAC (61%) had ultrasonographic findings consistent with either pituitary‐ or
adrenal‐dependent HAC, equivocal adrenal asymmetry was a common finding in dogs with
HAC, occurring in 30 of 85 dogs (35%).
Disclosures
No disclosures to report.
ESVE‐P‐5
Ultrasonographic accuracy in primary adrenal insufficiency: a retrospective cohort
study of 182 dogs
G. Ledda, C. Tullio, A. Costa, L. Angeloni, M. Caldin
San Marco Veterinary Clinic, Veggiano (Padova), Italy
The clinical relevance of ultrasonography in canine primary adrenal insufficiency
has been evaluated in very few studies. This retrospective cohort‐study evaluated
in a large canine population referred to our facility, the diagnostic performance
of ultrasonographically assessed adrenal gland dimensions in distinguishing dogs with
primary adrenal insufficiency (Exposed or Group 1) from dogs without primary adrenal
insufficiency (Non ‐exposed or Group 2).
Group 1 included 91 consecutive client‐owned dogs diagnosed with primary adrenal insufficiency
on the base of signalment, history, clinicopathologic tests (CBCs, serum biochemistry,
urinalyses) and ACTH stimulation test results (including basal plasma ACTH and serum
aldosterone pre‐ and post‐ACTH determination). Group 2 included 91 dogs without primary
adrenal insufficiency, individually matched with Group 1 dogs for breed, sex, sexual
status and age (± 6 months). To reduce technological bias, Group 2 dogs selection
took place in contiguous time periods with each Group 1 dog recruitment. Dogs that
had received mitotane, trilostane or steroid medications and ace‐inhibitors before
our clinical evaluation, were excluded from both groups.
Ultrasonographic adrenal lengths (AL), caudal and cranial pole thicknesses (CdT and
CrT, respectively) were determined on longitudinal images in both Groups and compared.
Median (IQR) right and left CdTs in Group 1 were 0.30 (0.16) cm and 0.29 (0.10) cm,
respectively; in Group 2 were 0.50 (0.17) cm and 0.51 (0.16) cm, respectively (p value
<0.0001 for both comparisons). Median (IQR) right and left CrTs in Group 1 were 0.32
(0.18) cm and 0.28 (0.10) cm, respectively; in Group 2 were 0.53 (0.12) cm and 0.49
(0.16) cm, respectively (p value <0.0001 for both comparisons). Median right and left
ALs in Group 1 were 1.40 (0.55) cm and 1.42 (0.76) cm, respectively; in Group 2 were
1.92 (0.75) cm and 2.08 (0.66) cm, respectively (p value <0.0001 for both comparisons).
From the analysis of ROC curves, global diagnostic accuracy separating Group 1 from
Group 2 resulted 0.899 and 0.900 for the right and left CdT, respectively; 0.861 and
0.911 for the right and left CrT, respectively; 0.762 and 0.760 for the right and
left AL, respectively.
This study shows that Group 1 sonographic adrenal gland measures were significantly
lower compared to Group 2 and strengthens the role of adrenal ultrasonography as a
reliable screening test for dogs suspected of primary adrenal insufficiency.
Disclosures
No disclosures to report.
ESVE‐P‐6
Effect of sample dilution on free T4 depends on physiological state and analytical
method
P.A. Graham
University of Nottingham, Sutton Bonington, United Kingdom
The binding capacity of human sera for thyroxine is such that, in the absence of conditions
that would reduce thyroid binding capacity (TBC), e.g., non‐thyroidal illness (NTI),
pregnancy or free fatty acids, sera may be diluted more than 100‐fold without affecting
the measured result for Free T4 using an appropriate analytical technique such as
equilibrium dialysis. However, in conditions associated with reduced TBC, results
may decrease at dilutions as low as 1:10. Free T4 dilution profiles have been used
to determine the validity of free T4 methods for humans.
In dogs and cats, TBC is much lower and it is not clear what the equivalent dilution
would be that would cause a decrease in measured Free T4. The analytical impact of
physiological states including NTI have not been investigated. Analytical methods
which are less resistant to the effects of sample dilution may be more susceptible
to interference from lowered TBC (eg., NTI) and consequently may generate diagnostically
misleading results.
Surplus serum samples from dogs and cats in a selection of physiological states were
analysed by an equilibrium dialysis method (FT4 by equilibrium dialysis, Antech Laboratories
(FT4d)) and an analogue chemiluminescent method (Immulite 2000 Veterinary Free T4,
Siemens (VF4)) with and without dilution in HEPES buffer at 1:2, 1:10, 1:20, 1:40,
1:80. Samples included: normal cat (TT4 = 11.8 nmoL/L), hyperthyroid cat (TT4 = 104),
suspected canine NTI (TT4 = 12.8, normal TSH), suspected feline NTI (TT4 = 40, FT4d
= 112), feline lipaemia (TT4 = 52).
Percentage decreases could not be calculated for all samples because of the reporting
limits of the assays. However, in all samples, there was a decrease in FT4d between
20 and 32% at the 1:10 dilution which compared to decrease of 59 to 79% by VF4 at
the same dilution for samples in which percentage decrease could be calculated. The
steepest decline in concentration beyond 1:10 was in the suspected feline NTI sample
and the least decline in the normal cat.
Veterinary samples were more susceptible to the effects of sample dilution (and therefore
conditions of reduced TBC) than reported for human sera. The VF4 method was more susceptible
to dilution than the FT4d method. As in humans, some physiological states demonstrate
a greater decline in FT4 measurements in serial dilution. Further studies could determine
whether comparisons between undiluted and diluted FT4d results within an individual
sample, could differentiate NTI from thyroid dysfunction in diagnostically challenging
cases.
Disclosures
Disclosures to report.
NationWIde Laboratories (Consultancy) Dechra Veterinary Products (Consultancy).
ESVE‐P‐7
Survival in cats with diabetes mellitus and chronic pancreatitis: a preliminary study
of 36 cases
A.M. Canonne‐Guibert, E. Cristofini, V. Freiche
National Veterinary School of Alfort, Maisons‐Alfort, France
Previous studies suggest that pancreatitis could be a significant comorbidity in diabetic
cats, even in absence of digestive signs. Long‐term studies of diabetic cats with
pancreatitis are lacking and potential survival factors in such population are unknown.
The main objectives were 1/to review epidemiological, biological and ultrasonographic
findings in cats with concurrent chronic pancreatitis (CP) and diabetes mellitus (DM)
and 2/to document chronology of both diseases, survival time (ST) and potential prognostic
factors.
Thirty‐six cats diagnosed with CP and DM were retrospectively recruited at Veterinary
Teaching Hospital of National Veterinary School of Alfort between January 2008 and
June 2017. For all cats, signalment, medical history, physical findings, biochemistry
panel, complete blood count, standard urine analysis, and abdominal ultrasonography
(US) were available. ST was known for all cases. Potential prognostic factors including
elevation of hepatic enzymes, hyperbilirubinemia, hypokalemia, episode of ketoacidosis,
history of hospitalization and US features suggesting biliary tract disease were evaluated.
Association of each criteria and ST was tested with univariate analysis (Log rank
test); significance was set at P < 0.05.
Median age of study population was 12 years. Recruited cats were previously overweight
(71%) with weight loss (80%). The most frequent biochemical abnormalities included
elevation of liver enzymes (63%), hyperproteinemia (61%), hyperbilirubinemia (47%)
and hypokalemia (54%). Median survival time (MST) was 955 days. Mortality rate of
cats having at least one US finding compatible with biliary tract disease was significantly
higher and MST was also 2,57 times shorter (P = 0.05). The other studied criteria
were not associated with ST.
Long‐term outcome of cats suffering from CP and DM may be favorable. However, MST
of cats diagnosed with those concurrent diseases and having at least one ultrasonographic
finding compatible with a biliary tract disease is shorter than cats without any biliary
lesion on US.
Disclosures
No disclosures to report.
ESVE‐P‐8
Efficacy of once daily Protamine Zinc Recombinant Human Insulin (ProZinc®) in canine
diabetes mellitus
S.J.M. Niessen1, C. Kroh2, S. Maruyama2, K.A. Jerrentrup2, A. Keller2, R. Klee2, A.
Mori3, T. Sako3
1Royal Veterinary College, North Mymms, United Kingdom, 2Boehringer Ingelheim, Ingelheim,
Germany, 3School of Veterinary Nursing and Technology, Faculty of Veterinary Science,
Nippon, Japan
Quality of life research among diabetic dog owners emphasizes the negative impact
of diabetes mellitus (DM) treatment on owner lifestyle, even leading to euthanasia.
Once‐daily (SID) insulin injection regimens reduce such impact.
This prospective, baseline‐controlled, multi‐centre clinical field study evaluated
the efficacy of SID administered ProZinc insulin in dogs diagnosed with DM in line
with the ALIVE‐criteria. Seven follow‐up visits occurred over an 84‐day period. Between
days 28‐42, the veterinarian was permitted to switch to twice‐daily (BID) treatment
on the basis of clinical signs, maximum blood glucose (BG) or minimum BG obtained
from a 9‐hour BG‐curve. Satisfactory diabetic control was defined as an improvement
in ≥1 glycemic laboratory parameter and in ≥1 clinical sign.
Thirty dogs were enrolled; 5 withdrew early (n = 2 consent withdrawn, n = 2 compliance,
n = 1 lack of improvement). Overall, 76% (19/25) of dogs showed satisfactory diabetic
control at day 84; 77% (10/13) of SID treated dogs and 75% (9/12) of BID treated dogs.
In treatment‐naïve dogs, satisfactory control was achieved in 91% (10/11; 7 SID, 3
BID) and in insulin pre‐treated dogs in 64% (9/14; 3 SID, 6 BID). At study conclusion,
80% (20/25) showed improvement in ≥1 one clinical sign (PU/PD, body weight). Mean
BG decreased from 482 ± 125 to 295 ± 65 mg/dL, minimum BG from 437 ± 140 to 218 ± 84 mg/dL,
and fructosamine from 566 ± 119 to 394 ± 83 μmol/L. Clinical hypoglycemia was observed
once in two SID treated dogs, which recovered after feeding.
SID ProZinc was effective and safe in controlling DM in the majority of dogs, particularly
in naïve dogs.
Disclosures
Disclosures to report.
S.J.M. Niessen ‐ consultancy work for Dechra, Purina, Boehringer Ingelheim C. Kroh
‐ employee Boehringer Ingelheim S. Maruyama ‐ employee Boehringer Ingelheim K. Jerrentrup
‐ employee Boehringer Ingelheim A. Keller ‐ employee Boehringer Ingelheim R. Klee
‐ employee Boehringer Ingelheim A. Mori ‐ consultancy work Boehringer Ingelheim T.
Sako ‐ consultancy Boehringer Ingelheim.
ESVE‐P‐9
Brachycephalic morphotype and pituitary tumor size in dogs with Cushing's disease
M. Garcia1, V. Colas2, L. Desquilbet3, P. de Fornel4, F. Delisle4, G. Benchekroun2,
D. Rosenberg4
1Internal Medicine Unit, Micen Vet, Creteil, France, 2Department of Internal Medicine,
Ecole Nationale Vétérinaire d'Alfort, Maisons‐Alfort, France, 3Department of Biostatistics
/ Epidemiology, Ecole Nationale Vétérinaire d'Alfort, Maisons‐Alfort, France, 4Micen
Vet, Creteil, France
Cushing's disease (CD) is a common canine endocrinopathy, due to a deregulated secretion
of ACTH by a pituitary microadenoma or macroadenoma. A recent study focusing on histopathologic
findings in canine pituitary gland identified an overrepresentation of brachycephalic
dogs (BD) among macroadenomas, disregarding their secretory status.
We therefore hypothesised that pituitary tumor size and brachycephalic morphotype
were associated in dogs with CD.
Medical records of dogs with CD presented at the Internal Medicine Units of 2 referrals
hospitals were retrospectively evaluated. Inclusion criteria were: 1/ clinical signs
suggestive of hyperadrenocorticism; 2/ hyperadrenocorticism confirmation by at least
1 endocrine test; 3/ a brain and abdominal CT scan indicative of a pituitary origin.
Macroadenomas were diagnosed when the pituitary height/brain area ratio (P/B) was
≥0.40x10−2 mm−1. A skull index (SI: skull width/lengthx100) was calculated to differentiate
BD from non‐brachycephalic dogs (NBD).
The SI accuracy to distinguish between BD and NBD breeds was tested after calculation
of the area under the curve (AUC) of the Receiver Operator Characteristic (ROC) curve.
The optimal cut‐off was selected based on the value of the Youden's index. The correlation
between SI and P/B was evaluated using the Spearman's test.
Hundred and twenty dogs were included. The median [range] age at first clinical signs
was of 9 [5‐15] years. According to their breeds, 52 were BD, 61 were NBD, and 5 were
unclassified.
The AUC (95% confidence interval) of the ROC curve of SI for distinguishing BD from
NBD was 0.92 (0.85‐0.98). Using a cut‐off at 71.03, the sensibility and the specificity
of SI for morphotype distinction were 0.90 (0.77‐0.96) and 0.87 (0.70‐0.95) respectively.
The median [range] P/B were 0.3x10−2 mm−1 [0.2‐1.4x10−2 mm−1] and 0.4x10−2 mm−1[0.1‐1.7x10−2
mm−1] in BD and NBD respectively. No correlation could be established between SI and
P/B (ρ = 0.02, P = 0.80).
Brachycephalic morphotype quantitatively evaluated was not associated with pituitary
tumor size in dogs with CD. Our results are in contrast with a previous study focusing
on pituitary samples collected mainly by necropsy and embracing dog with and without
CD. The sole inclusion of dogs with CD in our study may explain this discrepancy.
A possible predisposition of BD to undifferentiated, rapidly growing non‐functioning
pituitary tumors remains to be assessed.
Disclosures
No disclosures to report.
ESVE‐P‐10
Critical illness‐related corticosteroid insufficiency (CIRCI) in dogs with systemic
inflammatory response syndrome (SIRS)
A. Pierini, M. Marchetti, G. Favilla, E. Gori, I. Lippi, G. Ceccherini, V. Marchetti
University of Pisa, San Piero a Grado, Pisa, Italy
Critical illness‐related corticosteroid insufficiency (CIRCI) is an inadequate corticosteroid
activity in relation to the patient's current degree of stress or illness. CIRCI occurs
in 30‐60% of critically‐ill human patients and up to 48% of dogs with sepsis.
This study investigated the frequency of CIRCI in systemic inflammatory response syndrome
(SIRS) dogs and associations between CIRCI and hypotension and mortality.
A single‐center prospective study was performed between December 2016 and May 2017
(ethical approval n°63 711/2016). SIRS was diagnosed if dogs presented at least two
of the following criteria at the admission in ICU: 1) rectal temperature > 39.0°C
or < 38.0°C; 2) heart rate > 120 bpm; 3) respiratory rate > 20 bpm; 4) white blood
cells <6 x 103/μL or > 16 x 103/μL or > 3% of band neutrophils. Dogs were excluded
if they have a history of or suspected adrenal illness or if they received glucocorticoids
within the previous 72 hours or long acting formulations within the previous month
or other drugs known to affect the hypothalamic‐pituitary‐adrenal axis.
ACTH stimulation test was performed in all dogs immediately after inclusion in the
study and dogs with a Δ cortisol (difference between post‐ACTH stimulation and basal
cortisol) ≤3 μg/dL supported diagnosis of CIRCI. Non‐invasive blood pressure (petMAP™graphic
II, Ramsey Medical) was measured in all dogs and hypotension was defined as a mean
arterial pressure (MAP) <60 mmHg. Information about survival at 28 days after admission
were collected. Dogs were divided into survivors and non‐survivors. Dogs that were
euthanized for financial reasons were excluded. D'Agostino‐Pearson's test tested data
for normality. Age, basal cortisol and MAP were compared between dogs with or without
CIRCI. Δ cortisol, basal cortisol and MAP were compared between survivors and non‐survivors
using t‐test. Association between CIRCI, hypotension and mortality were evaluated
with Fisher's exact test. For all analyses, a P‐value ≤0.05 was considered significant.
Twenty‐one dogs met the inclusion criteria and were enrolled in the study. CIRCI and
hypotension was detected in 10/21 (48%) and 7/21 (33%) dogs, respectively. Age, MAP,
basal cortisol and hypotension were similar between dogs with or without CIRCI. 14/21
dogs (67%) died within 28 days from admission. As independent factor, hypotension
and basal hypercortisolemia were associated with higher risk of death (P = 0.04 and
P = 0.0251, respectively).
CIRCI seems to occur frequently in SIRS dogs. However, only presence of hypotension
or basal hypercortisolemia was associated with increased mortality risk.
Disclosures
No disclosures to report.
ESVE‐P‐11
Prednisolone induced hyperglycaemia and diabetes mellitus in cats
S. Nerhagen, H. Moberg, B. Glanemann
The Royal Veterinary College, Hatfield, United Kingdom
Prednisolone is a commonly used drug in cats. Potential adverse effects include glucocorticoid‐induced
hyperglycaemia (GIH) and diabetes mellitus (GIDM) but predisposing factors for the
development and the overall incidence rate of GIH and GIDM are currently unknown.
The aims of this study were: (1) to evaluate the incidence rate of GIH and GIDM, and
(2) evaluate for predisposing risk factors of GIH and GIDM in cats receiving prednisolone.
The electronic records of a tertiary referral centre were searched for cats receiving
prednisolone at a dose of >1.9 mg/kg/day of >3 weeks duration, and that had follow‐up
data available of >6 weeks during a study period between January 2010 and June 2017.
In total 143 cats were included in the study. Of these cats, 14 cats (9.8%) were diagnosed
with GIH or GIDM. Nine cats (6.3%) developed GIDM, with 8 requiring insulin therapy
and 1 was euthanized due to diabetic ketoacidosis. The remaining 5 cats (3.4%) were
identified as GIH with none requiring insulin treatment. Twelve out of 14 cats (85.7%)
developed GIH or GIDM within 3 months after the initiation of prednisolone therapy,
the remaining two cats developed GIDM after 27 and 32 months. Four of the cats developing
GIDM/GIH were < 2 years of age. Comparison between cats developing GIH or GIDM to
those that did not, showed no statistical difference in the baseline (pre‐prednisolone)
blood glucose, presence of glucosuria, body weight and body condition score. A trend
towards cats developing GIDM/GIH if receiving >3.0 mg/kg starting dose (OR 2.7) was
seen, however this was not statistically significant (P 0.097).
We conclude that in a tertiary referral population, approximately 10% of cats receiving
prednisolone develop GIH or GIDM. There was atrend towards cats receiving higher doses
of prednisolone being more likely to develop GIH/GIDM.
Disclosures
No disclosures to report.
ESVE‐P‐12
Accuracy and precision of insulin administration using human and veterinary pen‐injectors
and syringes
E. Malerba, F. Fracassi, F. del Baldo, S. Golinelli, M. Ceccherini, A. Barbarossa
University of Bologna, Ozzano dell'Emilia, Italy
Many diabetic dogs and cats require small doses of insulin, which may be administered
with syringes or pen‐injector devices. It is important that these small doses are
administered accurately and that the magnitude of potential dosage error is appreciated.
The aim of this study was to compare the accuracy and precision of insulin syringes
and pen devices.
To determine how accurately and precisely insulin doses are delivered, 0.5, 1, 2,
4, 8 and 16 U doses were dispensed 25 times from five SoloSTAR® containing insulin
glargine, five FlexPen® containing insulin detemir, five KwikPen® containing insulin
lispro, five JuniorSTAR® containing insulin glargine, five VetPen® 0.5‐8 U and five
VetPen® 1‐16 U containing insulin Caninsulin®, and by five veterinarians using 30 U/0.3 mL
and 40 U/mL insulin syringes. Each dose was weighed immediately using a precision
balance (resolution of 0.00001 g), and the intended and delivered doses were compared.
All pen‐injectors tended to deliver less insulin than the intended dose, underdosage
being inversely proportional to dose (accuracy from −6.86% to −0.84%). The differences
between intended and delivered dose were not significant only using JuniorSTAR and
VetPen 0.5‐8 U at insulin dosage of 0.5, 1, 2 and 4 U. Using 30 U/0.3 mL insulin syringes
the intended dose was significantly overdosed when attempting to deliver 0.5, 1 and
2 U (+26.51%, +10.32% and + 3.26%, respectively), and significantly underdosed at
8 and 16 U (−3.44% and − 4.46%, respectively). Using 40 U/mL syringes the intended
dose was significantly overdosed when attempting to deliver 0.5, 1 and 2 U (+30.77%,
+5.63% and + 2.84%, respectively). With all six pen‐injectors and with both 30 U/0.3 mL
and 40 U/mL insulin syringes, the coefficient of variation (precision) diminished
with increasing doses of insulin. Precision was <8% for all six pen‐injectors (from
7.67% to 0.69%). Conversely, precision using 30 U/0.3 mL and 40 U/mL syringes at insulin
dosage of 0.5 U was 12.08% and 9.39%, respectively; precision improves at insulin
dosages ≥1 U (from 5.80% to 0.46%).
All devices, with the exception of JuniorSTAR and VetPen 0.5‐8 U, are unacceptably
inaccurate when delivering 0.5, 1, and 2 U doses of insulin. The accuracy improves
when higher doses are dispensed, but the delivery of 8 and 16 U doses resulted sufficiently
accurate compared to intended doses only using 40 U/mL syringes. In conclusion, if
pen‐injectors tend to be more accurate at lower dosages, syringes tend to be more
accurate at higher dosages.
Disclosures
Disclosures to report.
Federico Fracassi Financial support: Dechra, MSD. Speaking & consultancies: Boehringer
Ingelheim, Dechra, MSD, Royal Canin, Hill's, Nestlé Purina, La Vallonea. Stefania
Golinelli Consultancies: Dechra.
ESVE‐P‐13
Fractional excretion of electrolytes in dogs with primary hypoadrenocorticism before
and after treatment
G. Carotenuto, A. Maugeri, F. Dondi, E. Malerba, C. Grisetti, F. Fracassi
University of Bologna, Ozzano dell'Emilia, Italy
Electrolytic abnormalities in dogs with primary hypoadrenocorticism (PH) have been
widely described, while fractional excretion (FE) of urinary electrolytes (FEe) has
not yet been evaluated. Furthermore, mineralocorticoid supplementation's monitoring
is based on blood sodium([Na]) and potassium ([K]) concentrations, and it is possible
that FEe could add useful information regarding the monitoring of the treatment.
The aim of this study were to evaluate FEe in dogs with PH. Study‐population was grouped
as follow: 1) dogs with acute adrenal insufficiency (AAI), dogs treated for PH (TD)
[both with fludrocortisone and desoxycorticosterone pivalate (DOCP)] 2) dogs with
PH treated with DOCP classified as well controlled ([Na] and [K] in the RI), under‐controlled
(hyponatremia and/or hyperkalemia) and over‐controlled (hypernatremia and/or hypokalemia),
respectively 3) dogs well controlled classified based on drug administration's timing:
9‐15, 23‐27 and 28‐33 days after DOCP injection, respectively.
Only dogs with “typical” PH (hyponatremia and/or hyperkalemia) at the time of diagnosis
were included. Healthy dogs (HD) were used as controls. Serum and urine chemistry
were performed on combined samples using an automated analyser, and FEe was calculated.
Nonparametric tests were used to compare FEe among groups. Data are expressed as median
and (range). P < 0.05 was considered significant.
Seven dogs with AAI, 18 TD and 115 HD were enrolled; 76 follow‐up from TD (13 DOCP,
5 fludrocortisone) dogs were evaluated.
FE of sodium (FENa), cloride (FECl) and calcium (FECa) were elevated in AAI [FENa%
2.64(1.48‐7.77); FECl% 3.76(1.87‐8.15); FECa% 1.68(0.68‐8.11)]; they were significantly
lower in TD [FENa% 0.41(0.04‐1.91); FECl% 0.73(0.07‐21.85); FECa% 0.35(0.07‐1.82)],
but still significantly higher compared to HD [FENa% 0.25(0.01‐1.55); FECl% 0.54(0.05‐2.28);
FECa% 0.14(0.03‐0.66)]. AAI and TD had a significantly higher FE of K (FEK%) [18.53(8.34‐62.74);
16.01(4.33‐44.19)] compared to HD [10.54(2.23‐45.20)].
FENa and FEK were not significantly different among the 3 groups; nevertheless, despite
not significant, over‐controlled dogs had lower FENa and higher FEK if compared to
controlled dogs [FENa% 0.43(0.04‐0.95) vs 0.40(0.04‐1.91); FEK% 16.14(4.33‐42.95)
vs 17.10(5.76‐44.19)]. FECa was significantly lower in under‐controlled compared to
well controlled and over‐controlled dogs [FECa% 0.11(0.07‐0.14); 0.33(0.07‐1.60);
0.55(0.17‐1.82)].
FENa, FECl and FEK did not differ significantly among 3 groups; nonetheless, despite
not significant, all showed an increasing trend over time. Although not significant,
FECa was lower at 23‐27 days after DOCP.
Dogs with AAI have high FENa, FECl, FECa and they decrease after treatment. Further
studies are necessary to clarify the clinical utility of the FEe in dogs treated for
PH.
Disclosures
Disclosures to report.
Federico Fracassi Financial support: Dechra, MSD Speaking & consultancies: Boehringer
Ingelheim, Dechra, MSD, Royal Canin, Hill's, Nestlé Purina, La Vallonea. Francesco
Dondi Financial support: Zoetis Speaking & consultancies: Boehringer Ingelheim, La
Vallonea.
ESVE‐P‐14
Effects of bodyweight, age and pituitary hyperadrenocorticism on the adrenal gland
size of dogs, measured by ultrasonography
G. Kiss, C.S. Hetyey, F.V. Héthársi
University of Veterinary Medicine, Budapest, Hungary
Ultrasonography is a sensitive method to measure adrenal gland size. The most reliable
indicator of adrenal gland size is the maximum diameter of the caudal pole (thickness).
However pituitary hyperadrenocorticism has an increased prevalence in small‐breed
dogs, there are only few informations in the scientific literature about the correlation
between the bodyweight, age and size of adrenal glands in dogs (general upper limit
is 7,4 mm). Recently one retrospective study suggested 6 mm cut‐off value for dogs
below 10 kg and another found an age dependency of the size.
We aimed to examine adrenal gland's thickness of dogs in a retrospective study. Results
of 67 dogs (healthy and diagnosed with pituitary hyperadrenocorticism) were used.
Diagnosis of pituitary hyperadrenocorticism was based on clinical symptoms and dexamethason
supression test. Bodyweight ranged from 3,0 to 42,0 kg (12,7+/−9,6), while age ranged
from 1,2 to 14,4 years (7,9+/−3,6). The correlation of bodyweight, age and adrenal
gland thickness were analysed in healthy dogs (n = 31). The subgroup below 10 kg (n
= 17) was compared to dogs diagnosed with pituitary hyperadrenocorticism below 10 kg
(n = 17). To data analysis descriptive statistics, correlation‐ and regression‐analysis,
hypothesis‐tests and ROC‐analysis were used (P < 0,05).
There was a significant correlation between adrenal gland size and bodyweight in the
entire range of 3‐42 kg and no significant correlation in the subgroup of dogs below
10 kg. There was no age dependency. We found significant difference between adrenal
gland sizes of dogs below 10 kg and those of weighting more. Adrenal gland sizes were
normally distributed. In the group of dogs weighting less than 10 kg the thickness
of the left adrenal gland's caudal pole was 4,5+/−0,7 mm, while the right adrenal
gland's size was 4,7+/−0,8 mm. Normal range for the left adrenal gland's size was
3,0‐6,0 mm and 3,1‐6,1 mm for the right one (95% CI). Comparing data of healthy dogs
and dogs with pituitary hyperadrenocorticism resulted 5,5 mm to be the optimal upper
cut‐off value for dogs below 10 kg. This value provided 82% sensitivity and 94% specificity
for the left adrenal gland and 76% sensitivity and 88% specificity for the right one
to diagnose pituitary hyperadrenocorticism using ultrasonography.
Different results between the left and right sides are caused by the more difficult
imaging of the right sided organ. Our results strenghten the findings of the available
few literature regarding the size‐range and bodyweight correlation, but we could not
find any age dependency.
Disclosures
No disclosures to report.
ESVIM‐P‐2
Retrospective study of 23 cases of canine nasal polyposis, of which 10 were treated
endoscopically
E. Bottero, P. Ruggiero, F. Raponi, E. Mussi
Gruppo Endovet Italia, Ceva, Italy
Nasal polyposis is a pathology of unknown etiology, rarely described in canine species,
that can provoke chronic clinical symptoms including discharge, sneezing and stertor.
The diagnosis is based on diagnostic imaging, endoscopic aspect and histologic exam
of the nasal biopsy. Rhinotomy, despite possible surgical complications and the possibility
of relapse, is to date the first choice in treatment1,2.
In our retrospective study we looked at 23 cases of nasal polyps over 8 years. The
dogs were principally mixed breeds; males (60%) and females (40%); and adult or elderly,
but 39% of the patients were less than 8 years old. They presented with sneezing,
stertor and nasal discharge. The clinical exam showed 6 cases of frontonasal deformation
with a clear presence of newly formed polypoid tissue in the nostrils and in the opening
of the nasolacrimal ducts. X‐rays and computerized tomography reveal abnormalities
compatible with newly formed endonasal tissue in 84.6% and 100% of the cases, respectively.
Anterograde rhinoscopy reveals newly formed tissue with a smooth translucent surface,
pink in color, and with an elastic consistency, completely occupying the nasal meatus
and in 12 dogs the nasopharynx as well. The histological exam shows an exophytic structure
bounded by the respiratory epithelium that are often hyperplastic or with squamous
metaplasia. The stroma is, as a rule, myxoid, fibrillary and surrounds serous or mucus
glands, which are present in highly variable quantities. In the corium the inflammatory
infiltrate is polymorphous. The stroma can show areas of hyperplasia of the mesenchyme
and/or hyperplasia and dilation of the vascular system. Serious dysplasia was not
observed in any of the cases.
Twelve of the subjects underwent only medical treatment, 10 underwent medical treatment
and endoscopic debulking with mixed techniques (external grasping forceps plus diode
laser 5 W, continuous rhythm, 600 μm fiber), and 1 patient underwent surgical rhinotomy.
In all the dogs treated only with Prednisolone, despite the clinical improvement,
there were constant relapses. All of the subjects that underwent endoscopic debulking
showed clinical improvement of the symptoms and absence of relapse, for 6 months in
77.8% of the cases and for 24 months in 44.5% of the cases. In conclusion, nasal polyposis
is an infrequent pathology that can present serious clinical symptoms, even in young
subjects, and that tends to relapse. Therapy with endoscopic debulking is a less invasive
alternative than traditional surgery, even though it does not prevent relapse in the
medium and long term.
Disclosures
No disclosures to report.
ESVIM‐P‐3
Diagnostic utility of reticulocyte haemoglobin content (RETIC‐HGB) to detect iron‐limited
erythropoiesis in cats
M. Keiner, N. Bauer, A. Moritz
Justus‐Liebig‐University Gieβen, Gieβen, Germany
Reticulocyte haemoglobin content (CHr) (Siemens ADVIA 2120) is a diagnostic marker
of iron deficiency in humans and dogs. RETIC‐HGB (IDEXX ProCyte Dx) is a new parameter
for analysis of iron deficiency for veterinary use. Aim of this prospective study
was to evaluate the clinical and diagnostic utility of RETIC‐HGB compared to CHr in
the diagnosis of feline iron‐limited erythropoiesis (ILE).
First, reference intervals (RIs) for RETIC‐HGB and CHr were established analysing
59 healthy non‐anaemic cats. Second, 275 cats were classified as having ILE or not.
Low plasma iron or low transferrin saturation (%TfS) in combination with either anaemia
and/or altered red blood cell (RBC) indices was required for diagnosis of ILE. Haematologic
variables, parameters of iron metabolism as well as serum amyloid A were compared
between both groups and correlation between RETIC‐HGB and CHr was assessed.
RIs for RETIC‐HGB and CHr were 12.5‐18.0 pg and 14.0‐19.9 pg, respectively. In respect
of iron and haematologic variables, 20/275 cats (7.3%) were classified as ILE cats.
Compared to non‐ILE cats, ILE cats had significantly lower median values of RETIC‐HGB
and CHr. Not unexpectedly, HCT, HGB, MCH, and RBC were significantly decreased in
ILE cats. Additionally, ILE cats had significantly increased median SAA values. Correlation
between RETIC‐HGB and CHr was moderate (rs = 0.59) with a small bias of −1.2 pg.
CHr and RETIC‐HGB may be suitable early indicators of ILE, especially when used in
addition to parameters of iron metabolism. The moderate correlation between RETIC‐HGB
and CHr is likely due to species and different methodology.
Disclosures
Disclosures to report.
Miriam Keiner: none N. Bauer: Bayer Animal Health GmbH, DFG, Eickemeyer, GKF, IDEXX
laboratories Inc, Norma, Fuji, SCIL Animal Care, Ushio Inc A. Moritz: Bayer Animal
Health GmbH, DGK‐DVG, DVG, Eickemeyer, IDEXX laboratories Inc, MSD Animal Health,
Norma, SCIL Animal Care, Synlab, Ushio Inc.
ESVIM‐P‐4
A comparison of the diagnostic utility of the classic model, the value of the Anion
Gap (AG), corrected Anion Gap (AGcorr) and the chloride/sodium ratio in the diagnosis
of acid‐base basalnce disturbances in cats with chronic kidney disease (CKD)
P. Slawuta, A. Sikorska‐Kopylowicz, A. Kurosad, G. Sapikowski
University of Environmental and Life Sciences, Wroclaw, Poland
In addition to hypophosphatemia, metabolic acidosis is the most common complication
of chronic kidney disease in cats. Using the standard approach, metabolic acidosis
is diagnosed based on the concentration of HCO3
− and pCO2 in arterial blood.
The aim of the study was to assess the possibility of using the value of the anion
gap (AG), corrected anion gap (AGcorr) and the chloride/sodium ratio (Cl−/Na+) in
the diagnosis of metabolic acidosis. The study was carried out on 100 cats (both sexes,
7‐9 years old). The control (C) group consisted of 20 healthy cats, while 80 cats
that were diagnosed with CKD based on their blood creatinin, SDMA and urea levels
were included in the study group. The cats with CKD were divided into four groups:
I, II, III and IV, depending on the IRIS stage. Arterial and venous blood was collected
from all the animals. Parameters of the acid‐base balance (ABB): pH, pCO2 and HCO3
− were measured in arterial blood. The concentration of Na+, K+, Cl−, HCO3
−, albumin were measured in venous blood. Based on the obtained results, the values
of the AG, AGcorr and Cl−/Na+ were calculated using the following formulae: AG = (Na+
+ K+) ‐ (Cl− ‐ HCO3
−), AGcorr = AG + (39 g/L ‐ albakt g/l)/4, where 39 g/L was the upper reference limit
of serum albumin in cats, albakt was the measured albumin concentration in the studied
cats and Cl−/Na+ = (Cl−): (Na+).
The analysis of the arterial blood revealed the presence of metabolic acidosis in
cats from group IV. In the remaining groups, the ABB parameters were within the reference
range. The values of AG and AGcorr, in cats from group II, III and IV were significantly
lower than those in group C, while the Cl−/Na+ value in cats from group II, III and
IV was significantly higher than in cats from group C.
The following conclusions were drawn based on the obtained results: 1) the ABB analysis
based on the classic model enables detection of ABB disturbances in cats with stage
IV kidney disease, 2) the analysis of the AG, AGcorr,and Cl/Na+ values enable the
diagnosis of ABB disturbances in cats with stage II, III and IV kidney disease, 3)
The analysis of the changes in the ion concentrations in CKD are a more accurate tool
to diagnose ABB disturbances than the classic model.
Disclosures
No disclosures to report.
ESVIM‐P‐5
Evaluation of different cleaning methods for bacterial decontamination of feline aerosol
chambers
B. Schulz1, F. Schroer1, V. Desimoi1, G. Wolf2
1Clinic of Small Animal Medicine, Muenchen, Germany, 2Institute for Infectious Diseases
and Zoonoses,Department for Veterinary Science, Muenchen, Germany
For aerosol therapy of cats with chronic respiratory conditions commonly aerosol chambers
specifically designed for use in cats are utilized. Depending on the type of chamber,
certain cleaning procedures are recommended by the different manufacturers to prevent
bacterial contamination. Aim of the study was to investigate, if chambers can be adequately
decontaminated using different recommended cleaning or sterilizing procedures after
standardized bacterial contamination.
For that purpose the chambers “RC Chamber” (RC) (Cegla Medizintechnik) (n = 10) and
“AeroKat” (AK) (Trudell Medical International) (n = 5) were evaluated. Standardized
bacterial contamination was performed using a Pseudomonas‐aeruginosa‐suspension that
was previously established by serial dilution. Aliquots of 50 mL were applied with
a pipette on three pre‐defined locations of the chamber. After 24 hours chambers were
cleaned/sterilized according to manufacturers` instructions. For RC this included
a cleaning procedure using a special bag in the microwave for 3 minutes at 800 watt
(n = 5) or placement in boiling water for 5 minutes (n = 5). AK was placed in lukewarm
water with cleaning detergent for 15 minutes (n = 5). After air drying of all chambers
swabs were taken from three defined areas of each chamber (mask, valve, chamber),
applied on Mueller‐Hinton‐agar, and incubated for 24 hours.
With all three cleaning protocols no bacterial growth could be detected in any of
the 15 chambers tested. The study shows that with manufacturer recommended cleaning
procedures adequate bacterial decontamination of feline inhalation chambers can be
achieved.
Disclosures
No disclosures to report.
ESVIM‐P‐6
Evaluation of clinico‐pathological alterations including some leukocyte ratios and
survival rate in dogs with IMHA transfused and not transfused: a retrospective study
G. Lubas1, A.A. Medina Valentin1, A. Gavazza2, A. Aramonte1, P. Simcic1, V. Marchetti1,
G. de Feo1
1University of Pisa, San Piero a Grado, Pisa, Italy, 2University of Camerino, Camerino,
Italy
Immune‐Mediated Hemolytic Anaemia (IMHA) is a common hematological disorder in dogs.
It can be primary or secondary and it is characterized by anti‐RBC antibodies production.
IMHA requires a detailed diagnostic pathway as well as a complex therapeutic approach
that can include blood transfusion. Unfortunately, IMHA presents a high mortality
rate, especially within 15 days after onset.
This retrospective study evaluated: a) the clinical and clinico‐pathological alterations
that influenced the choice to perform a blood transfusion in an IMHA patient; b) if
blood transfusion could be an additional therapeutic approach; c) application of leukocyte
ratios in the prognosis.
Sixty‐seven cases of IMHA, both primary and secondary, admitted to the Veterinary
Teaching Hospital between May 2010 and July 2018, were included. Signalment, history,
clinical signs, clinico‐pathological parameters and survival rate were collected.
Patients were divided in two groups: 44 patients (IMHAnt) treated with immunosuppressive
therapy alone (primary n = 36, secondary n = 8) and 23 patients (IMHAt), which received
also a blood transfusion (primarily packed RBC) (primary n = 16, secondary n = 6).
For all collected parameters, both groups were statistically compared.
The IMHAt patients compared to IMHAnt patients (un‐regarding to primary or secondary
cause) presented: worse marks according to Tokyo Score System (TSS) (Chi Squared,
P = 0.003); a lower erythrocyte count (T‐test, P = 0.039), hemoglobin concentration
(T‐test, P = 0.029) and platelet count (Mann‐Withney, M‐W, P = 0.008); a higher value
of band neutrophils (M‐W, P = 0.022), band neutrophil to lymphocyte ratio (M‐W, P
= 0.005), (band neutrophil/neutrophil) to lymphocyte ratio (M‐W, P = 0.006) and a
lower value of lymphocyte to monocyte ratio (M‐W, P = 0.013); a higher value of C‐reactive
protein (M‐W, P = 0.011) and activated partial thromboplastin time (M‐W, P = 0.014);
and a lower survival rate at day 120 (Kaplan‐Meyer, logrank, P = 0.004) and not at
7, 15 and 30 days. Blood transfusions were performed based on the severity of clinical
and clinico‐pathological signs.
IMHAt patients showed a more severe disease (according to TSS), a greater acute inflammatory
condition and more coagulative defects. The high death rate among IMHAt patients at
120 days was related to their critical condition, which is probably why the desired
benefit of blood transfusion wasn't reached. However, a link between blood transfusions
and the related worse clinical signs in IMHAt patients could not be ruled‐out. Finally,
the leukocyte ratios in dogs affected by IMHA were assessed for the first time so
far and they were proven to be useful markers of acute inflammation and could have
a prognostic value.
Disclosures
No disclosures to report.
ESVIM‐P‐7
Expression of serum exosomal miRNA 122 in dogs naturally infected by Leishmania infantum
A. di Loria1, V. Dattilo2, D. Santoro3, J. Guccione1, A. de Luca1, P. Ciaramella1,
C. Riillo4, M. Pirozzi5, E. Iaccino4
1University Federico II of Napoli, Napoli, Italy, 2University Magna Graecia Department
of Health Sciences, Italy, 3University of Florida, Department of of Small Animal Clinical
Sciences, United States of America, 4University of Magna Graecia, Departement Experimental
and Clinical Medicine, Italy, 5Institute of Protein Biochemistry, National Research
Council, Napoli, Italy
Leishmaniasis a zoonosis caused by Leishmania spp., is a chronic and often fatal disease
for humans and dogs if left untreated. In recent years, microRNAs (miRNAs), a group
of small, single‐stranded non‐coding RNAs able to regulate gene expression have been
shown to play a critical role in the development and function of immune responses.
While in circulation, free‐serum miRNAs are highly degradable, when transported in
mycelial vesicles (exosomes) they become stable (protected from RNAse degradation)
and reliable diagnostic biomarker in diseased patients. In 2013, using murine animal
the role played by exosomes and miRNAs was explored during Leishmania infection; a
reduction in the activity of miR‐122, the most abundant miRNA present in the liver
tissue, was obtained. Very little is known about the role of exosomal miRNA in canine
leishmaniasis (CL); in particular, the interaction between exosomal miR‐122 and lipid
alterations. The aim of this study was 3fold: 1) isolate/characterize exosomes in
canine serum obtained from 6 healthy dogs; 2) evaluate their quality/quantity of exosomal
miRNAs and proteins; 3) evaluate the expression of serum exosomal miR‐122 in 10 healthy
dogs and 10 leishmaniotic dogs.
Blood samples were collected for routine hematological/biochemical analyses on healthy
dogs or before anti‐Leishmania therapy. Biochemical panel was completed with a serum
cholesterol profile (HDL, LDL). Serum exosomes were isolated using a polymer‐based
kit and characterized by flow cytometry and electron microscopy. miR‐122‐5p expression
was analyzed via quantitative RT‐PCR. Differences between the two groups were statistical
analyzed. A P value of <0.05 was considered significant.
This is the first study showing the detection of circulating serum exosomes content
of miR122 in in dogs affected by CL. Serum exosomes of 30‐130 nm in diameter containing
miR‐122 and RNU6‐2 miRNAs were isolated. A concentration of 12 ng/μL of miRNAs and
10 μg/μL of proteins were recovered. Albumin and HDL were decreased whereas total
proteins and LDL were significantly increased in affected compared to healthy dogs.
As shown in an experimental study performed in mice, a significant decreased expression
of miR‐122‐5p was seen in leishmania infected dogs compared with healthy ones.
This study suggests that alterations of circulating lipoproteins associated with a
low expression of exosomal miR‐122 indicate a liver dysfunction in dogs naturally
affected by Leishmania infantum.
Disclosures
No disclosures to report.
ESVIM‐P‐8
Anemia and hypoferremia in cats with hepato‐pancreatic and intestinal involvement
F. Tulone, E. Gori, A. Pierini, I. Lippi, G. Lubas, V. Marchetti
University of Pisa, Pisa, Italy
In veterinary medicine, although red blood cells (RBC) and iron serum levels seem
to be influenced by inflammation, specific investigations regarding red blood cell
parameters and iron serum levels in enteropathic cats are lacking.
The aim of this study was to investigate which type of anemia and how are the serum
iron levels in cats with hepato‐pancreatic and intestinal involvement.
A retrospective review was conducted on ten‐year medical records of cats presented
to the University Veterinary Teaching Hospital, looking for ultrasonographic signs
of concurrent inflammation of at least two organs among liver, pancreas and intestine.
Cats were included if information about clinical signs and laboratory tests (CBC and
serum iron level) were available.
Sixty‐three cats met the inclusion criteria and were enrolled in the study. Patients
were divided into two groups according to ultrasonographic signs: cats with concurrent
involvement of pancreas, liver and intestine (Group A, n = 19) and cats with concurrent
involvement of only two organs between pancreas, liver and intestine (Group B, n =
44). Differences between groups were statistically investigated by Mann‐Whitney test
for iron, and Unpaired t‐test for anemia parameters. Categorical data were analyzed
with Fisher's exact test.
Twenty‐nine cats (46%) showed anemia which was more frequently mild (Hct < 26%; 62.1%)
or moderate (13% < Hct < 19%; 31%), normocytic‐normochromic (72.4%), and non‐regenerative
(86.2%). Microcytosis was an infrequent finding (6.3%), and only two cats had microcytosis,
anemia and hypoferremia concurrently. Hypoferremia (serum iron <90 mcg/dL) was present
in 34 cats and concurrent anemia was observed in 15 cats (without any association
between these two parameters). Both hypoferremia and anemia were more severe in group
A (median serum iron 60 mcg/dL; mean RBC 6.06 M/μL; P = 0.0321) than group B (median
serum iron 90.5 mcg/dL; mean RBC 7.00 M/μL). Moreover, anemia was more frequently
present in group A (63%; P = 0.0321). A ROC curve was used to determine the optimal
cut‐off of serum iron to identify cats with hepato‐pancreatic and intestinal involvement.
Cats with serum iron lower than 61.5 mcg/dL were more frequently belonging to group
A (sensitivity 82.2%; specificity 52.6%; P = 0.0048).
The most plausible hypothesis for the origin of anemia was the presence of a chronic
disease. Decreased serum iron levels may be considered as a marker of inflammation
in enteropathic cats. Hepato‐pancreatic and intestinal inflammation may cause more
severe hypoferremia, erythropoiesis suppression, and anemia.
Disclosures
No disclosures to report.
ESVIM‐P‐10
Lung ultrasound findings in dogs using a regionally based protocol (Vet BLUE) versus
entire thorax scanning
M.C. Lam, P.Y. Lo, H.D. Wu, C.H. Lin
National Taiwan University, Taipei City, Taiwan
Lung ultrasound (LUS) can be used to detect comet‐tail artifacts (B lines) in animals
with trauma, pulmonary edema or alveolar‐interstitial syndrome. The scanning protocols
used in previous studies include four anatomic sites on each hemithorax (Vet BLUE)
and scanning for all intercostal spaces. The regionally based protocol has the advantage
of quickly assessing critically ill patients in respiratory distress; however, it
is unclear how the results from Vet BLUE protocol correlate with the findings from
entire thorax scanning (ETS). The present study aimed to compare the frequency and
numbers of B lines, as well as other parenchymal abnormalities, between the Vet BLUE
and ETS protocols. We hypothesized that B lines would be more frequently detected
by ETS but not significantly affect the final conclusion.
Thirty‐four dogs with various clinical problems (16 with cardiac disease, 12 with
cardiorespiratory comorbidities, 5 with respiratory disease, and 1 with non‐cardiorespiratory
problem) were recruited in this prospective study. Dogs that were uncooperative or
too critically ill to tolerate the two scanning protocols were excluded. All scans
were performed by a single clinician who had completed an LUS training session. The
thorax of each dog was first scanned by the Vet BLUE protocol and then by ETS without
hair clipping.
Compared with the Vet BLUE protocol, B lines were significantly more frequent in ETS
(26.5% vs. 50.0%, P = 0.004). Assessment of the severity of B lines (absent, rare,
numerous, or confluent) showed more severity in ETS than that of B lines by the Vet
BLUE protocol (P < 0.001). Nevertheless, when a final conclusion was drawn based on
≥2 positive sites (>3 B lines) per hemithorax as used in the previous studies, the
final conclusions of the two protocols were not significantly different (P = 0.25),
and agreement between the two protocols was substantial (kappa = 0.72). The detection
of other parenchymal lesions by the two protocols was not significantly different
(P = 0.5).
In conclusion, these results suggest that LUS findings from the Vet BLUE protocol
substantially agree with those from ETS. However, it should be brought in mind that
the most severe lesions on LUS may be underestimated using a regionally based protocol.
Disclosures
Disclosures to report.
This study was supported by Ministry of Science and Technology, Taiwan (MOST 107‐2311‐B‐002‐011
‐).
ESVIM‐P‐11
Comparison of plasma metabolomic profiles of healthy adult cats with low or high plasma
homocysteine concentration
A. Drut1, J.M. Chao de la Barca2, P. Nguyen1, G. Simard2, Y. Mallem1
1Oniris ‐ Nantes Atlantic National College of Veterinary Medicine, Nantes, France,
2University Hospital of Angers, Angers, France
Several prospective observational studies providing data on plasma homocysteine concentration
in healthy cats revealed a larger‐than‐expected inter‐individual variability. Investigations
conducted on healthy laboratory cats suggested impaired homocysteine metabolism in
some individuals, using a methionine loading test. The aim of our study was to determine
differences in the metabolomic profile of healthy cats exhibiting low or high plasma
homocysteine concentration, respectively.
We used left‐over frozen plasma samples from client‐owned healthy adult cats previously
enrolled in a prospective observational study that aimed at determining a reference
interval for plasma homocysteine concentration in the feline species. We extracted
10 individuals with high plasma homocysteine concentration, and we selected 10 epidemiologically‐matched
individuals with low plasma homocysteine concentration. Plasma samples were subjected
to a targeted metabolomics analysis using an AbsoluteIDQ p180 kit (Biocrates Life
Sciences AG), assessing six biochemical classes: acylcarnitines, amino acids, biogenic
amines, glycerophospholipids, sphingolipids and hexoses.
The orthogonal partial least‐squares discriminant analysis identified a model discriminating
plasma samples from the two populations of healthy cats (R2X = 0.665, R2Y = 0.959,
Q2 = 0.715). The cross‐validation performance of the model was confirmed by analysis
of variance (CV‐ANOVA P‐value = 0.013). Based on this analysis, 56 differentiating
metabolites were identified. Cats with high plasma homocysteine concentration exhibited
higher concentrations of 29/90 glycerophospholipids, 9/15 sphingolipids, 7/21 biogenic
amines, 3/21 AMino acids, and 2/40 acylcarnitines, and showed lower concentrations
of 3/21 AMino acids, 2/90 glycerophospholipids and 1/21 biogenic amine, compared to
cats with low homocysteine concentration.
This is the first study to investigate the feline metabolome, in relation to the plasma
homocysteine concentration. Our results suggest that the inter‐individual variability
of plasma homocysteine concentration in healthy cats may be associated with metabolic
peculiarities. Several discriminating amino acids and biogenic amines are involved
in pathways of methionine metabolism. Additionally, higher concentrations of plasmalogens
in cats with high plasma homocysteine concentration may indicate enhanced oxidative
stress or increased activity of protective mechanisms against oxidative stress.
Disclosures
No disclosures to report.
ESVIM‐P‐12
Association between immune‐mediated hemolytic anemia (IMHA) and acute pancreatitis
in dogs
G. Gianesini1, M. Drigo2, A. Zoia1
1San Marco Veterinary Clinic, Veggiano, Italy, 2University of Padova, Padova, Italy
Evidences in humans, rats and cats suggest that acute pancreatitis is a complication
of hemolysis, including hemolysis from IMHA. This study investigates the association
between IMHA and pancreatitis in dogs.
Case control study with nested retrospective cohort study, including 3 groups of 95
dogs matched for age, breed, and sexual status: dogs with IMHA (group‐1), clinically
healthy dogs (group‐2), sick dogs without IMHA (group‐3). Dogs in group‐1 had a HCT < 30%
(reference interval [RI], 38.6%” — 54.5%) and positive anti‐erythrocyte membrane antibodies
test. Acute pancreatitis was diagnosed if dogs had: amylase and lipase concentrations
above RI (>1101 mg/dL and > 725 mg/dL, respectively), CRP concentration > 3.0 mg/dL
(RI, 0.01 — 0.22), and anorexia and/or vomiting. Frequency of pancreatitis was compared
among the 3 groups (fisher exact test). After admission dogs with IMHA with and without
pancreatitis had a 7‐day follow‐up. If some of the dogs with IMHA without pancreatitis
developed pancreatitis, they switched to the IMHA with pancreatitis group and were
followed‐up for 7 days after the pancreatitis event. Free plasma hemoglobin (Hbfp)
for dogs with IMHA with pancreatitis (at the time of pancreatitis diagnosis) and without
pancreatitis (at presentation) was calculated (Hbfp = Hbtot ‐[RBC x CHCM x MCV]/1000)
and compared (Mann‐Whitney test). ROC curve analysis was used to identify the best
Hbfp cutoff value (Youden index) discriminating IMHA dogs with and without pancreatitis.
Relative Risk (RR) of developing pancreatitis in dogs with IMHA and Hbfp concentration ≥ the
Youden Index, was calculated. Finally, 7‐day mortality between IMHA dogs with and
without pancreatitis was evaluated (chi square test).
At presentation, frequency of pancreatitis was significantly (P = 0.0013) higher in
dogs with IMHA (12/95) compared to the controls (0/95 group‐2 and 5/95 group‐3, respectively).
During the 7‐day follow‐up period a further 9 dogs with IMHA developed pancreatitis.
IMHA dogs with pancreatitis (n = 21) had a significantly (P = 0.0067) higher Hbpf
(median = 0.17 g/dL, range, 0.0 — 1.55) compared to the IMHA dogs without pancreatitis
(n = 74; median = 0.0 g/dL, range, 0.0 — 2.89). The Youden index for Hbpf was 0.08 g/dL
(sensitivity = 61.9%, specificity = 75.7%; AUC = 0.672, 95%CI, 0.569 — 0.765; P = 0.0096).
In dogs with IMHA, a Hbpf concentration ≥ 0.08 g/dL resulted in an increased risk
of pancreatitis (RR = 2.54, 95%CI, 1.51 — 4.29). There was no difference in mortality
(P = 0.211) between IMHA dogs with (8/21) and without (18/74) pancreatitis.
Dogs with IMHA are at increased risk of pancreatitis. Several dogs developed pancreatitis
after being diagnosis with IMHA, this may suggest that IMHA may cause pancreatitis
and that Hbfp is a trigger for it.
Disclosures
No disclosures to report.
ESVIM‐P‐13
Evaluation of Serum Procalcitonin in Dogs with Induced Endotoxemia as a Biomarker
for Sepsis
A.F. Easley1, A.J. Birkenheuer1, E.W. Lashnits1, H. Marr1, M.K. Holowaychuk2, S.K.
Nordone1
1College of Veterinary Medicine, North Carolina State University, Raleigh, United
States of America, 2Ontario Veterinary College, University of Guelph, Canada
Sepsis is a leading cause of death in veterinary patients and remains challenging
to diagnosis in a prompt and accurate manner. Procalcitonin (PCT) has been studied
extensively in human medicine and is commonly used as a biomarker for sepsis. Little
information regarding PCT as a biomarker for sepsis in dogs exists, with no controlled
studies evaluating the kinetics of PCT during sepsis.
The aim of this study was to evaluate the response of serum PCT in dogs with experimentally
induced endotoxemia. We hypothesized that PCT would be rapidly detectable in serum
after injection of LPS and would remain elevated for at least 24 hours.
Six healthy mixed breed dogs were included in this study. Experimental endotoxemia
was induced by injecting healthy dogs with lipopolysaccharide (LPS; 2 ug/kg, IV, once).
Vital signs were monitored and serial blood samples were collected for measurement
of serum PCT for 72 hours following LPS injection. Difference in mean serum PCT between
serial time points was assessed using a mixed effects model.
All dogs developed lethargy and gastrointestinal signs within 30 minutes of LPS administration.
Within 1 hour of LPS administration all dogs experienced a decrease in mean arterial
pressure (MAP) and within 2 hours of LPS administration all dogs developed a fever.
All dogs had serum PCT concentrations above baseline by 2 hours post LPS administration
(P = 0.0002) with an average peak at 4 hours. Average serum PCT concentrations remained
significantly elevated at each two‐hour time point through 12 hours post LPS administration,
and were non‐significantly elevated at 24 hours but remained above baseline for 48 hours.
The results of the current study suggest that PCT was expressed in response to experimentally
induced endotoxemia and the kinetics of the PCT expression were favorable and support
its use as a biomarker for sepsis in dogs. Additionally, as changes in serial measurements
were in agreement with clinical evaluation of improvement, PCT may have an additional
role in prognostication and therapeutic decision‐making.
Disclosures
Disclosures to report.
Funding for this study was provided in part by the Ontario Veterinary College Department
of Clinical Studies.
ESVIM‐P‐14
Effect of a weight loss program on metabolic and immunological profile, blood leptin
level and cardiovascular parameters in obese dogs
L. Cortese1, A.T. Palatucci2, V. Rubino2, A. Giovazzino2, M. Filosa3, G. Ruggiero2,
G. Terrazzano4, D. Piantedosi5
1University of Naples Federico II, Naples, Italy, 2Department of Translational Medical
Sciences, University of Naples Federico II, Napoli, Italy, 3Department of Veterinary
Medicine and Food Productions University of Naples Fe, Naples, Italy, 4Department
of Science, University of Basilicata, Potenza, Italy, 5Department of Veterinary Medicine
and Food Productions University of Naples Fede, Naples, Italy
In these last years, the increasing obesity incidence in canine species has enshrined
its relevance as an important worldwide disease. Recently, obesity has been associated
with impaired immunity and chronic low‐grade inflammation in humans as well as mouse
models. Increased concentration of leptin and other pro‐inflammatory cytokines have
been described in obese dogs. A reduced number of T regulatory cells (Treg) has been
reported in visceral adipose tissue and blood of obese humans, and recently also in
Labrador retriever obese dogs. Moreover, some evidences addressed the possible impact
of obesity on cardiovascular apparatus in dogs. The aim of this study was to investigate
the effect of a weight loss program on metabolic and immunological profile, blood
leptin level and cardiovascular parameters in obese dogs. Ten overweight dogs (OB)
(BCS > 7/9) were recruited into the study, and they underwent blood testing (complete
blood count, serum biochemistry, blood level assay of CD3 + CD4+, CD3 + CD8+ T cells,
CD4/CD8 ratio, CD21+ B cells, Treg cells by immune‐fluorescence and flow cytometry
and measurement of serum leptin by species‐specific ELISA kit) and assessment of cardiovascular
function (blood pressure measurement, electrocardiography and echocardiography) before
(T0) and after five months (T1) of commercially available weight loss diet. Ten normal
weight (BCS 4‐5) healthy dogs represented a control group (CTR). Regarding metabolic
profile, a mild no significant decrease in total cholesterol but a significant decrease
in triglycerides serum levels (P < 0.05) were observed in the obese dogs at T1. There
were no significant differences in the other biochemical parameters as well as in
haematological values between the two observation times. Concerning the cardiovascular
parameters, no significant differences were observed at T1, and particularly systolic
arterial blood pressure values were in the reference range in both times. OB had elevated
serum leptin concentrations that decrease significantly (P < 0.005) after weight loss,
however remaining higher compared to CTR. OB dogs showed significant low levels (P < 0.005)
of Treg compared to CTR but they did not increase after weight loss. Our data suggested
that a deranged immune‐regulation, combined with high leptin levels, might characterize
obese dogs in the absence of cardiovascular alterations. Furthermore, on the basis
of our results we may suggest that probably in dogs a greater reduction in fat mass,
and long‐term weight loss programs, are necessary in order to restore immunological
balance.
Disclosures
No disclosures to report.
ESVIM‐P‐15
Life expectancy and causes of mortality of dogs at the National Veterinary School
of Toulouse between September 2007 and September 2017: retrospective study
M. Beaujard, D. Concordet, A. Diquélou
ENVT, Toulouse Cedex 03, France
Data on canine life expectancy are important for the owners, veterinarians and assurance
companies, but they are sparse in Europe (United Kingdom excepted), especially in
France.
The aim of this retrospective cohort study was to determine the life expectancy and
causes of death of dogs seen at the Toulouse Veterinary Teaching Hospital (TVTH, France)
and the effect of various factors (breed, gender, size) on these data.
The database of the TVTH was searched for dogs recorded dead between September 2007
and 2017. Their records were screened to determine the age at death and classify its
cause between neoplastic, cardiovascular, behavioral, dermatological, endocrinological,
gastroenterological, hematopoietic, infectious, musculoskeletal, neurological, ophthalmological,
reproductive, respiratory, trauma, age‐related and uronephrological causes. Breed
and weight category (< 10, 10‐25, 25‐45 and > 45 kg) were recorded if specified. Results
were analyzed using commercial software (R® and Excel®). Log rank test was used for
life expectancy; the effect of breed, gender, reproductive status and weight category
was assessed by Khi2 test and multivariate analysis.
A total of 3256 dogs belonging to 151 breeds were included; the number of dogs in
each breed varied from 1 to 224. Cause of death and weight could be identified in
2164 and 3054 dogs respectively.
The median life expectancy of dogs was 10.7 years (range [0‐24]). Weight had a significant
effect on longevity, dogs <10 kg (n = 848) and dogs >45 kg (n = 107) living respectively
longer (median 12.7 years) and shorter (median 6.1 years) than dogs weighting 10‐25
(n = 723) and 25‐45 kg (n = 1254) (median longevity 9.9 and 10.4 years respectively,
P < 0.05). Other factors significantly associated with increased longevity in dogs
were being female, spayed, and mixed breed (P < 0,01).
Neoplasia was the most common cause of death (30%), especially in Boxers and Bernese.
Breed's influence on the cause of death was significant (P < 0,05): Brittany Spaniels
died mostly after dermatological disorders, Cavalier King Charles and Bulldogs from
respiratory causes and Cavalier King Charles and Spitz from cardiovascular diseases.
Under 7 years, the most common causes were trauma (15%) and infections (7%). Compared
to the whole population, intact females were more likely to die from reproductive‐related
and endocrinological causes, neutered females from neoplastic disorders (P < 0,01).
This study suggests that canine longevity is highly influenced by weight. The dominant
causes of death in French dogs varies with breed, gender and reproductive status.
This study has to be enlarged to first opinion practice.
Disclosures
No disclosures to report.
ESVIM‐P‐16
Comparison of habitual physical activity levels in French Bulldogs and normocephalic
dogs ‐ a pilot study
M. Aromaa, L. Lilja‐Maula, M.M. Rajamäki
Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland
In addition to respiratory difficulties, brachycephalic obstructive airway syndrome
(BOAS) causes exercise intolerance. Daily habitual physical activity can be quantified
as counts by accelerometers measuring frequency, duration and intensity of activity.
The first aim of this study was to establish the cut points for sedentary, moderate
and high activity and the second to compare the activity levels in French Bulldogs
with moderate or severe signs of BOAS (BOAS+), French bulldogs with none or mild signs
of BOAS (BOAS‐) and normocephalic dogs.
Cut off points for Actical accelometer readings for sedentary (lying, slight movement
of trunk), moderate and high (trotting at speed of 8 km/h or more) were collected
with one‐minute epoch lengths for sedentary (100 epochs) and high (117 epochs) activities.
The upper limit for sedentary and lower limit for high activity was defined as mean
+/−2 x SD (SD) and moderate as values between these. BOAS + (n = 10) dogs, BOAS ‐
(n = 9) dogs and normocephalic (n = 11) dogs of comparable body sizes wore the Actical
collar over seven consecutive days. Statistical comparisons in activity levels between
groups were performed with an ANOVA method, Tukey's correction was used in comparisons.
For sedentary activity, established cut point was 347 and for high activity 1343.
All dogs spent most of the time at sedentary activity (91% ± 3% for BOAS+ dogs, 89% ± 3%
BOAS‐ dogs and 85% ± 5% controls; mean, SD). Significant differences were found only
between BOAS+ and normocephalic dogs at sedentary and high activity percentages (P
= 0.005 and 4% ± 1%, 7% ± 3% P = 0.01; respectively).
In conclusion, dogs with marked BOAS signs spend less time at high activity and more
time at sedentary activity than normocephalic dogs.
Disclosures
No disclosures to report.
ESVIM‐P‐17
Normal or mild increased C‐reactive protein values in 16 dogs with bronchial and pulmonary
infection with Bordetella bronchiseptica
A.M. Canonne‐Guibert1, M. Menard1, C. Maurey1, G. Benchekroun1, N. Fernandes Rodrigues2,
F. Billen2, C. Clercx2
1National Veterinary School of Alfort, Maisons‐Alfort, France, 2Faculty of Veterinary
Medicine, University of Liège, Liège, Belgium
C‐reactive protein (CRP) is a well‐known acute phase protein in dogs. It has been
recently shown to be particularly useful in discriminating bacterial bronchopneumonia
from other pulmonary diseases and promising in guiding antibiotic therapy duration.
However, in those publications, dogs infected by Bordetella bronchiseptica(Bb) have
not been specifically distinguished from others. In an experimental study, high elevations
of CRP have been identified in dogs inoculated with Bb. Nevertheless, the amplitude
of increase of CRP in naturally‐infected dogs with Bb has not been described.
The aim of this study was to describe the values of CRP in dogs with lower airways
Bb infection with or without radiographical pulmonary involvement. Magnitude of CRP
elevation was also compared with dogs diagnosed with bacterial aspiration bronchopneumonia
(ABP).
Sixteen dogs with lower airways Bb infection and 36 dogs with ABP were selected. For
each included dog, a CRP value and thoracic radiographs at diagnosis were available.
Bb infection was confirmed by bacterial culture and/or quantitative PCR on bronchoalveolar
lavage fluid. ABP was diagnosed based on compatible history, physical examination
and radiographic findings and favorable evolution on empiric antimicrobial therapy.
Median age of dogs with Bb infection and ABP were 0.6 and 5 years respectively (P
< 0.001). Eleven dogs with Bb infection had alveolar lesions on radiographs with only
one out of 11 dogs having another bacterial coinfection. CRP value was mildly elevated
in 11/11 dogs and 1/5 dogs with and without alveolar lesions, respectively (P = 0.002)
and the median CRP value was significantly higher in dogs with alveolar lesions compared
with dogs without alveolar lesions (20 mg/L, [14‐38], versus 5 mg/L, [5‐11], P = 0.002).
Duration of clinical signs was longer than 2 weeks for all Bb dogs; duration was not
different between dogs with normal or elevated value as well as between dogs with
or without alveolar lesions. In dogs with Bb infection and alveolar lesions, median
CRP value was significantly lower than in dogs with ABP (17 versus 118 mg/L, P < 0.001)
and ranges of elevation of CRP did not overlap between these two groups ([15‐38 mg/L]
and [55‐270 mg/L] respectively).
In conclusion, regardless of the presence of alveolar lesions, Bb may be suspected
in coughing dogs with normal to slightly elevated CRP suggesting that CRP is not a
good marker to hep guiding type and duration of treatment in bordetellosis.
Disclosures
No disclosures to report.
ESVIM‐P‐18
Polycythemia is uncommon in dogs with chronic hypoxic pulmonary disease
S.J. Viitanen, H.P. Laurila, S. Holopainen, M.M. Rajamäki
University of Helsinki, Helsinki, Finland
Prolonged tissue hypoxia caused by chronic pulmonary disease is commonly cited as
an important mechanism in the development of secondary physiologically appropriate
polycythemia. However, the prevalence and severity of polycythemia has not been described
in detail in dogs with chronic hypoxic pulmonary disease.
44 dogs (median age 11.9, interquartile range 10.0‐13.3 years) with chronic pulmonary
disease and documented chronic hypoxia (partial pressure of arterial oxygen [PaO2]
<80 mmHg on at least two separate arterial blood gas measurements minimum of 1 month
apart) were retrospectively identified from patient records. Dogs of sight hound breeds
were excluded. The diagnosis was based on thorough clinical examinations including
bronchoscopy and brochoalveolar lavage, thoracic computed tomography, lung histopathology
or a combination of the aforementioned. Statistical correlation between PaO2 and red
blood cell parameters was analyzed using Pearson's correlation coefficients.
The group comprised of 23 West Highland white terriers with canine idiopathic pulmonary
fibrosis and 21 dogs of other breeds with the following lung diseases; chronic bronchitis
13/21, eosinophilic bronchopneumopathy 2/21 and interstitial lung disease 2/21. In
4/21 dogs with chronic respiratory signs (cough and/or tachypnea) and chronic diffuse
radiographic lung changes, a final diagnosis was not established.
Median duration of hypoxia was 8 months (IQR 4‐18 months) and the mean PaO2 at the
end of the period was 62.2 mmHg (SD [STD] ± 9.9 mmHg). Red blood cell parameters measured
at the end of hypoxemia period were within the laboratory reference range in majority
of dogs; Erythrocyte count (Erytr) was normal in 35/44 dogs (mean 7.4 ± STD 0.9 x1012/L,
range 4.9‐9.3 x1012/L, laboratory reference range 5.3‐8.0 x1012/L), hemoglobin concentration
(Hb) was normal in 42/44 dogs (mean 173 ± STD 21 g/L, range 121‐221 g/L, laboratory
reference range 140‐203 g/L) and hematocrit (Hkr) was normal in 39/44 dogs (mean 51.0 ± STD
5.7%, range 35‐64%, laboratory reference range 38‐57%). Marked polycythemia (hematocrit
≥65%) was not noted in any of the dogs. Red blood cell parameters were not correlated
with the severity of hypoxia (correlation to PaO2: Erytr r = −0.054, P = 0.728; Hb
r = −0.141, P = 0.360; Hkr r = −0.99, P = 0.521).
These results indicate that polycythemia is uncommonly encountered in dogs with chronic
hypoxic pulmonary disease and when encountered, only mild increases in red blood cell
parameters are noted.
Disclosures
Disclosures to report.
S.J. Viitanen has received research grants for other projects that the study described
in this abstract from the Finnish Foundation of Veterinary Research and the Finnish
Veterinary Foundation. S.J. Viitanen has received salary from a recidency program
partially supported by Royal Canine.
ESVIM‐P‐19
A statistical analysis to predict persistence of canine sinonasal aspergillosis at
endoscopic follow‐up by comparing three different scoring systems: a retrospective
study of 47 cases treated with one hour 1% clotrimazole per‐endoscopic infusion and
undergoing endoscopic follow‐up
V. Greci1, A. Cocci2, C.M. Mortellaro3
1Ospedale Veterinario Gregorio VII, Roma, Italy, 2Clinica Veterinaria Ca' Bianca,
Milano, Italy, 3Università degli Studi di Milano, Milano, Italy
The aim of this study was to investigate three different scoring system for Canine
Sinonasal Aspergillosis (CSA) in order to predict whether they can indicate persistence
of CSA at endoscopic follow‐up.
Medical records of dogs treated for CSA were reviewed. Inclusion criteria were the
presence of a full medical history, radiological investigation, after meticulous debridement
of the fungal plaques and endoscopic follow‐up between 30 and 90 days after treatment.
Forty‐seven dogs fulfilled the inclusion criteria and were included in this study.
To each dog a CSA grade score was given according to Sharp (1989) at the time of diagnosis;
a rhinoscopic scoring according to Zonderland (2002) was given after endoscopic examination.
The score was modified by the authors by creating three categories of severity: mild
CSA (score between 0 and 5), moderate CSA (score between 6 and 10) and severe CSA
(score between 11 and 16). The amount of fungal plaques was considered mild when countable,
moderate when partially occupying the sinonasal cavity and abundant when obliterating
the sinonasal cavity. A clinical scoring proposed by Schuller (2007) was modified
and used to assess the patients prior to endoscopic follow‐up: dogs were classified
as having no (no clinical signs reported), mild (occasional sneezing, occasional reverse
sneeze, serous to mucoid discharge), moderate (mucopurulent discharge, frequent sneezing,
frequent reverse sneezing) or severe (severe mucopurulent discharge, stertor, persistent
reverse sneezing, persistent sneezing, epistaxis, generalized malaise) clinical signs.
The three scoring system were statistically analised and explicitly, we addressed
the question: is there any chance to predict the persistence of fungal infection based
on the score system outcome? If yes, than that scoring method was considered predictive
for fungal infection persistence. A contingency table for each scoring system was
computed and the null hypothesis of independence between the scoring methods and persistence
of fungal infection was statistically tested by Fisher‐Freeman‐Halton Exact Test.
According to the statistical results, the Sharp grade score system can be considered
significantly associated with persistence, or not persistence, of fungal infection
at the endoscopic follow‐up, and therefore it can be considered as a predictor of
the fungal infection persistence (Sharp score system Fisher P‐value = 0.021).
Endoscopic follow‐up is strongly recommended to assess CSA treatment effectiveness.
Sharp grade score can be used to predict treatment outcome in dogs treated with one
hour 1% clotrimazole per‐endoscopic infusion. Sharp grade score might apply also to
other different methods for treating CSA; further studies are warranted.
Disclosures
No disclosures to report.
ESVIM‐P‐20
Evaluation of feline packed red blood cell units obtained by blood sedimentation and
stored for 42 days for transfusion purposes
E. Spada, R. Perego, L. Baggiani, P.A. Martino, D. Proverbio
University of Milan, Milan, Italy
Component therapy involves separation of whole blood (WB) into its components (packed
red blood cells ‐PRBCs‐ and plasma), for specific replacement therapy and to reduce
transfusion reactions. In cats, blood for transfusion is commonly collected using
an open system and administered as WB, in part because of the challenge of preparing
components from a small blood volume. Feline blood has a high erythrocyte sedimentation
rate; therefore, if the syringe containing collected blood is placed upright, plasma
can be removed from the red cells shortly after collection for separate storage of
plasma and PRBCs. The aim of this study was to assess the characteristics of feline
PRBC units obtained by blood sedimentation both at collection and after storage for
42 days.
Blood was collected from fourteen feline blood donors into three 20 mL syringes pre‐charged
with CPDA‐1:blood ratio of 1:7 using an open system. A pre‐donation CBC was performed
in each donor. The three syringes were allowed to sediment for approx. 1 hour at room
temperature. Then plasma was aseptically expressed into plain transfer bags and RBC
expressed into another transfer bag pre‐charged with 10 mL of SAG‐M. PRBCs units were
stored in a blood‐dedicated refrigerator and sampled using blood bag segments at preparation
time (D0) and after 42 days storage (D42). On pre‐donation blood and on PRBC units
at D0 and D42 the following parameters were evaluated: I) hematological parameters
(RBC, Hb, Hct, WBC, PLT); II) percentage hemolysis; III) morphological index (only
for PRBC units), scored of 0 to 3 based on echinocyte transformation of the normal
discocyte; IV) aerobic and anaerobic blood culture (only for PRBC units).
From donor to PRBC units there was a significant increase in RBC count (mean increase
+1886 ± SD1399 μL/103), Hb concentration (+2.8 ± 2.2 g/dL), Hct percentage (+8.3 ± 5.5%).
Significant reduction was found in PLT count (−249 ± 189 μL/103). Comparing PRBC at
D0 and D42 a significant increase was found in percentage hemolysis (+ 1.2%), morphological
index (+ 0.9) and a significant reduction in RBC count (−460 ± 679 μL/103), Hct percentage
(−3.2 ± 3.5%), WBC count (median − 2589 μL/103), and PLT count (median − 43 μL/10).
All blood cultures were negative for bacterial growth.
PRBC units obtained by sedimentation of donated blood appear to be a suitable blood
component for treatment of normovolemic anemia. However storage for 42 days, as suggested
for canine and feline PRBC units, resulted in significant hematological changes that
could reduce oxygen delivery after transfusion.
Disclosures
No disclosures to report.
ESVIM‐P‐21
Bronchoscopic findings in dogs with bronchial vegetal foreign bodies: a retrospective
study of 52 cases (2010‐2019)
J. Flageollet, L. Poujol, C. Peyron, S. Gibert, A. Dunié‐Merigot, L. Blond, F. Bernardin
Centre Hospitalier Vétérinaire Languedocia, Montpellier, France
Vegetal foreign bodies are a frequent cause of cough in dogs during spring and summer
in France. They can result in a variety of other clinical signs and endoscopic abnormalities.
The aim of this study was to describe the foreign body location, rate of retrieval
success, complications, and macroscopic endoscopic findings in dogs with vegetal foreign
bodies. Fifty two dogs were included in this retrospective evaluation from the medical
records of dogs admitted between 2010 and 2019 for a bronchial vegetal foreign body.
Diagnosis was based on direct visualisation during the bronchoscopic exam or after
surgical retrieval.
27 males and 25 females were included in this study. More than half were hunting dogs
(29/52). Duration of clinical signs ranged from 1 to 1400 days. Cough was the main
clinical sign (49/52). Foreign bodies were removed from a right‐sided bronchus in
35/52 (67%) cases, from a left‐sided bronchus in 11/52 (21%) cases, from both right
and left bronchi in 6/52 (12%) cases. Endoscopic retrieval was successful in 43 of
52 cases (83%). Nine dogs needed a surgical treatment. The survival rate was 100%.
Endoscopic images were reviewed in 44 dogs. They showed purulent exsudate in the ventral
larynx region (29/44), the trachea (38/44) and the bronchi where the foreign body
is located (43/44).The presence of large bronchial nodule or an irregular mucosal
surface were other frequent observations (36/44). A mild bleeding was the main complication
(30/44).
This retrospective study confirm the safety and usefulness of bronchoscopy in diagnosis
and treatment of bronchial vegetal foreign bodies in dogs. Mucosal nodules associated
with purulent material within the airways are frequent endoscopic findings.
Disclosures
No disclosures to report.
ESVIM‐P‐22
Assessment of nasal microbiota in healthy dogs of different breeds
E. Vangrinsven1, A. Fastrès1, B. Taminiau2, A. Tutunaru1, F. Billen1, G. Daube2, C.
Clercx1
1University of Liege, Liege, Belgium, 2Department of Food Sciences ‐ Microbiology,
University of Liege, Liege, Belgium
Dolichocephalic breeds are predisposed to sinonasal aspergillosis while brachycephalic
dogs are not affected. Since disruptions in the resident microbiome may contribute
to disease pathogenesis by modulating immune responses and since microbiota dictates
the type of host‐fungus relationship, we hypothetized that differences in predisposition
to nasal disease in dogs could be associated with differences in core nasal microbiota
between breeds.
Fourty‐six healthy dogs were recruited, including 22 medium to large dogs from dolichocephalic
breeds (DC), 12 brachycephalic dogs (BC) and 12 terrier dogs (T). All dogs were older
than 14 months. Dogs were living either in rural (n = 21) or urban domestic conditions
(n = 25). Nasal swabs were obtained under anesthesia and banked at −80°C until batched
analysis. After DNA extraction, a PCR targeting the V1‐V3 region of the 16S rDNA was
performed. Amplicons were then sequenced on a MiSeq Illumina sequencer. Taxonomical
assignation and microbiota community analysis were done with MOTHUR V1.41.0 with an
OTU clustering distance of 0.03.
Analysis of ecological indexes showed that bacterial richness (P = 0.01) and α‐diversity
(P < 0.01) were significantly higher in BC group compared to the two other groups.
The AMOVA analysis indicated that the BC group was different compared to DC and T
groups (BC vs DC P = 0.02; BC vs T P < 0.01). There was no difference in bacterial
load between groups and no effect of the living conditions.
The nasal microbial population was predominantly composed of the phyla Proteobacteria(mainly
represented by the family Moraxellaceae), Actinobacteria, Firmicutes and Bacteroidetes,
in agreement with previous studies. However, within each breed group, the relative
abundance in phyla was highly variable and no significant differences were found between
groups while at the family level, the relative abundance in Pasteurellaceae was significantly
higher in the BC group. Distinct species and genera were found as indicators of discrimination
(P < 0.05) among which 8 species and 9 genera in the BC group and 1 species in the
T group.
Our study mainly demonstrated significant differences in the nasal microbiota in the
BC group compared with the two other groups. Such differences might be associated
to a particular facial morphology and/or breathing pattern in brachycephalic dogs.
We did not identify nasal microbiota breed‐differences that would be in favor of a
breed susceptibility of dolichocephalic dogs for nasal diseases. Further studies are
needed to investigate the role of nasal microbiota variations as a trigger or a perpetuating
factor in nasal diseases, especially in dogs with sinonasal aspergillosis.
Disclosures
No disclosures to report.
ESVIM‐P‐23
Canine sino‐nasal aspergillosis in Italy (38 cases)
A. Peano1, G. Fortini1, P. Ruggiero2, M. Tricarico2, E. Bottero2
1Dipartimento di Scienze Veterinarie, Grugliasco, Italy, 2Endovet Freelance Group,
Italy
Sino‐nasal aspergillosis (SNA) is an important cause of chronic nasal disease in the
dog, characterized by the formation of a superficial mucosal fungal plaque within
the nasal cavity and/or frontal sinus of systemically healthy dogs. Aspergillus fumigatus
is classically recognized as the most important etiological agent. Notably, this species
is now considered a “group” (the Fumigati group) including several species distinguishable
only via molecular exams. To date, few studies have analyzed fungal isolates involved
in canine SNA cases at genetic level, showing that A. fumigatus sensu stricto was
the main causal species. On the opposite, other species of the Fumigati group (the
so called criptic species of the viridinutans complex) have been found associated
to SNA in cats (in cats SNA is more invasive and has a poor prognosis, due to the
involvement of the retro‐orbital space). The aim of this study was to described the
clinical and mycological features of a series of 38 cases of canine SNA in Italy.
Cases were recruited by veterinarians belonging to ENDOVET (a group specialized in
endoscopy). The diagnosis was achieved by a combination of exams (endoscopic visualization
of fungal plaques and/or visualization of fungal elements at cytology/histology of
nasal biopsies). Fungi were isolated from biopsies and identified by morphological
keys and molecular analyses (sequencing of the ß‐tubulin gene). Twenty isolates chosen
randomly were tested in vitro against some antifungal agents commonly used in the
dog with SNA (itraconazole, clotrimazole, enilconazole) and other agents more used
in human patients (voriconazole, posaconazole).A.fumigatus sensu stricto was identified
in most of the cases (34/38, 89%), with the remaining cases due to A. flavus, Fusarium
spp. and Paecilomyces spp. (for one case a definitive identification was not achieved).
In vitro MIC (Minimum Inhibitory Concentration) values were within expected limits,
therefore resistance was not detected. A breed predisposition was not noted. On the
contrary, in agreement with some past studies, a sex predisposition could be noted,
since males accounted for 66% of the sample. Clinical signs more frequently observed
are those already reported in the literature (eg. nasal discharge was present in 100%
of the cases, it was monolateral in 82%). Frontal sinus involvement was confirmed
in 47% of cases. Although data on follow up visits were incomplete, the most effective
treatment seemed to be represented by mechanical debridement of fungal plaques plus
local treatment using clotrimazole cream or enilconazole solution (procedures conducted
during endoscopy).
Disclosures
No disclosures to report.
ESVNU‐P‐1
Uroliths in dogs from Europe and China ‐ a comparative study
D. Breu, C. Wenk, E. Müller
LABOKLIN, Bad Kissingen, Germany
Our study aimed to evaluate and compare the nature of canine uroliths. The study involved
4204 dogs from predominantly Central Europe (CE) and 830 dogs from China (CN) during
the year 2016‐2018. Analyses were performed using infrared spectroscopy.
The global statistics of uroliths in CE:CN dogs were male (40%:45%), female (24%:31%),
neutered (18%:15%) and spayed dogs (17%:9%). The population of CE:CN dogs consisted
of 511:71 mongrels and 163:45 breeds.
The uroliths comprised struvite (CE:CN = 43.3%:48.3%), calcium oxalate (33.2%:41%),
cystine (13.3%:4.8%), ammonium urate (5.1%:1.9%) and others (<5%). The CE:CN dogs
had median ages (years): struvite (7:6), calcium oxalate (9:8), and cystine (5:3).
Struvite uroliths in CE:CN dogs accounted for: females (81%:81%), spayed (79.5%:74.4%),
males (17%:33.9%) and neutered dogs (17%:26.5%).
Calcium oxalate uroliths in CE:CN dogs were: males (43.5%:46.6%), neutered (53.6%:42.8%),
females (15%:15%) and spayed dogs (15%:15%).
Cystine uroliths in CE:CN dogs accounted for: males (28.6%:9.1%), neutered (9.6%:2.4%),
females (1.2%/1.2%) and spayed dogs (0.7%/0%).
In CE cohorts, cystine uroliths were present in 11/13(=84.6%) of Irish terriers, a
breed reported to have a genetic predisposition to cystine calculi. Cystine uroliths
were also found in American Staffordshire terriers (25/30 = 83.8%), bulldogs (39/77
= 50.6%), French bullterriers (30/71 = 42.3%), huskies (5/12 = 41.7%) and Chihuahuas
(61/177 = 34.5%). In CN cohorts having no Irish terriers population, cystine uroliths
were primarily found in bulldogs (9/11 = 81.8%) and French bullterriers (7/9 = 70%).
Our study revealed that, in both CE:CN cohorts, uroliths were common in the order
of struvites, calcium oxalates, cystines and ammonium urates. Among the CE breeds,
Yorkshire terriers and Parson Russel terriers were more subject to calcium oxalate
while pugs were to struvite formation. Among the CN breeds, miniature schnauzers,
bichons and poodles were more subject to struvite uroliths.
Struvite uroliths in CE:CN dogs occurred equally in females but at rates substantially
higher than those in males. Within males, CN dogs were 2 times more susceptible than
their CE counterparts. Considering the role of urease‐producing bacteria in the genesis
of struvite uroliths, our data suggest the influence of gender as well as habitats.
Calcium oxalate uroliths were ~3 times more prevalent in male dogs than females in
both CE:CN cohorts.
Cystine uroliths were substantially more prevalent in males than female dogs in both
CE:CN cohorts. Notably, male CE dogs were 3 times more susceptible than the CN counterparts.
Overall, our data suggest that canine urolith formation is widely dependent on breed,
gender and environmental factors like diet and regional care practices.
Disclosures
Disclosures to report.
The authors Breu D1 and Wenk C2 are employed at Laboklin GmbH & Co KG, Bad Kissingen,
Germany1 and Laboklin GmbH & Co KG, Basel, Switzerland2. Müller, E is owner/manager
of the Laboklin GmbH & Co KG, Germany.
ESVNU‐P‐2
Significant Feline Proteinuria: a retrospective study of its aetiology in 61 cats
M.A. Fidalgo1, R. Oliveira Leal2, J.H. Duarte Correia2
1Center for Interdisciplinary Research in Animal Health ‐ Fac. Vet. Med.,U.Lisbon,
Lisbon, Portugal, 2Centre for Interdisciplinary Research in Animal Health ‐ Fac Vet
Med, U.Lisbon, Lisbon, Portugal
Urinary Protein/Creatinine Ratio (UPC ratio) is currently the most frequent method
for proteinuria quantification. Proteinuria can be classified in physiological versus
pathological (pre‐renal, renal or post‐renal). Although chronic kidney disease (CKD)
is assumed to be the most common cause of proteinuria in cats, few studies have been
conducted to assess its aetiology.
The aim of this study was to determine the main causes of proteinuria in cats from
the region of Lisbon, Portugal.
All the cats presented between 2016 and 2018 in a veterinary hospital and identified
with significant proteinuria (UPC ratio > 0.4) were included. The cause of proteinuria,
International Renal Interest Society (IRIS) staging and systolic blood pressure (SBP)
were obtained from medical records.
Sixty‐one cats were selected, including 28 females (21 spayed, 7 intact) and 33 males
(26 neutered, 7 intact), with an average of 12 years old. No cats had physiological
or pre‐renal proteinuria, 46/61 (75%) presented renal proteinuria, 4/61 (7%) had post‐renal
proteinuria and 11/61 (18%) had a suspected mixed origin (renal + post‐renal). In
detail, the causes of renal proteinuria were CKD (39/61; 64%), CKD complicated with
co‐morbidities (2/61; 3%), acute kidney injury (AKI) (2/61; 3%) and diseases capable
of decreasing renal permselectivity (3/61; 5%). Post‐renal proteinuria was due to
urinary tract infection (UTI) (3/61; 5%) and cystitis (1/61; 2%). Mixed‐proteinuria
was attributed to CKD + cystitis (7/61; 11%) and CKD + UTI (4/61; 7%).
Complete IRIS staging was obtained in 30 out of the 52 cats with CKD (58%). Two cats
were on stage I (both hypertensive), 8 cats were on stage II (6 hypertensive, 2 non‐hypertensive),
11 cats were on stage III (9 hypertensive, 2 non‐hypertensive) and 9 cases were on
stage IV (8 hypertensive, 1 non‐hypertensive).
Regarding SBP, data was available in 36/61 cases. From these, 24/36 (67%) were severely
hypertensive, 6/36 (17%) were hypertensive, 5/36 (14%) were pre‐hypertensive and one
cat was normotensive.
This study strengthens that pre‐renal proteinuria is rare in cats and CKD is the most
frequent cause of significant proteinuria in this species. Severe hypertension is
a common finding, highlighting the relevance of SBP measurement in these cats. The
fact that IRIS staging was only possible in 58% of the cats still reflects a poor
awareness of veterinarians for this classification.More than contributing to better
knowledge of causes of proteinuria, this study suggests that physiological and pre‐renal
causes do not induce significant proteinuria in cats.
Disclosures
No disclosures to report.
ESVNU‐P‐3
The role of vector‐borne diseases in the aetiology of overt canine proteinuria: a
retrospective study in 106 dogs
M.L.Q.M. Paz, J.H. Duarte Correia, R. Oliveira Leal
CIISA ‐ Centre for Interdisciplinary Research in Animal Health ‐ FMV ‐ U.Lisboa, Lisbon,
Portugal
Canine vector‐borne diseases (CVBD) are highly prevalent in Southern Europe. They
are a well‐known cause of glomerular disease in dogs, being commonly associated with
a significant proteinuria. However, few studies have evaluated the role of CVBD in
the aetiology of proteinuria in these endemic countries. According to its origin,
proteinuria can be classified in pre‐renal, renal or post‐renal and it is currently
quantified by the Urinary Protein/Creatinine Ratio (UPC).
The aim of this study was to assess the main causes of proteinuria in dogs from the
region of Lisbon in order to estimate the role of CVBD on it.
All dogs presented to a Lisbon veterinary hospital between January 2017 and December
2018 identified with significant proteinuria (UPC ratio > 0.5) and with an established
primary diagnosis were selected. Based on the medical records, cases were classified
according to proteinuria origin.
106 dogs were selected. From these, 54% were females and 46% were males, with an average
of 9.5 years old (range between 0.83 and 16 years old). None had pre‐renal proteinuria,
76% had renal proteinuria, 17% had post‐renal proteinuria and 7% had a suspected mixed
origin (renal+post‐renal). Detailing renal proteinuria, 46% had a presumptive diagnosis
of glomerulonephritis secondary to CVBD, 27% showed chronic kidney disease, 26% had
systemic diseases possibly inducing an impaired glomerular permselectivity (bronchopneumonia,
enteropathies, liver disease, hyperadrenocorticism, diabetes mellitus or neoplasia)
and 1% had acute kidney injury (AKI). Post‐renal proteinuria included dogs with pyometra
and urinary tract infection (UTI). Mixed proteinuria was considered in dogs with systemic
diseases (CVBD, CKD, AKI and hyperadrenocorticism) and a concurrent UTI and/or cystitis.
Considering dogs diagnosed with CVBD, 82% were positive on serology for a single‐agent
while 18% were positive for more than one agent. Detailing serology results, 90% of
dogs were positive for Leishmania infantum, 13% Rickettsia spp, 8% heartworm disease,
5% Borrelia burgdorferi, 5% Ehrlichia spp, 3% Babesia canis and 3% Anaplasma spp.
Whilst pre‐renal significant proteinuria was uncommon, CVBD were the main cause of
renal proteinuria in these dogs. Leishmaniosis was the most frequent CVBD identified
on serology. Despite the increasing preventive measures, these are expected results
since CVBD are highly prevalent in Portugal.
This study suggests that CVBD are the most common differential diagnosis of renal
proteinuria in dogs from Lisbon. These results might be extrapolated to other endemic
southern European countries, but further studies are needed to confirm it.
Disclosures
No disclosures to report.
ESVNU‐P‐4
Evaluation of the diagnostic value of urinary albumin to protein ratio in proteinuric
dogs
F.A. Falus, Z.S. Vizi, B. Török, F. Manczur
University of Veterinary Medicine, Budapest, Budapest, Hungary
Renal protein loss is mainly caused by either tubular or glomerular dysfunction, and
the differentiation between these two types holds a high diagnostic and therapeutic
significance. Tubular proteinuria is defined by the loss of low molecular weight proteins,
whereas in glomerulopathies albuminuria is more pronounced.
We hypothesized that by assessing the urine albumin‐to‐total protein ratio (uAPR)
we will be able to identify the source of proteinuria: whether it is solely of tubular
origin or glomerular damage is present as well.
27 proteinuric canine left‐over urine samples were used in this study. 11 samples
belonged to laboratory beagles and 17 to clinical patients. In addition to urinary
protein and creatinine concentration determination, albumin was measured by immunoturbidimetric
method. The urinary albumin‐to‐creatinine ratio (UAC), urinary protein‐to‐creatinine
ratio (UPC), and the ratio of UAC and UPC (uAPR) were calculated. The findings were
compared to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS‐PAGE).
Solely tubular proteinuria was considered ‘tubular’, while mixed (tubular and glomerular)
and glomerular proteinuria were considered as ‘non‐tubular’.
The median (lower and upper quartile) of the UPC was 1.27 (0.48; 3.53), the UAC was
0.51 (0.10; 2.69), and the uAPR was 0.56 (0.15; 0.77) in the urine specimens. With
receiver operating characteristic (ROC) curve analysis the ideal cut‐off value was
determined to be 0.37, below which the tubular proteinuria could be identified with
high confidence (sensitivity = 93.75%, specificity = 75.0%, positive predictive value
= 82.35%, negative predictive value = 81.81%).
Using this cut‐off value, tubular proteinuria was diagnosed in 10 dogs (35.71%) and
non‐tubular proteinuria in 17 animals (60.71%). The uAPR results showed a high correlation
with the electrophoresis outcomes. There was only one dog with a false negative result
(‘tubular’ on uAPR and ‘non‐tubular’ on electrophoresis), and 3 dogs had false positive
results (‘non‐tubular’ on uAPR and normal protein excretion pattern on electrophoresis).
Based on these findings we suggest that uAPR could be a simple and affordable method
to identify the source of proteinuria, thus the determination of uAPR may help in
the diagnostic and therapeutic decision‐making in proteinuric dogs.
The gold standard to differentiate between tubular and glomerular damage is histopathology,
thus our future plan is to compare uAPR with histopathological diagnosis.
Disclosures
No disclosures to report.
ESVNU‐P‐5
N‐acetil‐β‐D‐glucozaminidase index as an early renal tubular damage marker in male
cats with obstructive lower urinary tract disease
D.M. Neagu, A.R. Codea, C. Popovici, A.N. Muresan, A. Biris, D.I. Marcutan, I. Cimpoies,
O. Sarpataki, M.V. Mircean
USAMV FMV CLUJ‐NAPOCA, Cluj‐Napoca, Romania
Feline lower urinary tract disease (FLUTD) is a recurrent chronic disease commonly
found in current practice. Male cats (2‐8 years‐old), neutered, sedentary and overweight
present the highest risk of developing FLUTD.
The aim of the study is to evaluate the activity of the N‐acetil‐β‐D‐glucozaminidase
(NAG) index as an early tubular damage marker in neutered male cats with obstructive
FLUTD.
57 male cats of different breeds and ages, diagnosed with obstructive lower urinary
tract disease were included in this study. Diagnosis was based on physical examination,
haematological, biochemical, radiological and ultrasound exam.
Urine specimens collected via cystocentesis were subjected to complete urinary analysis
(urinary biochemistry, urinary sediment, and culture and sensitivity tests). Complementary,
urinary NAG index activity was evaluated in these samples.
Higher values of urinary NAG index were found in male cats with obstructive FLUTD
and bacterial implication (median value of 55,52 ± 12,3 U/g) when compared with aseptic
obstructive FLUTD were median NAG index values were found to be 33,12 ± 14,8 U/g.
Prolonged anuria consecutive to uretral obstruction as well as repeated obstructive
episodes induces kidney tubular lesions. The use of this marker in current medical
practice allows early diagnosis of patients with tubular damage consecutive to urethral
obstruction and urinary reflux. Obstructed male cats with UTI have a greater risk
of developing tubular lesions especially those with septic cystitis.
Disclosures
No disclosures to report.
ESVNU‐P‐6
Non‐symptomatic bacteriuria is common in young female boxer dogs
S. Pagnamenta1, D. Gonin Jmaa2, M. Wenger3, B. Gerber1
1Vetsuisse Faculty University of Zurich, Zurich, Switzerland, 2Centre Veterinaire
Agy, Granges‐Paccot, Switzerland, 3Bessy's Kleintierklinik AG, Regensdorf, Switzerland
Reflux nephropathy is considered a possible cause of end‐stage kidney disease in young
Boxer dogs. Furthermore, vesicoureteral reflux was found to be associated with urinary
tract infection. The aim of this study was to evaluate the prevalence of bacteriuria
in young Boxer dogs and to describe changes in the urine composition of these dogs.
In 165 clinically healthy Boxer puppies, urine was collected by cystocentesis. Urinalysis
including urine culture was performed.
Dogs were examined at the age of 48 to 106 days (median 61 days). There were 22 male
and 143 female dogs. Culture was positive in 36 female dogs (25% of the female dogs).
None of the male dogs had a positive culture. Of the cultured bacteria, 82% were E.
coli. Pyuria was seen in 52% of the culture positive dogs and in 4% of the culture
negative dogs. Bacteria in the sediment were seen in 75% of the culture positive dogs
and in 5% of the culture negative dogs. The combination of pyuria and bacteria in
the sediment was seen in 42% of the culture positive dogs and in 2% of the culture
negative dogs. Urine specific gravity ranged from 1.005 to 1.051 (median 1.034) and
was significantly lower in culture positive dogs compared to culture negative dogs
(median 1.024 vs. 1.037).
Bacterial colonization of the urine is common in young female Boxer dogs. The significance
of this finding specifically concerning a possible association to the development
of kidney disease has to be determined.
Disclosures
Disclosures to report.
The Study is supported by ‘Schweizerischer Boxer‐Club’ B Gerber was a speaker for
Boeringer Ingelheim.
ESVNU‐P‐7
Evaluation of symmetric dimethylarginine (SDMA) in canine acute pancreatitis
E. Gori, A. Pierini, I. Lippi, V. Meucci, F. Battaglia, F. Perondi, V. Marchetti
University of Pisa, Pisa, Italy
Symmetric dimethylarginine (SDMA) is a sensitive renal biomarker whose concentrations
increase earlier than creatinine as glomerular filtration rate decreases. So far in
humans, SDMA is considered an important early biomarker of kidney dysfunction.
The aim of this study was to evaluate SDMA in dogs with acute pancreatitis (AP) and
their association with kidney injury and severity of disease.
Dogs with AP, presented at the Veterinary Teaching Hospital of University of Pisa
between 2017 and 2019, were prospectively enrolled. AP diagnosis was based on compatible
clinical and laboratory parameters, abnormal SNAP cPL test (Idexx Laboratories) and
positive abdominal ultrasound within 48 h from admission. Dogs with a history of renal
diseases (clinical records/history, bloodwork and diagnostic imaging), urinary tract
infection and/or on hemodialysis treatment were excluded, along with dogs that had
received known nephrotoxic drugs (eg. non‐steroidal anti‐inflammatory drugs, aminoglycosides).
For each dog, data about urea, creatinine and urinary output (UO) were recorded. Acute
kidney injury (AKI) grading was made based on current IRIS consensus. Canine Acute
Pancreatitis Severity (CAPS) was calculated for each dog at presentation and previously
described cut‐off of 11 was used to divide dog into two groups (CAPS < and > 11).
SDMA was measured using high performance liquid chromatography (HPLC). The SDMA was
compared between UO groups (O, NO), presence of AKI and with CAPS score groups using
Mann‐Whitney U‐test or Welch's t‐test based on normality distribution. SDMA was correlated
with urea and creatinine levels using Spearman's correlation test.
Fifty‐one dogs with diagnosis of AP were enrolled with owners' informed consent. Sixteen
dogs showed AKI and 11 of them were oligo‐anuric. Overall median SDMA was 13.8 mg/dL
(range 0.6‐65 mg/dL). Twenty‐three dogs (45%), of which 13 in non‐AKI group, had SDMA
above reference range (15 mg/dL). Median SDMA was significantly higher in AKI dogs
(18.5 vs. 12.4 mg/dL; P = 0.01). Both urea and creatinine concentration showed a positive
correlation with SDMA level in AKI dogs (P = 0.01 r = 0.6 and P = 0.006 r = 0.7, respectively)
but the same correlations were not significant in non‐AKI group. No association between
SDMA and UO was found. Finally, dogs with CAPS>11 had higher SDMA compared to dogs
with CAPS<11 (26.9 ± 5 mg/dL vs. 13.8 ± 1.5 mg/dL, P = 0.03). Based on our results,
SDMA seems to be associated with disease severity (CAPS).
SDMA correlates well with kidney disfunction parameters (urea and creatinine) and
results higher in AKI dogs. Interestingly, about 1/3 of non‐AKI dogs presents abnormal
SDMA that can be related to a subclinical kidney impairment.
Disclosures
No disclosures to report.
ESVNU‐P‐8
Evaluation of a point‐of‐care lateral flow immunoassay for detection of significant
bacteriuria in dogs and cats
S.S. From1, M.F. Drews1, P. Damborg1, L.R. Jessen1, A.B. Kjærgaard2, T.M. Sørensen1
1University of Copenhagen, Frederiksberg, Denmark, 2AniCura Københavns Dyrehospital,
Copenhagen, Denmark
There is a need for affordable point‐of‐care (POC) tests to accurately detect significant
bacteriuria in dogs and cats.
Such tests may help practitioners in limiting unnecessary empirical antimicrobial
treatment while improving patient outcome.
The aim of the study was to compare a lateral flow immunoassay POC (RapidBac™Vet)
for detection of bacteriuria, to standard aerobic quantitative bacterial culture (QBC)
at a reference laboratory.
The study was designed as a prospective cohort study. Urine samples were collected
from dogs and cats presenting to the University Hospital for Companion Animals. Samples
were subjected in parallel to RapidBacVet and QBC. POC results were interpreted by
six investigators blinded to the gold standard results for coefficient of variation
calculations.
Surplus urine samples from 79 dogs and 21 cats were included (58% by cystocentesis).
Forty‐four samples yielded ≥1000 colony forming units (CFU)/ml on QBC, of which 20
yielded heavy growth (≥100 000 CFU/mL). POC sensitivity and specificity and positive
and negative predictive values were 71%, 77%, 71% and 77%, respectively. Eight of
the 13 false negative samples grew Staphylococcus spp. By applying a cut‐off of ≥100 000 CFU/mL,
sensitivity, specificity and positive and negative predictive values changed to 80%,
65%, 36% and 93%, respectively. The intra‐assay and inter‐rater coefficients of variation
were 1.4‐3.23% and 83%, respectively.
These results suggest that RapidBac™Vet is of limited value as a sole discriminatory
test for urinary tract infection. A negative test result does not rule out urinary
tract infection but may justify withholding of antimicrobial therapy pending the urine
culture result.
Disclosures
No disclosures to report.
ESVNU‐P‐9
Antioxidant enzyme activity in dogs with acute uraemia managed with haemodialysis
F. Perondi, E. Mennillo, V. Marchetti, E. Gori, A. Pierini, I. Lippi
University of pisa, Pisa, Italy
Impairment in antioxidant enzyme activity is involved in several complications in
human patients managed with intermittent haemodialysis (HD). Different factors, concerning
uraemia and HD treatment, can promote oxidative stress in these patients. HD may generate
oxidative stress due to several factors, such as reduced dialyzer biocompatibility,
extensive contact between blood and synthetic surfaces of extra‐corporeal circuit,
and poor dialysate sterility. The aim of the present study was to evaluate antioxidant
enzyme activity between pre‐ and post‐ haemodialysis treatment in dogs with acute
uraemia, and its correlation with systemic inflammatory response syndrome (SIRS),
and disseminated intravascular coagulation (DIC). Ten uremic dogs managed with HD
(HDG) and ten clinically healthy dogs (CG) were included. Enzymatic activities of
catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx) were
assessed in blood hemolysates of dogs of both groups. In HDG dogs, blood samples were
taken immediately before HD, and at the end of HD (15 seconds into bypass at standard
blood flow of 50 mL/min). HDG dogs were classified according to IRIS guidelines for
AKI. The presence of SIRS and DIC were diagnosed on the basis of emathological, biochemical
and coagulation profile according to the recently published criteria. Enzymatic activities
of CAT, SOD and GPx were compared among CG, pre HD treatment (n = 17) and post HD
treatment (n = 17), using the Tukey's Multiple Comparison Test. Enzymatic activities
of CAT, SOD and GPx showed no significant differences between pre‐dialysis and post‐dialysis
values, although GPx was significantly increased (P < 0.0001) in HDG compared to CG.
Dogs with DIC (n = 4) showed significantly lower CAT (P < 0.0001) and GPx (P < 0.0001)
levels, than dogs without DIC (n = 6). CAT and GPx activities in patients with SIRS
(n = 3) appeared to be significantly lower than patients without SIRS (n = 7). In
our cohort of dogs, intermittent HD did not seem to significantly affect antioxidant
enzyme activity. However the reduced enzymatic activities in uremic dogs with DIC
and SIRS is worthy of further investigations.
Disclosures
No disclosures to report.
ESVNU‐P‐10
Risk factors for urinary tract infection in dogs with natural occurring leptospirosis:
a retrospective cohort study of 76 dogs
V. Pantaleo, T. Furlanello, M. Caldin
San Marco Veterinary Clinic, Veggiano, Italy
Leptospirosis is a zoonotic disease. Due to the risk of dog‐to human transmission
of leptospirosis and the need of monitoring urine output in dogs with acute kidney
injury it is highly recommended to place an indwelling urinary catheter during hospitalization.
Urinary catheterization can predispose to urinary tract infection (UTI). The aim of
this retrospective cohort study was to evaluate type and frequency of UTI in dogs
with leptospirosis and to identify risk factors associated with UTI in leptospirotic
dogs.The electronic data‐base of the San Marco Veterinary Clinic P.O.A System‐Plus
9.0 was searched between January‐2008 and December‐2018 for dogs with diagnosis of
leptospirosis (n = 78). Diagnosis of leptospirosis was consistent clinicopathologic
signs, a positive microscopic agglutination test (titer ≥1:1600 in vaccinated dogs,
titer ≥1:800 in non‐vaccinated dogs or ≥ 4‐fold increase in convalescent titer) and/or
a positive PCR (urine and/or blood). Dogs with leptospirosis to be included in the
study need to met the following criteria: negative urine sediment and urine culture
at arrival, ≥ 3 days hospitalization, and a urine sample for cytologic examination
and bacterial culture during hospitalization. Dogs meeting inclusion criteria were
divided in 2 groups: catheterized dogs (group 1) and non‐catheterized dogs (group
2). Differences in UTI frequency between groups was evaluated (Fisher's exact test).
Association between duration of catheterization and risk of developing UTI was analysed
(Wilcoxon‐Mann‐Whitney test). Age, sex, diarrhoea, antecedent antibacterial and/or
immunosuppressive treatment were evaluated for association with UTI (Chi‐square test).
Significance level for all statistical test was set at α < 0.05. A total of 76 dogs
met inclusion criteria: 25 in group 1 and 51 in group 2. Overall 5/76 (7%, all in
group 1) dogs developed a UTI. Identified bacteria were: Escherichia coli (3 dogs),
Pseudomonas aeruginosa (1 dog) and Klebsiella pneumoniae (1 dog). All UTI were defined
as multidrug‐resistant. Frequency of UTI was significantly higher in group 1 (5/25,
20%) compared to group 2 (0/51, 0%; OR = ∞; CI = 2.082 — ∞). Infected dogs had a significantly
longer catheterization time (median = 6 days, IQR = 2.3) compared to non‐infected
dogs (median = 2 days, IQR = 2.6; P = 0.026). Age, sex, diarrhoea, antecedent antibacterial
and/or immunosuppressive treatment were not significantly associated with UTI. Urinary
catheterization and duration of urinary catheterization represented important risk
factors for development of UTI in dogs with Leptospirosis.
Disclosures
No disclosures to report.
ESVNU‐P‐11
Accuracy of refractometric urine specific gravity determination in cats
F. Manczur, B. Szabó
University of Veterinary Medicine, Budapest, Hungary
Urine‐specific gravity (USG) is used as a proxy for urine concentration or osmolality
and usually determined by using a refractometer. There is a long held belief that
feline urine has higher specific refractivity than human or canine urine, thus human
refractometer scales may result in falsely high readings for feline samples. There
are some commercially available veterinary refractometers that are calibrated with
different scales for cats and a conversion formula has also been recommended if a
refractometer with human scale is used in order to avoid overestimation of the USG
in cats. Two recent studies questioned whether a separate scale is necessary for the
correct interpretation of the refractometer readings in feline urine.
The aim of this study was to compare canine and feline USG readings obtained by a
commercial human refractometer with weight/volume measurement USG data. A second aim
of the study was to test whether the centrifugation of the urine samples may have
an effect on the accuracy of refractometric USG determination.
The USG of thirteen canine and fifteen feline urine left over specimens were compared
using refractometry and precise weight/volume measurement. All urine samples were
clear, pale to dark yellow in color. The bias between the two methods was determined
by Bland‐Altman analysis. The measurements were performed both on uncentrifuged and
centrifuged samples. The effect of centrifugation was evaluated by paired T test.
The median (1st, 3rd quartiles) USG of the canine samples was 1015 (1008, 1024). The
mean (±SD) USG of the feline samples was 1033 (±11). There were no significant differences
between the refractometric USG values of canine or feline urine samples before and
after centrifugation. The mean bias between the refractometric and weight/volume determined
USG values of the feline samples was 1,8 ± 2,4. Using the generally accepted feline
correction formula changed the mean bias to −3,1 ± 3,6. For comparison, the mean bias
of the canine samples was −2,9 ± 5,7.
Based on our results we can conclude that it is unnecessary to use different scales
or correction formulas during the refractometric USG determination of canine or feline
urine samples. The use of the feline correction formula may result in a clinically
important underestimation of the USG. The USG measurements can be performed both on
native and centrifuged urine samples if the urine is clear. The inaccuracies of the
refractometers irrespective of the species should be taken into consideration during
the clinical decision making.
Disclosures
No disclosures to report.
ESVNU‐P‐12
Early detection of tubular damage in dogs infected with Leishmania infantum: use of
N‐acetyl‐β‐D‐glucosaminidase (NAG) and glutamyl transferase (GGT)
J. Duque1, A. Ayuso1, B. Macías‐García1, P. Ruiz1, D. Casamian‐Sorrosal2, J.I. Cristobal1,
C. Zaragoza1, R. Barrera1
1Veterinary Teaching Hospital, University of Extremadura, Cáceres, Spain, 2Cardiology
and Cardiopulmonary Service / Southfields Veterinary Specialist, Basildon, United
Kingdom
Renal damage associated with canine leishmaniasis induces nephritis and glomerulonephritis
which cannot always be detected using classical laboratorial biomarkers (creatinine,
urea, protein/creatinine ratio and urine specific gravity). N‐acetyl‐β‐D‐glucosaminidase
(NAG) and glutamyl https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/transferases
(GGT) are hydrolytic enzymes found in the epithelial cells of the proximal tubule
of the kidney being their presence in the urine associated to tubular damage. Hence,
we aimed to evaluate the diagnostic power of urinary NAG and GGT as early markers
of renal disease in dogs affected with leishmaniasis using a modified IRIS chronic
kidney disease staging.
A prospective study was conducted in 5 groups of dogs:17 healthy dogs (C),13 dogs
(G1) with an urinary protein/creatinine ratio (UP/C) ≤0.2 and plasma creatinine (CR)
<1.4 mg/dL, 5 dogs (G2) with UP/C between 0.21‐0.4 and CR < 1.4 mg/dL, 6 dogs (G3)
with UP/C ≥ 0.41 and CR <1.4 mg/dL and 15 dogs (G4) with UP/C ≥ 0.41 and CR≥1.4 mg/dL.
Dogs presented to the University of Extremadura small animal hospital with a variety
of clinical signs and diagnosed with visceral Leishmaniasis were included in the study.
All dogs had haematology, biochemistry, blood protein electrophoresis, Leishmania
ELISA (quantititative), abdominal ultrasonography, and full urine analysis and culture
(including UP/C, NAG and GGT) carried out.
NAG was determined using a commercial kit (Diazyme®, Germany), GGT by a specific kit
from RAL® (Spain). The results are all normalized to their respective urinary creatinine
and expressed as ratios: uNAG/CR and uGGT/CR. All groups were not normally distributed
and a Mann‐Whitney‐U test was used to compare among groups; P < 0.05 was considered
statistically significant.
The urinary uNAG/CR (IU/g; mean ± SD) was 1.6 ± 0.7 in group C;5.77 ± 5.04 for G1;10.27 ± 6.96
in G2;12.61 ± 13.1 in G3 and 57.51 ± 54.36 in G4. For uGGT/CR (IU/g; mean ± SD) the
values obtained were 0.8 ± 0.69 for group C;1.43 ± 1.58 in G1;5.07 ± 10 in G2;3.34 ± 5.72
in G3 and 17.75 ± 31.22.1 in G4.
uNAG/CR differed statistically in all groups compared to control and G1, G2 and G3
differed from G4; significant differences for uGGT/CR were only found between C and
G4.
This study shows that uNAGC/CR appears to be a good biomarker for early detection
of renal tubular damage at early stages of canine leishmaniasis, prior to the presence
of azotaemia and proteinuria. On the contrary, uGGT/CR appears to be less useful for
this purpose, as it is only consistently elevated at more advanced stages of leishmania‐associated
chronic kidney disease.
Disclosures
No disclosures to report.
ESVNU‐P‐13
Usefulness of urine neutrophil gelatinase‐associated lipocalin (NGAL) and Cystatin
C (CysC) in the diagnosis of renal disease in dogs affected with leishmaniasis
J. Duque1, P. Charlo1, B. Macías‐García1, P. Ruiz1, D. Casamian‐Sorrosal2, J.I. Cristobal1,
C. Zaragoza1, R. Barrera1
1Veterinary Teaching Hospital, University of Extremadura, Cáceres, Spain, 2Cardiology
and Cardiopulmonary Service / Southfields Veterinary Specialist, Basildon, United
Kingdom
Canine leishmaniasis is a highly prevalent zoonotic disease in Spain. All dogs affected
present structural and/or functional abnormalities in their kidneys ranging the clinical
presentation from asymptomatic to severely diseased individuals being the clinical
signs, creatine and proteinuria used to assess the evolution of their condition. Evaluation
of other markers of early renal damage could be used for redefining disease classification
or for prognostic and/or therapeutic guidance purposes. Moreover, dogs with Leishmaniasis
are optimal natural models for the study of tubular damage biomarkers such as NGAL
and CysC in canine chronic kidney disease. We aimed to evaluate the diagnostic power
of urinary NGAL and CysC as early markers of renal disease in dogs diagnosed with
L. infantum using a modified IRIS chronic kidney disease staging.
Dogs presented to the University of Extremadura veterinary hospital with a variety
of clinical signs and diagnosed with visceral Leishmaniasis were included in the study
and 5 groups were stablished: 10 healthy dogs (C),13 dogs with an urinary protein/creatinine
ratio or UP/C ≤ 0.2 and plasma creatinine or CR < 1.4 mg/dL (G1),7 dogs presenting
UP/C 0.21‐0.4 and CR < 1.4 mg/dL (G2),16 dogs with UP/C ≥ 0.41 and CR < 1.4 mg/dL
(G3) and 16 dogs with UP/C ≥ 0.41 and CR≥1.4 mg/dL (G4).Some dogs also had other testing
including thoracic radiographs, echocardiography or Leishmania PCR in a variety of
tissues.
NGAL was determined using the canine NGAL Elisa kit (Abcam, USA) and the results are
expressed as NGAL/creatinine ratio (uNGAL/CR). Cystatin C was measured using a turbidimetric
latex assay (Spinreact, Spain) and is expressed as CysC/creatinine ratio (uCysC/CR).
Mann‐Whitney‐U test was used to run all comparisons due to the non‐gaussian distribution
of the data with P < 0.05 considered as statistically significant.
The urinary uNGAL/CR (μg/g; mean ± SD) was 1082 ± 782 in group C;5210 ± 3676 for G1;38 446 ± 12 269
in G2;453 219 ± 322 898 for G3 and 4 306 983 ± 3 852 666 in G4. For uCysC/CR (μg/g;
mean ± SD) the values obtained were 80 ± 54 in C; 485 ± 249 in G1; 475 ± 81 in G2;
9294 ± 7992 in G3 and 36 450 ± 22 571 in G4. For both biomarkers statistically significant
differences were found between the control group and all the rest. G1 and G2 were
significantly different compared to G3 and G4 for NGAL and CysC. Additionally, CysC
values differed significantly between G3 and G4.
Our results demonstrate that urinary uCysC/CR and uNGAL/CR are highly sensitive biomarkers
that detect tubular damage in non‐azoemic, non‐proteinuric dogs affected with canine
leishmaniasis.
Disclosures
No disclosures to report.
ESVNU‐P‐14
Complicated UTI in dogs: uropathogens, antimicrobial resistance and comorbidity
J. Zambarbieri, F. Celi, S. Faverzani, P.A. Martino, P. Scarpa
University of Milan, Lodi, Italy
Complicated urinary tract infections (cUTI) occur in the setting of a urinary tract
with underlying metabolic, functional, or structural abnormalities that typically
require longer antibiotic courses and carry a higher risk of treatment failure.
UTI are major reasons for antibiotic prescription in dogs and the responsible bacterial
populations have developed increasing resistances.
The aim of this retrospective study was to investigate the prevalence of pathogens,
their susceptibility patterns, the comorbidities and the urinary sites involved (detected
by ultrasonography) in a population of dogs affected with cUTI.
Four hundred thirty one urine samples collected by cystocentesis from 260 dogs underwent
to urine culture for diagnostic purposes. Antimicrobial sensitivity tests were obtained
by Kirby‐Bauer method. Comorbidities were deduced by the analysis of patient clinical
and ultrasound reports.
A control group of 360 dogs (4fold the dogs affected) was randomized among the whole
canine population examined during the same period of time (2013‐2017). Wilcoxon, Kruskal‐Wallis
and Chi‐square tests were used for statistical analysis.
One hundred forty one urine samples (32.7%) from 90 dogs (34.6%) had a positive culture.
Crossbreeds (29%) and spayed females (42%) were prevalent and the mean age was 9.2 years.
A significant higher prevalence, among the “UTI‐dogs” was observed for Labrador Retriever,
English Bulldog, Golden Retriever, Beagle and Cocker Spaniel, spayed females and dogs
between 8 and 13 years old.
Escherichia coli was the predominant pathogen (43%), followed by Staphylococcus pseudintermedius
(8%), Staphylococcus aureus (8%), Streptococcus faecalis (7%), Klebsiella pneumoniae
(6%), Pseudomonas aeruginosa (5%) and other 13 species. A predominance of single isolates
(89.4%) compared to polymicrobial infections (10.6%) was observed.
Marbofloxacin was overall the most effective molecule (63.1% sensitivity), followed
by Cefovecin (58.6%), Ceftriaxone (55.1%), Enrofloxacin (54%) and Pradofloxacin (53.3%).
Escherichia coli showed the highest sensibility versus Cefovecin (70%), Marbofloxacin
(67.2%), Trimetoprim/Sulphamide (64.3%), Ceftriaxone (63.5%), Pradofloxacin (61.5%)
and Enrofloxacin (60.9%).
The most represented identified comorbidities were urolithiasis (25%), CKD (24%),
hyperadrenocorticism (11%) and extra‐urinary neoplasms (10%). Eight dogs were included
because of the recurrence of the infections.
Of the 68 dogs underwent to abdominal ultrasound, 58 (85.3%) showed ultrasonographic
abnormalities involving the urinary system: 36 (52.9%) in the upper tract, 41 (60.3%)
in the lower tract and 19 of these in both (27.9%).
The high rate of antimicrobial resistance detected could lead to treatment failures
and poor prognosis; additional guidelines are needed because of the public health
concern determined by the zoonotic potential of the isolated bacteria.
Disclosures
No disclosures to report.
ESVNU‐P‐15
Cats at risk or with spontaneous CKD. What affects survival and prognosis?
P. Scarpa, A. de Sanctis, J. Zambarbieri
University of Milan, Lodi, Italy
Chronic kidney disease (CKD) is among the major causes of morbidity and mortality
in cats, with a significant prevalence up to 31% over 15 years old.
The aim of this retrospective observational study was to evaluate the prevalence of
death, survival time and risk factors in a population of cats at risk or affected
with CKD.
One hundred thirty three cats, from a starting population of 472 (years 2013‐2018),
were included in this study. One or more of the following criteria had to be observed
during their first clinical examination: age over 9 years, serum creatinine (SCr)
>1.6 mg/dL, borderline (0,2‐0,4) or pathologic (>0,4) urinary protein/creatinine ratio
(UPC), urine specific gravity (USG) <1.035. Furthermore, their “follow‐up data” have
been obtained through an online questionnaire filled by the owners (beginning of 2019).
The nephropathic cats were staged according to IRIS guidelines, and not nephropathic
cats were included in stage 0.
Wilcoxon test and Kaplan Meyer survival curve analysis were performed.
Median age of the population was 11 ± 4,31 years; male were over‐represented (55 vs
45%); Domestic Shorthair was the predominant breed (76%).
Forty nine (36,8%) cats were included in stage 0; 21 (15,8%) in stage 1; 48 (36,1%)
in stage 2; 7 (5,3%) in stage 3; 8 (6%) in stage 4, with a mean sCr value of 1,98
mg/dL ± 1,54.
Sixty (45,1%) cats were naturally dead or euthanized at the time of the survey; 25
(18,8%) of these due to CKD. Some parameters were significantly different between
the two groups: “dead by CKD” and “dead by other diseases”. Serum creatinine was higher,
while USG, red blood cells (RBC), white blood cells (WBC) and hematocrit (Ht) were
significantly lower in “dead by CKD” cats. Survival time in nephropathic cats was
related with age, IRIS staging, serum phosphorus, RBC, WBC, Ht. Cats staged as IRIS‐2
survived longer than cats staged as IRIS‐1, because other comorbidities are the reason
for the consultation in stage‐1 cats. A lower survival time was observed in cats with
a body condition score different than normal (higher or lower). Lower survival was
observed in hypertensive conditions when the whole population of cats was considered,
and not only the CKD one.
Other than sCr, results from CBC and USG are to keep in consideration in a prognostic
evaluation of cats at risk or affected with CKD. Age has to be considered a risk and
a prognostic factor.
Disclosures
No disclosures to report.
ESVONC‐P‐1
Multicentric and prospective study on 271 cases of endonasal neoformations in the
dog
E. Bottero1, S. Astorina1, E. Benvenuti1, P. Ruggiero1, M. Martano2, D. Cattaneo1,
A. Campanile1, N. di Girolamo3
1Association Professional Endovet Italy, Rome, Italy, 2Department of Veterinary Science,
University of Turin, Turin, Italy, 3Oklahoma State University, United States of America
Tumors of the nasal cavity represent 1‐2% of all canine neoplasms. They are more frequent
in elderly animals, of epithelial origin and locally invasive with a low metastatic
incidence.
All the subjects included in this multicenter and prospective study were examined
between June 1, 2016 and December 31, 2018; the rhinoscopy revealed new tissue formation
in the nasal cavity and in the nasopharynx. The case histories, including clinical
exams, laboratory exams, X‐rays, endoscopies, tomographies, histology, therapeutic
choices, and follow‐ups, of 271 subjects were collected and analysed.
The dogs were principally dolichocephalic breeds, 50% males and 48% females, with
an average age of 10 and average BCS 2.9 (0‐5). Most of the subjects (78%) underwent
symptomatic treatment before the diagnosis, and in 43% symptoms had been present for
over 3 months. The most common clinical symptom was nasal discharge (87%), unilateral
in 55%. Serosanguinous discharge and/or epistaxis were present in 62% of the cases;
stertor in 63%; facial swelling, deformation of the nasal planum, and/or exophthalmos
in 20%.
Endoscopic examination found neoformation, which was unilateral in 34.7% of the cases
and nasal and nasopharyngeal in 55%. The histological types of the neoplasms were
classified as malign epithelial (70%), malign mesenchymal (12%), benign (11%), round
cell tumors (4%), and other (3%).
Of the 271 subjects evaluated, 23 underwent endoscopic debulking (diode laser associated
with grasping forceps), 31 metronomic therapy, 28 debulking and metronomic therapy,
4 radiation treatment, 5 radiation and metronomic radiotherapy, 8 chemotherapy, 2
surgery, 1 debulking and radiotherapy and 169 no specific therapy. Of the 166 deceased
patients (61.3%), the average survival time was 160 days for malign epithelial tumors
and 206 days for malign mesenchymal tumors. In patients that underwent debulking and
metronomic therapy the average survival time was 442 days, in those treated with debulking
alone 227 days, metronomic therapy alone 216 days, and in those that did not have
therapy 115 days. To date, of the 29 subjects with benign neoplasia, 21 (72.5%) are
alive.
In conclusion our study shows that nasal tumors are often diagnosed late, when the
nasopharynx is already affected. The most common histological type is adenocarcinoma;
benign neoplasia, which is rarely described in the literature, is also frequent. The
good response to nasal debulking combined with metronomic therapy makes this multimode
approach worthy of further evaluation, both for its reduced cost and for the high
quality of life for the patients.
Disclosures
No disclosures to report.
ESVONC‐P‐2
Sensitivity of canine and human cancer cell lines towards thermoradiotherapy
P.E. Thumser‐Henner1, K.J. Nytko1, M. Weyland2, E.R. Beebe1, J. Ettlin1, E. Markkanen1,
S. Scheidegger2, C. Rohrer Bley1
1Vetsuisse faculty, Zurich, Switzerland, 2ZHAW School of Engineering, Zurich University
of Applied Sciences, Zurich, Switzerland
Hyperthermia (41°C to 43°C) combined with radiotherapy (HT‐RT), or thermoradiotherapy,
is used clinically in particular cases of human and canine cancer. Hyperthermia provokes
changes at different levels: in the tumor microenvironment by increasing perfusion
and oxygenation and inducing an immune response, in the tumor cells by induction of
cell death and inhibition of DNA repair mechanisms. These changes increase the efficacy
of radiation treatment towards a better tumor response. However, the molecular mechanisms
of this cellular sensitization have not been fully elucidated. The aims of our study
were firstly to screen human and canine cancer cell lines for their sensitivity towards
hyperthermia‐radiotherapy treatment, and investigate the role of heat‐shock protein
HSP70, and DNA repair proteins in the radiosensitization mechanism.
Survival curves after treatment were determined in a panel of human and canine cancer
cell lines using a clonogenic survival assay. We analyzed the effect of HT‐RT on cell
proliferation and apoptosis. Further, we tested the influence of the HT‐RT time gap,
different temperatures and order of the treatment, using A549 cells that are sensitized
by hyperthermia as positive controls. Levels of HSP70 and the DNA repair protein RAD51
were analyzed in HT‐sensitive and ‐resistant cell lines by Western‐Blot. Knockdown
of HSP70 was performed in A549 cells using siRNA against HSP70. Additionally, we evaluated
mRNA levels of BRCA2 in an ex vivo canine tumor model (soft tissue sarcomas, carcinomas,
mast cell tumors), and whether they were affected by hyperthermia. Out of eight cell
lines tested, only A549 and Abrams cells showed significant decrease in clonogenic
cell survival when pre‐treated with hyperthermia at 42°C. A549 showed high baseline
levels of HSP70, which was further induced upon treatment. All other cell lines had
low or non‐detectable baseline expression levels, but showed strong induction upon
treatment. Levels of RAD51 were not affected. Additionally, HSP70 knockdown did not
affect clonogenicity after HT‐RT. However, BRCA2 mRNA levels were lowered by heat,
notably in ex vivo treated canine soft tissue sarcomas.
Our results show that a majority of cell lines are not radiosensitized in vitro, indicating
that the tumor microenvironment is responsible for the major effect of hyperthermia.
Interestingly, we discovered a heat‐induced suppression of BRCA2 transcription, potentially
inhibiting the homologous recombination repair pathway. This is promising in the light
of future combination of hyperthermia with PARP inhibitors.
Disclosures
No disclosures to report.
ESVONC‐P‐3
Interest of the association of abdominal ultrasound and alanine transaminase (ALT)
measurements in the determination of hepatic infiltration in case of nodal diffuse
large B‐cell lymphoma (DLBLCL)
D. Lanore1, P. Vajdovich2, J. Borrego3, F. Mellet4, D. Moniot4, J. Laxalde4, J. Bayle4
1Clinique vétérinaire Alliance, Bordeaux, France, 2University of Veterinary Medicine,
Budapest, Hungary, 3Aúna Especialidades Veterinarias, Paterna, Spain, 4Royal Canin
SAS, Aimargues, France
In canine nodal DLBCL one important step in diagnosis is the determination of the
presence of a hepatic infiltration, which correspond to a stage IV based on the World
Health Organization's staging for lymphoma. The assessment of liver involvement is
classically made by ultrasonography and is confirmed by cytology, which remains the
usual procedure. The efficacy to determine hepatic infiltration based on abnormal
images has been evaluated at 77% with respective sensitivity, specificity, positive
prognostic value (PPV) and negative prognostic value (NPV) of 73%, 81%, 77% and 76%
(Crabtree 2010).
The aim of this work was to evaluate if the association of abdominal ultrasound and
ALT measurements can help in the determination of hepatic infiltration.
A complete clinical staging was prospectively performed in 76 dogs (examined in 9
oncology referral centers) with a confirmed diagnosis of a nodal DLBCL. Liver ultrasound,
cytology and plasma ALT measurements were performed for each dog. The ultrasonographic
patterns characteristic for canine lymphoma in liver included coarse parenchyma, ill‐defined
hypoechoic areas, hypoechoic nodules, diffuse hypoechogenicity, and diffuse hyperechogenicity
with or without hepatomegaly (Nyland 1984, Crabtree 2010). ALT analysis was performed
in‐house, and results were interpreted against each laboratory‐specific reference
ranges and classified as normal vs elevated. Ethics approval was granted by Royal
Canin's Ethical Committee.
Hepatic infiltration, confirmed by cytology, was found in 70% of cases. To evaluate
the interest of the association of liver ultrasound and ALT in the determination of
infiltration, dogs were classified as positive if they had ALT outside laboratory
range in combination with abnormal ultrasound images. Dogs with all other findings
were considered as negative. Sensitivity, specificity, PPV and NPV were 17%, 100%,
100% and 34% respectively.
Our results suggest that the simultaneous finding of elevated ALT and abnormal ultrasonography
allows to identify dogs with hepatic infiltration in case of nodal canine DLBCL. To
confirm these findings further research is needed.
Disclosures
Disclosures to report.
This work has been financially supported by Royal Canin SAS (Mars Petcare). F. Mellet,
D. Moniot, J.Laxalde and, J. Bayle are employees in Royal Canin.
ESVONC‐P‐5
Pet owner feedback on psychological support service in an Italian veterinary hospital:
a survey data
M. Campigli1, G. Strizzolo2
1San Marco Veterinary Clinic, Padova, Italy, 2ADO Fondation, Ferrara, Italy
Pet owner burden has been recently explored in a few studies in veterinary medicine
taking humans model. Veterinary studies identify this phenomena in pet owners with
companion animals affected by chronic or terminal illness. Furthermore, clients burden
may exacerbate occupational stressors of the veterinarians.
This study aimed to understand if pet owners are interested on a psychological support
provided directly by the veterinary hospital.
A survey was given in the waiting room of single Italian veterinary hospital to dog
and cat pet owners, coming to visit for several medical reasons (3rd January‐23th
March 2019). The survey included questions on socio‐demographic data, on the emotional
experiences of the owner during the disease and the care of their pets, and on their
opinion of having a psychologist for their support.
A total of 350 surveis were administrated, and 268 were returned (76.58% of adherence
to the study). Twelve were discarded because incomplete. The sample was composed of
62,9% female and 37.1% male. The most represented age group was 40/60 years (55.5%),
had a dog (76.9%) instead of a cat (12.5%) or both (10.6%). Most of the pets presented
to the department of internal medicine (43%), followed by oncology (14.8%) and emergency
(10.9%); 95.7% of the sample declared to have anxiety, was concerned or demoralized
for the health of their animals, and 69.7% of the subjects reported that would have
appreciated to receive help from someone competent. In contrast, 30.3% declared “non‐desiring”
support. The most reported motivation for their decision was the desire to live their
emotions alone (50.6%). Sixty‐six % of the sample would use the service itself and/or
suggest it to its family members in case of difficult decisions, poor prognosis, or
emotional management particularly, those who claimed to normally feel anxiety and
concern about the health of their animals (47.7%). They were among those who would
most likely use the service (32%). Finally, those who declared themselves probable
beneficiaries of the service of psychological support, considered in 57% of the cases
the hilliness and mourning of their pet comparable, in terms of distress, to the illness
and the loss of a loved one.
Our survey showed that a large percentage of owners express the desire to be followed
by a professional figure in the field of psychological support, during the treatment
of their pets. To our knowledge, this aspect has never been investigated before in
an Italian veterinary hospital.
Disclosures
No disclosures to report.
ESVONC‐P‐6
Evaluating the myelosupressive effects of a single dose of vincristine in dogs with
lymphoma
A. Mosca, E. Dobson, J. Dobson
University of Cambridge, Queen Veterinary School Hospital, Cambridge, United Kingdom
Lymphoma is the most common haematopoetic neoplasm in the canine population. Chemotherapy
protocols, such as COP, CHOP and LOPP are used to treat lymphoma due to its chemosensitive
nature. These protocols routinely involve vincristine. Current literature reports
the most common vincristine induced toxicity to be gastrointestinal effects but also
suggests a degree of myelosupression especially during combination protocols. Little
research has focused on the myelosupressive effects of vincristine alone and after
a single dose. Neutropenia leading to treatment delays or dose reductions, have been
associated with longer remission times.
The aim of this study is to investigate the myelosupressive effects of vincristine
in dogs after a single administration.
The records of dogs with previously untreated, confirmed lymphoma receiving vincristine
between July 2015 to March 2019 were analysed. Patients were included if they had
a haematology performed prior to receiving vincristine and repeated within 5‐14 days,
prior to receiving a second dose of chemotherapy. Patients were excluded if they received
any other chemotherapeutic medication during this time, oral prednisolone therapy
was permitted.
Forty‐four dogs treated with 0.5‐0.7 mg/M2 intravenous vincristine were included in
the study, all of the dogs had lymphoma. Boxers (4), Labradors (4) and Spaniels (6),
were over‐represented. The study population had a mean age of 7.8 years, ranging from
2.7‐13 years. Mean body weight was 22.9 kgs ranging from 3.4‐63kgs.
Four dogs (9%) experienced neutropenia (neutrophil count <2.0 x 10^9/L) following
a single administration of vincristine, two of which were borderline neutropenic at
the start. Two dogs developed VCOG grade 4 neutropenia, one dog grade 3 and one grade
2. The study population had a mean neutrophil count of 9.96 x 10^9 (range 1.25‐55.22
x 10^9/L), prior to vincristine administration and a mean of 8.7 x 10^9/L (range 0.4‐35.2
x 10^9/L), one week post vincristine. 27/44 (61%) cases had a decreased neutrophil
count on the second sample. Neither weight nor age influenced likelihood of developing
neutropenia.
Fifteen of the cases were thrombocytopenic (<150 x 10^9 /L) prior to vincristine,
compared to only two post vincristine, with a mean of 213.65 and 372.45 respectively.
37/43 (84%) of the cases showed an increase in platelet count following a single administration
of vincristine.
This study shows that a small proportion (9%) of dogs receiving vincristine, initially
as a sole agent, but as part of a chemotherapy protocol for lymphoma, developed a
significant neutropenia within one week of vincristine administration.
Disclosures
No disclosures to report.
ISCAID‐P‐2
Circulating immune complexes levels correlate with the progression of canine leishmaniosis
J.C. Carnés1, N. Parody1, C. Cacheiro‐Llaguno1, C. Osuna1, A. Renshaw‐Calderon2, C.
Alonso2
1Laboratorios LETI S.L., Tres Cantos, Spain, 2Centro de Biología Molecular Severo
Ochoa, CSIC‐Universidad Autónoma de Madrid, Spain
Dogs are the main domestic reservoir of L. infantum. In Leishmania infected dogs unable
to control the infection, a large and uncontrolled humoral immune response is elicited,
which is inefficient against parasites. The high concentration of antibodies and circulating
antigens in canine leishmaniosis can result in the formation of Circulating Immune
Complexes (CICs). Their deposition in tissues has been associated with tissue damage
and especially glomerulonephritis and renal failure. However, little is known about
the relationship between the presence of CICs and the progression of the disease.
The objective was to evaluate the levels of CICs and their correlation with the severity
of the disease in serum samples from healthy and infected animals.
A total of 44 dogs, classified according to the LeishVet criteria (Healthy (n = 13),
Infected Asymptomatic (n = 12) and Infected Symptomatic ‐stage I (n = 9), II (n =
17), III (n = 8) and IV (n = 1)), were included in the study. CICs were isolated from
serum samples using a slightly modified PEG‐precipitation method, and their levels
measured by ELISA. The protein content was estimated by bicinchoninic acid (BCA) protein
assay. A Nanoparticle Tracking Analysis (NTA) of CICs was done in order to investigate
the relationship between CIC molecular size distribution and the progression of the
disease.
Results showed a statistical significant correlation between CICs levels and the stage
of the pathology in infected dogs. As expected, healthy and infected asymptomatic
animals did not show CICs related with the infection and there was a direct relationship
of levels of CICs, total protein concentration and progression of the disease. It
was also confirmed the correlation between IFAT titers and CICs levels. In addition,
data showed that dogs with more severe clinical signs presented large size protein
aggregates whereas higher concentration of smaller size aggregates were observed in
non infected and asymptomatic dogs. This fact demonstrates a clear positive correlation
between clinical stage and the size of precipitated‐CICs.
This is the first study correlating the CICs levels with the progression of the disease.
in canine leishmaniosis. The measurement of CICs probably represents a valuable tool
to not only diagnose but also to predict disease progression and activation in asymptomatic
but seropositive dogs or even follow up the efficacy of treatments. Even more, the
measurement of CICs as a biomarker of the progression of the disease could provide
interesting information about vaccines or immunotherapy treatments to confirm the
control of the disease.
Disclosures
Disclosures to report.
Employee of Laboratorios LETI.
ISCAID‐P‐3
Clinicopathological findings in canine leishmaniosis and its association with signalment
M. Cabré1, L. Solano‐Gallego2, M. Planellas1, L. Ordeix1
1Fundació Hospital Clínic Veterinari, Universitat Autònoma de Barcelona, Bellaterra,
Spain, 2Departament de Medicina i Cirurgia Animals, Universitat Autònoma de Barcelona,
Bellaterra, Spain
Canine leishmaniosis (CanL) is a vector‐borne disease caused by Leishmania infantum.The
type of predominant individual immune response is crucial in the presentation of the
disease and determinates the clinical signs and clinicopathological abnormalities
in each dog.
Age, sex and breed seem to be determinant in the type of clinical manifestations that
dogs develop as well as the outcome of infection. The objective of the study was to
define clinicopathological findings of CanL and its association with signalment.
A total of 123 dogs with a diagnosis of leishmaniosis were retrospectively included.
The information obtained through the clinical history, physical examination and laboratorial
tests of each dog was used to fill out a database that included signalment, clinical
signs, laboratorial abnormalities and clinical stage of disease.
Most dogs studied were classified as moderate clinical stage of canine leishmaniosis
(70.2%). Young dogs have less tendency to develop systemic signs (P = 0.0059), renal
(P = 0.0015) and hematologic (P = 0.0267) abnormalities, while dermatologic signs
appear to be more common in young dogs compared with old ones (P = 0.0451). Young
dogs showed proteinuria less often than older dogs (P = 0.0029). Dogs younger than
3 years did not present renal azotemia, while older dogs showed occasionally renal
azotemia (P = 0.0284). Younger dogs were mainly classified as Stage I or II‐mild‐moderate
disease, and very rarely as Stage III or IV‐ severe or very severe disease, compared
with dogs older than 3 years old (P = 0.0153). Pure breed dogs seem to have significantly
more tendency to develop ulcerative dermatitis compared to mixed breed dogs (P = 0.0460).
This study describes, for the first time, that age appears to be associated with differences
in clinicopathological findings of CanL. Young dogs appear to present less severe
manifestation of disease and are more prone to develop dermatologic signs than adult‐old
dogs. Moderate clinical stage is commonly found in CanL.
Disclosures
No disclosures to report.
ISCAID‐P‐4
Correlation between the molecular epidemiology of canine Babesia species and the distribution
of vector ticks on dogs in Taiwan
B.L. Su1, J.C. Fang1, F. Jongejan2
1Institute of Veterinary Clinical Sciences, National Taiwan University, Taipei, Taiwan,
2Utrecht Centre for Tick‐borne Diseases, Utrecht University, Utrecht, Netherlands
Babesia gibsoni and Babesia vogeli have both been identified in canine babesiosis
in Taiwan, where information on the epidemiology of the disease is limited. Although
direct transmission of B. gibsoni between fighting dogs has been reported from the
USA, Korea and Romania, this mode of transmission does not occur in Taiwan. The objective
of our study was to correlate the distribution of Babesia with the distribution of
ticks infesting dogs in Taiwan.
A total of 389 surplus blood samples and 3037 ticks were collected from 389 roaming
and free ranging owned dogs, during neutering procedures, at various residential sites
in Taiwan between January 2014 and December 2017. The prevalence of B. gibsoni and
B. vogeli was determined by PCR, whereas all ticks were identified under a stereomicroscope
using various morphological keys.
An average of 7.8 ticks was collected from 261 dogs in the north of Taiwan, 83 dogs
in the middle and 45 dogs from the south of Taiwan. Five different species of ticks
were found: Rhipicephalus sanguineus (throughout Taiwan), Rhipicephalus haemaphysaloides
(only in the north), Haemaphysalis hystricis (only in the north and middle of Taiwan),
Amblyomma testidunarium and Ixodes ovatus (both only in the north). The prevalence
of B. gibsoni and B. vogeli infection was 13.4% (56/389) and 10.3% (40/389), respectively.
Most positive B. gibsoni dogs were found in the northern part of the country 51/56
(91%), whereas a few were found in the middle part 5/56 (9%). Babesia vogeli infections
were distributed as follows: 29/40 (72.5%) in the north, 3/40 (7.5%) in the middle
and 8/40 (20%) in the south of the country. None of the dogs in the south were infected
with B gibsoni, which correlated with the absence of H. hystricis, a tick recently
identified as the local vector for B gibsoni. Babesia vogeli was more equally distributed
coinciding with the occurrence of R.sanguineus, which tick is present throughout Taiwan.
These findings are discussed in relation to the local clinical relevance and treatment
of canine babesiosis in Taiwan.
Disclosures
No disclosures to report.
ISCAID‐P‐5
Risk factors of Babesia gibsoni infection from client‐owned dogs
P.C. Liu1, B.L. Su2
1Veterinary Medical Teaching Hospital of National Chung Hsing University, Taichung,
Taiwan, 2Institute of Veterinary Clinical Sciences, National Taiwan University, Taipei,
Taiwan
Babesia gibsoni (B. gibsoni) is increasingly recognized as an anemic cause of canine
tick‐borne disease worldwide. Taiwan is an epidemic area in Asia. The purpose of this
study was to investigate the risk factors associated with B. gibsoni infection. A
total of 112 dogs with compatible clinical signs suggestive of B. gibsoni infection
e.g. pale mucous membranes, apathy, anorexia, fever, abnormal urine color and ruling
out of large piroplasmas infection (ie. B. canis or B. vogeli) were collected from
National Taiwan University Veterinary Hospital between January 2014 to December 2015.
Polymerase chain reaction (PCR) test for B.gibsoni was performed firstly to divide
the dogs into positive (59 dogs) and negative (53 dogs) groups. Factors including
environment, season, breed, gender, intact or neuter status, living lifestyle, external
parasites prevention, urine color, mucous membrane color and history of babesiosis
were analyzed by using of chi‐square test initially. Variables with P‐value ≤0.1 were
further analyzed with a stepwise multivariate logistic regression analysis. Differences
were considered to be statistically significant when their associated P‐values were ≤ 0.05.
The odds ratio of irregularly external parasites prevention (P = 0.001, OR = 4.623,
CI:1.935‐11.044) and presenting of dark brown urine (P = 0.005, OR = 3.336, CI:1.432‐7.774)
were 4.623 and 3.336, respectively. Therefore, the both factors were most likely to
be associated with infection.
The results revealed that regular prevention of external parasites and observation
of urine color are very important in babesiosis epidemic areas.
Disclosures
No disclosures to report.
ISCAID‐P‐6
Acantocheilonema reconditum in hunting dogs from Southern Italy: distribution, risk
factors and haemato‐biochemical findings
L. Pacifico1, N. Ferrari2, G. Sgroi3, C. Romeo2, F. Buono3, B. Neola4, M. Beall5,
J. Buch5, R. Chandrashekar5, V. Veneziano3, D. Piantedosi3
1University of Naples Federico II, Naples, Italy, 2Department of Veterinary Medicine,
Università degli Studi di Milano, Milan, Italy, 3Department of Veterinary Medicine
and Animal Productions, University of Naples F, Naples, Italy, 4Istituto Zooprofilattico
Sperimentale del Mezzogiorno, Portici, Naples, Italy, 5IDEXX Laboratories, Inc., Westbrook,
ME, United States of America
Acantocheilonema reconditum is a parasite transmitted by fleas, lice and ticks and
is included among the filaroid species infecting dogs. Contrary to the more well‐studied
Dirofilaria immitis and Dirofilaria repens, A. reconditum is believed to be less pathogenic,
as adult worms are localized in the subcutaneous tissues and in the perirenal fat.
Although previous studies reported the absence of clinical symptoms in infected dogs,
there are few data regarding the haematological and biochemical changes that could
be potentially caused by this parasite.
Because hunting dogs are frequently exposed to vector‐borne pathogens, the aim of
the present study was to assess the prevalence, risk factors and potential hematobiochemical
abnormalities associated with A. reconditum infection in this specific canine population.
Blood samples were collected from 3020 hunting dogs living in Campania region, and
were tested by a modified Knott technique to count and identify microfilariae. Out
of 3020 dogs tested, 84 were positive to A. reconditum, with an overall prevalence
of 2.78% (95% CI: 2.19% ‐ 3.37%). The number of microfilariae/ml ranged from 1 to
442. After excluding dogs co‐infected by different filarial worm species and/or other
vector‐borne pathogens common in Southern Italy, n. 74 dogs showed A. reconditum single
infection. The main clinical features observed were dehydration (n. 1), fever (n.
1), congested mucous membranes (n. 2) and exercise intolerance (n. 2). Complete blood
cell count results revealed leukocytosis (n. 16), anaemia (n. 2), thrombocytopenia
(n. 8), eosinophilia (n. 1). Biochemical data showed increased serum values of total
globulins (n. 14), albumins (n. 9), gamma glutamyl transferase (n. 2) and alkaline
phosphate (n. 1), hypoalbuminemia was observed in one dog.
Dogs co‐infected with other vector‐borne pathogens were not included in the statistical
analysis. The living area (P < 0.0001), type of hunted species (P = 0.0004) and ectoparasite
infestation (P = 0.018) were variables significantly associated to A. reconditum infection.
Living in Caserta province (OR = 6.0, 95% CI: 2.6‐14.2) and in Napoli province (OR
= 7.0, 95% CI: 2.4‐20.2), hunting of wild mammals (OR = 2.9, 95% CI: 1.6‐5.1) and
ectoparasite infestation (OR 1.9, 95% CI: 1.1‐3.4) represented risk factors. Concerning
the haematochemical parameters of infected dogs, a significant negative correlation
between microfilaraemic load and serum albumin level was found (Pearson Correlation
Coefficient: −0.35; P = 0.025).
The obtained data confirm the circulation of A. reconditum within the hunting dog
population of Southern Italy and provides more information about the pathogenic potential
of this filarial worm.
Disclosures
Disclosures to report.
IDEXX Grant for Scholarship for collaboration in research activities (Laura Pacifico).
ISCAID‐P‐7
Effect of human antiretroviral compound Tenofovir in the treatment of cats naturally
infected with feline immunodeficiency virus (FiV)
O. Sarpataki, A.R. Codea, I. Marcus, M. Cenariu, E. Pall, B. Sevastre
Faculty of Veterinary Medicine, Cluj‐Napoca, Romania
Feline immunodeficiency virus (FiV) is one the most common infectious agents of cats.
FIV is a lentivirus that shares many properties with human immunodeficiency virus
(HIV), can cause an acquired immune deficiency syndrome (AIDS) due to gradual loss
in T helper cell numbers and function, characterized by increased susceptibility to
secondary pathogens. Both viruses preferentially infect CD4+ T lymphocytes, leading
to an inversion of the CD4+/CD8+ lymphocyte ratio. Tenofovir, a Nucleotide Analogue
Reverse Transcriptase Inhibitor, is effective against FIV in vitro, and there is some
evidence that tenovovir might have greater anti‐FIV efficacy with less cytotoxicity
than other antiretroviral compounds.
In the present study the therapeutic efficacy of the human antiretroviral compound
used in acquired immune deficiency syndrome, was investigated in the treatment of
cats naturally infected with feline immunodeficiency virus (FiV). Cats presenting
symptoms of recurrent infections (sinusitis, stomatitis) were tested for their FIV
and FeLV status by IDEXX SNAP FIV/FeLV Combo test. Cats were included in this study
if they tested positive for FiV and presented chronic oral or nasal inflammation.
Nine cats met the mentioned inclusion criteria. Tenofovir (Virofob, Alvogen) was administered
orally, once daily at a dose of 50 mg/cat for 30 days, alongside specific treatment.
For the experimental group, day 0 and day 30 measures included complete blood count,
CD4+/CD8+ ratio, BUN and creatinine. One of the nine cats did not tolerate Tenofovir
administration and was excluded from the study after five days, due to severe hypersalivation.
Tenofovir had a benefical effect on the severity of oral and nasal inflammation and
induced an improvement in the general condition of the FiV infected cats. The cats
showed an increased CD4+/CD8+ lymphocyte ratio after treatment without signs of nephrotoxicity
or myelotoxicity.
This study suggests that Tenofovir, a human antiretroviral compound, is effective
in the treatment of cats naturally infected with feline immunodeficiency virus (FiV)
and has no side effects on bone marrow activity and kidney function in the short‐term
administration.
Disclosures
Disclosures to report.
ISCAID‐P‐8
The many faces of Lyme borreliosis in dogs: a review of 29 suspected clinical cases
M. Gatellet1, L. Adaszek2, B.L. Blagburn3, V. Choumet4, F. Jongejan5, T.N. Mather6,
L.A. Starkey3, M. Varloud1
1Ceva Santé Animale, Libourne, France, 2University of Life Science, Lublin, Poland,
3Auburn University, Auburn, United States of America, 4Paster Institute, Paris, France,
5Utrecht University, Utrecht, Netherlands, 6University of Rhode Island, Kingston,
United States of America
Canine Lyme borreliosis (LB) is a disease common and well‐documented in the northeastern
and midwestern parts of the USA, while in Europe the clinical presentation and the
existence of the disease are controversially discussed. Fever and arthritis are clinical
manifestations most often associated with LB; other presentations such as renal, cardiac,
neurological, and muscular disorders are suspected to be sequelae of Borrelia burgdorferi
(Bb) infection, but were not reproduced experimentally. The aim of this study was
to document various presentations of canine LB in North America and Europe. Twenty‐nine
dogs were included in this retrospective study based on clinical signs consistent
with LB and at least positive antibody detection. Nineteen dogs lived in endemic areas
in the USA, while 10 dogs resided in Europe. Medical records were available for 28
cases, and a phone contact with the owner and the attending veterinarian was established
for the 29th case.
LB was discovered accidentally in three cases, presented to veterinarians for wellness
exams and vaccinations. Clinical signs were apparent to the examining veterinarians
but not to the owners. Orthopedic disorders were reported for 20/29 cases (69%). Four
dogs (14%) showed only general signs of disease. Kidney failure occurred in four cases
(14%); one dog (3%) died of a dilated cardiomyopathy and one suspicious dog presented
barking troubles that responded well to doxycycline. Specific antibody levels against
Bb did not correlate with clinical signs and severity of the disease but were useful
for the follow‐up checks. Furthermore, concurrent specific antibodies against Bb and
Anaplasma phagocytophilum were detected in 5/29 cases (17%). Borrelial DNA was found
in synovial fluid of four dogs with orthopedic disorders and from one heart sample.
Recovery after antibiotic treatment was observed in all dogs with orthopedic or general
disorders. Dogs with renal and cardiac manifestations showed a poor prognosis as the
dog with cardiac presentation and 3/4 cases with kidney failure died. Application
of parasiticides was not always recorded; 6/29 dogs (21%) did not receive regular
treatment, 7/29 were treated regularly with isoxazoline systemic products (24%), 2/29
with fipronil‐based spot‐ons (7%) and 2/29 (7%) with collars (one flumethrin‐based
and one unrecorded brand).
This study suggests that canine LB may present itself in various clinical forms and
should be considered not only in cases of musculoskeletal problems or impaired general
condition, but also in cases of renal and cardiac disorders. Further research is required
to investigate this disease in dogs.
Disclosures
Disclosures to report.
Marina Gatellet and Marie Varloud are employees of Ceva Santé Animale. A consent form
was signed by the veterinary clinics or the owners prior to enrolment.
ISCAID‐P‐9
Distribution and risk factors of canine hemotropic mycoplasmas in hunting dogs from
Southern Italy
D. Piantedosi1, L. Pacifico2, G. Sgroi2, F. Buono2, B. Neola3, M. Beall4, J. Buch4,
A.T. Palatucci5, V. Veneziano2, R. Chandrashekar4, L. Cortese2
1University of Naples Federico II, Naples, Italy, 2Dep. of Veterinary Medicine and
Animal Productions, University Federico II, Naples, Italy, 3Istituto Zooprofilattico
Sperimentale del Mezzogiorno, Portici, Naples, Italy, 4IDEXX Laboratories, Inc., Westbrook,
ME, United States of America, 5Department of Translational Medical Sciences, University
Federico II, Naples, Italy
Mycoplasma haemocanis (Mhc) and Candidatus Mycoplasma haematoparvum (CMhp) are two
species of canine hemoplasma that may cause hemolytic anemia and chronic disease in
canine species. While understanding is limited, blood transfusions, bloodsucking arthropods,
biting and fighting are suspected routes of hemoplasma transmission in dogs. The aim
of the present survey was to determine the prevalence of hemotropic mycoplasma infections
in hunting dogs from Southern Italy and assess related risk factors. Blood samples
were collected from 1433 hunting dogs in the Napoli, Avellino and Salerno provinces
of Campania region of Southern Italy, and tested by real time polymerase chain reaction
(RT‐PCR) assays for amplification of Mhc and CMhp DNA. The dogs had no clinical signs
at the time of sampling. The overall PCR positive rates were13.1% for Mhc and 11.4%
for CMhp. Coinfection with both hemoplasma species was found in 4% of animals. Statistical
analysis revealed living in Salerno province (Mhc: OR = 2.94, 95% CI: 2.10‐4.11; CMhp:
OR = 2.27, 95% CI: 1.61‐3.20), hound breeds (Mhc: OR = 4.0, 95% CI: 2.86‐5.59; CMhp:
OR = 1.61, 95% CI: 1.16‐2.24), pack size more than 10 animals (Mhc: OR = 1.67, 95%
CI: 1.14‐2.47; CMhp: OR = 1.61, 95% CI: 1.06‐2.44) and wild mammals hunting (Mhc:
OR = 3.53, 95% CI: 2.51‐4.98; CMhp: OR = 15.7, 95% CI: 8.83‐28.0) as associated risk
factors for both canine hemoplasma infection. Adult age was a variable significantly
associated only to infection by CMhp (OR = 1.93, 95% CI: 1.25‐2.97). To the authors'
knowledge, this is the first large‐scale molecular survey on Mhc and CMhp infections
in dogs living in Southern Italy. The obtained data confirm the circulation of these
two species of canine hemoplasma within the hunting dog population of Southern Italy,
although their pathogenic potential and the possible epidemiological relationships
between hunting dogs and sympatric wild animal populations are still unclear.
Disclosures
Disclosures to report.
Grant supported by IDEXX Inc.
ISCAID‐P‐10
Prevalence of vector‐borne diseases in free‐roaming cats
J.S. Palerme, C. Cicerchi, M. Zhang, J. Olds
Iowa State University, Ames, United States of America
Though the role of cats as a reservoir for B. henselae has long been established,
the prevalence of infection or exposure of cats to other Bartonella species or to
other vector‐borne diseases remains unreported. Using serology and polymerase chain
reaction (PCR), the prevalence of exposure and bacteremia of vector‐borne infections
(Anaplasmaspp, Babesiaspp, Cytauxzoonspp, Ehrlichiaspp, Rickettsiaspp, Piroplasma,Mycoplasmaspp,
and Bartonellaspp.) was assessed in a population of free‐roaming cats in a rural area
of the Midwestern United States. Serum and EDTA blood samples were collected from
65 free‐roaming cats captured as part of a community spay and neuter program. Testing
with PCR revealed that 9 cats (14%) were positive for Bartonella species (6 for B.
henselaeand 3 for B. clarridgeiae) and 7 cats (11%) were positive for Mycoplasma species
(6 for M. haemominutim and 1 for M. haemofelis). Serological testing revealed that
50 cats (83%) were positive for antibodies against Bartonella species. More specifically,
50 cats were positive for B. koehlerae, 47 were positive for B. henselae and 42 were
positive for B. vinsonii subspecies berkhoffi. A significant positive correlation
was identified between positive Bartonella spp. PCR results and the presence of antibodies
against B. vinsonii berkhoffi and B. henselae. All cats that were positive for Bartonella
by PCR had positive serologies for all three species of Bartonella tested. Odds ratio
analysis of age, sex and weight revealed that male cats were at increased risk for
exposure to B. vinsonii berkhoffi.
Disclosures
Disclosures to report.
I (Jean‐Sebastien Palerme) am a consultant for Infiniti Medical, LLC.
ISCAID‐P‐11
Retrospective analysis of cases tested for leptospirosis at a university teaching
hospital
H.K. Walker, N.X. Bommer, S. Salavati, R.J. Mellanby, A. Gow
Royal (Dick) School of Veterinary Studies, Easter Bush Campus, Midlothian, United
Kingdom
Pathogenic Leptospira species pose a risk to canine and human health worldwide. There
is very little published data on positive cases of leptospirosis seen in veterinary
practice in the United Kingdom. This study aims to analyze all cases tested for leptospirosis
in a UK university teaching hospital between 2011 and 2018.
Data was retrospectively collected from a university database; all dogs that were
screened for leptospirosis via urine PCR, blood PCR, or serum MAT were included (n
= 153). Cases vaccinated within 12 months with an MAT titre<1:800, in addition to
testing negative for both urine and blood PCR, were excluded from the positive category
(n = 17). Of the remaining 136 cases, 39 tested positive for leptospirosis.
The number of positive cases among those tested was 11/30 (36.6%) in 2016, 18/64 (28.1%)
in 2017 and 10/56 (17.8%) in 2018; the 3 cases tested between 2011 and 2016 were all
negative. Of the positive cases, 61.5% (24/39) had been vaccinated with a leptospiral
vaccine within 12 months and 53.8% (21/39) had received antibiotic therapy prior to
referral.
The most common presenting clinicopathological abnormalities of positive cases were
increased hepatic (13/39) or renal (12/39) values, with four of these cases presenting
with both. None of the positive cases presented with pulmonary haemorrhage or dyspnea.
Primary leptospirosis was the final diagnosis for 27 of the 39 positive cases, while
six cases had an unrelated final diagnosis (neoplasia (n = 3); biliary mucocele (n
= 1); necrotizing fasciitis (n = 1); pericardial effusion (n = 1)). Three of the positive
cases had a final diagnosis of chronic renal insufficiency, two of these secondary
to congenital dysplasia, and three cases had a final diagnosis of chronic hepatopathy.
Positive cases were predominantly medium to large breed dogs, with Labradors, followed
by beagles, cross breeds, and border collies being most commonly observed in the positive
category.
In conclusion, prior vaccination or antibiotic use should not preclude testing for
leptospirosis. In contrast to cases reported in mainland Europe, clinical pulmonary
disease does not appear to be a feature in these cases. Leptospirosis appears to have
been detected incidentally in some cases, potentially signifying a population of dogs
with subclinical infection.
Disclosures
Disclosures to report.
Dr A. Gow: Speaker honorarium, companion animal magazine, ACVIM,ECVIM H.Walker: MSD
may provide assistance for travel, had no involvement in study design, data collection
or results.
ISCAID‐P‐12
Canine urine culture and antimicrobial susceptibility patterns over an eight‐year
period: increasing antimicrobial and multidrug resistance
P.J. Guzmán Ramos1, R.E. Shiel1, C. Fernández Pérez2, J.I. Ballester Aguado3, A.M.
Ríos Boeta4, N. Ruiz‐Duro5, G. Oriz‐Díez3
1School of Veterinary Medicine, University College Dublin, Dublin, Ireland, 2Hospital
Universitario Clínico San Carlos (Servicio de Medicina Preventiva), Madrid, Spain,
3Facultad de Veterinaria. Universidad Alfonso X el Sabio, Madrid, Spain, 4Hospital
Veterinario Puchol, Madrid, Spain, 5Facultad de Veterinaria, Universidad Alfonso X
el Sabio, Madrid, Spain
Urinary tract infections (UTIs) are common in dogs but appropriate use of antimicrobial
drugs is necessary to prevent emergence of multidrug resistant (MDR) bacteria. Awareness
of the prevalence of urinary tract infections, causative agents and resistance patterns
is essential to guide appropriate therapy.
The aims of the present study were to describe the prevalence of bacterial UTIs in
dogs, identify the most commonly isolated microorganisms, and analyze the progression
of susceptibility patterns over the study period.
The results of canine urine culture and antimicrobial susceptibility tests performed
between January 2010 and December 2017 at the Veterinary Teaching Hospital of the
Alfonso X El Sabio University were retrieved from the laboratory database. All samples
were collected by cystocentesis and cultured within 24 hours of collection. Antimicrobial
susceptibility was determined using the Kirby‐Bauer disc diffusion method. Multidrug
resistance was defined as resistance to at least one antimicrobial agent in more than
three different antimicrobial categories.
A total of 3420 urine samples were identified, with positive culture results in 771
(22.5%). There was no increase in the frequency of positive bacterial cultures over
the study period (interval relative risk (IRR) 0.98, 95%CI 0.92‐1.0, P = 0.565). The
relative effect of developing UTI was significantly higher in females than males (RE
1.42, 95%CI 1.26‐1.61, P < 0.001). The most commonly isolated microorganisms were
Escherichia coli (52.9%), Staphylococcus spp. (12.0%), Enterococcus spp. (5.8%), Pseudomonas
spp. (5.7%) and Streptococcus spp. (5.6%). The overall prevalence of resistance within
the Enterobacteriaceae family was 45.6% for cefazolin, 33.8% for pradofloxacin, 32.1%
for trimethoprim‐sulfamethoxazole, 30.9% for cefuroxime, 29.3% for enrofloxacin, 26.5%
for marbofloxacin, 25.8% for amoxycillin clavulanate, 18.4% for cefovecin and 11.5%
for fosfomycin. The prevalence of MDR infections ranged from 2.1% in 2010 to 8.6%
in 2017 which meant an increased trend of MDR bacteria of 22% (IRR 1.22 CI95% 1.06‐1.42
P = 0.005).
The high frequency and increasing trend of antibiotic resistance observed in this
study is concerning and has implication for veterinary and public health. These results
emphasise the importance of performing urinary culture and antimicrobial susceptibility
testing to allow appropriate selection of therapy. Although resistance to fosfomycin
was comparably low, this antimicrobial agent is not licensed for veterinary use in
Europe, and given its use in human MDR and methicillin‐resistant Staphilococcus aureus
infections, the use of this antibiotic must be reserved for human medicine.
Disclosures
No disclosures to report.
SCH‐P‐1
The use of MRI and gadoxetic acid to differentiate hepatic parenchymal hyperplastic
lesions in dogs
P. Borusewicz1, E. Stanczyk1, P. Podgórski2, K. Kubiak1, J. Spuzak1, K. Glinska‐Suchocka1,
M. Jankowski1, P. Slawuta1, D. Kubiak‐Nowak1
1University of Environmental and life Sciences, Wroclaw, Poland, 2Wroclaw Medical
University, Wroclaw, Poland
Magnetic resonance imaging (MRI) using gadoxetic acid (Gd‐EOB‐DTPA) is widely used
in human medicine to characterize hepatic nodular lesions. In veterinary medicine
there are few reports of Gd‐EOB‐DTPA use in liver examinations in dogs.
The aim of the study was to describe a contrast enhancement pattern for different
types of liver lesions after administration of Gd‐EOB‐DTPA in dogs.
The study was carried out on six dogs with a presumptive diagnosis of a focal liver
lesion. A clinical examination, laboratory blood tests and abdominal ultrasound were
carried out prior to MRI. The animals were examined using a 1.5‐Ingenia Philips MRI
system. The imaging protocol consisted of breath triggered pre‐contrast T1, T2 and
post‐contrast T1 weighted sequences performed in transverse plane. Gd‐EOB‐DTPA was
administered intravenously at 0.1 mL/kg, followed by 15 mL of a 0.9% saline solution.
The post‐contrast T1‐W sequences were acquired 26 minutes after contrast administration.
Samples for histopathological examination were collected from all the cases (surgical
resection ‐ 1 case, core‐needle biopsy ‐ 4 cases, necropsy ‐ 1 case).
Parenchymal liver metastasis was found in one case. The lesion was strongly hypointense
compared to the surrounding liver tissue in both pre‐contrast sequences and no signal‐enhancement
following contrast administration was observed. Focal nodular hyperplasia was observed
in one case. It was isointense compared to the surrounding liver tissue in pre‐contrast
sequences, and it showed signal‐enhancement post contrast, similar to that observed
in the surrounding healthy tissue. A non‐enhancing central scar was observed within
this lesion. A hepatocellular adenoma was diagnosed in two cases. The lesions were
T1‐W hypointense and T2‐W hyperintense on pre‐contrast images compared with the surrounding
liver tissue. In both cases, contrast enhanced MRI of the lesions were observed. In
one case, a hepatic carcinoid was found in the liver parenchyma. The tumour was weakly
hypointense in T1‐W pre‐contrast sequences, while it was weakly hyperintense with
a strongly hyperintense centre in T2‐W images. No contrast enhancement was noted.
A hepatocellular carcinoma was also diagnosed in one case. This lesion was heterogenous
in pre‐contrast sequences, with moderate T1‐W hypointensity and moderate T2‐W hyperintensity.
It did not show contrast enhancement and remained strongly hypointense compared to
the surrounding tissue.
The obtained results indicate that contrast‐enhancement patters in dogs with various
hepatic neoplastic lesions are similar to those in humans. The enhancement patterns
used in human medicine to assess hepatic hyperplastic parenchymal lesions may be of
use in veterinary medicine.
Disclosures
No disclosures to report.